HEALTHY FOREVER - Dr. Reddy’s · forever dr. reddy’s laboratories limited annual report 2013-14...
Transcript of HEALTHY FOREVER - Dr. Reddy’s · forever dr. reddy’s laboratories limited annual report 2013-14...
HEALTHYFOREVER
DR. REDDY’S LABORATORIES LIMITEDANNUAL REPORT 2013-14
DR. REDDY’S LABORATORIES LTD.8-2-337, ROAD NO. 3, BANJARA HILLS, HYDERABAD 500034, INDIAwww.drreddys.com
DR. REDDY’S LABORATORIES LIMITED | A
NN
UA
L R
EP
OR
T 2
01
3-1
4HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED www.drreddys.com
HEALTHYFOREVER
DR. REDDY’S LABORATORIES LIMITEDANNUAL REPORT 2013-14
Contents
CASE STUDIES
METFORMIN: SMALL IS BIG
VIVA: COLLABORATING TO CURE
SMT: IMBIBING PATIENT-CENTRICITY
PROMIUS PROMISE: GUIDING RIGHT
10-11
16-17
20-21
24-25
CHAIRMAN’S LETTER 2
CELEBRATING GOOD HEALTH FOR DECADES 4
DOING WHAT MATTERS MOST 6
KEY PERFORMANCE INDICATORS 8
HEALTHY FOREVER
A FIRM FOUNDATION FOR SUSTAINED R&D INITIATIVES 12
BUILDING WORLD-SCALE MANUFACTURING CAPABILITIES 18
HARNESSING PEOPLE POTENTIAL 22
BOARD OF DIRECTORS 26
MANAGEMENT COUNCIL 30
BUSINESS RESPONSIBILITY REPORT 32
MANAGEMENT DISCUSSION & ANALYSIS 50
CORPORATE GOVERNANCE 62
ADDITIONAL SHAREHOLDERS’ INFORMATION 79
FIVE YEARS AT A GLANCE & RATIO ANALYSIS 90
SECRETARIAL AUDIT REPORT 92
DIRECTORS’ REPORT 94
IGAAP STANDALONE FINANCIAL STATEMENTS 103
IGAAP CONSOLIDATED FINANCIAL STATEMENTS 155
EXTRACT OF AUDITED IFRS CONSOLIDATED FINANCIAL STATEMENTS 207
STATEMENT 212 210
INFORMATION ON FINANCIALS OF SUBSIDIARIES 211
NOTICE OF THE ANNUAL GENERAL MEETING 212
Aff ordable healthcare for
the world is a mission we
have dedicated ourselves to,
since inception. However,
as the world around us
changes, the means to
achieving our mission must
evolve at every step. It is
important that we build
the necessary capabilities
and competencies that are
aligned to emerging and
unmet medical needs across
the globe.
With this realization, we decided to fi rmly focus
on getting diffi cult to produce medicines fi rst-
to-market. This is in step with the strategic
priorities we have outlined for ourselves.
In FY2014, we not only reported excellent
numbers but took eff ective steps towards
fulfi lling our priorities. We tasked ourselves
with identifying the right products to focus
on and building capabilities across our
businesses. We strengthened our R&D
infrastructure to remain ahead of the curve
and worked on creating the relevant scale
for manufacturing. And, we are developing a
talented workforce who can drive our vision
from the ground up. We believe these three
initiatives will help bring our mission to life.
HEALTHYFOREVER
2
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Chairman’sLetter
DEAR SHAREHOLDERS,I am pleased to share with you the fi nancial and operational results of our Company for FY2014. In a nutshell:
Consolidated revenue was `132.2 billion – up 13.7% over the previous year. In US$ terms, this amounted to US$ 2.20 billion.
Earnings before interest, taxes, depreciation and amortization (EBITDA) grew by 19.3% to `33.2 billion, amounting to 25% of consolidated revenue.
Profi t before taxes (PBT) was `26.6billion – which was a growth of 22.7% over the previous year. In US$ terms, it was US$ 443 million.
Profi ts after tax (PAT) was `21.5 billion – an increase of 28.2% over the previous year and was at 16% of consolidated revenue.
The high point has been the 27.4% growth in revenue from Global Generics in FY2014, which stood at `105.2 billion. This was driven largely by North America and the emerging markets. The low point was the 21.9% decline in revenue from Pharmaceutical Services and Active Ingredients (PSAI), which reduced to `24 billion in the course of the year. This was due to lower demand from several major customers coupled with a fewer launches compared to the previous year. Hopefully, PSAI’s performance will improve substantially in the coming year.
3
CORPORATE OVERVIEW/CHAIRMAN’S LETTER
Reddy. Your Company should be able to steadily introduce a large number of diffi cult to produce, innovative medicines – oral formulations, injectables or biosimilars – and do so year after year. We should be among the global best in R&D and new product development. We should have manufacturing facilities that not only pass the most stringent tests by global regulatory agencies but are also recognized as outstanding in their engineering, design, quality, health and safety and margins. We should have best in class employees that work together in a positive, engaging environment to create an enterprise that each is proud of. And together, our Company should be known as a nimble, innovative provider of medicines that address critical yet unmet medical needs and, in doing so, earn greater returns for our stakeholders.
Are we there? Not yet. Are we getting there? I believe that we are. With more confi dent and determined steps with every passing year.
My belief is that we will see an even better FY2015. We have all the ingredients in place. We need to make them work as I believe we shall.
Thank you for your support. The management, the Board of Directors and I cherish it very much.
With warm regards,
Profi t is important. But to my mind, it is an enabler and not an end in itself. Ultimately, the raison d’etre of your Company is to continuously improve patient care – and do so by providing innovative and aff ordable medicines across the globe. I look at performance through the lens of that fundamental objective.
Though we have miles to go to become one of the best in the world in meeting this objective, I have the satisfaction of saying that we are making good progress on this front. Consider, for instance, your Company’s performance in North America Generics in FY2014. A growth in revenue of over 46% to `55.3 billion was mostly on account of your
Company successfully introducing innovative and limited competition products to meet critical unmet medical needs.
In the course of the year, nine new products were launched in North America. The major ones were (i) decitabine, a complex injectable to treat blood cell disorders including acute myeloid leukemia; (ii) azacitadine, also for blood cell and bone marrow cancer; (iii) zolendronic acid, to prevent osteoporosis; (iv) divalproex extended release, for treating seizures and epilepsy; and (v) donepezil 23 mg, to treat patients with dementia. These types of highly specialized medicines – be they in oral forms or in injectable dosages – were not produced by Dr. Reddy’s earlier. Thanks to systematic investments in R&D and better organization of both intellectual property rights as well as the planning of a pipeline of specialized products, your Company can today provide tough-to-make generics to patients all over the world.
During FY2014, Dr. Reddy’s R&D expenses amounted to `12.4 billion – an increase of 62% over the previous year and amounting to 9.4% of sales. This is an essential ingredient for growth and the basis for your Company to create innovative medicines that meet unmet patient needs.
I am happy to inform you that FY2014 also saw 13 product fi lings in the USA. Cumulatively, 62 Abbreviated New Drug Applications (ANDAs) are pending for approval from the US Food and Drug Administration (USFDA). Of these, 39 are Para IVs – out of which we believe nine have ‘First to File’ status. These are the pathway to state-of-the-art growth.
What is my vision for your Company?A company which was founded and nurtured by a scientist of the caliber of Dr. K Anji
G V PrasadChairman & Chief Executive Offi cer
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-144
HEALTHY FOREVER
Celebrating Good Health For Decades
STRENGTHENING A GLOBAL MISSIONOur corporate mandate is to create greater access to aff ordable medicines and reach patients worldwide. We have a strong presence in key generics markets globally. Our medicines and services are available in North America, Europe and the emerging markets of Asia, Africa and South America. This helps us stay close to patients, doctors, healthcare providers and business partners, wherever they are.
We supply active pharmaceutical ingredients to other generics companies across theworld to help them quickly bring medicines to market and create aff ordable options to high-cost medicines. We also help innovator companies get their proprietary medicines to patients faster by providing a range of products and services.
North America garnered the largest share of the revenue pie in FY2014.
Good health is everyone’s primary need. At Dr. Reddy’s, we realize this and strive to help patients across the world gain access to aff ordable healthcare. This objective underpins our business strategies.
We are a global organization, with a diverse basket of products designed to off er solutions for unmet medical needs and better access to existing medicines. Our off erings cover active pharmaceutical ingredients, branded formulations, generic drugs, biologics, specialty products and New Chemical Entities (NCE).
We are headquartered in Hyderabad, India, with a presence across 20 countries. Our manufacturing facilities span 24 locations, supported by fi ve technology development centers, an integrated product development facility and two R&D centers.
RUSSIA
Nise®
Omez®
Ketorol®
Cetrine®
Ciprolet®
Senade
Sirdalud
Ibuclin®
Novigan®
Femibion
Celebrating Good Health For Decades
REVENUE
`132.2 bn 13.7% growth YoY
EBITDA
`33.2 bn 19.3% growth YoY
PROFITS AFTER TAX
`21.5 bn 28.2% growth YoY
FULLY DILUTED EARNINGS PER SHARE
`126.04 28% growth YoY
FY2014 CONSOLIDATED HIGHLIGHTS
TOP 10 PRODUCTS
NORTH AMERICA
Decitabine Injection
OTC Omeprazole Mg
Azacitidine
Metoprolol ER
Zolendronic Acid (Reclast)
Fondaparinux
Omeprazole DR
Tacrolimus
Atorvastatin
OTC Fexo
INDIA
Omez®
Omez-DSR®
Nise®
Stamlo®
RedituxTM
Stamlo BetaTM
RazoTM
Razo-D®
AtocorTM
Econorm®
5
19,000GLOBAL WORKFORCE
20 countriesGLOBAL FOOTPRINT
CORPORATE OVERVIEW/CELEBRATING GOOD HEALTH FOR DECADES
SALES & MARKETING OFFICES
RESEARCH & DEVELOPMENT CENTERS
MANUFACTURING FACILITIES
HEADQUARTERS
62ANDA FILINGS
13 US fi lings were made in FY2014, which include 1 NDA fi ling under the section 505(b)(2) and 12 ANDA fi lings, bringing the cumulative ANDA fi lings to 209. As on 31 March 2014, the ANDA pipeline has 62 ANDAs pending approval with the USFDA, of which 39 are Para IV fi lings of which 9 are believed to have First-to-File status.
61DMF FILINGS
12 DMFs were fi led in the US, 13 in Europe and 36 in other countries. As on 31 March 2014, there were 631 cumulative DMF fi lings.
54NEW PRODUCTS
New products launched in FY2014, of which 9 were launched in the US, 11 in Europe, 23 in Emerging markets and 11 in India.
FY2014 FILINGS & LAUNCHES
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-146
HEALTHY FOREVER
Revenue from GG
segment increased by
27% to `105,164 million.
Revenue from North
America increased
46% to `55,303
million.
Revenue from
Russia and other CIS
countries increased
17% to `19,819
million.
Revenue from India
increased 8% to
`15,713 million.
Doing WhatMatters Most
GLOBAL GENERICSOur Generics products make aff ordable healthcare a reality. We achieve this by bringing expensive medicines within the reach of patients by reducing the cost of therapy. Global generics is our biggest business driver. We off er over 200 high-quality and reasonably priced generic versions of expensive innovator medicines by leveraging our integrated operations. Our knowledge of active ingredients, product development skills, research-led understanding of regulations and intellectual property rights as well as our streamlined supply chain makes us a leader in this segment.
BIOLOGICSBiologics represent the next step in the evolution of modern medicine where
medicines are produced from living organisms and biological processes using biotechnology. At Dr. Reddy’s, we were quick off the block to build capabilities for this eventual reality.
Large-molecule protein therapies, Biologics are extremely eff ective in treating complex diseases such as cancer and diabetes. These medicines are highly targeted with fewer side eff ects, but are very expensive. Our generic biosimilars off er aff ordable yet equally eff ective alternatives to their innovator versions. Our product development capabilities and commercial reach have made us a global leader in this industry with four products in the market and an industry-leading pipeline spanning oncology, nephrology and auto-immune diseases.
TOP: Technology Development Center, OctoPlus N.V., The Netherlands
7
CUSTOM PHARMACEUTICAL SERVICESWe have one of the largest customized pharmaceutical businesses in India. We off er other generics companies and innovator fi rms pre-clinical and commercial supply capabilities. We bring a range of technology platforms and product services at competitive costs. We have a track record of bringing innovations to the market quickly, effi ciently and economically, thereby addressing patients’ needs better and faster.
PROPRIETARY PRODUCTSOur Proprietary Products business provides innovative medicines that increase patient’s comfort and convenience. This business develops and markets new formulations of currently marketed drugs or combinations of complementary drugs and technologies to enhance safety or effi cacy or both.
PHARMACEUTICAL SERVICES & ACTIVE INGREDIENTSACTIVE PHARMACEUTICALS INGREDIENTSWe believe the trust of patients in our medicines needs to be continuously reinforced. Therefore, we endeavor to create high-quality Active Pharmaceutical Ingredients (APIs), enabling our customers to create end formulations for patients that are eff ective and safe.
As we push the envelope further and strive for excellence, our eff orts have already paved the way for credible achievements. We have emerged as one of the world’s largest producers of APIs and help innovator companies launch their products fi rst in the market. Apart from helping customers capture market opportunities at the earliest,APIs also help our own generics business reach consuming markets faster and become cost-competitive.
Revenue from PSAI
segment was `23,974
million.
BUSI
NESS
VER
TICA
LS
PHARMACEUTICAL
SERVICES &
ACTIVE
INGREDIENTS
`24 bn18% OF NET REVENUE
PROPRIETARY
PRODUCTS &
OTHERS`3 bn2% OF NET REVENUE
BIOLOGICSFY2014 REVENUESGLOBAL
GENERICS `105.2 bn80% OF NET REVENUE
FY2014 REVENUES
FY2014 REVENUES
FY2014 REVENUES
Revenue from
Proprietary Products
& Others was `3,032
million.
CORPORATE OVERVIEW/DOING WHAT MATTERS MOST
8
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Key PerformanceIndicators
70,2
77
FY20
10
FY20
11
FY20
12
FY20
13
FY20
14
74,6
93
96,7
37
116,2
66
132,1
70
CONSOLIDATED REVENUE
` MILLION
CHART A
EBIDTA*
` MILLION
CHART B
AConsolidated revenue grew by 13.7% Y-O-Y primarily due to increased business in the North America and Emerging markets regions in the Global Generics business segment.
BEBITDA increased by 19.3% to `33,180 million
(25.1% of consolidated revenues) in FY2014, from `27,819 million in FY2013.
CPAT increased by 28.2% `21,512 million
(16.3% of consolidated revenues) in FY2014, from `16,776 million in FY2013.
PROFIT AFTER TAX
` MILLION
CHART C
CAGR17%FY2010-FY2014
CAGR20%FY2010-FY2014
15,8
44
FY20
10
FY20
11
FY20
12
FY20
13
FY20
14
16,4
24
25,4
09
27,8
19
33,1
80
1,0
68
FY20
10
FY20
11
FY20
12
FY20
13
FY20
14
11,0
40
14,2
62
16,7
76
21,5
12CAGR
112%FY2010-FY2014
* Adjusted for non-cash impairment charge and other non-recurring costs/income
9
DILUTED EARNINGS
PER SHARE
`
CHART E
EEarnings per share grew by 28.0% to `126.04 in FY2014 from `98.44 in FY2013.
DReturn on Capital Employed remained at 28% in FY2014, at par with FY2013.
ROCE
IN PERCENT
CHART D
CORPORATE OVERVIEW/KEY PERFORMANCE INDICATORS
FY 2014 REVENUE DISTRIBUTION AND
GEOGRAPHICAL MIX
IN PERCENT
CHART F
FY 2013 REVENUE DISTRIBUTION AND
GEOGRAPHICAL MIX
IN PERCENT
CHART G
NORTH AMERICA RUSSIA & OTHER CIS
EUROPE REST OF THE WORLD
INDIA
NORTH AMERICA RUSSIA & OTHER CIS
EUROPE REST OF THE WORLD
INDIA
12
39
17
17
15
22
FY20
10
FY20
11
FY20
12
FY20
13
FY20
14
21
30
28
28
6.3
0FY
20
10
FY20
11
FY20
12
FY20
13
FY20
14
64.9
5
83.8
1
98.4
4
126.0
4CAGR111%FY2010-FY2014
47
12
15
15
11
10
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
India is facing a diabetes epidemic with 67 million
confi rmed diabetes patients and another 30 million in
the pre-diabetes group. By 2030, India will have the
largest number of patients in the world. The
treatment for diabetes and the allied ailments it
brings, needs a lot of daily care and preventive
medication. But the medicine itself was inconvenient
to consume because of its size.
METFORMINSMALL IS BIG
11
CORPORATE OVERVIEW/CORPORATE OVERVIEW
Patients fi nd it easier to take Metsmall® and thus manage their disease eff ectively on a daily basis – reassuring their family and their doctors, who now can confi dently prescribe a drug they know their patients will not miss taking.Small, sometimes, is truly big.
Working closely with cross-functional teams across every domain, we developed a solution for an acute need, where the existing drug was an issue in itself!
WHAT WE DIDSince 1989, many companies had been attempting to make a smaller version of the pill but few had succeeded. The major technical hurdle was reducing the size while ensuring the right quantity of the drug was available in the blood stream. Investment in R&D for Metformin was also lean considering that it was an ‘economical drug’. Recognizing a silent need that many had overlooked, we decided to create a smaller pill that still packed in the same impact. We did this by working together with our R&D, formulations, IP and marketing teams. They came up with Metsmall®, named after the solution and we got it to market at the earliest.
THE IMPACT WE HAD33% reduction in size; 36% reduction in weight*.Metsmall® was born. A smaller version of Metformin, the pill works with the patient, putting their needs and comfort fi rst.
THE NEEDMetformin is the fi rst in line medicine for the treatment of patients suff ering from Type-2 diabetes. The pill is very big and hence uncomfortable to swallow. But it had come to be accepted by doctors and patients, given that there was no alternative. However, our survey on drug usage showed some patients were skipping the medicine while a large number were breaking the pill in half to get it down more easily. This is not advisable as it may aff ect the medicine’s dissolution pattern.
* for Metsmall® 500 mg
12
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
A Firm Foundation For Sustained R&D Initiatives
TOP: IPDO at Hyderabad, India
At Dr. Reddy’s, we believe tomorrow’s innovative solutions are the outcome of today’s research and development (R&D) eff orts. Therefore, we have invested generously in expanding our Research & Development capabilities to lay a fi rm foundation for sustained eff orts in this area. We showcase below a brief insight into our focus on growing our R&D backbone.
ONE TO MANYWe successfully progressed from a single site R&D organization to multiple sites, because we believe in tapping excellence wherever it is. Currently, we have eight R&D, Product and Technology Development Centers across the globe – one in Cambridge, UK, another being developed in Princeton, US, a third
in The Netherlands, four in Hyderabad and one in Bangalore, India. The multi-locational R&D strategy has empowered us to deliver solutions across therapeutic areas, irrespective of geographical boundaries.
Sensing, and identifying opportunities in diff erent markets, we expanded from an Oral TOP: IPDO at Hyderabad, India
8Global R&D and
Product and Technology
Development Centers
9.4%of Total Sales in FY2014
invested in R&D
13
CORPORATE OVERVIEW/A FIRM FOUNDATION FOR SUSTAINED R&D INITIATIVES
TOP: Technology Development Center, Cambridge
Solid Dosages (OSD) only portfolio to include diversifi ed dosage development capabilities for the manufacture of Injectables and Topicals.
COMPLEXITY IS THE KEY The barometer of complexity is increasing across the world. We are consciously moving towards large diffi cult to produce molecules in order to target fi rst-to-market tough to make products. Therefore, our eff orts are focused on fostering the twin capabilities of developing complex products as well as developing them at a rapid pace to be the fi rst to market.
VALUE THROUGH INNOVATIONOur Product Development team has a unique repertoire of skills to crystallize the Active Pharmaceutical Ingredients (API) using diff erent process parameters. This enables us to develop unique polymorphs which are diff erent from those patented by the innovator. We have also built infrastructure, which allows us to screen polymorphs in a
R&D EXPENSES/R&D EXPENDITURE AS A
PERCENTAGE OF SALES
IN ` MILLION/%
CHART A
5.5%
6.5%
6.0%
9.4%
3,7
93
FY2010
FY2011
FY2012
FY2013
FY2014
5,0
60
5,9
11
7,6
74
12,4
02
high throughput mode. A lot of the fi lings that we do today in the API business are novel polymorphs.
A world-class Advanced Characterization Technology Lab (ACT Lab) with cutting-edge characterization tools and best-in-class talent, both sourced from outside India, was also put together last year. This lab houses cutting edge tools like electron microscopes and Advanced Spectroscopy facilities.
DERIVING VALUE FROM CATALYSTSOur Chirotech facility in Cambridge is a Center for Excellence in Catalysis. It was originally aligned to our CPS business and worked for external customers, typically innovator companies. Today, Chirotech is aligned to our API business and has made substantial progress in helping the development of our APIs. This change in organizational structure has had a signifi cant infl uence on our ability to make cost-eff ective complex products, along with speed of development.
R&D
EXPENSES
R&D
EXPENSES
AS A % OF
SALES
6.5%
CHANGE IN FILINGS IN TERMS
OF DOSAGE FORMS
CHART BFY
2010
FY2011
FY2012
FY2013
FY2014
1321
6
7
5
4
8
14
OSD
INJ
OTHERS
7
8
9
5
14
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
A FIRM FOUNDATION FOR SUSTAINED R&D INITIATIVES
BiologicsBusiness of the future
Proprietary Products Innovation with a lower risk
Biologics is an exciting future opportunity for us as a large number of biotech drugs (USD 75-85 billion) are coming off patent in 2020. Our current biologics portfolio covers most of the top biologics coming off patent. In addition, we also entered into an alliance with Merck Serono, a division of Merck KGaA, Germany, in 2012 to co-develop a portfolio of biosimilar compounds in oncology; primarily focused on Monoclonal Antibodies (MAbs). It covers co-development, manufacturing and commercialization of the compounds globally, with some specifi c country exceptions. This alliance maximizes the complementary capabilities and assets of both companies and off ers a risk-mitigation pathway for us to take our development capabilities through the clinical phase and then into commercialization.
In our Proprietary Products business, we are pursuing an innovative R&D approach with a lower risk by targeting specifi c segments of patients in Dermatology and Neurology. We intend to develop and take these products all the way to the patient ourselves and complement them with patient-oriented solutions that can further improve the treatment outcomes for these patients. We have more than 15 products at diff erent developmental/clinical stages with a peak sales potential from USD 30 mn to 300 mn. Two products are in advanced clinical trials between Phase II and Phase III and we expect to fi le our fi rst NDA in the next two years.
15
CORPORATE OVERVIEW/A FIRM FOUNDATION FOR SUSTAINED R&D INITIATIVES
to be directly injected into the human blood stream. As OctoPlus had never developed generic products (end-to-end), our expertise matched their capabilities perfectly and in turn allowed us to expand our off erings.
IT DRIVES BUSINESS INTEGRATIONAt Dr. Reddy’s, our IT investments are turning out to be a key diff erentiator in our endeavor to bring access to good healthcare to patients globally. Electronic Lab Notebooks were introduced in our R&D facilities which ensure that every single experiment/study done in the labs is centrally documented. They also connect the development team with other cross-functional teams in a seamless manner. The result: uninterrupted workfl ow, better progress visibility at all organizational levels, eff ective documentation, and paperless operations. Besides, this IT architecture also addresses the quality and compliance parameters with speed, because approvals
STRATEGIC EXTERNAL PARTNERSHIPSWe began the journey of external development through partnerships withpartners and have since completed six fi lings. We partner with those who have expertise and yet require handholding to make the association mutually rewarding. Our strategic analytical methods and validation tools ensure that we reach the fi nal fi ling stage of the product and continue to consolidate our leadership position.
DEDICATED SYNERGIES Our acquisition of OctoPlus in 2013 refl ects insight, as well as an ability to leverage our strengths exponentially. OctoPlus is a specialty research facility in the Netherlands, focused on the formulation development and cGMP manufacturing of controlled release and other complex injectable therapeutics.While we understood the process of making generic products and fi ling them, OctoPlus had the unique capability of enclosing toxic drugs in a matrix that then makes them safe
of reports happen electronically. This is fully compliant with CFR 11, which is an FDA mandate and aids the process of development and documentation of products in our organization.
39 56 77 119174 181
346430
638
833
1,225
1,502
2,159
FY2010
FY2009
FY2008
FY2007
FY2006
FY2005
FY2004
FY2003
FY2002
FY2011
FY2012
FY2013
FY2014
1
2 2 2
1 1 1
3 3
1
2
1
2
1
4
INDIA
INDIA UKRAINE SRI LANKA
PERU SRI LANKA JAMAICA
INDIA VIETNAM
VIETNAM
VIETNAM
MYANMAR
MYANMAR
IRAN
INDIA
1 REDITUX 2 GCSF 3 PEG GCSF 4 DARBEPOETINBIOLOGICS REVENUE
PROGRESSION Y-O-Y
` MILLION
PRODUCTS LAUNCHED
CHART C
16
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Access to medicines goes beyond aff ordability. It is also about
availability – when patients need it, where they need it. By
deploying innovative technology and close collaboration with
our retail partners, we designed a fully-integrated approach to
stock management and ensured that patients in Russia never
go without essential medicines.
VIVA COLLABORATING TO CURE
17
CORPORATE OVERVIEW/CORPORATE OVERVIEW
Not only did our eff orts enable our partners to increase their effi ciency and profi tability, but helped them respond to the exact need-profi le of patients in a way that was not possible before.
We are ensuring that patients in a geography like Russia, with diffi cult weather and terrain and lack of infrastructure, do not have to worry about medicine availability.
WHAT WE DIDWe created deep, collaborative relationships with our channel partners to give them what they need, to be eff ective distributors in their localities.
In line with this approach, we tied up with a technical partner to set up a replenishment tool. Using technology, we assessed distributors’ inventory and sales data on a daily basis, allowing us to react instantly to shortages in the system. By establishing a synchronized supply chain and integrating our systems – sales, supply chain and IT – we became true partners to distributors, understanding their stock needs, refi lling their warehouse and seldom leaving patients without medicines.
THE IMPACT WE HADShortages were halved. Inventory turns were doubled.
THE NEEDMedicine distribution to rural and remote locations is especially complex in Russia, given the existing weather and terrain conditions. It can take up to thirty days for supplies to reach their destination from Moscow. A complete stock-out situation is serious and needs to be avoided at all cost.
We work closely with Russian distributors to help avoid these situations – empowering them with information and capabilities to get drugs to patients, always. Working closely with our retail partners, we designed a fully-integrated approach to stock management, enabled through innovative technology, to ensure that patients never go without medicine.
18
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Building World-ClassManufacturing Capabilities
We are focused on rapidly scaling up our manufacturing capabilities to keep pace with the progress in R&D initiatives. And it is not just about growing in volume terms, but also qualitative improvements. We present below a few of the salient initiatives.FOCUSED ON STANDARDIZATION AND AUTOMATIONLack of standardized equipment in our R&D eff orts and the manufacturing process was a challenge for the longest time. Our engineering team spent signifi cant time to standardize the R&D and manufacturing equipment in all our new manufacturing facilities, thus enabling seamless and faster scale up. Our Product Development teams
also played a critical role making Product Development methods more automation friendly, minimizing human intervention. Dr. Reddy’s API Srikakulam Plant (SEZ) is our most modern plant with signifi cantly enhanced levels of automation, minimizing human exposure to the production process.
TOP: API Srikakulem Plant (SEZ)
4New Manufacturing
Facilities at API
Srikakulam Plant (SEZ),
Formulations Srikakulam
Plant (SEZ), Formulations
Vizag SEZ (Plant 1 &
Plant 2)
19
MAKING QUALITY MATTER AT EVERY STEPAt Dr. Reddy’s, we have adopted the principle of Quality by Design (QbD). Our aim is to integrate quality monitoring processes at every step proactively. We have implemented Process Analytical Technology (PAT), which measures and monitors all online processes, ensuring product quality.In the manufacture of Oral Solid Dosages – a multiple unit operation, comprising mixing, granulation, compression and coating, PAT sensors in each process measure the product, as it moves from one unit to the other. We enjoy a signifi cant early-adopter advantage for this technology among generic companies.
NEW OPERATING PHILOSOPHYOur Operating Philosophy, in force, in all our new manufacturing facilities features new generation shopfl oor management practices like closed transfer systems, simplifi ed gowning, state-of-the-art equipment and better time and people management to maximize output. In-plant processes are based on maximum automation use, which entails less manual labor and more error-free results. For instance, at these plants, there is no manual recording of environmental conditions. The automated control system regulates and monitors ventilation, lighting, power systems, fi re and security systems of the plant. Similarly, Safety, Health and Environment (SHE) operations are guided by an automated environment monitoring system.
BUILDING CORE COMPETENCE IN FERMENTATION – TECHNOLOGY DEVELOPMENT CENTER (FTDC)A FTDC was established at our existing Technology Development Center 2 to enter the fi eld of complex APIs that are fermentation derived and diffi cult to synthesize. Using fermentation, we will produce direct APIs or make core nucleus (intermediate), which can later be converted to fi nal API either by chemical or enzymatic process. About 28 scientists with experience in Strain development (conventional
The SEZ Plant, with a
capacity of 6-8 billion
capsules and tablets in
the next 3-5 years, is
the latest addition to our
OSD capacity, leveraging
our knowledge of
the platform. It is
a next-generation
plant with ‘paperless
manufacturing’ capability
through Electronic
Batch Processing
Record (eBPR) which
automatically generates
usage logs, ensuring
100% compliance and
enhancing regulator
confi dence.
mutagenesis and genetic engineering), process and Analytical development have been recruited for this facility. We can now carry out fermentation from a scale of 10L to 200L. FTDC has developed a novel platform for producing peptides of varying sizes, using recombinant approach with very short lead time, i.e. 2-3 months for Proof Of Concept (POC). Using this platform, POCs for three peptides have already been developed.
CORPORATE OVERVIEW/BUILDING WORLD-CLASS MANUFACTURING CAPABILITIES
TOP: Analyst performing chemical analysis in Formulations
Srikakulam Plant (SEZ)
LEFT: Employee operating a reactor in API Srikakulam Plant (SEZ)
20
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Giving back to society that supports us is an inherent
part of our culture. What is a better way of doing it than
by helping economically disadvantaged youth, from
locations around our manufacturing operations, fi nd
meaningful employment?
SMTRESPONSIBLE EMPOWERMENT
21
CORPORATE OVERVIEW/CORPORATE OVERVIEW
Over the course of three to four years, SMT recruits become highly skilled technicians in their fi eld, contributing signifi cantly to their family’s sustenance. This also ensures that our medicines are made and delivered to patients with utmost quality.
If this helps us build an empowered workplace which is better tuned to patient needs, this will become a win-win for all.
WHAT WE DIDYoung people from around our manufacturing operations are recruited to become a part of our Self Managed Teams (SMT) program. We provide them with the right training, appropriate tools and an enabling environment to help them build multiple skills to handle end-to-end jobs, so that they become an asset to our company. We have also tied up with local Pharmacy colleges and sponsor their professional training there, post which they are absorbed as full time employees of the company. Learning while they are earning gives them an opportunity to gain work experience and a professional qualifi cation simultaneously; thus helping them develop into well rounded professionals.
THE IMPACT WE HADOur SMT program creates individuals who are an asset not only to our company but the healthcare eco-system as a whole. The SMT way of working creates a fl at organization with fewer hierarchies, thereby ensuring that those responsible for on-ground execution also remain connected with the purpose of the organization. Therefore, training and culture of the SMT program instills an innate, patient-centric perspective in them.
THE NEEDThe locations around our manufacturing facilities play an important role in our sustenance. Without their cooperation and support, we cannot function the way we do today. These localities are also home to a good number of young people in search of guidance and training to help them fi nd fulfi lling work.
The health eco-system the world over is changing. Patients are demanding access to better, high quality medicine at lower costs. We can achieve this only by investing in our human talent and building an empowered work force.
22
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HarnessingPeople Potential
At Dr. Reddy’s, we work together to drive positive health outcomes for patients in need of aff ordable healthcare. As an organization, we are driven by leadership, intelligence and motivated people. We continuously develop and support our teams, increasing their engagement and capabilities.
Today, Dr. Reddy’s attracts and retains the best industry talent. With a presence in over 20 countries, we invest in various vocational and professional training for our people. We are building a talent pool to identify the right skills that will drive the organization ahead.
EVOLVED HIRING FOCUSOver the years, the hiring process has evolved to encompass two distinct levels. One, entry-level hiring from foreign universities and category A universities within India to build and grow future capability in niche areas. Two, the lateral hiring from other domains by mapping key talent in specifi c areas and conducting a targeted selection process TOP: Employees at our Princeton (US) offi ce
1,800
14
Total number of SMTs in
the organization
Manufacturing locations
have SMTs
23
TOP: A group of scientists at our Integrated Product
Development Organization (IPDO), Hyderabad
to recruit the best-in-class talent. Apart from usual methods like industry mapping, employee referrals and headhunting through consultants and job portals, we are also actively engaging in forums like YIM to showcase our capabilities and attract Ph.Ds We are also targeting conferences like AAPS and ACS to network and hire the right talent.
DRIVEN BY EXPERTSWe have recruited individuals both in the chemistry and engineering areas who will strengthen our capabilities. These experts will help counter tough challenges in chemistry and technological areas to make molecules that will drive growth. For instance, we have dedicated experts now working on synthesis of peptides. This has resulted in fi lings of complex molecules like Fondaparinux where complex oligosaccharides were developed internally. We have also recruited specialists who have worked on complex polymorphs for our particle engineering and polymorphism team. People with niche capabilities in fermentation and semi-synthetic technology were also hired for our new FTDC.
PEOPLE DRIVING QUALITY – THE QBD BLACK-BELTS! The Quality by Design (QbD) Black-Belts, is a dedicated team of experts in our QbDinitiative. Their role is to mentor the teams as they go through the entire feasibility and optimization process for developing APIs. We have also trained people to apply QbD in their own projects. This will allow us to have a robust process system, which can be scaled up eff ortlessly.
EMPOWERING FOR GOODEmpowering our human assets is an affi rmation of our larger commitment to the patients community we serve. Dr. Reddy’s is an equal opportunity employer with a deep sense of responsibility for our people. With more than 600 Self-Managed Teams (SMT) members recruited at our API facility, we recently had an agreement with the Enhance Academy (an affi liate of Tata Institute of
Social Sciences – School of Vocational Education). The SMT Higher Education Program is the fi rst-of-its-kind in the country, where the industry has conceived a vocational education framework. We are also collaborating with the Andhra University to conduct B.Sc. programs for our SMT members in the distance mode for producing peptides of varying sizes, using recombinant approach with very short lead time, i.e. 2-3 months for Proof Of Concept (POC).
BUILDING FUTURE LEADERSAND DIVERSE SKILL SETS We are following a two-fold approach implementing the SMT way of working across all locations and building leaders at diff erent levels. Based on the philosophy of lead self, lead others, lead business, a three-tier program is structured with a duration of around 6-9 months. There is considerable focus on learning by doing at both the functional and leadership levels. We are also working on building diverse skill sets within our talent pool by bringing in people with specialized skills, be it in science, manufacturing, business management, sales or mergers and acquisitions.
Value proposition for
attracting talent in R&D:
Creating an
environment of
continuous learning
Creating an
environment of
motivation through a
culture of reward &
recognition
Capability building
through exposure
to some of the
most up-to-date
technologies in R&D
Building a culture
of scientifi c
collaboration and
knowledge sharing
CORPORATE OVERVIEW/HARNESSING PEOPLE POTENTIAL
24
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Zenatane™ Capsules are used in the treatment of
severe recalcitrant acne. It is one of the most complex
and costly treatment processes. To help, we created
the Promius Promise™, a service to help patients
through treatment requirements and gives doctors
the additional support they need for a successful
outcome.
PROMIUS PROMISETM
GUIDING RIGHT!
25
CORPORATE OVERVIEW/CORPORATE OVERVIEW
WHAT WE DIDPromius Pharma, our US subsidiary and the North American Generics team partnered to bring Zenatane™ to patients through Promius Promise™. A customer-centric service, it provides information and frequent reminders while helping to reduce product cost for eligible patients through a co-pay off set. We have established a strategic relationship with an iPLEDGE™ certifi ed pharmacy that receives and processes prescriptions and delivers Zenatane™ to all iPLEDGE™ eligible patients within 24 hours.
We have set up a 25-member call center to address queries and provide product updates and organized US$ 1 million savings for patients through automatically applied rebate.
People who are not capable of paying for therapy may qualify to receive the drug free of cost through a newly launched Patient Assistance Program.
THE IMPACT WE HADSince we began the program in April 2013, 7,000 patients have been enrolled in Promius Promise™, with 99% receiving consistent treatment. Over 3,000 iPLEDGE™ eligible healthcare providers are also involved in the program, which already represents 20% of the dermatologists in the US.
THE NEEDAs many patients of severe recalcitrant acne are young, adherence to medication can be a problem as it involves the FDA program, iPLEDGE™. Therefore, while dermatologists believe isotretinoin is one of the most eff ective drugs for treating this severe form of acne, potential safety concerns and high costs make it very challenging for all patients to receive proper therapy. The potential severe side eff ects mean that it is important to counsel, monitor and guide the patient at every stage of the treatment regimen. In fact, based on an FDA review of the fi rst fi ve years of the iPLEDGE™ program, over 400,000 attempts to fi ll isotretinoin prescriptions were denied due to failures to meet iPLEDGE™ requirements.
Being with the patient means developing a service to help them and their doctor navigate the journey of a complex treatment.
The program has eff ectively enabled patients and doctors to make the system work for them – making it more streamlined and as effi cient as possible.
26
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Board ofDirectors
MR. ANUPAM PURIINDEPENDENT DIRECTOR
DR. ASHOK S GANGULYINDEPENDENT DIRECTOR
DR. BRUCE L A CARTERINDEPENDENT DIRECTOR
MR. G V PRASADCO-CHAIRMAN,
MANAGING DIRECTOR AND
CHIEF EXECUTIVE OFFICER
MR. SATISH REDDYCHAIRMAN
27
DR. J P MOREAUINDEPENDENT DIRECTOR
MS. KALPANA MORPARIAINDEPENDENT DIRECTOR
DR. OMKAR GOSWAMIINDEPENDENT DIRECTOR
MR. SRIDAR IYENGARINDEPENDENT DIRECTOR
For profi les of the Members of the Board, turn overleaf.
CORPORATE OVERVIEW/BOARD OF DIRECTORS
MR. RAVI BHOOTHALINGAMINDEPENDENT DIRECTOR
28
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
MR. SATISH REDDYCHAIRMAN
Mr. Reddy joined Dr. Reddy’s in 1993 as Executive Director. He played an instrumental role in the Company’s transition from a bulk drugs manufacturer to a global player in the branded generics space by spearheading the Company’s entry into emerging markets. In 1997, he was appointed as Managing Director and became the Vice-Chairman on 30 March 2013, following the demise of Dr. K Anji Reddy. He has been re-designated as the Chairman of the Company on 13 May 2014. In the mid-90s, as the Company prepared for its global foray, Mr. Reddy anchored the establishment of key systems and initiatives that positioned Dr. Reddy’s for rapid expansion and helped build the Company’s brand and corporate identity. He focused on translating Dr. Reddy’s strategy into action to drive its growth and performance globally.
Mr. Reddy graduated in Chemical Engineering from Osmania University, Hyderabad and holds a Masters in Medicinal Chemistry from Purdue University, USA.
DR. BRUCE L A CARTERINDEPENDENT DIRECTOR
Dr. Carter joined our Board in 2008, prior to which he was the Chairman of the Board and Chief Executive Offi cer of ZymoGenetics Inc., USA. He has also served as the Corporate Executive Vice President and Chief Scientifi c Offi cer for Novo Nordisk A/S. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin, from 1975 to 1982. Dr. Carter is also on the Board of Regulus Inc., Xencor Inc., Enanta Pharmaceutical Inc. and TB Alliance, all in the US. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
MR. G V PRASADCO-CHAIRMAN, MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER
Mr. Prasad joined our Board in 1986 and became Vice-Chairman & CEO in 2001, when Cheminor Drugs Ltd., the company of which he was then Managing Director, merged with Dr. Reddy’s. Following the demise of Dr. K Anji Reddy, he was appointed as Chairman and CEO eff ective 30 March 2013 and has been subsequently re-designated as the Co-Chairman, Managing Director and CEO of the Company eff ective 13 May 2014. Mr. Prasad has played a key role in the evolution of Dr. Reddy’s from a mid-sized pharmaceutical company into a globally respected pharmaceutical major.
Mr. Prasad holds a degree in Chemical Engineering from the Illinois Institute of Technology, Chicago, USA and a Masters in Industrial Administration from Purdue University, USA.
MR. ANUPAM PURIINDEPENDENT DIRECTOR
Mr. Puri joined our Board in 2002 prior to which he was associated with McKinsey & Company. He spearheaded the development of McKinsey’s India practice, oversaw the Asian and Latin American offi ces and was an elected member of the Board. He is currently a management consultant. He is also on the Boards of: Mahindra & Mahindra Ltd., Tech Mahindra Ltd., Mumbai Mantra Media Ltd. and our wholly-owned subsidiary, Dr. Reddy’s Laboratories Inc., USA. Mr. Puri holds an M.Phil. in Economics from Nuffi eld College, Oxford University, UK, an M.A. in Economics from Balliol College, Oxford University and a B.A. in Economics from Delhi University, India.
C4
C5 C6 C7 C8
C2 C3
C5 C6
BOARD OF DIRECTORS
DR. ASHOK S GANGULYINDEPENDENT DIRECTOR
Dr. Ganguly joined our Board in 2009. He is currently the Chairman of ABP Private Ltd. (Ananda Bazar Patrika Group) and is a member of the Prime Minister’s Council on Trade and Industry, the India US CEO Council and the National Knowledge Commission. He was the Chairman of Hindustan Lever Ltd. from 1980 to 1990 and member of the Unilever Board from 1990 to 1997. He was a Director on the Central Board of Reserve Bank of India from 2001 to 2009. He also serves as a Director on Board of Wipro Ltd. and as a member of Advisory Board of Diageo India Pvt. Ltd. He is a recipient of the ‘Padma Bhushan’ as well as ‘Padma Vibhushan’, two of India’s prestigious civilian honors. At present, he serves as a member of the Rajya Sabha, the upper house of the Parliament of India.
C3C2
C7 C8 C3
29
MS. KALPANA MORPARIAINDEPENDENT DIRECTOR
Ms. Morparia joined our Board in 2007. She is the Chief Executive Offi cer of J.P. Morgan, India, where she leads their Business Groups & Service Groups. Prior to joining J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group and was the Joint Managing Director of ICICI Group from 2001 to 2007. She has been named among the most powerful women in International and Indian Business by magazines like Fortune, Forbes and Business Today.She also serves on the Boards of Bennett, Coleman & Co. Ltd., CMC Ltd., J.P. Morgan Services India Private Ltd., J.P. Morgan Asset Management India Private Ltd. and Philip Morris International Inc., USA. She is also a member of the Governing Board of Bharati Foundation and a graduate in law from Bombay University.
MR. SRIDAR IYENGARINDEPENDENT DIRECTOR
Mr. Iyengar joined our Board in 2011. He is an independent mentor investor in early stage start-ups and companies. Earlier he was a senior partner with KPMG in the US and UK and also served as the Chairman & CEO of KPMG’s operations in India. Mr. Iyengar also holds directorship in Rediff .com India Ltd., Mahindra Holidays and Resorts India Ltd., CL Educate Ltd., ICICI Venture Funds Management Company Ltd., Cleartrip Private Ltd., in India, AverQ Inc., Kovair Software Inc., Rediff Holdings Inc., Cleartrip Inc., American India Foundation Inc. in the US, iYogi Ltd. in Mauritius and our wholly owned subsidiary, Dr. Reddy’s Laboratories S.A., in Switzerland. He holds a B.Com. (Hons.) degree from the University of Calcutta and is a Fellow of the Institute of Chartered Accountants in England and Wales.
DR. J P MOREAUINDEPENDENT DIRECTOR
Dr. Moreau joined our Board in 2007. He founded Biomeasure Inc. based near Boston, prior to which he was working as Executive Vice-President and Chief Scientifi c Offi cer of the IPSEN. He has published over 50 articles in scientifi c journals and has more than 30 patents to his name. He is a regular speaker at scientifi c conferences and a member of Nitto Denko Scientifi c Advisory Board. Dr. Moreau was responsible for establishing Kinerton Ltd. in Ireland in March, 1989, a wholesale manufacturer of therapeutic peptides. in the US. Dr. Moreau is also on the Board of Mulleris Therapeutics Inc. and ProteoThera Inc. in the US. Dr. Moreau has a degree in Chemistry from the University of Orleans and a D.Sc. in biochemistry. He has also conducted post-doctorate research at the École Polytechnique.
MR. RAVI BHOOTHALINGAMINDEPENDENT DIRECTOR
Mr. Bhoothalingam joined our Board in 2000. He has served as the President of The Oberoi Group of Hotels and was responsible for the Group’s worldwide operations. He has also served as Head of Personnel at British American Tobacco (BAT) Plc, Managing Director of VST Industries Ltd. and as a Director of ITC Ltd. He is also a Director of Sona Koyo Steering Systems Ltd. Mr. Bhoothalingam holds a Bachelor of Science degree in Physics from St. Stephens College, Delhi and Master’s degree in Experimental Psychology from Gonville and Caius College, Cambridge University.
DR. OMKAR GOSWAMIINDEPENDENT DIRECTOR
Dr. Goswami joined our Board in 2000. He is the Founder and Chairman of CERG Advisory Private Ltd., a consulting and advisory fi rm. He taught and researched Economics for 18 years at reputed institutions like the Oxford University, Harvard University, Tufts University and the Delhi School of Economics. Later, he became the Editor of Business India. He is also a Director on the Boards of Infosys Ltd., Crompton Greaves Ltd., IDFC Ltd., Ambuja Cements Ltd., Cairn India Ltd., DSP Black Rock Investment Managers Private Ltd., Godrej Consumer Products Ltd., Bajaj Finance Ltd., Max Healthcare Institute Ltd. and Infosys BPO Ltd. Dr. Goswami did his Masters in Economics from the Delhi School of Economics and his D.Phil. (Ph.D.) from Oxford University.
DR. REDDY’S BOARD-LEVEL COMMITTEES
C1.
C2.
C3.
C4.
C5.
C6.
C7.
C8.
AUDIT COMMITTEE
NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE
SCIENCE, TECHNOLOGY AND OPERATIONS COMMITTEE
RISK MANAGEMENT COMMITTEE
SHAREHOLDERS’ GRIEVANCE COMMITTEE
CORPORATE SOCIAL RESPONSIBILITY COMMITTEE
INVESTMENT COMMITTEE
MANAGEMENT COMMITTEE
COMMITTEE CHAIRMANSHIP COMMITTEE MEMBERSHIPC1
C1 C4C3 C4
C1 C2
C4
CORPORATE OVERVIEW/BOARD OF DIRECTORS
C5C1 C2 C6 C7 C8
30
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
ManagementCouncil
31
1 G V PRASAD CO-CHAIRMAN, MANAGING DIRECTOR AND
CHIEF EXECUTIVE OFFICER
Age 54 | B.Sc.(Chem. Eng.), M.S.(Indl. Admn.)Joined the Company on 30 June 1990
8 M V RAMANA EXECUTIVE VICE-PRESIDENT AND HEAD,
EMERGING MARKETS, GLOBAL GENERICS
Age 46 | MBAJoined the Company on 15 October 1992
2 SATISH REDDY CHAIRMAN
Age 47 | B.Tech., M.S.(Medicinal Chemistry)Joined the Company on 18 January 1993
6 SAMIRAN DAS EXECUTIVE VICE PRESIDENT AND
HEAD, FTO AND GGPM
Age 54 | B.Tech.(Mech.)Joined the Company on 15 June 2011
4 DR. S CHANDRASEKHAR PRESIDENT AND HEAD, HUMAN RESOURCES
Age 57 | MBA, Ph.D. Joined the Company on 12 August 2013
11 DR. K V S RAM RAO SENIOR VICE-PRESIDENT AND HEAD, CHEMICAL
TECHNICAL OPERATIONS (CTO)
Age 51 | B.Tech., M.E., Ph.D.(Chem. Engg.)Joined the Company on 03 April 2000
13 SAUMEN CHAKRABORTY PRESIDENT, CHIEF FINANCIAL OFFICER AND
GLOBAL HEAD, IT & BPE
Age 53 | B.Sc.(H), MBAJoined the Company on 02 July 2001
3 DR. R ANANTHANARAYANAN PRESIDENT, PHARMACEUTICAL SERVICES AND
ACTIVE INGREDIENTS
Age 49 | B.Pharm., Ph.D. Joined the Company on 06 August 2010
10 ABHIJIT MUKHERJEE CHIEF OPERATING OFFICER
Age 56 | B.Tech.(Chem.)Joined the Company on 15 January 2003
5 ALOK SONIG SENIOR VICE PRESIDENT AND HEAD, INDIA
BUSINESS (GENERICS)
Age 42 | B.E., MBAJoined the Company on 11 June 2012
12 DR. CARTIKEYA REDDY EXECUTIVE VICE-PRESIDENT AND HEAD,
BIOLOGICS
Age 44 | B.Tech., M.S., Ph.D.Joined the Company on 20 July 2004
14 UMANG VOHRA EXECUTIVE VICE-PRESIDENT AND HEAD, NORTH
AMERICA GENERICS
Age 43 | B.E., MBAJoined the Company on 18 February 2002
In order of appearance from bottom to top
7 DR. RAGHAV CHARI EXECUTIVE VICE-PRESIDENT, PROPRIETARY
PRODUCTS
Age 44 | M.S. (Physics), Ph.D.Joined the Company on 25 September 2006
CORPORATE OVERVIEW/MANAGEMENT COUNCIL
9 DR. AMIT BISWAS EXECUTIVE VICE-PRESIDENT, INTEGRATED
PRODUCT DEVELOPMENT
Age 54 | B.Tech.(Chem.), Masters (Polymer Science), Ph.D.Joined the Company on 12 July 2011
32
HEALTHY FOREVERHEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Business Responsibility Report
TOP: Classroom at Kalam Anji Reddy Vidyalaya
At Dr. Reddy’s, we consider sustainability a philosophy that helps society stay healthy forever. It is more than a matter of compliance to norms or regulations for us.
33
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
PRINCIPLE 1ETHICS TRANSPARENCY & ACCOUNTABILITYBusinesses should conduct and govern themselves with Ethics, Transparency and Accountability.
PRINCIPLE 2PRODUCT LIFE CYCLESUSTAINABILITYBusinesses should provide goods and services that are safe and contribute to sustainability throughout their lifecycle.
PRINCIPLE 3EMPLOYEE WELL-BEINGBusinesses should promote the well-being of all employees.
Disclosures on the nine principles as charted by the Ministry ofCorporate Aff airs in the “National Voluntary Guidelines onSocial, Environmental and Economic Responsibilities of Business”.
PRINCIPLE 4STAKEHOLDER ENGAGEMENTBusinesses should respect the interests of and be responsive towards all stakeholders, especially those who are disadvantaged, vulnerable and marginalized.
PRINCIPLE 5HUMAN RIGHTSBusinesses should respect and promote human rights.
PRINCIPLE 6ENVIRONMENTBusinesses should respect, protect and make eff orts to restore the environment.
PRINCIPLE 7POLICY ADVOCACYBusinesses, when engaged in infl uencing public regulatory policy, should do so in a responsible manner.
PRINCIPLE 8EQUITABLE DEVELOPMENTBusinesses should support inclusive growth and equitable development.
PRINCIPLE 9CUSTOMER VALUEBusinesses should engage with and provide value to their customers and consumers in a responsible manner.
34
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
We believe that our approach to sustainability will benefi t the larger ecosystem comprising all our stakeholders. Our eff orts to integrate sustainability with all operations helps us create long-lasting value across the environmental, social and economic landscapes. Corporate governance is the foundation of our sustainability strategy. It provides business value and competitive advantage, along with quantifi able results on the triple bottom line paradigm.
Our stakeholders are entitled to ethical, social and environmental expectations beyond fi nancial goals and statutory requirements from us. Their expectations guide our decisions, from our manufacturing units to the Boardroom. Therefore, we consistently engage with them to collectively approach our sustainability objectives. We think such engagements are key to nurturing stakeholder trust and ensuring business sustainability.
Sustainability is a non-negotiable business practice for us. We have been voluntarily publishing comprehensive Sustainability Reports since 2004. These Reports detail our
environmental, social, product and economic performance as per globally recognized GRI guidelines. Readers can access our Sustainability reports at: www.drreddys.com/aboutus/media/st-reports.html
Disclosures on the nine principles charted by the Ministry of Corporate Aff airs in the “National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business” are given in the following pages:
SECTION ACorporate Identity Number (CIN) of the Company L85195TG1984PLC004507
Name of the CompanyDr. Reddy’s Laboratories Limited
Registered Address8-2-337, Road No. 3, Banjara Hills Hyderabad 500 034, Andhra Pradesh, India
Website www.drreddys.comE-mail ID [email protected]
`198.6 mnTotal spending on Corporate Social
Responsibility (CSR)
TOP: Employees at the Technology Development Center Hyderabad 1
Corporate governance
is the foundation of our
sustainability strategy.
It provides business
value and competitive
advantage, along with
quantifi able results on
the triple bottom line
paradigm.
35
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
Financial Year reportedApril 2013 to March 2014
Sector(s) that the Company is engaged in (industrial activity code-wise)‘Pharmaceuticals’ is the primary reportable segment.
List three key products/services that the Company manufactures/providesGiven in the fi nancial statements.
Total number of locations, where business activity is undertaken by theCompanyOur manufacturing and sales & marketing operations span around 20 countries. We also serve API customers globally.
Number of international locations (Provide details of major 5)We have manufacturing facilities in Tennessee, New York, Mexico, Louisiana (USA), Mirfi eld (UK) and China and three Development Centers in Princeton (USA), Cambridge (UK) and Leiden (The Netherlands)Refer page 89.
Number of national locations17 manufacturing units, 3 R&D units and 2 Technology Development Centers. Refer page 88.
Markets served by the Company – Local/State/National/InternationalOur major markets include UnitedStates of America (USA), India, Russia and CIS, Germany, United Kingdom (UK), Venezuela, South Africa and Romania.
We also reach out to patients in various other markets like Brazil, Mexico, Chile, the Philippines, the Middle East and North Africa through our strategic alliance with GlaxoSmithKline (GSK) for emerging markets.
SECTION BPaid up Capital (INR)`850.54 million (as on 31 March 2014)
Total Income (Standalone) (INR)`98,795 million (as on 31 March 2014)
Total Profi t After Taxes (Standalone) (INR)`19,328 million (as on 31 March 2014)
Total spending on Corporate Social Responsibility (CSR) as a percentage of profi t after tax (%)1.03% (as on 31 March 2014)
List of activities in which the above expenditure has been incurredRefer to Principle 8 (page 45)
SECTION C Does the Company have any Subsidiary Company/Companies?Yes
Do the Subsidiary Company/Companies participate in the BR Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s).Our Subsidiary Companies are closely integrated with our Corporate BR Initiatives.
Do any other entity/entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/entities? [Less than 30%, 30-60%, More than 60%].Yes. We have a code of conduct for partners, which we encourage and expect them to follow.For more details, please refer to:www.drreddys.com/media/pdf/Supplier_CodeofConduct.pdf
SECTION D a. Details of the Director responsible for the implementation of BR policy/policiesSatish ReddyVice-Chairman & Managing DirectorDIN Number 00129701
b. Details of the BR headMr. Alok MehrotraVice-President & Head, Global Quality ManagementTel: +91-40-4900 2339E-mail ID: [email protected] Number (if applicable): NA
36
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
TABLE 1 PRINCIPLE-WISE (AS PER NVGS) BR POLICY/POLICIES (REPLY IN Y/N)
P1 P2 P3 P4 P5 P6 P7 P8 P9
Do you have a policy/policies for... Yes Yes Yes Yes Yes Yes NA Yes Yes
Has the policy being formulated in consultation with the relevant stakeholders?
Yes
Does the policy conform to any national/international standards? If yes, specify. (50 words)
We abide by all laws of the land and are a signatory to the 10 principles of the UN Global Compact. We take into account industry best practices and global benchmarks in defining our policies.
Has the policy been approved by the Board? If yes, has it been signed by MD/owner/CEO/appropriate Board Director?
Statutory policies are placed before the Board for consideration and approval. All other policies are approved by CEO/MD.
Does the Company have a specified committee of the Board/Director/Official to oversee the implementation of the policy?
The responsibility of the implementation policies and their review primarily lies with the respective business/function head.
Indicate the link for the policy to be viewed online.
ww
w.d
rred
dys.c
om
/in
vesto
rs/p
df/
co
be-b
oo
kle
t-2
01
2.p
df
ww
w.d
rred
dys.c
om
/ab
ou
tus/p
df/
SH
E_p
olic
y.p
df
ww
w.d
rred
dys.c
om
/ab
ou
tus/p
df/
SH
E_p
olic
y.p
df,
w
ww
.drr
ed
dys.c
om
/in
vesto
rs/p
df/
co
be-b
oo
kle
t-2
01
2.p
df
ww
w.d
rred
dys.c
om
/in
vesto
rs/p
df/
co
be-b
oo
kle
t-2
01
2.p
df
ww
w.d
rred
dys.c
om
/med
ia/p
df/
Su
pp
lier_
Co
deo
fCo
nd
uct.
pd
f
ww
w.d
rred
dys.c
om
/med
ia/p
df/
Su
pp
lier_
Co
deo
fCo
nd
uct.
pd
f
NA
ww
w.d
rred
dys.c
om
/in
vesto
rs/p
df/
co
be-b
oo
kle
t-2
01
2.p
df
ww
w.d
rred
dys.c
om
/in
vesto
rs/p
df/
co
be-b
oo
kle
t-2
01
2.p
df
Has the policy been formally communicated to all relevant internal and external stakeholders?
Employees are required to sign an undertaking, at least annually, stating that they have read the Code of Business Ethics (COBE) and comply with the principles of the Code. New employees are required to sign a similar undertaking at the time of joining. Additionally, all our policies with respect to the nine principles are available on the Company’s website.
Does the Company have in-house structure to implement the policy/policies?
Yes
Does the Company have a grievance redressal mechanism related to the policy/policies to address stakeholders’ grievances related to the policy/policies?
We address concerns from our stakeholders at respective department levels. We have a Shareholder’s Grievance Committee to address all shareholder concerns. We also have a dedicated Ombudsperson Procedure to address all concerns related to Company-level policies.
Has the Company carried out independent audit/evaluation of the working of this policy by an internal or external agency?
We comply with the Nine Principles broadly through the following policies: Code of Business Conduct and Ethics (COBE), SHE Policy and Principles, Quality Policy, Purchase policy and HR policies. These policies are regularly reviewed by various internal and external agencies, including regulatory agencies. We also pro-actively follow public advocacy through various forums.
GOVERNANCE RELATED TO BR
Indicate the frequency with which the Board of Directors, Committee of the Board or CEO assess the BR performance of the Company (within 3 months, 3-6 months, annually, more than 1 year).
The Management Council meets every quarter under the Chairmanship of the CEO. It identifies, measures, monitors and controls risk factors in the business and ensures safe, sound and efficient operation on a regular basis. The Board of Directors/Committee of Directors also periodically review certain elements of BR performance.
Does the Company publish a BR or a Sustainability Report?What is the hyperlink for viewing this report? How frequently is it published?
We have been publishing our Sustainability Report every year since 2004. The latest report may be viewed at: www.drreddys.com/sustainability/index.html
37
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
SECTION EPRINCIPLE 1 ETHICS, TRANSPARENCY AND ACCOUNTABILITYWe believe that a globally-respected business enterprise must be built on an ethical foundation. It should respect and satisfy diverse stakeholder aspirations. Compliance, integrity and transparency are deeply embedded in our people, systems and processes. They pave the way for maintaining sound corporate governance, enhancing shareholder trust and maximizing long-term corporate value.
High Standards of Compliance We are the fi rst non-Japanese
pharmaceutical company from Asia to be listed on the New York Stock Exchange (NYSE).
We are also the fi rst manufacturing company in India and one of the fi rst in Asia, to be Sarbanes-Oxley compliant.
We comply fully with Clause 49 of the Listing Agreement of the Indian Stock Exchanges and with applicable corporate governance standards of the New York Stock Exchange (NYSE).
Responsible and Ethical ConductHigh standards of ethical conduct are evident and expected at Dr. Reddy’s at all levels. We have a variety of governance mechanisms that help us achieve this objective:
Code of Business Conduct and Ethics (COBE) that lays down principles on ethics, bribery and corruption, which apply to all Directors and employees, our subsidiaries and affi liates
Annual affi rmation to COBE by all employees
An Ombudsman (Whistle-blowing) Procedure articulated to investigate the violation or suspected violation of COBE
A Supplier Code of Conduct to guide our suppliers, vendors and service providers
Regular review of internal control systems by both external and internal auditors
Multi-mode, multi-level training programs to drive awareness and to transform our values into a way of life for our people
Anti-Corruption and Free CompetitionOur business practices are based on sound ethics and fair play. We do not, under any circumstances, engage in or encourage corrupt practices and anti-competitive behavior. We undertake relevant measures to ensure all employees conduct operations in accordance with all applicable competition laws and regulations. These include:
Widespread awareness of our whistle-blowing procedures
Looking into and appropriately addressing issues concerning corruption, if any
Not permitting the giving or receiving of gifts, hospitality or expenses by employees, either directly or indirectly from those conducting or seeking to conduct business with us
Committing to free competition and employees expected to conduct operations in accordance with all applicable competition laws (also known as Anti-Trust laws in certain jurisdictions) and regulations
Compliance, integrity
and transparency are
deeply embedded in our
people, systems and
processes. They pave the
way for maintaining sound
corporate governance,
enhancing shareholder
trust and maximizing long-
term corporate value.
TOP: Our Values Statement
38
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Prevention of Sexual HarassmentWe are committed to providing a work environment free from any form of Sexual Harassment for all our employees. A framework is in place to ensure that no complaint on harassment goes unheard. To this eff ect, we have set up an Apex Complaints Committee and regional Internal Complaints Committees (ICC) at our locations across India to investigate sexual harassment cases in line with Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act 2013.
A sexual harassment policy has also been drafted and rolled out across the company. Manager awareness sessions were held and posters were put up across locations.
Sustainability at the HeartSustainability guides all our business decisions and is integrated with our core business processes at two levels:
at the corporate level, where overall policies and strategic directions are set and capital is allocated; and
at the Business Group level, where revenue is generated and the impact on communities and the environment is most immediate.
Transparency and AccountabilityRelevant information is shared with our stakeholders through established systems and procedures. Our website (www.drreddys.com) is the primary source of information regarding our operations. Financial data is communicated through quarterly fi nancial result announcements and annual fi nancial reports, while our triple bottom line performance is presented through the Sustainability Report. In addition, various communication channels are deployed to reach out to our stakeholders. For detailed information on them, refer Principle 4 on Stakeholder Engagement (page 41).
PRINCIPLE 2 PRODUCTS LIFECYCLE SUSTAINABILITYWe think that our products are our means of bringing about sustainable change; that they
can fulfi l much more than their immediate objective of healing. Therefore, we continue to focus our energies on making our products aff ordable, accessible, eff ective, safer and more eco-sensitive. We have tried to embed ‘Responsibility by Design’ into every phase of our product lifecycle and bring about an operational transformation.
The key drivers of our journey towards product excellence include:
Aff ordability and AccessibilityWe are governed by our founding principle of ‘Providing access to aff ordable medicine’. Our commitment to this principle is complete and set. We try to incorporate the tenets of Availability, Aff ordability and Accessibility in every aspect of our operations, from development to distribution. Our three core businesses – Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) and Proprietary Products – help us realize this principle.
Safety and Effi cacyThe safety of our products is the principal priority for us. This stems from the non-negotiable nature of health and well-being of our patients. We are focused on removing ‘quality and safety hazards’ through advanced process engineering, globally-benchmarked equipment and industry-next manufacturing practices. In the past year, we undertook manufacturing automation to the extent possible to optimally minimize human contact and contamination.
The principles of Quality by Design (QbD) are being integrated into all our product development and manufacturing processes. This ensures that we get all our products right the fi rst time in terms of product effi cacy and compliance. We also have ahighly vigilant Pharmacovigilance team that tracks and addresses any reported Adverse Drug Reactions (ADRs) across the entire life cycle of our products.
Green ChemistryGreen Chemistry has empowered us to develop a number of new products using environmentally benign solvents that can
A framework is in
place to ensure that
no complaint on
harassment goes
unheard. To this effect,
we have set up an Apex
Complaints Committee
and regional Internal
Complaints Committees
(ICC) at our locations
across India.
We are the only generic
company in the Green
Chemistry Consortium of
the American Chemical
Society. We use a green
matrix to manage the
various aspects of
product development,
in accordance to
the principles of
Green Chemistry &
Engineering.
39
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
be disposed/recycled without any challenge. In accordance to the principles of Green Chemistry & Engineering, we use a green matrix to manage the various aspects of product development. We are the only generic company in the Green Chemistry Consortium of the American Chemical Society (ACS).
Sustainable SourcingOur business partners form an important section of our stakeholder group. We value them and strive to nurture them by constantly presenting opportunities to enhance their capabilities through various training and knowledge sharing processes.
We also try to embed sustainable practices among our raw material suppliers, contract manufacturers and authorized business partners, as every action impacts the sustainability of every other member. We focus on four core aspects:
Training Mandatory Supplier Induction Training
for all new vendors Penetration of safety culture among our
suppliers Periodic trainings on quality excellence
Knowledge Sharing Sharing of best practices via audits and
conferences Cascading the Supplier Code of Conduct Troubleshooting Labs and Support Labs
for vendors
Sustainable Logistics Focus on shifting vendors near the plant
site Increasing sea shipments by 50% Introduction of new packaging solutions
for cold chain products
Conservation of Resources Reducing solvent usage and enhancing
its recovery Cutting down repeated testing of raw
materials, which have a stable track record
Adopting Green IT practices for waste minimization and resource conservation
PRINCIPLE 3PROMOTING EMPLOYEEWELL-BEINGWe believe high potential transforms into high performance through motivation, equal opportunities and a healthy work-life balance. We recognize that it is our people who help translate strategies from the drawing board to an on-ground reality. It is they who embrace challenges and bring about real change. Therefore, fostering a stimulating work culture that encourages, empowers and energizes people is important to us.
Employee CompositionWe are committed to building a rich and diverse workforce, without discriminating against culture, age, gender, caste, religion, language or ethnicity. Initiatives that help strengthen this diversity include inducting young talent, employing diff erently-abled individuals and enhancing the number of female employees. Employee selection is solely based on talent and merit. Today, 19,000 employees from more than 20 countries form our global workforce. TOP: Women’s Day Celebration at Dr. Reddy’s
33%Women recruited during
campus recruitment drive
in FY2014
We focus our energies
on making our products
affordable, accessible,
effective, safer and
more eco-sensitive.
We have tried to
embed ‘Responsibility
by Design’ into every
phase of our product
lifecycle and bring
about an operational
transformation.
40
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
In 2014, we reinforced workforce diversity by recruiting 33% women during our campus recruitments.
Talent PoolWe facilitate periodic enhancement of our employees’ competence, skills and attitudes to help them keep pace with the changing environment and their evolving job profi les. Our people are trained, based on the improvement areas identifi ed during our rigorous talent review process. In the reporting year, 3,862 man-days of training was imparted at our Leadership Academy. Our employees also attended 140 external programs and 165 internal programs. Additionally, multiple technical training programs were conducted at various business units. We follow a structured Talent Management Process consisting of a three-tier Talent Management Board (TMB). The TMB identifi es high potential employees and emerging leaders to groom them for greater responsibility.
Performance PerksA host of policies, facilities and incentives to enable our employees strike a healthy work-life balance, have been institutionalized. These include but are not limited to fl exible work timings, sabbatical leave, part-time work, paternity and maternity leaves and leave for those adopting a child.
‘Well Done’, an employee appreciation platform, was launched during the fi nancial year. It aims at fostering a culture of appreciation in the organization.
Active EngagementAt Dr. Reddy’s, employee engagement is a healthy two-way communication system. We empower our employees through communication platforms across regions and time zones. Some of these platforms include quarterly employee communication sessions, open houses at plants, 360º feedback and focused interviews.
We were recognized as the Best Place to Work in Biotech and Pharma companies in
TOP: SMT Members’ Parents Meet at FTO
India in Great Places to Work 2013 survey. We ranked 5th among companies with over 10,000 employees and 26th from the over 580 companies that participated in the survey.
Freedom of AssociationOur employees, including contract workmen, across operations enjoy freedom of association. We recognize their associations/unions through a code of disciplines and negotiate on all matters pertaining to service conditions, leading to mutual benefi ts. We have recognized unions in eight of our manufacturing units in India and all permanent workmen in these units are members of the union. About 5% of our total workforce are members of the union.
Beyond WorkWe believe in mixing work with play, in sharing and celebrating our successes as a team. Various platforms are provided for employees to socialize at the corporate, business and unit levels. ‘Celebrations’, our annual employee event, promotes team spirit and celebrates inclusiveness. At the plant level, multiple cultural events and collective celebrations of successes and birthdays are hosted regularly.
A gymnasium at our corporate offi ce and sports facilities at some of our other locations ensure that our employees are fi t and healthy. Yoga classes are conducted at various locations including the corporate offi ce after work hours.
Health and SafetyWe adopt carefully-chosen manufacturing practices and processes to ensure safety of our workforce. ‘Parivartan’, our operations transformation exercise, is driving a new safety and quality paradigm across the organization. We intend to achieve a ‘Safety Cultural Transformation’ by demonstrating commitment to safety at all levels, line management ownership of safety and capability building in the area of safety.
Our journey has progressed well with safety standards improving signifi cantly and the
41
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
awareness and ownership of safety increasing considerably across the organization.
Employees are provided with a free annual health check-up as well as medical insurance. Additionally, we have initiated health awareness programs for our employees including talks and programs on nutrition and weight management. Beyond employee healthcare, we also extend medical support to employees’ parents/dependents.
PRINCIPLE 4STAKEHOLDER ENGAGEMENTAt Dr. Reddy’s, we build lasting bonds with all our stakeholders – internal and external, through meaningful deliberations. It helps us review our actions, rethink our roadmap, redress grievances and recognize new avenues for revenues. Table 2 details our Stakeholder Engagement platforms.
Identifi cation and InteractionsWe have identifi ed clusters of stakeholders who are directly and indirectly aff ected by our operations and have developed targeted engagement mechanisms for each cluster.
A total of 21 shareholder complaints were received and resolved during the FY2014.
PRINCIPLE 5HUMAN RIGHTSMeritocracy is highly regarded at Dr. Reddy’s. We support and uphold the execution of fair practices and inclusive growth. In October 2010, we became a signatory to the UN Global Compact, supporting the 10 principles of the Global Compact with respect to human rights, labor, environment and anti-corruption. Our Code of Business Conduct and Ethics sets forth high standards of human rights. We condemn non-compliance with any of our principles. This applies to all our Directors,
TABLE 2 STAKEHOLDER ENGAGEMENT PLATFORMS
OUR KEY STAKEHOLDERS OUR KEY ENGAGEMENT PLATFORMS
EMPLOYEES
Employees who are the driving forces of the organization, deserve a safe, inclusive and empowering workplace with freedom to act, innovate and grow not just as professionals, but also as individuals
Organization Health Index | Employee Communication meets | In-house Publications Intranet | CEO, COO communication | 3600 feedback | Celebrations | Training Programs
For details, refer Dr. Reddy’s Sustainability Report’s stakeholder engagement section at: www.drreddys.com/sustainability/stakeholder-engagement.asp
INVESTORS & SHAREHOLDERS
Investors and shareholders who place trust and financial capital in the organization and expect a steady return on their investment
Analyst Meets | Quarterly Results | Annual Report | Sustainability ReportEarnings Calls | E-mail Communication | Official news releases and presentations
For details, refer Dr. Reddy’s Sustainability Report’s stakeholder engagement section at: www.drreddys.com/sustainability/stakeholder-engagement.asp
SOCIETY
Communities across the world, especially the economically weaker sections of society, whose lives are impacted by our social contributions
Dr. Reddy’s Foundation (DRF), the non-profit arm of Dr. Reddy’s Laboratories
For details, refer Principle 8 or Dr. Reddy’s Sustainability Report at:www.drreddys.com/sustainability/drf.asp
Patients and healthcare professionals who rely on today’s products and tomorrow’s innovations
Dr. Reddy’s Foundation for Health Education (DRFHE)Patients: Life at Your Doorstep | Living Well programmes | Sparsh
Health Professionals: DRFHE PGDHM | Case Manager’s program for cancer counselling Inner Circle: Relationship building programs | Abhilasha: Nursing Efficiency program Sarathi: Doctor’s Assistant Program
For details, refer Principle 8 or Dr. Reddy’s Sustainability Report at:www.drreddys.com/sustainability/drfhe.asp
CUSTOMERS & PARTNERS
Insurers, vendors, suppliers, distributors, government, regulators and business partners who support various aspects of our operations
Customers: Customer satisfaction survey, Regular business meetingsBusiness Partners/Vendors: Vendor meets, Strategic business partner training and development
For details, refer Dr. Reddy’s Sustainability Report’s stakeholder engagement section at: www.drreddys.com/sustainability/stakeholder-engagement.asp
‘Well Done’ – an employee
appreciation platform, was
launched during the fi nancial year.
It aims at fostering a culture of
appreciation in the organization.
5th
Best Place to Work in Biotech and
Pharma companies in India
(Great Places to Work 2013 survey)
42
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
employees, subsidiaries and affi liates. A separate Supplier Code of Conduct has been drafted for our suppliers, vendors and service providers.
All individuals are treated with equal dignity at all our offi ces and plants. They enjoy equal rights and have the freedom to voice their opinion without any inhibitions. Harassment in any form is not tolerated. We do not employ nor encourage any child or forced labor at any of our locations. Anyone found to be engaged in unlawful discrimination is subject to disciplinary action, up to and including termination. In the reporting year, no serious human rights violations were brought to our notice.
In case of new investments, we conduct human rights screenings and also have related assessments for strategic suppliers. Regular HR audits are conducted to ensure compliance with HR principles. Monthly meetings of HR heads from respective departments provide an ideal platform to articulate concerns, if any, and collectively propose and execute refi nements.
In the healthcare industry, awareness is not limited to the information printed on the packaging. It also involves managing social perceptions about medical conditions and demystifying myths and fears about them. We have many ongoing initiatives to help generate the right kind of awareness among people.
PRINCIPLE 6ENVIRONMENTWe believe that climate change is a real and growing challenge for our planet. According to a recently published report (Climate Change 2014: Impacts, Adaptation and Vulnerability) by the Intergovernmental Panel on Climate Change (IPCC), climate change is adversely impacting the life and livelihood of millions of people, globally. Such a scenario, makes it imperative for governments and enterprises to work together to create a greener, cleaner world.
Hence, we work constantly to embed environmental sustainability right at
the design and development stage of our products. This approach helps us champion green endeavors that go beyond regulatory compliance. We are spearheading the uptake of Green Chemistry not just within the company, but also within the Indian pharmaceutical industry and the global generics space. Our wastewater recycling plant, commissioned in FY2005, holds the distinction of being the fi rst of its kind in India’s pharmaceutical sector.
During the reporting year, 29 signifi cant environment management projects were initiated with an investment of `302 million. Detailed below are a few of the initiatives that are helping us raise our green quotient.
Green RoadmapOur Safety, Health and Environment (SHE) Policy and Principles inspire our workforce to reduce environmental stress. They are also shared with all our stakeholders and eff orts are being made to make them responsible towards its compliance. We have also institutionalized an organization-wide Environmental Commitment Statement charting ambitious targets and actionable steps for key environmental performance indicators like a 5% reduction in specifi c water and specifi c energy consumptions.
Year-on-year, we assess each unit’s progress on the said targets and strategize appropriate actions. The objective is to encourage and engage every employee to contribute towards making the organization greener, cleaner and sustainable.
Our Active Pharmaceutical Ingredients (API) Research & Development (R&D) team has religiously adopted a Green Chemistry metrics system to map synthetic routes to ensure that all the calculated values regarding Atom Effi ciency in feasibility, stay constant all the way till commercialization. This system involves:
Selection of the best environment friendly solvents, catalysts and reagents for the process
Screening based on physiochemical attributes of solvents
9%Total energy consumed from
renewable sources
76Score in the Carbon
Disclosure Leadership Index
(Carbon Disclosure Project)
We have undertaken pilot studies
to dispose market returned/off
specifi ed pharmaceutical goods. To
this end, we are working closely with
regulators and cement industries
to obtain necessary permits to
commercialize the process.
We assess each unit’s progress
on key environmental performance
targets and strategize appropriate
actions. The objective is to
encourage and engage every
employee to contribute towards
making the organization greener,
cleaner and sustainable.
During the year, we reduced energy
costs by 8% at Chemical Technical
Operations (CTO) from the FY2013
cost base by sourcing power at
competitive rates from open access,
sourcing coal from e-auction and
implementing of various energy
conservation measures.
43
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
Optimizing process parameters and operations with energy effi ciency in mind
Action against Climate ChangeWe are committed towards managing climate change both within and beyond our sphere of infl uence. A culture of conservation has been embedded in our employees and business partners. We continually implement initiatives on several green parameters like clean technology, energy effi ciency and renewable energy. During the year under review, 9% of total energy consumed was from renewable sources. We also participated in the Carbon Disclosure Project (CDP) initiative, scoring a 76 in the Carbon Disclosure Leadership Index.
Energy ConsumptionOur belief is that the fundamental root of emissions is enhanced energy consumption. Hence, we strive to recreate and redefi ne processes that help us tread lightly.
During the year, we reduced energy costs by 8% at Chemical Technical Operations (CTO) from the FY2013 cost base by sourcing power at competitive rates from open access, sourcing coal from e-auction and implementing various energy conservation measures. We identifi ed an energy conservation project including a co-generation power plant with an annual savings potential of `240 million with a total investment of `620 million.
Additionally, various business units implemented energy conservation initiatives such as:
Project resulting in savings of `3.6 million at our Custom Pharmaceutical Services (CPS) unit
24 energy conservation projects resulting in savings of `55 million at our Formulation Technical Operations (FTO) units
Better sourcing strategy leading to savings of `14.9 million by our Biologics Development Center
We are also planning to implement rooftop solar power plants of 1.1 MW and 1.18 MW at our Bachupally and CTO-SEZ and Vizag
campuses, respectively, which will reduce 10% of grid power consumption.
Waste ManagementIn continuation of our earlier practice of disposing organic waste to cement industries as auxiliary fuel, we have undertaken pilot studies to dispose market returned/offspecifi ed pharmaceutical goods. To this end, we are working closely with regulators and cement industries to obtain necessary permits to commercialize the process. We have also taken several initiatives to manage the waste generated, including:
Identifying specifi c waste stream from the Ranitidine manufacturing process to recover pure sodium sulphate salts (up-cycling)
Installing a new onsite incinerator at FTO-4 to dispose hazardous waste accumulated over years
Replacing the existing Spray Dryer at CTO-2 with ATFDs to comply with
TOP: Placeholder Image - TBD
Team Romania of Dr. Reddy’s in collaboration with the National Geographic started a project titled ‘The Noah’s Ark’. This nature conservation project clearly conveys the message about the importance of the Romanian biodiversity and the need for immediate action to protect it. The project conveys this message to the civil society, press, administration and political class through compelling visuals. It has two main features: an itinerant poster exhibition and the editing of an album featuring the most representative fauna species. The exhibition was showcased in the principal cities at prominent locations in Romania. In the last two years, this initiative has garnered wide acclaim of the general public and our customers.
CARE FOR THE PEOPLE, CARE FOR THE PLANET
CASE STUDY A
Members of Dr. Reddy’s Romania team
directions from the regulator Enhancing solvent recovery under our
program to achieve cost and capabilities
ReduceDuring the year, our eff ort to reduce environmental footprint was implemented through:
Installation of 350 KLD RO systems to treat rejects from existing utilities and process ROs, reducing water consumption by 250 KLD at CTO-5
Installation of an Electro Coagulation unit at CTO-5 to improve quality effl uents into RO systems and reduction of chemical consumption of up to 20 tons/month at CTO-5
Replacement of small cooling towers with a higher capacity under our cooling tower consolidation initiative at CTO-6, resulting in a reduction of 80 KLD fresh water consumption
44
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Condensate and seal water recovery at BDC CCM-2, resulting in a saving of 30 KLD of fresh water consumption
RecycleWe continued our focus on recycling by installing a new 150 KLD ZLD facility in FTO-1, reducing our fresh water consumption by 25 KLD. Additionally, a new 350 KLD sewage treatment plant was commissioned in FTO-2, reducing our water footprint by 80 KLD.
ReplenishWe replenished fresh water in our units by completing a rainwater harvesting survey at CTO-5 and initiating civil works for the construction of storm water drains. We also carried out similar activities at FTO-1 to replenish rainwater with a sequestration potential of 150 KL.
Air QualityManaging air quality is on our development agenda. We already track particulate matter, NOx and SOx emissions and closely follow evolving norms on other pollutants, such as Volatile Organic Compounds (VOCs). Our emissions generated are well within permissible limits fi xed by Central and State Pollution Control Boards (PCB).
Over the year, we installed continuous ambient air quality monitoring stations in three API manufacturing units to monitor quality of ambient air. Three more units are in the process of being installed. The results acquired from these units are directly logged into the Andhra Pradesh PCB server. Moreover, proactive continuous VOC monitoring stations are installed at CPS and three API units to improve the quality of ambient air.
Compliance & BeyondFour of our units are ISO 14001 Environmental Management System certifi ed. We are currently in the process of developing comprehensive internal corporate environmental standards and procedures, which shall provide a framework to:
Assess potential environmental risks associated with our operations
Prevent, mitigate and control environmental damage and possible disasters
Our achievements in setting benchmarks in environmental standards included:
Receiving the Green Manufacturing Excellence Award by M/s. Frost & Sullivan for FTO-3, showcasing sustainable measures incorporated in our manufacturing processes
Rolling out 21 safety and 2 environmental standards to achieve goal “zero” and reduce our resource footprint
Participating in Carbon Disclosure Project (CDP), earning a score of 76 in the assessment and being placed in the Carbon Disclosure Leadership Index
Green Value ChainTo strengthen our position in the Green Value Chain, safety awareness sessions were held at the Leadership Academy with Strategic Business Partners (SBP) and Loan Licensing (LL) sites in November 2013. They covered:
Good safety practices in the manufacture of intermediates and API Products
Need, selection, use, limitation, maintenance and replacement of Personal Protection Equipment (PPE)
Emergency Response (Identifi cation of Emergencies and their mitigation measures)
61 members, including plant head, Engineering and Safety personnel, participated in the training sessions from 27 SBP and LL sites.
Additionally, our Program to achieve Cost and Capabilities Excellence (PACE) initiatives during the year included:
Recovering Acetone which was being sold as a spent solvent in the Clopidogrel EP grade. It was introduced in the CB 23 stage after necessary R&D trials. For Clopidogrel US grade, losses were addressed which resulted in more than 15% improvement in overall recovery
Recycling Acetone used in Losartan for chasing purpose, where only fresh Acetone was used for manufacturing in ESE 24 stage previously, resulted
4ISO 14001 Environmental
Management System
certifi ed units
We replenished fresh water in our
units by completing a rainwater
harvesting survey at CTO-5
and initiating civil works for the
construction of storm water drains.
We encourage our people to be
vocal on issues they feel deeply
about at public forums and help
infl uence policy decisions. Our
technical and commercial teams
participated in many professional
forums, including CII, IPA, Chapters
of ICAI and industry round tables.
45
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
in a more than 50% reduction of total Acetone requirement. After the necessary RA approvals for use of recovered solvent in the API stage, the idea was implemented in October 2013
Implementing process and facility modifi cations in manufacturing and SRS areas for the use of 2-Butanol in the CB 24 stage of Clopidogrel Bisulphate. The modifi cations resulted in substantial improvements in overall recovery and reuse of 2-Butanol
Addressing vent losses in the manufacturing area and improved SRS to enhance overall recovery of Ethyl Acetate used in the LCM 1 and LCM 2 stages in Levitracetum at CTO-6. The ideas were implemented within a very short span of 2 months
Addressing the loss of Tolulene through aqueous layer, condenser and other vent losses in Quetiapine (both CIP and non-CIP process) for improvement of recovery. The project was implemented in September 2013
These initiatives resulted in an overall savings of US$ 3.22 million.
PRINCIPLE 7POLICY ADVOCACYWe encourage our people to be vocal on issues they feel deeply about at public forums and help infl uence policy decisions. During the period under review, our technical and commercial teams participated in many professional forums, including CII, IPA, Chapters of ICAI and industry round tables.
Our Vice-Chairman, Satish Reddy, is the President of the Indian Pharmaceutical Alliance (IPA).
We are members of some of the leading industry bodies and chamber associations in India including:
Confederation of Indian Industry (CII) Federation of Indian Chambers of
Commerce and Industry (FICCI) Indo American Chamber of
Commerce (IACC)
Indian Pharmaceutical Alliance (IPA) Pharmexcil Bulk Drug Manufacturers Association
(BDMA) Indian Drug Manufacturers Association
(IDMA) CII Green Business Centre WWF India Federation of Andhra Pradesh Chambers
of Commerce & Industry (FAPCCI)
PRINCIPLE 8 EQUITABLE DEVELOPMENTAt Dr. Reddy’s, we own social responsibilities with equal passion and professionalism. We leverage our expertise and resources to scrutinize community needs, develop and pilot new projects, scale them up, assess their impact and once proven successful, collaborate with the government and various Non-Governmental Organizations (NGOs) to roll them out.
We engage with the community at two levels: at the vicinity of campuses with the active
involvement of our employees; and at locations, where we lend support to
TOP: Child at a Pudami school run by Dr. Reddy’s Foundation
Non-Profi t Organizations, such as Dr. Reddy’s Foundation (DRF), Naandi Foundation and the Centre for Social Initiative and Management (CSIM).
While we touch several lives in multiple ways, our focus remains on the three main life-altering areas of Livelihoods, Education and Patient Care.
Local interventionsUplifting the health quotient of underprivileged patientsOur patient care initiatives are geared towards making life more comfortable for patients – fi nancially, physically as well as emotionally. A key focus area is cancer care. Our well-thought-out initiatives address every facet of patient care — from accessing quality medications, emotional support, treatment interventions, awareness camps to organizing free check-up camps.
46
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Changing the paradigmsof rural educationWe work to make education more accessible for India’s rural children. We believe interventions (Scholarships for Higher Education, Coaching camps, Distributing learning tools) can improve school infrastructure and educational standards.
Empowering Transformations through SMTsAs India’s fi rst pharmaceutical company to implement a Self-Managed Team (SMT) initiative, we aim to provide employment to youth from economically disadvantaged communities. The recruitment strategy primarily focuses on rural and semi-urban areas, where employability is a challenge. These students earn, while they learn. Our team members are encouraged to pursue higher education on the completion of which they take on higher responsibilities and grow as professionals or entrepreneurs.
Nation-wide InterventionsDr. Reddy’s FoundationDr. Reddy’s Foundation (DRF), the non-profi t arm of Dr. Reddy’s Laboratories, acts as a social change agent, by identifying and pursuing new opportunities to serve the community in two core areas:
LIVELIHOODSOur livelihood programs work towards enhancing the employability of urban and rural youth.
LABS – Our Livelihood Advancement Business School programs are developed for youth between the ages of 18 and 35, who have limited opportunities and inadequate skill sets. To enable these youth to gain a foothold in today’s competitive job market, LABS equips them with job-specifi c skills, soft skills and placement linkages. Currently, DRF operates 75 LABS centers across 19 states and has generated over 2,92,834 livelihoods till date.
Rural Livelihoods Program – In FY2014, 7,639 farmers benefi ted through 5,946 substantive interventions of this program.
TOP: Placeholder Image - TBD
Dr. Reddy’s Mexico took a step forward in encouraging superior academic performance of employees’ children studying from the second grade onwards till the university level. Children with merit, securing a minimum of 8.5 Grade Point were identifi ed in primary, secondary, high school and university levels.
Dr. Reddy’s partnered with Project Nanhi Kali on Facebook. Nanhi Kali is an NGO jointly managed by KC Mahindra Educational Trust and Naandi Foundation. The project provides academic, material and social support to girl children. We launched a Facebook campaign titled ‘Share a Pill of Happiness’ to make a diff erence in the lives of girls in India. The campaign had over 1,000 people participating and helpedDr. Reddy’s contribute `100,000 for the noble cause. The girls of Nanhi Kali interacted with Satish Reddy, Vice-Chairman, who handed over the cheque and some gifts to the special visitors.
SCHOLARSHIPS FOR EMPLOYEES’ CHILDREN
CASE STUDY B
DR. REDDY’S AND NANHI KALI
CASE STUDY C
The meritorious recipients of the scholarships
Nanhi Kalis receiving the cheque
47
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
LABS-PWD – Our LABS-People With Disabilities (PWD) program was successful in generating 1,610 livelihoods during the fi nancial year.
SRI (Skilling Rural India) – Our SRI initiative helps rural youth gain skills, which translate into rural employment generation, despite pressing problems like need for migration, poor income, isolation from family and village life, the tribulations of adjusting to an urban way of life and the poor retention rate. Apart from technical training, the SRI training module also comprises lifeskills training.
EDUCATIONDRF strives to provide various opportunities for learning to those who have never been to school, or have dropped out. It also works to improve the quality of education in schools through diverse initiatives and programs. We work with a well-woven fabric of stakeholders, communities, offi cial institutions and schools to encompass children from all walks of life and to introduce them to mainstream education.
DRF’s education initiatives include:Education Resource Centre (ERC) | Pudami Neighbourhood Schools and English Primaries | Kallam Anji Reddy Vidyalaya (KARV) | Special School for Homeless Children | Kallam Anji Reddy Vocational Junior College (KAR-VJR) | Yuva Youth Learning Centres | Non-Residential Bridge Centres (NRBCs) and Residential Bridge Centres (RBCs).For more details please refer: www.drreddysfoundation.org.
Dr. Reddy’s Foundation for Health Education (DRFHE)DRFHE works in collaboration with the medical fraternity to facilitate an integrated multidisciplinary approach to good health.
EDUCATION AND TRAINING INITIATIVESThe aim of our education and training initiatives is to bring about a transformation in patient care by teaching as well as imparting soft skills and life skills training to healthcare stakeholders via focused programs such as:
Abhilasha which trains nurses to sharpen their skills and self-confi dence
Sarathi which enhances skill-sets of doctors’ assistants
Inner Circle which teaches patient- handling skills to young doctors (PGs)
Sanjeevani which helps pharmacists improve their skills and develop empathy towards customers
Aakriti which empowers dentists to sharpen their skills
Disaster Preparedness Workshop which trains hospital staff towards effi cient crisis management
HEALTHCARE AWARENESSAwareness for Life is aimed at spreading awareness about lifestyle diseases among Corporate India.
PATIENT INITIATIVESLife at Your Doorstep (LAYD) is a well-equipped medical van, which dispatches a team of doctors, nurses and patient counsellors to provide home care for terminally ill patients.
Aastha sensitizes doctors and nurses to palliative care and increases theirawareness levels.For more details, please refer: www.drreddys.com/sustainability/drfhe.asp.
PRINCIPLE 9CUSTOMER VALUEEvery day, our products provide aff ordable medical care and impact the lives of millions of patients, globally. Therefore, we remain committed to ensuring 360o
customer value – safety, effi cacy, cost-competency, accessibility, transparency
7,639Farmers benefi ted through
Rural Livelihoods Program
1,610Livelihoods generated through
LABS-PWD Program
We remain committed to ensuring
3600 customer value – safety,
effi cacy, cost-competency,
accessibility, transparency and
accountability. Pharmacovigilance,
Safety by Design, pharmacopeia
adherence and bioethics are
active ingredients in our product
development formula.
The CSR initiatives undertaken by our
PSAI business were recognized as
‘Asia’s Best CSR Practices for 2013’
by CMO Asia and World CSR Day.
48
HEALTHY FOREVERHEALTHY FOREVER
BUSINESS RESPONSIBILITY REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
and accountability. Pharmacovigilance, Safety by Design, pharmacopeia adherence and bioethics are active ingredients in our product development formula.
The following steps help us ensure that we are worthy of the trust our customers repose in us:
360o Safety CommitmentWhether products or processes – safety comes fi rst at Dr. Reddy’s. We adhere to globally-recognized, safety benchmarks like the International Conference on Harmonization (ICH) guidelines and have instituted a comprehensive safety assurance model that weeds out safety and quality hazards from the development stage of a product to its end distribution.
PharmacovigilanceThe Pharmacovigilance (PV) and Clinical Management groups are key arms of our organization that guard our medicines against adverse eff ects, if any. The Pharmacovigilance team intervenes at an early stage, rather than acting as a watchdog.
We incorporate global Pharmacovigilance mandates across the entire product development lifecycle. We have put in place structured processes to monitor signals and events across the world and identify cause-eff ect relationships. Toll-free numbers have been set up globally, in various countries, to facilitate the reporting of adverse events and a Drug Safety Assessment and Reporting team is in place to administer swift action.
Addressing CounterfeitApart from IP infringements and reputation drain, counterfeit drugs are the biggest risk to a patients’ health, besides causing huge sales losses to the healthcare industry. At Dr. Reddy’s, we have deployed a robust process to prevent counterfeiting of our products. Some of the key systems and initiatives we have instituted to avert this breach include:
Use of a specifi c sequence for batch numbering, manufacturing and expiry date
TOP: Placeholder Image - TBD
On the occasion of World Hypertension Day, Team Aqura-HG launched a leaning initiative called the ‘e-Hypertension Academy’ in Hyderabad. There were 34 eminent cardiologists and 115 consulting physicians who attended the seminar held by the partnership of Association of Physicians in India (API) and Dr. Reddy’s. The objective of the programme was to upgrade the knowledge and expertise of practising physicians in the fi eld of hypertension. The program was webcast live across 50 locations, connecting over 1,200 physicians across India.
The world’s fi rst-of-its-kind country-specifi c online repository on breast cancer (www.ibcr.in) helps facilitate cancer research by assimilating relevant information from various sources. In addition, the information platform maintains contributions from more than 60 oncologists from various parts of India. The insights focus on treatment strategies, side eff ects and management of breast cancer from the Indian perspective.
E-HYPERTENSION ACADEMY
CASE STUDY D
INDIAN BREAST CANCER RESOURCE (IBCR)
CASE STUDY E
Launch of e-Hypertension Academy, Hyderabad
Homepage of IBCR website
49
STATUTORY REPORTS/BUSINESS RESPONSIBILITY REPORT
Use of hologram stickers Employment of specialized printing
techniques to safeguard products from cheap counterfeits
Implementation of a coin reactive zone
Customer AwarenessMedicines are a product category, where even a slight misappropriation of information could lead to fatalities. We ensure that this responsibility towards our customers is demonstrated throughout our marketing and promotional material and all information is provided in an unambiguous and precise manner.
At all times, we seek to engage with our customers in utmost transparency and accountability. We keep them updated about the composition and eff ects of our pharmaceutical products. Literature pertaining to promotional content or any Customer Relationship Management activity, scientifi c seminar and symposium, among others, undergoes a stringent authentication process by our Product Management and Medical Aff airs teams. Our Professional Sales Representatives (PSRs) undergo in-depth training to become well versed with product information and communication skills. Our in-house Medical Aff airs Team addresses queries from PSRs and doctors, regarding our products, within 48 hours.
During FY2014, over 21,000 man-days of training was provided to trainee Professional Sales Representatives (PSRs). Training Managers also provided On-Job-Training (OJT) to select PSRs as joint fi eldwork, amounting to over 500 man-days in FY2014. Additionally, over 4,500 man-days of training was provided to the fi eld force through various e-learning courses.
However, awareness in the healthcare industry is not limited to information printed on packages. It also encompasses social perceptions about medical conditions and debunking myths and fears related to them. Hence, we have multiple initiatives that help generate awareness among people.
PromOTE India is an initiative that encourages early detection, awareness and diagnosis, which helps prolong lives of cancer patients. The initiative works by connecting Oncologists and General Practitioners (GP), which in turn empowers GPs and other non-oncology doctors to detect cancer early. We also run ‘Lymphoma Awareness’, an interactive campaign on radio channels across India, where eminent oncologists address listeners’ queries on the subject.
ROSHINI is an initiative to diagnose all undetected diabetic cases in India. Launched in November 2008, the initiative includes activities like glucose screening camps at doctors’ clinics and talks at schools, which provide children information about diabetes, obesity, diet pattern and physical activities to help prevent diabetes.
50
HEALTHY FOREVERHEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Management Discussion and Analysis
TOP: Technology Development Center, The Netherlands
Notes: (1) FY2014 represents fi scal year 2013-14, from 1 April 2013 to 31 March 2014, and analogously for FY2013 and previously such labeled years. (2) Unless otherwise stated, fi nancial data given in this Management Discussion and Analysis is based on the Company’s consolidated IFRS fi nancial statements.
We are an integrated global pharmaceutical company committed to providing aff ordable and innovative medicines through our three core business segments: Global Generics, Pharmaceutical Services and Active Ingredients and Proprietary Products.
51
STATUTORY REPORTS/MANAGEMENT DISCUSSION AND ANALYSIS
*US dollar values based on the convenience translation rate as on 31 March 2014, i.e. US$ 1 = `60
Global Generics includes our branded and unbranded prescription and Over-The-Counter (OTC) drug products business and also includes the operations of our Biologics business; Pharmaceutical Services and Active Ingredients (PSAI) consists of our Active Pharmaceutical Ingredients (API) and Custom Pharmaceutical Services (CPS) businesses; andProprietary Products comprisesof our New Chemical Entities (NCEs), Diff erentiated Formulations and our dermatology focused specialty business.
We have a presence in the regulated markets such as the United States, the United Kingdom and Germany, as well as in other key markets such as India, Russia, Venezuela, Ukraine, Romania, South Africa and certain countries of the former Soviet Union.
Given below is a brief outline of the businesses. Further details are to be found in subsequent sections of this chapter.
GLOBAL GENERICS (GG)Revenue from Global Generics for FY2014 increased by 27.4% and stood at `105.2 billion — driven largely by North America and the emerging markets.Revenue from North America for FY2014 was ̀ 55.3 billion, recording a year-on-year growth of 46.1%.Growth was largely driven by key ‘complex to make’ products launched during the year. Nine new products were launched during the year; the major ones being decitabine, azacitadine, zolendronic acid (5 mg/100 mL), divalproex ER and donepezil 23 mg. There was also a signifi cant increase in the market share of key existing products such as metoprolol succinate and atorvastatin. FY2014 also saw 13 product fi lings in the USA. Cumulatively, 62 Abbreviated New Drug Applications (ANDAs) are pending for approval from the US Food and Drug Administration (USFDA). Of these, 39 are Para IVs — out of which we believe nine to have ‘First to File’ status.
Revenue from Emerging Markets for FY2014 was `27.2 billion registering a year-on-year growth of 21.1%. Within Emerging Markets:
Revenue from Russia and other CIS markets was `19.8 billion recording a growth of 17.2%.
Revenue from the Rest of World (RoW) territories was `7.4 billion growing at 33%.
Revenue from India for FY2014 was `15.7 billion achieving a growth of 7.9%.
PHARMACEUTICAL SERVICES AND ACTIVE INGREDIENTS (PSAI)
Compared to the previous year, revenue from PSAI in FY2014 declined by 21.9% to `24 billion. This was on account of decreased sales of Active Pharmaceutical Ingredients (APIs) as some of our key customers lost market shares during the year, coupled with lower sales from “launch molecules” vis-à-vis the previous year.
CONSOLIDATED NET REVENUE
`132.2 bn 13.7% YoYUS$ 2.20* billion
EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION (EBITDA)
`33.2 bn 19.3% YoY25% of consolidated revenue
PROFITS BEFORE TAX (PBT)
`26.6 bn 22.7% YoYUS$ 443* million
PROFITS AFTER TAX (PAT)
`21.5 bn 28.2% YoY16% of consolidated net revenue
CASH & CASH EQUIVALENTS AND OTHER INVESTMENTS
`33.5 bn 50.3% YoYas on 31 March 2014 (US$ 559* million)
HIGHLIGHTS FOR FY2014
52
HEALTHY FOREVERHEALTHY FOREVER
MANAGEMENT DISCUSSION AND ANALYSIS
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
During the year, 61 DMFs were fi led globally, including 12 in the US and 13 in Europe. The cumulative number of DMF fi lings as of 31 March 2014 is 631.
OUTLOOK FOR THE GLOBAL PHARMACEUTICAL INDUSTRYThe global pharmaceutical market is expected to reach US$ 1.2 trillion in 2017, up from US$ 0.96 trillion in 2012, growing at the compound annual growth rate (CAGR) of 4.5% over the fi ve-year period.1
Developed markets2 will account for more than half of the business even in 2017, or approximately US$ 668 billion in value.
Simultaneously, with a higher CAGR of around 11.6%, the pharmerging markets3
will signifi cantly increase their share from 23% of the market in 2012 to 32% in 2017.
Refer Chart A.
Over the next few years, diff erent factors will drive growth in developed and pharmerging markets detailed in Table 1:
Another way to look at the growth of the global pharmaceutical market is the mix between branded and generic drugs. Here are the estimates the IIHI provides:
The market for branded drugs is expected to grow modestly to reach US$ 620 billion in 2017.
The generic drugs market is expected to grow at a CAGR of 10.5%, from around US$ 260 billion in 2012 to about US$ 430 billion in 2017.
1 Source: IMS Institute for Health Informatics (IIHI), Global Use
of Medicine: Outlook Through 2017, November 2013.
2 Developed markets are defi ned as the US, Japan, the top fi ve
European countries (i.e. Germany, France, Italy, Spain and the
UK), Canada and South Korea.
3 Pharmerging markets are defi ned as those with more than
US$1 billion absolute spending growth over 2013-17 and
with a GDP per capita of less than US$ 25,000 in terms of
purchasing power parity. These can be classifi ed as: Tier 1
has China; Tier 2 comprises Brazil, India and Russia; Tier
3 consists of Mexico, Turkey, Venezuela, Poland, Argentina,
Saudi Arabia, Indonesia, Colombia, Thailand, Ukraine, South
Africa, Egypt, Romania, Algeria, Vietnam, Pakistan and
Nigeria.
Generic medicines will meet a signifi cant part of increasing global demand, rising from a market share of 27% in 2012 to 36% in 2017.
The share of generics is expected to rise everywhere: (i) in developed markets from 16% in 2012 to 21% in 2017; (ii) in pharmerging markets from 58% to 63%; and (iii) in the rest of the world from 27% to 31%.
Refer Chart B.
OPPORTUNITIESCHANGING DEMANDGrowth will arise from diff erent factors in the developed and pharmerging markets. Major factors shaping demand in developed markets include:
The shift to generics: A large proportion of spending is steadily moving to generic drugs. In the US, 34% of 2012 brand spending, or US$ 83 billion in value, will shift to generics at substantially lower prices. In Canada, this proportion will be 30%. And in other developed markets, 22% of average brand spending will be exposed to generics competition.Increased access to medicines in the US due to healthcare reform:The Patient Protection and Affordable Care Act in the US aims to extend public and private insurance coverage to an increasingly larger share of the population. Once fully implemented, it will increase the access to medicines for the public, which should boost demand.
THE GLOBAL PHARMACEUTICAL
MARKET
US$ BILLION
CHART A
Source: IMS Institute for Health Informatics (IIHI), November 2013.
2012 2017
668622
388
224
144
119
1,200
965
DEVELOPING
PHARMERGING
OTHERS
TABLE 1 GROWTH DRIVERS IN DEVELOPED AND PHARMERGING MARKETSDEVELOPED MARKETS PHARMERGING MARKETSSlow economic recovery Moderate economic growth — but higher than
the developed markets
Fiscal austerity measures affecting
healthcare spends
Government reforms gradually improving
quality and reach of national and sub-national
healthcare systems
Competitive pricing due to growing involvement and
influence of health insurance companies
Improved state and private insurance funding
with wider reach across population groups
Patent expiries resulting in greater generics
penetration
Demographic and epidemiologic changes
Growing availability of lower cost generic substitutes Growing disposable incomes and affluence
Slower uptake of new and more expensive,
innovative medicines
Increasing prevalence of lifestyle related heath
disorders
53
STATUTORY REPORTS/MANAGEMENT DISCUSSION AND ANALYSIS
CUSTOMER CONSOLIDATIONMajor alliances between pharmaceutical wholesalers, distributors and retail chains across the US and parts of Europe will have an impact on demand pattern. These alliances will help large buyers to optimize generic drug purchases through wholesalers selling to distributors and manufacturers selling to wholesalers or distributors. While this trend will erode price points faster than otherwise, it is expected that manufacturers with reliable, high volume and high quality supply will get preferred status.
AGEING POPULATIONImproving medical reach, increasing life expectancy and decreasing mortality along with declining fertility have created ageing populations in developed countries, as well as in some developing countries, such as China. Consider the facts depicted in Chart C.
In 1985, a year after Dr. Reddy’s was founded, the number of people in the world aged 60 years or above was less than 433 million, or 8.9% of the global population. Two decades later, in 2005, the absolute number of people aged 60 years and above exceeded 672 million. This group now accounts for 10.3% of the global population. By 2025, this group will comprise almost 1.2 billion people, or 14.8% of the population. By 2050, there will be over 2 billion such people in the world, accounting for over 21% of the population. This major change will impact both the quantity and the pattern of medicine consumption.
BIOLOGICS AND BIOSIMILARSIncreasing demand for biologic drugs will also drive growth in both developed and pharmerging markets. Medical science has substantiated that, where possible, ‘living cell-based’ therapy can be more eff ective than their chemical drug equivalents in treating complex diseases such as cancer and auto immune disorders. Growth in this sphere is expected to outpace overall pharmaceuticals growth to reach approximately US$ 220 billion in value, or to 20% of the total market value by 2017. This growth will be driven primarily by Monoclonal Antibodies (MAbs) and human insulin.
DEVELOPED
US$ 622 bn
US$ 650-680 bn
2012
2017
72%
67%
16%
21%
12%
12%
PHARMERGING
US$ 224 bn
US$ 370-400 bn
2012
2017
31%
26%
58%
63%
11%
11%
REST OF THE WORLD
US$ 120 bn
US$ 125-155 bn
2012
2017
57%
52%
27%
31%
16%
17%
WORLD
US$ 965 bn
US$ 1,170-1,200 bn
2012
2017
61%
52%
27%
36%
12%
12%
GLOBAL DEMAND FOR
PHARMACEUTICAL PRODUCTS,
2012 AND 2017
%, US$ BILLION
CHART B
OTHERS
GENERIC
BRAND
Source: IMS Health Thought Leadership, September 2013.
Though benefi cial, biologics are large-molecule drugs and are inherently complex to develop and manufacture. This increases the cost for innovator companies and makes treatment very expensive. Very few organizations in the world are capable of developing and making such products. This has begun to open the opportunity for biosimilars, i.e. generic versions of branded biologic drugs. Various developed and developing nations are working on biosimilars approval processes to decrease the cost of treatment.
Currently, biosimilars account for less than 1% of the total branded biologic drug spends in the developed markets and around 10%
of those in pharmerging markets. This will increase signifi cantly in the years ahead.
INCREMENTAL INNOVATIONThere is a recent trend in the industry wherein an increasing number of generic pharmaceutical companies are increasing their portfolio through incremental innovation to create new specialty products that address unmet patient needs. Typically, these are directed towards: (a) known molecules, or those with proven effi cacy, (b) reduced cost and risk of development, (c) shorter timelines and (d) off ering greater convenience and compliance over the existing options. Regarding IP protection in the US, these products are eligible for
GROWTH OF OLDER PEOPLE
’000 persons, % of population ≥ 60
CHART C
Source: United Nations, Population Division, World Population Prospects, The 2012 Revision.
1970
1990
1975
1995
2010
1980
2000
2020
2015
1985
2005
2025
2030
2035
2040
2045
1,500,000
1,000,000
750,000
250,000
1,750,000
2,000,000
2,250,000
500,000
15
12.5
10
0
17.5
20
22.5
7.5
2.5
5
2050
IN ‘0
00
PE
RS
ON
S
% O
F P
OP
ULA
TIO
N ≥
60
POPULATION ≥ 60
% OF POPULATION ≥ 60
54
HEALTHY FOREVERHEALTHY FOREVER
MANAGEMENT DISCUSSION AND ANALYSIS
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
(i) three-year data exclusivity with effi cacy studies and (ii) seven-year orphan indication, where relevant.
In India, Dr. Reddy’s has a similar business model of focusing on incremental innovation. On the global scale, Teva Pharmaceuticals has also announced a similar program.
BUSINESS CONSOLIDATIONRegulatory pressure is building in pharmaceutical industry in terms of (a) development, (b) approval, (c) pricing and (d) cost containment. While the larger companies can access big pockets to combat these forces, the unreliable situation that relatively smaller fi rms face is aggravated by signifi cantly constricted credit. Against this backdrop, many pharmaceutical companies are turning to mergers and acquisitions as a way to bolster their pipelines and improve effi ciencies. This kind of inorganic growth has been quite prevalent in developed markets in the recent past. Now, although at a nascent stage, developing nations too are witnessing similar M&A trends.
CHALLENGESECONOMIC UNCERTAINTYAt the end of the fi fth year since the beginning of the global economic slowdown, macroeconomic indicators are improving, but at a slower than expected rate. Growth is minimal in developed countries and lower-than-expected in developing nations. This has created uncertainty about how global and national economies will shape up in the future — which can directly aff ect healthcare spends as these form a large part of national budgets of almost all developed and some emerging market economies. Various policy approaches ranging from generic-drug preferences to reference or tender-driven pricing models have come into play. These are expected to intensify, with their corresponding impact on the global pharmaceutical industry.
HEIGHTENED REGULATORY OVERSIGHTAcross the globe there has been an increase in the involvement of governments and their regulatory agencies in a number of areas that
technological capabilities, fostering R&D for innovative medicines, protecting the internal market against what it considers unfair competition and others. Such interventions are expected to intensify in some developed and pharmerging markets and, therefore, may aff ect global pharmaceutical companies that export to several regions.
RISING COSTSDeveloping new medicines is becoming an increasingly expensive business, although how expensive, is the subject of fi erce debate. The combination of incremental innovation by key generics players and rising annual average costs per approved new molecule pose a major challenge in the long run, especially for the global pharmaceutical majors in a milieu where most of them are facing imminent falls off the patent cliff .
DR. REDDY’S MARKET PERFORMANCE, FY2014 VERSUS FY2013Refer Table 2 for a snapshot of our geography-wise performance for FY2014.
NORTH AMERICA (NA) GENERICSThe US is the largest pharmaceutical market in the world. Generic penetration in the US has jumped from approximately 70% of prescriptions to around 85% over the last 5 years and is expected to increase further, aided by patent expiries and with health providers and insurers attempting to cut their pharmaceutical costs. The market share in terms of total prescriptions of generics manufactured by Indian companies has increased from around 12% in 2008 to the region of 26% in 2013.
As mentioned in the earlier section, there has been a clear trend towards (a) consolidation among pharmaceutical wholesalers/distributors and pharmacy chains and (b) increasing competition in the generics space. Taken together, these two factors have created pressure on price realization among the existing generic manufacturers.
are impacting the pharmaceutical industry. These include:
Marketing codes: All pharmaceutical companies attempt to update doctors on the latest information about the latest trends, innovations and benefi cial eff ects of newer formulations and injectable products. Dr. Reddy’s, for instance, follows a strict marketing code in dealing with medical practitioners across all geographies that usually exceeds the standards laid down by the national regulators. However, in recent times, governments are putting in place even tighter standards in this area. While we welcome the change in standards as these are intended to safeguard patients’ interests, it needs to be recognized that such interventions impose higher cost of sales.Quality standards: There has been a sharp increase in the frequency of site inspections by international regulatory agencies. Quite often, these are surprise inspections. Any signifi cant slip in standards usually results in an immediate ban on the production unit. It needs emphasizing that Dr. Reddy’s follows strict quality, safety and Good Manufacturing Practice (GMP) standards across all its production facilities, which incorporate regular internal programs on quality and safety awareness and production discipline along with the advice of specialized quality consultants.Barriers to competition: In certain developed and pharmerging nations, there has been a rise in the use of tariffand non-tariff barriers to support domestic manufacturers against foreign competition. These involve raising import duties, prohibiting certain imports and creating price diff erentiation and other interventions to promote locally manufactured products. For example, in 2009, Russia initiated its ‘Pharma 2020’ program with the goal to increase the share of locally produced medicines up to 50%. To achieve this, the program has laid out objectives such as developing the local production and
55
STATUTORY REPORTS/MANAGEMENT DISCUSSION AND ANALYSIS
In such a scenario, Dr. Reddy’s North America Generics (NAG) operations’ revenues increased by 46% to `55,303million in FY2014.
This growth was largely contributed by new product launches, as well as improved market share in key existing moleculessuch as metoprolol succinate and atorvastatin.
Overall, the focus has been on launching diffi cult to make products which are likely to provide a sustainable stream of cash fl ows over the coming years. In this direction, we reached two key milestones in FY2014:a) Laying the foundation for our growing
complex injectable portfolio. Our top fi ve injectable products contributedto more than US$ 200 million for the year.
b) The non-injectable space also saw some good launches, especially divalproex extended release and donepezil 23 mg.
Dr. Reddy’s OTC portfolio continues to be a signifi cant component of the overall performance. We are currently ranked 2nd in the store brand OTC space. This segment is poised for rapid growth in the coming years with increasing coverage and prescription to OTC switches.
Strong capabilities, effi cient processes and systems, established sales and distribution networks and better execution have fuelled this year’s growth. Continued focus on developing niche limited competition products and investing prudently to build capabilities in key areas should continue to aid growth in the foreseeable future.
EMERGING MARKETS: RUSSIA, CIS AND THE REST OF THE WORLD (ROW)RUSSIAAccording to the IMS, the Russian pharmaceutical market is expected to grow at a CAGR of 12% between 2012 and 2017, driven by personal income growth and governmental reforms to increase access to healthcare. In FY2014, however, the nation faced several challenges, three of which are given below.
The Ukraine crisis: There has been an economic slowdown at the start of 2014 as the Ukraine crisis forced investors to pull money out of the country. In the fi rst three months of 2014, the Rouble lost 9% against the US Dollar, making imports more expensive, while investors pulled out some US$ 70 billion out of the country, more than in all of 2013.Business environment: Investments rose by a modest 1.8% in 2013 compared to 9.1% in 2012, largely due to an unpredictable business environment.
TABLE 2 THE COMPANY’S REVENUES ` million
FY2014 FY2013 RATE OF GROWTH,
FY2014 VS. FY2013
` % ` %
Global Generics (GG) 105,164 80% 82,563 71% 27.4%
North America 55,303 53% 37,846 46% 46.1%
Europe 6,970 7% 7,716 9% (9.7%)
India 15,713 15% 14,560 18% 7.9%
Russia and CIS 19,819 19% 16,908 20% 17.2%
Rest of the World (RoW) 7,359 7% 5,533 7% 33.0%
PSAI 23,974 18% 30,702 26% (21.9%)
North America 3,820 16% 5,744 19% (33.5%)
Europe 9,058 38% 12,007 39% (24.6%)
India 3,787 16% 4,638 15% (18.3%)
Rest of the World (RoW) 7,309 30% 8,313 27% (12.1%)
Prop. Products and Others 3,032 2% 3,001 3% 1.1%
Total 132,170 100% 116,266 100% 13.7%
46%Growth in Sales, YoY, to
reach `55.3 billion
9New products launched
13New product fi lings made,
including one New Drug
Application (NDA) under
section 505(b)(2)
NORTH AMERICA GENERICS HIGHLIGHTS
16%Growth in Revenue, YoY, to
reach `16.3 billion
34%OTC sales as a percentage of
total sales. Dr. Reddy’s Rank in
the OTC market improved by 5
positions (IMS Health)
RUSSIA GENERICS HIGHLIGHTS
According to IMS Health,
Dr. Reddy’s sales value and
volume growths for 12 months
ended March 2014 were 7.7%
and 4.1%, respectively versus a
market value growth of 1.9% and
a market volume decline of 5.0%.
56
HEALTHY FOREVERHEALTHY FOREVER
MANAGEMENT DISCUSSION AND ANALYSIS
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Physician-medical representative interaction: Tougher regulations on interaction between pharmaceutical companies and medical professionals will require new access strategies. These involve key account management approaches and, more gradually, greater use of digital communication. Face-to-face detailing will, however, still be critical to the promotion of new drugs.
Taking these factors into consideration, volumes in the Russian pharmaceutical space declined by 5.0% in FY2014 (IMS). Relatively speaking, therefore, Dr. Reddy’s did well with a volume growth of 4.1%. In value terms, our revenues in Russia grew by 16% to `16.3 billion. This growth has been driven by:a) increased market coverage;b) enhanced fi eld force eff ort on the major
brands in the prescription segment; andc) increased focus on the OTC portfolio.
OTC continues to lead the growth at 22% — driven by top brands such as Cetrine and Nise Gel. As per IMS Health, we are the 3rd
fastest growing company among the top 25 in the OTC space and have gained fi ve ranks compared to FY2013. In the prescription segment, we are ranked 13th, with a growth faster than the market both in terms of value and volume.
OTHER CIS COUNTRIESDr. Reddy’s CIS presence is in Ukraine, Kazakhstan, Uzbekistan and Belarus. Revenues from other CIS countries grew by 22% to `3.5 billion in FY2014. Growth in CIS as a whole is largely on account of increasing business in the Ukraine market which remains unaff ected despite serious political issues. The focus area for these markets is on improving the portfolio with diff erentiated prescription and OTC products through both in-house manufacturing and in-licensing deals.
REST OF THE WORLD (ROW)RoW for Dr. Reddy’s includes markets like Venezuela and South Africa which have
experienced high growth rates in the past few years — in addition to Australia, New Zealand and markets in Southeast Asia.
Venezuela has been one of the fastest growing RoW geographies for Dr. Reddy’s with a growth of 53% compared to the previous year. This has taken place notwithstanding numerous challenges such as: (a) sharp currency devaluation, (b) continued protests against the incumbent government, (c) massive infl ation running at over 60% per annum and (d) an unsettled and agitated population due to periodic non-availability of essential goods. Our increased market share has been on account of eff ective sales and marketing eff orts backed by timely supplies.
South Africa reported a moderate growth of 6% in the current year on account of economic challenges leading to market slowdown and limited GDP growth. However, we retained the 9th rank in the overall generics market.
Dr. Reddy’s will continue to grow in these markets on the back of a diff erentiated portfolio introductions and a conscious movement towards the OTC segment over the coming years.
INDIAIndia’s pharmaceutical market is expected to grow at a CAGR of approximately 16%, driven primarily by favorable demographics including country’s aging population, changing disease profi les, growing affl uence and disposable income and increasing provider penetration.
Despite the hit due to price caps on the National List of Essential Medicines, 2013 (NLEM 2013) for some of our larger brands, the growth momentum of Dr. Reddy’s in domestic formulations in FY2014 continued to beat the overall market, as it had in FY2013. According to the IMS report for the trailing 12-month period ended 31 March 2014, the Company’s MAT (Moving Annual Total) sales growth stood at 12.2% against a market growth of 9.9%.
8%Growth in Sales, YoY, to
reach `15.7 billion
11New products launched
including Metsmall® and
Optidoz®
7%Total revenue accounted
for by Biosimilar products
33%Growth in Revenue, YoY,
to reach `7.4 billion
53%Growth in Revenue
from Venezuela despite
a major devaluation of
currency
INDIA GENERICS HIGHLIGHTS
ROW GENERICS HIGHLIGHTS
According IMS Health
data, the Company’s sales
growth for the 12-months
ended March 2014 was
12.2% versus a market
growth of 9.9%.
57
STATUTORY REPORTS/MANAGEMENT DISCUSSION AND ANALYSIS
Dr. Reddy’s India business saw strong performance of the top brands within the portfolio, which contributed close to 50% of sales. More than two-thirds of the top brands beat their respective market growths as refl ected in the IMS data. Even brands aff ected by NLEM 2013 displayed sizable volume growth due to strong price elasticities and specifi c actions to drive market expansion by leveraging lower NLEM 2013-driven prices.
The domestic formulations business launched 11 new products in the market with enhanced emphasis on fi rst-to-market and diff erentiated products. Signifi cant product innovations were introduced such as Optidoz®, which is a unique low dose combination of three anti-hypertensive drugs and Metsmall®, which is a smaller size, easier-to-swallow Metformin tablet to treat Type II diabetes.
In the course of FY2014, we increased our fi eld force coverage in many high-growth, super-specialty areas such as oncology, nephrology, urology, hepatology and rheumatology to drive growth for our diff erentiated products and biosimilars. Additionally, two new sales teams were launched to tap the growth potential from the government institutions and corporate hospitals segments. Multiple technology-based, patient-care services were also piloted for super-specialty drugs and chronic conditions to drive better patient outcomes through therapy adherence and patient counseling.
PHARMACEUTICAL SERVICES AND ACTIVE INGREDIENTS (PSAI)FY2014 was a challenging year for the PSAI business with revenues declining by 22% compared to FY2013. Decreased sales of Active Pharmaceutical Ingredients was primarily due to some of our key customers losing market shares during the year, coupled with lower sales from ‘launch molecules’ vis-à-vis the previous year. The pharmaceutical services business also saw a slowdown in the demand for custom services from some of our innovator company customers. However, being vertically integrated, the API business continues to support our Global Generic launches.
Asia Pacifi c is fast becoming a dominant player in the global API business, both in terms of supply and demand. Countries such as India and China have become global hubs for API outsourcing, primarily due to their low cost of production and strong domestic demand. However, the industry is also facing some challenges, with newer market entrants increasing competition and eroding API prices. Mergers, collaborations, high levels of cost competency and optimal inventory management are strategies that have been noticed across the API industry in order to survive and grow.
Dr. Reddy’s is one of the highest Drug Master File (DMF) fi lers worldwide. During FY2014, we fi led 61 DMFs globally, including 12 in the US, 13 in Europe and 36 in other markets. The cumulative number of DMF fi lings as on 31 March 2014 was 631.
FINANCIALSCONSOLIDATED FINANCIALSTable 3 overleaf gives the abridged IFRS consolidated fi nancial performance ofDr. Reddy’s for FY2014 compared to FY2013.
REVENUESRevenues increased by 14% to `132,170million in FY2014. Revenue growth was largely driven by our Global Generics segment’s operations in the US and ‘Emerging Markets’ (which comprises Russia, other countries of the former Soviet Union and certain other countries from our Rest of the World markets).
GROSS PROFITGross profi t rose by 25% to `75,801 million in FY2014. This translates to a gross profi t margin of 57.4% in FY2014 versus 52.1% in FY2013. The gross profi t margin for Global Generics was 65.8%; and for the PSAI business, it was 20.2%. After accounting for the favorable currency eff ect in FY2014, the factors that positively aff ected gross profi t margins for the Global Generics segment were:
higher contribution from new product launches with better margins; and
22%Decline in Revenue, FY2014
`24 billion
18%Of the Company’s total revenue
contributed by PSAI
631Cumulative DMF fi lings as on 31
March 2014
3rd
Largest API seller in the world
PSAI HIGHLIGHTS
Sales of ‘launch molecules’ refer to sales of API to generic
customers to support their generic product launches related to
impending patent expirations.
58
HEALTHY FOREVERHEALTHY FOREVER
MANAGEMENT DISCUSSION AND ANALYSIS
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
TABLE 3 CONSOLIDATED FINANCIAL PERFORMANCE ACCORDING TO IFRS ` million
PARTICULARSFY2014 FY2013
GROWTH %` MILLION % ` MILLION %
Revenues 132,170 100% 116,266 100% 14%
Cost of revenues 56,369 43% 55,687 48% 1%
Gross profit 75,801 57% 60,579 52% 25%
OPERATING EXPENSES
Selling, general and administrative expenses 38,783 29% 34,272 29% 13%
Research and development expenses 12,402 9% 7,674 7% 62%
Other operating (income)/expense (1,416) (1%) (2,479) (2%) (43%)
Results from operating activities 26,032 20% 21,112 18% 23%
Net finance income 400 0% 460 0% (13%)
Share of profit of equity accounted investees, net of income tax 174 0% 104 0% 67%
Profit before tax 26,606 20% 21,676 18% 23%
Tax expense (5,094) (4%) (4,900) (4%) 4%
Profit for the year 21,512 16% 16,776 14% 28%
Diluted EPS (` per share) 126.04 98.44 28%
higher price realizations from existing products.
Similarly, factors that negatively aff ected gross profi t margins for the PSAI segment were:
increased pricing pressures on key products; and
decrease in the proportion of sales of higher gross margin products.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (SG&A)SG&A expenses including amortization increased by 13% to `38,783 million in FY2014. This was primarily due to the rise in manpower expenses, sales and marketing costs and the unfavorable eff ect of the rupee depreciating against multiple currencies. SG&A expenses accounted for 29.3% of sales in FY2014 and has improved marginally as compared to FY2013 .
R&D EXPENSESR&D expenses increased by 62% to `12,402million in FY2014 and accounted for 9.4% of sales, compared to 6.6% in FY2013. This increase is in line with the Company’s eff orts to focus on the development of a specialized pipeline consisting of niche and diff erentiated products.
NET FINANCE INCOMENet fi nance income was `400 million in FY2014 versus `460 million in FY2013.
INCOME TAXIncome tax expense was `5,094 million in FY2014, with an eff ective tax rate of 19.1%, compared to `4,900 million with an eff ective tax rate of 22.6% in FY2013.
NET PROFITNet profi t increased by 28% to `21,512 million in FY2014. This represents a PAT margin of 16.3% of revenues, versus 14.4% in FY2013.
LIQUIDITY AND CAPITAL RESOURCESCash generated from operating activities in FY2014 was `19,463 million. Investing activities includes investment in property, plant, equipment and intangibles of `10,627million, to build capacity and capabilities for future business growth, with the residual being net purchase of investment securities. Cash outfl ow from fi nancing activities was `217 million. Table 4 gives data on consolidated cash fl ows and Table 5 onconsolidated working capital.
DEBT-EQUITYIn FY2014, long-term borrowings including the current and non-current portion increased by `6,371 million. Short-term borrowings rose by `1,611 million. As on 31 March 2014, the Company’s debt to equity position was at 0.49 as compared to 0.50 last year. The net debt to equity position was at 0.12 versus 0.20 last year. Table 6 gives the data.
INTERNAL CONTROLSDr. Reddy’s has a widespread system of internal controls with the objective of safeguarding the Company’s assets, ensuring that transactions are properly authorized and provide signifi cant assurance at reasonable cost of the integrity, objectivity and reliability of fi nancial information.
TABLE 4 CONSOLIDATED CASH FLOW UNDER IFRS ` million
PARTICULARS FY2014 FY2013
Opening cash and cash equivalents 5,054 7,379
Cash flows from:
(a) Operating activities 19,463 13,317
(b) Investing activities (16,620) (13,944)
(c) Financing activities (217) (1,792)
Effect of exchange rate changes 771 94
Closing cash and cash equivalents 8,451 5,054
59
STATUTORY REPORTS/MANAGEMENT DISCUSSION AND ANALYSIS
TABLE 5 CONSOLIDATED WORKING CAPITAL ` million
PARTICULARS AS ON31 MARCH 2014
AS ON31 MARCH 2013 CHANGE
Accounts Receivable (A) 33,037 31,972 1,065
Inventories (B) 23,992 21,600 2,392
Trade Accounts Payable (C) 10,503 11,862 (1,359)
Operating Working Capital (A+B-C) 46,526 41,710 4,816
Other Current Assets (D) 46,718 32,142 14,576
Total Current Assets (A+B+D) 1,03,747 85,714 18,033
Short and long term-loans and borrowings, current portion (E) 24,002 24,135 (133)
Other Current Liabilities (F) 19,558 18,094 1,464
Total Current Liabilities (C+E+F) 54,063 54,091 (28)
TABLE 6 DEBT AND EQUITY POSITION ` million
PARTICULARS AS ON31 MARCH 2014
AS ON31 MARCH 2013 CHANGE
Total stockholders’ equity 90,801 72,805 17,996
Long-term debt (current portion) 3,395 5,139 (1,744)
Long-term debt (non-current portion) 20,740 12,625 8,115
Short-term borrowings 20,607 18,996 1,611
Total debt 44,742 36,760 7,982
IGAAP STANDALONE PROFIT AND LOSSTable 7 gives the Company’s IGAAP standalone profi t and loss for FY2014 compared to FY2013.
TABLE 7 IGAAP STANDALONE FINANCIALS ` million
PARTICULARS FY2014 FY2013 CHANGE
Net sales/income from operations (Net of excise duty) 94,957 80,744 14,213
License fees and service Income 1,511 1,703 (192)
Other Income 2,327 3,310 (983)
Total Income 98,795 85,757 13,038
EXPENSES
a) Cost of materials consumed 22,480 23,409 (929)
b) Purchase of stock-in-trade 4,690 3,931 759
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,706) (1,006) (700)
d) Research and development expenses 9,982 6,509 3,473
e) Employee benefits expense 11,849 11,381 468
f) Selling expenses 8,990 7,668 1,322
g) Provision for decline in the value of long-term investments, net 245 223 22
h) Other expenditure 13,133 12,368 765
i) Depreciation and amortization 3,805 3,128 677
j) Finance Costs 783 614 169
Profit before tax 24,544 17,532 7,012
Tax Expense 5,216 4,877 339
Profit for the year 19,328 12,655 6,673
60
HEALTHY FOREVERHEALTHY FOREVER
MANAGEMENT DISCUSSION AND ANALYSIS
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
The management duly considers and takes appropriate action on recommendations made by the statutory auditors, internal auditors and the independent Audit Committee of the Board of Directors. Details on internal controls is given in the chapter on Corporate Governance.
ENTERPRISE-WIDE RISK MANAGEMENT (ERM)Dr. Reddy’s follows the COSO-ERM framework. The ERM function operates with the following objectives:
Proactively identify and highlight risks to the right stakeholders
Facilitate discussions around risk prioritization and mitigation
Provide a framework to assess risk capacity and appetite; and develop systems to warn when the appetite is getting breached
Provide an analysis of residual risk
The ERM team connects with business units and functions who are the primary source for risk identifi cation. It also regularly monitors external trends on liabilities and litigations as well as risks reported by peers.
RISK IDENTIFICATION AND MITIGATION AT THE BUSINESS UNIT OR FUNCTION LEVELThe ERM team conducts interviews, on-call discussions and facilitates polls to enable prioritization at the unit/function level. While the Company also has a functionally independent assurance process for compliance and fi nancial reporting under the Sarbanes-Oxley Act (SOX), the team focuses on identifi cation of business, operational and strategic risks.
Mitigation plans for the key business risks are identifi ed, along with timelines and owners. The ERM team periodically examines the mitigation process through discussions or reviews and these observations are discussed with the Company’s Management. Detailed polls and interviews are carried out once every two
years; and risk registers are updated with the new and/or emerging risks.
RISK AGGREGATION, PRIORITIZATION AND MITIGATION AT THE ORGANIZATIONAL LEVELRisks are aggregated at the unit/function and organization level by risk groups. There are some 60 such groups across the categories of (i) strategic, (ii) operational, (iii) fi nancial and (iv) compliance. A management-level Risk Committee comprising of business segment heads, fi nance, legal, HR, safety, pharmacovigilance and quality is entrusted to rank and prioritize organization-wide risks, review these and steer mitigation eff orts in line with the Company’s risk capacity and appetite.
Progress on risk mitigation, risk transfer and insurance initiatives are reviewed by the Finance Investment and Risk Management Council (FIRM Council) which is also responsible for fi nancial investments and capital allocation decisions.
REVIEWING THE STATUS OF MITIGATION AND RESIDUAL RISKSThe ERM function’s responsibility is to provide a periodic review of (i) risks identifi ed and prioritized across the Company, (ii) any breaches and how these have been dealt with, (iii) the status of mitigation and (iv) residual risks.
The Head of Dr. Reddy’s ERM team provides periodic updates to the Risk Committee of the Board of Directors. These include:a) Quarterly – on the status of key de-
risking initiatives and new initiatives or projects taken up by the ERM team
b) Annually – on key risks and their movement compared to previous years including the residual risks
During FY2014, the ERM team supported a pilot roll-out on business continuity planning across three Indian units of the Company. The exercise helped in understanding and planning for crisis. Learnings from this pilot shall be used for subsequent roll-out across
the rest of the organization. The ERM team also automated and expanded the Key Risk Indicator tracking process as well as its metrics to enable a uniform global roll-out across the Company and thus integrate risk management as a part of Dr. Reddy’s quantifi able and measurable strategy.
PEOPLE: HUMAN RESOURCES (HR) AT DR. REDDY’SWe strive to understand the ethos and cater to the requirements of our diverse yet unifi ed workforce. We currently stand at more than 19,000 employees worldwide of which around 2,800 are located outside India. We emphasize sound people practices that equip our people to succeed.
We were recognized as the Best Place to Work among biotech and pharmaceutical companies in India in the Great Places to Work ranking for 2013. In addition, Dr. Reddy’s was ranked 5th among companies having over 10,000 employees.
In FY2014, we launched our global recognition platform, ‘Well Done’. The program enables managers and colleagues to recognize and reward good work and foster a culture of appreciation.
Our focus continues to be on leadership development and talent management. With the objective of continually building leaders, we have customized and rolled out a leadership development program at Hyderabad, with the unique feature of individual breakthrough projects that participants complete during the course.
Our Annual Leadership Summit conducted in FY2014 was on ‘Delivering Industry Leading Growth’. Top leaders attended this program to put together our strategy for the coming year. A drive to simplify processes this year focused on employee touch-points, interactions with partners and all other processes with the aim of increasing ease and productivity. Our productivity has also improved by using overall equipment
61
STATUTORY REPORTS/MANAGEMENT DISCUSSION AND ANALYSIS
eff ectiveness metrics including HR inputs such as measuring and optimizing manpower availability and staffi ng.
OUTLOOKThe Company believes that its focus on profi table growth and targeting a leadership position in GG and PSAI will create signifi cant value in the near term.
In GG, improving depth through portfolio expansion, cost leadership, consistent delivery of limited competition products and supply chain excellence should lead to a leadership position in key markets. In PSAI, the objective is to be the partner of choice by creating compelling value for customers through leveraging IP, technology and cost leadership. In Proprietary Products, the aim is to create a viable business by calibrating investments to produce a self sustainable model.
The Company has a positive outlook for the next year. The largest increment of growth is expected to be contributed by the North America Generics and the Emerging Markets businesses.
In a dynamic business environment, the Company’s base business model in pharmaceuticals is exposed to considerable volatility, both upwards and downwards. While the upsides create non-linear value for the organization, there is a conscious attempt to protect it against the downsides.
CAUTIONARY STATEMENTThe management of Dr. Reddy’s has prepared and is responsible for the fi nancial statements that appear in this report. These fi nancial statements are in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board and accounting principles generally accepted in India and therefore include amounts based on informed judgments and estimates. The management also accepts responsibility for the preparation of other fi nancial information that is included
in this report. This write-up includes some forward-looking statements, as defi ned in the US Private Securities Litigation Reform Act of 1995. The management has based these forward-looking statements on its current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to diff er materially. These factors include, but are not limited to, changes in local and global economic conditions, the Company’s ability to successfully implement its strategy, the market’s acceptance of and demand for its products, growth and expansion, technological change and exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially diff erent from actual results in the future.
62 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVERHEALTHY FOREVER
CorporateGovernance
Dr. Reddy’s Laboratories Limited(Dr. Reddy’s or the Company) believes that timely disclosures, transparent accounting policies and a strong and independent Board go a long way in maintaining good corporate governance, preserving shareholders’ trust and maximizing long-term corporate value.
Given the Company’s size and complexity in operations, Dr. Reddy’s corporate governance framework is based on the following principles:
Appropriate composition and size of the Board, with each Director bringing in key expertise in diff erent areas
Proactive fl ow of information to the members of the Board and Board Committees to enable eff ective discharge of fi duciary duties
Ethical business conduct by the Board, management and employees
Well-developed systems and processes for internal controls across all operations, risk management and fi nancial reporting
Timely and accurate disclosure of all material operational and fi nancial information to the stakeholders
In India, the Securities and Exchange Board of India (SEBI) regulates corporate governance for listed companies through Clause 49 of its Listing Agreement. Dr. Reddy’s is in full compliance with Clause 49. It is also in compliance with the applicable corporate governance standards of the New York Stock Exchange (NYSE).
This chapter of the annual report together with information given under the chapters entitled Management Discussion and Analysis and Additional Shareholders’ Information constitute the compliance report of the Company on corporate governance during FY2014.
BOARD OF DIRECTORSCOMPOSITIONAs on 31 March 2014, the Board ofDr. Reddy’s had 10 Directors, comprising (i) two Executive Directors, including the Chairman, and (ii) eight Independent Directors as defi ned under SEBI’s Clause 49 of the Listing Agreement and the Corporate Governance Guidelines of the NYSE Listed Company Manual. Detailed profi les of the Directors have been discussed in thisannual report.
The Directors have expertise in the fi elds of strategy, management, fi nance, operations, science, technology, human resource development and economics. The Board provides leadership, strategic guidance, objective and independent views to the Company’s management while discharging its fi duciary responsibilities, thereby ensuring that the management adheres to high standards of ethics, transparencyand disclosure.
Each Director informs the Company on an annual basis about the Board and Board Committee positions he/she occupies in other companies including chairmanships and notifi es changes during the term of their directorship in the Company. Table 1 gives the composition of Dr. Reddy’s Board, their positions, relationship with other Directors, date of joining the Board, other Directorships and memberships of Committees held by each of them.
TERM OF BOARD MEMBERSHIPThe Board, on the recommendations of the Nomination, Governance and Compensation Committee, considers the appointment and re-appointment of Directors.
According to the Companies Act, 1956, one-third of the Board members (other
FY2014 represents fi scal year 2013-14, from 1 April 2013 to 31 March 2014. Analogously for FY2013 and previously such labeled years.
63
STATUTORY REPORTS/CORPORATE GOVERNANCE
Further, all Independent Directors (including existing Independent Directors) are also required to be appointed expressly under the provisions of the Companies Act, 2013.
In view of the above, approval of the shareholders is being sought for:i. The re-appointment of such
Independent Directors of the Company who are coming up for retirement this year, to hold offi ce for the period from 31 July 2014, the date of the Company’s Annual General Meeting (AGM) as stated in their respective resolutions.
ii. The appointment of other existing Independent Directors of the Company, under Section 149 of the Companies Act, 2013 from 31 July 2014 to hold offi ce for the period as stated in their respective resolutions.
iii. Variation of the terms of appointment of the Executive Directors for making their offi ce liable to retire by rotation.
SELECTION AND APPOINTMENTOF NEW DIRECTORSInduction of any new member on the Board of Directors is the responsibility of the
Nomination, Governance and Compensation Committee, which is entirely composed of Independent Directors.
Taking into account the existing composition and organization of the Board, and the requirement of new skill sets, if any, the Nomination, Governance and Compensation Committee reviews potential candidates in terms of their expertise, skills, attributes, personal and professional backgrounds and their ability to attend meetings in India. The Committee then places the details of such candidates that meet these criteria to the Board of Directors for its consideration. If the Board approves, the person is appointed as an Additional Director, subject to the approval of shareholders in the Company’s general meeting.
DIRECTORS’ SHAREHOLDINGIN THE COMPANYTable 2 gives details of shares held by the Directors as on 31 March 2014.
than Executive Directors) who are subject to retire by rotation, retire every year and, if eligible, approval of shareholders is sought for the re-appointment of such retiring members. Executive Directors are appointed by shareholders for a maximum period of fi ve years at a time, and, if recommended by the Board and approved by shareholders, are eligible for re-appointment upon completion of their term.
Eff ective 1 April 2014, Section 149 of the Companies Act, 2013 provides that an Independent Director shall hold offi ce for a term of up to fi ve consecutive years on the Board of a Company and shall be eligible for re-appointment on passing of a special resolution by the shareholders of the Company. However, such Independent Directors shall be eligible for only two such successive terms. Section 152 of the Companies Act, 2013 (eff ective 1 April 2014), states that one-third of the Board members other than Independent Directors who are subject to retire by rotation, shall retireevery year and shall be eligible for re-appointment, if approved by the shareholders at their meeting.
TABLE 1 COMPOSITION OF DR. REDDY’S BOARD AND OTHER DIRECTORSHIPS HELD AS ON 31 MARCH 2014
NA
ME
PO
SIT
ION
RE
LA
TIO
NS
HIP
WIT
H O
TH
ER
DIR
EC
TO
RS
DA
TE
OF
JOIN
ING
DIR
EC
TO
RS
HIP
SIN
IN
DIA
U/S
. 27
5 O
F T
HE
CO
MP
AN
IES
AC
T, 1
956
OT
HE
RD
IRE
CT
OR
SH
IPS
(1)
CO
MM
ITT
EE
ME
MB
ER
SH
IP(2
)
CH
AIR
MA
NS
HIP
IN
CO
MM
ITT
EE
S(2
)
Mr. G V Prasad Chairman and CEO Brother-in-law ofMr. Satish Reddy
8 April 1986 9 32 1 1
Mr. Satish Reddy Vice-Chairman & Managing Director
Brother-in-law ofMr. G V Prasad
18 January 1993 13 41 21
Dr. Omkar Goswami Independent Director None 30 October 2000 10 2 7 3
Mr. Ravi Bhoothalingam Independent Director None 30 October 2000 2 - 1 2
Mr. Anupam Puri Independent Director None 4 June 2002 4 1 2 -
Dr. J P Moreau Independent Director None 18 May 2007 1 2 - -
Ms. Kalpana Morparia Independent Director None 5 June 2007 3 3 1 1
Dr. Bruce L A Carter Independent Director None 21 July 2008 1 4 - -
Dr. Ashok S Ganguly Independent Director None 23 October 2009 2 2 - -
Mr. Sridar Iyengar Independent Director None 22 August 2011 5 8 - 4
(1)Other Directorships are those, which are not covered under Section 275 of the Companies Act, 1956. (2)Membership/Chairmanship in Audit and Shareholders’ Grievance Committees of all public limited companies, whether listed or not, including Dr. Reddy’s are considered. Foreign companies, private limited companies and companies under Section 25 of the Companies Act, 1956 have been excluded.
64
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
MEETINGS OF THE BOARDThe Company plans and prepares the schedule of the Board and Board Committee meetings in advance to assist the Directors in scheduling their program. The schedule of meetings and their agenda are fi nalized in consultation with the Chairman and Directors of Dr. Reddy’s. The agenda are pre-circulated with presentations, detailed notes, supporting documents and executive summaries.
Under Indian law, the Board of Directors must meet at least four times a year, with a maximum gap of four months (revised to one hundred and twenty days eff ective 1 October 2014) between two Board meetings. Dr. Reddy’s Board met fi ve times during the fi nancial year under review: on 14 May 2013, 30 July 2013, 19 August 2013, 31 October 2013 and 11 February 2014. The Company
held a minimum of one Board meeting in each quarter as required under Indian law. Details of Directors and their attendance in Board meetings and Annual General Meeting are given in Table 3.
The Board and its Committee meetings at Dr. Reddy’s typically comprise two-day sessions. In the course of these meetings, the business unit heads and key functional heads personnel make presentations to the Board and its Committees. The Board is updated on the discussions at the Committee meetings and their recommendations through the chairpersons of the respective Committees.
INFORMATION GIVENTO THE BOARDThe Company provides the following information to the Board and the Board
Committees, which are given either as part of the agenda papers in advance of the meetings or by way of presentations and discussion material during the meetings.
Annual operating plans and budgets, capital budgets and other updates
Quarterly, half-yearly and annual results of the Company and its operating divisions or business segments
Detailed presentations on the progress in research and development (R&D) and new drug discoveries
Minutes of meetings of the Audit Committee and other Committees ofthe Board
Information on recruitment and remuneration of key executives below the Board level including appointment or removal of Chief Financial Offi cer and the Company Secretary
Signifi cant regulatory matters concerning Indian or foreign regulatory authorities
Issues, which involves possible public or product liability claims of a substantial nature, if any
Risk analysis of various products, markets and businesses
Detailed analysis of potential acquisition targets or possible divestments
Details of any joint venture or collaboration agreements
Transactions that involve substantial payment towards, or impairment of, goodwill, brand equity or intellectual property
Signifi cant sale of investments, subsidiaries, assets, which are not in the normal course of business
Contracts in which Director(s) are interested
Materially important show cause, demand, prosecution and penalty notices, if any
Fatal or serious accidents or dangerous occurrences, if any
Signifi cant effl uent or pollution problems, if any
TABLE 2 SHARES HELD BY THE DIRECTORS AS ON 31 MARCH 2014
NAME NO. OF SHARES/ADRs HELD
Mr. G V Prasad(1) 1,365,840
Mr. Satish Reddy(1) 1,205,832
Dr. Omkar Goswami 22,800
Mr. Ravi Bhoothalingam 22,800
Mr. Anupam Puri (ADRs) 21,300
Dr. J P Moreau (ADRs) -
Ms. Kalpana Morparia 10,800
Dr. Bruce L A Carter (ADRs) 11,800
Dr. Ashok S Ganguly 4,800
Mr. Sridar Iyengar -
(1)APS Trust owns 83.11% of Dr. Reddy’s Holdings Limited, which in turn owns 39,729,284 shares of Dr. Reddy’s Laboratories Limited.
Mr. G V Prasad, Mr. Satish Reddy, Ms. G Anuradha, Ms. Deepti Reddy and their bloodline descendants are the benefi ciaries of APS Trust.
TABLE 3 DIRECTORS’ ATTENDANCE AT DR. REDDY’S BOARD MEETINGS AND AGM HELD DURING FY2014
NAME
MEETINGSHELD IN
DIRECTOR’S TENURE
NUMBER OF BOARD
MEETINGS ATTENDED
ATTENDANCEIN LAST
AGM ON31 JULY 2013
Mr. G V Prasad 5 5 Present
Mr. Satish Reddy 5 5 Present
Dr. Omkar Goswami 5 4(1) Present
Mr. Ravi Bhoothalingam 5 5 Present
Mr. Anupam Puri 5 5 Present
Dr. J P Moreau 5 5 Present
Ms. Kalpana Morparia 5 4(1) Present
Dr. Bruce L A Carter 5 5 Present
Dr. Ashok S Ganguly 5 5 Present
Mr. Sridar Iyengar 5 5 Present
(1)Given leave of absence on request.
65
STATUTORY REPORTS/CORPORATE GOVERNANCE
Materially relevant default in fi nancial obligations to and by the Company or substantial non-payment for goods sold by the Company, if any
Signifi cant labor problems and their proposed solutions, if any
Signifi cant development in the human resources and industrial relations fronts
Quarterly details of foreign exchange exposure and the steps taken by management to limit the risks of adverse exchange rate movement
Non-compliance of any regulatory or statutory nature or listing requirements as well as shareholders’ services such as non-payment of dividend and delays in share transfer, if any
Subsidiary companies minutes, fi nancial statements and signifi cant transactions & investments
Signifi cant transactions and arrangements
POST MEETINGFOLLOW-UP MECHANISMThe important decisions taken at the Board/Board Committees’ meetings are communicated to the concerned departments/divisions promptly. An action taken/status report on the decisions of the previous meeting(s) is placed at the next meeting of the Board/Board Committees for information and further recommended action(s), if any.
MEETINGS OF INDEPENDENT DIRECTORS IN EXECUTIVE SESSIONDuring FY2014, the Independent Directors of Dr. Reddy’s met four times in executive sessions without the presence of management. In addition to these four, the Company is ready to facilitate such sessions as and when required by the Independent Directors. An Independent Director, with or without other Independent Directors, takes the lead to provide structured feedback to the Board about the key elements that emerge out of these executive sessions.
ANNUAL BOARD RETREATDuring FY2014, the Annual Board Retreat was organized at Princeton, USA on 19-21 August 2013. In the retreat, the Board discussed various business strategies and governance matters. As a part of the retreat agenda, the Board conducted a strategy review of the Company’s business segments. Presentations were also made on topics covering global pharmaceutical trends.
DIRECTOR’S REMUNERATIONThe Executive Directors are appointed by shareholders’ resolution for a period of fi ve years. No severance fees is payable to the Executive Directors. Except the commission payable, all other components of remuneration to the Executive Directors are fi xed and in line with the Company’s policies.
The remuneration for the Executive Directors, including the commission based on net profi ts of the Company, is recommended by the Nomination, Governance and Compensation Committee to the Board for consideration. The commission to be paid to the Executive Directors is decided by the Board every year, within the limits approved by the shareholders.
Independent Directors are entitled to receive sitting fees for attending meetings of the Board and its Committees, as well as commission based on the net profi ts of the Company. The remuneration including commission payable to the Directors during the year under review is in conformity with the applicable provisions of the Companies Act, 1956, and duly considered and approved by the Board and the shareholders. The remuneration paid or payable to the Directors for FY2014 is given in Table 4.
The criteria for making payments to the Executive Directors are:
Salary, as recommended by the Nomination, Governance and Compensation Committee and approved by the Board and the shareholders. Perquisites and retirement benefi ts are also paid in accordance with the Company’s compensation policies, as applicable to all employees
TABLE 4 REMUNERATION PAID OR PAYABLE TO THE DIRECTORS FOR FY2014 (` ‘000)
NAME OF DIRECTORS COMMISSION(1) SALARIES PERQUISITES(2) TOTAL
Mr. G V Prasad 100,000 6,300 3,164 109,464
Mr. Satish Reddy 100,000 7,650 6,989 114,639
Dr. Omkar Goswami 9,157 - - 9,157
Mr. Ravi Bhoothalingam 9,462 - - 9,462
Mr. Anupam Puri 11,446 - - 11,446
Dr. J P Moreau 9,920 - - 9,920
Ms. Kalpana Morparia 9,157 - - 9,157
Dr. Bruce L A Carter 10,225 - - 10,225
Dr. Ashok S Ganguly 9,767 - - 9,767
Mr. Sridar Iyengar 10,530 - - 10,530
Notes: (1)Payment of commission is variable, and based on percentage of net profi t calculated according to Sections 198/349 of the Companies Act, 1956. The Board of Directors recommended for a fi xed commission of `6,714,950 (US$ 110,000) per Independent Director; a specifi c commission of `1,220,900 (US$ 20,000) to the Chairman of the Audit Committee; `915,675 (US$ 15,000) to the Chairman of Science, Technology and Operations Committee, Nomination, Governance and Compensation Committee and Risk Management Committee; `610,450 (US$ 10,000) to the other members of the Committees; `1,220,900 (US$ 20,000) to the Lead Independent Director and `305,225 (US$ 5,000) variable fee per meeting based on the attendance at the Board meeting to every Non-executive Director. Other than the above, a specifi c compensation of `91,568 (US$ 1,500) per meeting was paid towards foreign travel to the Directors.
(2)Perquisites include medical reimbursement for self and family according to the rules of the Company, leave travel assistance, personal accident insurance, Company’s vehicle with driver for offi cial use, telephone at residence and mobile phone, contribution to Provident Fund and Superannuation Scheme. All these benefi ts are fi xed in nature.
66
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Commission on profi ts, as recommended by the Nomination, Governance and Compensation Committee and approved by the Board and shareholders of the Company subject to (i) the percentage of net profi ts calculated in line with Sections 198 and 349 of the Companies Act, 1956, and (ii) approval of the shareholders
Remuneration paid to the Executive Directors is determined by keeping in view the industry benchmarks
The criteria for making payments to the Independent Directors are:
The shareholders of the Company have approved the payment of commission up to 0.5 percent of net profi ts calculated in accordance with Sections 198/349 of the Companies Act, 1956 collectively to all the Independent Directors
The Board decides the amount of commission payable to Independent Directors every year, within the overall limit of 0.5 percent of net profi ts and in line with the Company’s performance. The compensation is also benchmarked with some top Indian companies
Remuneration paid to Independent Directors is determined by keeping in view the industry benchmarks, and also based on their memberships in various committees of the Board
Shareholders of the Company approved granting of up to 200,000 stock options in aggregate at any point of time during the fi nancial years starting from 2011-12 and ending with 2015-16 to all the Directors (except the Executive Directors). Of this, up to 60,000 stock options can be granted in a single fi nancial year to the Directors, as previously mentioned, under any of the stock option plans, either existing or to be framed in future, on such terms and conditions as the Nomination, Governance and Compensation Committee/Board of Directors may think fi t. However, Section 197 of the Companies Act, 2013 eff ective 1 April 2014 and revised Clause 49 of the
Listing Agreement eff ective 1 October 2014, prohibits granting of stock options to Independent Directors.
INDEPENDENT DIRECTORSThe Independent Directors of the Company head the following governance and/or Board Committee functions:
Mr. Anupam Puri: Governance, corporate strategy and Lead Independent DirectorDr. Bruce L A Carter: Enterprise risk managementDr. Ashok S Ganguly: Science, technology and operationsMr. Sridar Iyengar: Chairman of the Audit Committee, hence, all fi nancial and audit matters that fall under the remit of the CommitteeMs. Kalpana Morparia: Internal audits and controlsDr. Omkar Goswami: Financial risk management, subsidiary fi nances and compliance with Section 404 of the US Sarbanes-Oxley Act, 2002Mr. Ravi Bhoothalingam:Compliance and Ombudsperson for the whistle blower policy of the CompanyDr. J P Moreau: Pharmaceutical regulatory compliance
RISK MANAGEMENTThe Company has in place an enterprise-wide risk management (ERM) system. An independent Risk Management Committee of the Board oversees and reviews the risk management framework, assessment of risks, their management and minimization procedures. The Committee reports its findings and observations to the Board. A section on risk management practices of the Company under the ERM framework forms a part of the chapter on Management Discussion and Analysis in this annual report.
COMPLIANCE REVIEWSDr. Reddy’s has a dedicated team under an identifi ed Chief Compliance Offi cer for overseeing compliance activities — which includes monitoring, and a defi ned
framework to review compliances with all laws applicable to the Company. The compliance status is periodically updated to the senior management team including the CEO and the COO through forums and review meetings. Presentations are scheduled in the quarterly Audit Committee meetings regarding the status on compliance.
CODE OF BUSINESS CONDUCT AND ETHICS AND OMBUDSPERSON PROCEDUREThe Company has adopted a Code of Business Conduct and Ethics (the Code), which applies to all its Directors and employees of the Company, its subsidiaries and affi liates. It is the responsibility of all Directors and employees to familiarize themselves with this Code and comply with its standards. The Board and the senior management across the globe annually affi rm compliance with the Code. A certifi cate of the Chairman and CEO of the Company to this eff ect is enclosed as Exhibit 1 to this chapter.
An Ombudsperson procedure has also been made under this Code, which:a) describes the Ombudsperson
framework;b) takes into account procedures for
investigation and communication of any report on any violation or suspected violation of the Code;
c) accepts appeal against any decision taken by Ombudsperson; and
d) encourages the submission of complaint against any retaliation action against any employee.
The Code of Business Conduct and Ethics and Ombudsperson procedure has been posted on the Company’s website:www.drreddys.com
An Independent Director is the Ombudsperson. The complaints and reports submitted to the Company and their resolution status are reported through the Ombudsperson to the Audit Committee and, where applicable, to the Board.
67
STATUTORY REPORTS/CORPORATE GOVERNANCE
RELATED PARTY TRANSACTIONSThe details of related party transactions are discussed in detail in page 132 of this annual report. All related party transactions during the year, in the ordinary course of business or otherwise, were placed before the Audit Committee and thereafter the Board. All related party transactions were on arm’s length basis.
SUBSIDIARY COMPANIESThe Audit Committee reviews the fi nancial statements of the subsidiary companies. It also reviews investment made by subsidiary companies, minutes of their Board meetings, statement of all signifi cant transactions and arrangements entered into by the subsidiary companies and the status of compliances by the respective subsidiaries. None of the Indian subsidiaries of the Company comes under the purview of the term ‘material non-listed Indian subsidiary’ as defi ned under Clause 49 of the Listing Agreement.
DISCLOSURE ONACCOUNTING TREATMENTIn the preparation of fi nancial statements for FY2014, there is no treatment of any transaction diff erent from that prescribed in the Accounting Standards notifi ed by the Government of India under Section 211(3C) of the Companies Act, 1956, other pronouncements of the Institute of Chartered Accountants of India and guidelines issued by the Securities and Exchange Board of India.
COMMITTEES OF THE BOARDThe Board Committees focus on specifi c areas and make informed decisions within the authority delegated. Each Committee is guided by its charter, which defi nes the composition, scope and powers. The Committees also make specifi c recommendations to the Board on various matters whenever required. All observations, recommendations and decisions of the Committees are placed before the Board for information or for approval.
Dr. Reddy’s has eight Board-level Committees, namely:
Audit Committee
Nomination, Governance and Compensation Committee
Science, Technology and Operations Committee
Risk Management Committee Shareholders’ Grievance Committee Corporate Social Responsibility
Committee Investment Committee Management Committee
AUDIT COMMITTEEThe management is responsible for the Company’s internal controls and thefi nancial reporting process while the statutory auditors are responsible for performing independent audits of the Company’s fi nancial statements in accordance with generally accepted auditing practices and for issuing reports basedon such audits.
The Board of Directors has entrusted the Audit Committee with the responsibility to supervise these processes and thus ensure accurate and timely disclosures that maintain the transparency, integrity and quality of fi nancial control and reporting.
The primary responsibilities of the Audit Committee are to:
Supervise the fi nancial reporting process Review the quarterly and annual
fi nancial results before placing them to the Board along with related disclosures and fi ling requirements
Review the adequacy of internal controls in the Company, including the plan, scope and performance of the internal audit function
Discuss with management, the Company’s major policies with respect to risk assessment and risk management
Hold discussions with statutory auditors on the nature, scope and process of audits and any views that they have about the fi nancial control andreporting processes
Ensure compliance with accounting standards and with listing requirements with respect to the fi nancial statements
Recommend the appointment and removal of external auditors and their remuneration
Recommend the appointment of cost auditors
Review the independence of auditors Ensure that adequate safeguards have
been taken for legal compliance for both the Company and its other Indian as well as foreign subsidiaries
Review and approval of related party transactions
Review the functioning of Whistle Blower mechanism
Review the implementation ofapplicable provisions of the Sarbanes-Oxley Act, 2002
The Audit Committee entirely consists of Independent Directors. All members are fi nancially literate and bring in expertise in the fi elds of fi nance, economics, human resource development, strategy and management. Presently, the Committee comprises: Mr. Sridar Iyengar (Chairman), Mr. Ravi Bhoothalingam, Ms. Kalpana Morparia and Dr. Omkar Goswami.
The Audit Committee met fi ve times during the year: on 3 April 2013, 13 May 2013, 30 July 2013, 30 October 2013 and 10 February 2014. It also met key members of the fi nance and internal audit teams along with the Vice Chairman & Managing Director and the CFO to discuss matters relating to audit, compliance and accounting.
During the year, the Committee also met statutory auditors without the presence of the management on more than one occasion. In addition, the Chairman of the Audit Committee and other members met to review other processes, particularly the internal control mechanisms to prepare for certifi cation under Section 404 of the Sarbanes-Oxley Act, 2002.
The Company is in compliance with the provisions of the Clause 49 of the Listing Agreement, as amended, on the time gap between any two Audit Committee
68
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
meetings. Table 5 gives the composition and attendance record of the Audit Committee.
The Vice Chairman & Managing Director, the CFO and the Chief Internal Auditor are permanent invitees to all Audit Committee meetings. Statutory auditors of the Company are also present in Audit Committee meetings during the year. The Company Secretary offi ciates as the Secretary of the Committee.
Audit Committee meetings are generally preceded by pre-Audit Committee conference calls with the Committee members, the CFO, the internal audit and compliance teams, the external auditors and other key fi nance personnel from the Company. These calls discuss major audit related matters and identify items that need further face-to-face discussion at the Audit Committee meetings.
The internal and statutory auditors of the Company discuss their audit fi ndings and updates with the Audit Committee and submit their views directly to the Committee. Separate discussions are held
with the internal auditors to focus on compliance issues and to conduct detailed reviews of the processes and internal controls in the Company. The report of the Audit Committee is enclosed as Exhibit 2to this chapter.
NOMINATION, GOVERNANCEAND COMPENSATION COMMITTEEThe Nomination, Governance and Compensation Committee entirely comprises of Independent Directors. The primary functions of the Committee are to:
Examine the structure, composition and functioning of the Board, and recommend changes, as necessary, to improve the Board’s eff ectiveness
Assess the Company’s policies and processes in key areas of corporate governance, other than those explicitly assigned to other Board Committees, with a view to ensure that the Company is at the forefront of good governance practices
Regularly examine ways to strengthen the Company’s organizational health, by improving the hiring, retention, motivation, development, deployment
and behavior of management and other employees. In this context, the Committee also reviews the framework and processes for motivating and rewarding performance at all levels of the organization, reviews the resulting compensation awards, and makes appropriate proposals for Board approval. In particular, it recommends all forms of compensation to be granted to the Executive Directors and senior management of the Company
The head of Human Resources (HR) makes periodic presentations to the Committee on organization structure, talent management, leadership, performance appraisals, increments, performance bonus recommendations and other HR matters.
The Nomination, Governance and Compensation Committee met three times during the year: on 13 May 2013, 30 October 2013 and 10 February 2014. The Chairman & CEO is a permanent invitee to all Nomination, Governance and Compensation Committee meetings. The head of HR is the Secretary of the Committee.
Table 6 gives the composition and attendance record of the Nomination, Governance and Compensation Committee. The report of this Committee is shown as Exhibit 3 to this chapter.
SCIENCE, TECHNOLOGYAND OPERATIONS COMMITTEEThe Science, Technology and Operations Committee of the Board entirely comprises of Independent Directors. Its primary functions are to:
Advise the Board and management on scientifi c, medical and technical matters and operations involving the Company’s development and discovery programs (generic and proprietary), including major internal projects, business development opportunities, interaction with academic and other outside research organizations
Assist the Board and management to stay abreast of novel scientifi c and technology developments and
TABLE 6 NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE MEMBERSHIP AND ATTENDANCE DURING FY2014
COMMITTEE MEMBERS POSITION MEETINGS HELD MEETINGS ATTENDED
Mr. Anupam Puri Chairman 3 3
Mr. Ravi Bhoothalingam Member 3 3
Ms. Kalpana Morparia Member 3 2(1)
Dr. Ashok S Ganguly Member 3 3
(1)Was given leave of absence on request.
TABLE 7 SCIENCE, TECHNOLOGY AND OPERATIONS COMMITTEE MEMBERSHIP AND ATTENDANCE DURING FY2014
COMMITTEE MEMBERS POSITION MEETINGS HELD MEETINGS ATTENDED
Dr. Ashok S Ganguly Chairman 4 4
Mr. Anupam Puri Member 4 4
Dr. J P Moreau Member 4 4
Dr. Bruce L A Carter Member 4 4
TABLE 5 AUDIT COMMITTEE MEMBERSHIP AND ATTENDANCE DURING FY2014
COMMITTEE MEMBERS POSITION MEETINGS HELD MEETINGS ATTENDED
Mr. Sridar Iyengar Chairman 5 5
Mr. Ravi Bhoothalingam Member 5 5
Ms. Kalpana Morparia Member 5 4(1)
Dr. Omkar Goswami Member 5 5
(1)Was given leave of absence on request.
69
STATUTORY REPORTS/CORPORATE GOVERNANCE
innovations and anticipate emerging concepts and trends in therapeutic research and development, and be assured that the Company makes well-informed choices in committing its resources
Assist the Board and the managementin creation of valuable IntellectualProperty (IP)
Review the status of non-infringementpatent challenges
Assist the Board and the management in building and nurturing science in the organization in line with the Company’s business strategy
The Chairman & CEO is a permanent invitee to all Science, Technology and Operations Committee meetings. Corporate offi cers heading IPDO, Proprietary Products and Biologics are secretaries of the Committee with regard to their respective businesses.
The Committee met four times during the year: on 13 May 2013, 30 July 2013, 30 October 2013 and 10 February 2014.Table 7 gives the composition and attendance record of the Committee. The report of the Committee is enclosed as Exhibit 4 to this chapter.
RISK MANAGEMENT COMMITTEEThe Risk Management Committee of the Board entirely comprises of Independent Directors. Its primary functions are to:
Discuss with senior management the Company’s Enterprise Risk Management
(ERM) and provide oversight as may be needed
Ensure that it is apprised of the more signifi cant risks along with the action, management is taking and how it is ensuring eff ective ERM
Review risk disclosure statements in public documents or disclosures,where applicable
The Vice Chairman & Managing Director is a permanent invitee to all Risk Management Committee meetings. The CFO acts as Secretary of the Committee. The Committee met thrice during the year: on 13 May 2013, 30 October 2013 and 10 February 2014. Table 8 gives the composition and attendance record of the Committee. The report of the Committee is enclosed as Exhibit 5 to this chapter.
SHAREHOLDERS’GRIEVANCE COMMITTEEThe Shareholders’ Grievance Committee is empowered to perform the functions of the Board relating to handling of shareholders’ queries and grievances. It primarilyfocuses on:
Review of investor complaints andtheir redressal
Review of queries received from investors
Review of work done by the share transfer agent
Review of corporate actions related to shareholder issues
The Shareholders’ Grievance Committee consists of three Directors, including two
Executive Directors. The Chairman of the Committee is an Independent Director. The Committee met four times during the year: on 13 May 2013, 30 July 2013, 30 October 2013 and 10 February 2014. Table 9 gives the composition and attendance recordof the Committee.
The Company Secretary offi ciates as the Secretary of the Committee and is also designated as Compliance Offi cer in terms of the Listing Agreement with the Stock Exchanges. An analysis of investor queries and complaints received during the year and disposed is given in this annual report in the chapter on Additional Shareholders’ Information.
CORPORATE SOCIAL RESPONSIBILITY (CSR) COMMITTEEThe CSR Committee was constituted by the Board of Directors at its meeting held on 31 October 2013. It comprises of Mr. Ravi Bhoothalingam (Independent Director) as Chairman, Mr. G V Prasad and Mr. Satish Reddy. The Head of Sustainability offi ciates as the Secretary of the Committee.
The primary function of the CSR Committee is to:
Formulate and recommend to the Board a CSR Policy indicating the activities to be undertaken by the Company as specifi ed in Schedule VII of the Companies Act, 2013
Recommend the amount of expenditure to be incurred on the activities referred to in clause (a) of Section 135(3) of the Companies Act, 2013
Monitor adherence to the CSR Policy of the Company from time to time
INVESTMENT COMMITTEEThe Investment Committee reviews the Company’s capital investment proposals and ongoing projects. It approves loans to subsidiaries or other entities/persons up to an overall limit of `250 million; and borrowings from any person up to an overall limit of `250 million.
It comprises of three Directors, including two Executive Directors. The Company Secretary
TABLE 8 RISK MANAGEMENT COMMITTEE MEMBERSHIP AND ATTENDANCE DURING FY2014
COMMITTEE MEMBERS POSITION MEETINGS HELD MEETINGS ATTENDED
Dr. Bruce L A Carter Chairman 3 3
Dr. Omkar Goswami Member 3 3
Dr. J P Moreau Member 3 3
Mr. Sridar Iyengar Member 3 3
TABLE 9 SHAREHOLDERS’ GRIEVANCE COMMITTEE MEMBERSHIP AND ATTENDANCE DURING FY2014
COMMITTEE MEMBERS POSITION MEETINGS HELD MEETINGS ATTENDED
Mr. Ravi Bhoothalingam Chairman 4 4
Mr. G V Prasad Member 4 4
Mr. Satish Reddy Member 4 4
70
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
offi ciates as the Secretary of the Committee. The Committee met four times during the year: on 13 May 2013, 30 July 2013, 17 December 2013 and 10 February 2014. All members of the Committee participated in all the meetings.
MANAGEMENT COMMITTEEThe role of Management Committee is to authorize Directors and officers of the Company to deal with day-to-day business operations such as banking, treasury, insurance, excise, customs, administration and dealing with other government/non-government authorities. The Committee consists of three Directors including one Independent Director, with the Chairman being an Executive Director. The Committee met six times during the year: on 13 May 2013, 10 July 2013, 30 July 2013, 1 October 2013, 30 October 2013and 10 February 2014. The Company Secretary officiates as the Secretary ofthe Committee.
MANAGEMENTThe management of Dr. Reddy’s develops and implements policies, procedures and practices that attempt to translate the Company’s core purpose and mission into reality. It also identifies, measures, monitors and minimizes risk factors in the business and ensures safe, sound and efficient operation. These are internally supervised and monitored through the Management Council.
MANAGEMENT COUNCILDr. Reddy’s Management Council consists of senior management from the business and corporate functions. Page 30 of this annual report gives details of the members of the Management Council.
The Council meets once in a quarter for two-days sessions. Background notes for the meetings are circulated in advance to facilitate decision-making. Listed below are some of the key issues that were considered by the Management Council during the year under review:
Company’s long-term strategy, growth initiatives and priorities
Overall Company performance, including those of various business units
Decision on major corporate policies Discussion and sign-off on annual
plans, budgets, investments and other major initiatives
Discussion on business alliances proposals and organizational design
MANAGEMENT DISCUSSIONAND ANALYSISThis chapter of the annual report constitutes the Company’s Management Discussionand Analysis.
MANAGEMENT DISCLOSURESSenior management of the Company (Senior Director level and above, as well as certain identifi ed key employees) make annual disclosures to the Board relating to all material fi nancial and commercial transactions in which they may have personal interest, if any, and which may have a potential confl ict with the interest of the Company. Transactions with key managerial personnel are listed in the fi nancial section of this annual report under Related Party Transactions.
PROHIBITION OF INSIDER TRADINGThe Company has a policy prohibiting insider trading in conformity with applicable regulations of the SEBI in India and the Securities and Exchange Commission (SEC) of the USA. Necessary procedures have been laid down for Directors, offi cers and designated employees for trading in the securities of the Company. The policy and procedures are periodically communicated to the employees who are considered as insiders of the Company. Trading window closure/blackouts/quiet periods, when the Directors and employees are not permitted to trade in the securities of the Company, are intimated to all Directors and employees, in advance, whenever required.
INTERNAL CONTROL SYSTEMSDr. Reddy’s has both external and internal audit systems in place. Auditors have access to all records and information of the Company. The Board recognizes the work of the auditors as an independent check on the information received from the management on the operations and performance of the Company. The Board and management periodically review the fi ndings and recommendations of the statutory and internal auditors and take corrective actions, whenever necessary.
INTERNAL CONTROLSThe Company maintains a system of internal controls designed to provide reasonable assurance regarding:
Eff ectiveness and effi ciency of operations Adequacy of safeguards for assets Reliability of fi nancial controls Compliance with applicable laws
and regulations
The integrity and reliability of internal control systems are achieved through clear policies and procedures, process automation, careful selection, training and development of employees and an organization structure that segregates responsibilities.
Internal Audit at Dr. Reddy’s is an independent and objective assurance function, responsible for evaluating and improving the eff ectiveness of risk management, control and governance processes. The internal audit department prepares annual audit plans based on risk assessment and conducts extensive reviews covering fi nancial, operational and compliance controls and risk mitigation. Areas requiring specialized knowledge are reviewed in partnership with external experts. Suggested improvement in processes are identifi ed during reviews and communicated to the management on an on-going basis.
The Audit Committee of the Board monitors the performance of internal audit department on a periodic basis through review of audit
71
STATUTORY REPORTS/CORPORATE GOVERNANCE
plans, audit fi ndings and speed of issue resolution through follow-ups. Each year, there are at least four meetings in which the Audit Committee reviews internal audit fi ndings, in addition to special meetings and teleconference calls.
CEO AND CFO CERTIFICATIONA certifi cate of the Chairman and Chief Executive Offi cer as well as the Chief Financial Offi cer of the Company on fi nancial statements and applicable internal controls as stipulated under Clause 49 of the Listing Agreement is enclosed as Exhibit 6 tothis chapter.
STATUTORY AND IFRS AUDITSFor FY2014, B S R & Co. LLP, Chartered Accountants, audited the fi nancial statements prepared under the Indian GAAP. The Company had appointed KPMG as independent auditors for issuing opinion on the fi nancial statements prepared under IFRS.
The independent statutory and IFRS auditors render an opinion regarding the fair presentation in the fi nancial statements of the Company’s fi nancial condition and operating results. Their audits are made in accordance with generally accepted auditing standards and include a review of the internal controls, to the extent necessary, to determine the audit procedures required to support their opinion.
While auditing the operations of the Company, the external auditors recorded their observations and fi ndings with the management. These were then discussed by management and the auditors at the Audit Committee meetings as well as through conference calls with members of the Audit Committee. Remedial measures suggested by the auditors and the Audit Committee have been either implemented or taken up for implementation by the management.
AUDITORS’ FEESDuring FY2014, the Company paid `10.46million to B S R & Co. LLP, Chartered Accountants, the statutory auditors as audit fees.
SHAREHOLDERSMEANS OF COMMUNICATION1. QUARTERLY AND ANNUAL
RESULTS: Quarterly and annual results of the Company are published in widely circulated national newspapers such as The Business Standard and the local vernacular daily, Andhra Prabha. These are also disseminated internationally through Business Wire and made available on corporate website: www.drreddys.com. The fi nancial results are also communicated to the shareholders through their registered email addresses.
2. NEWS RELEASES, PRESENTATIONS, ETC.:Dr. Reddy’s has established systems and procedures to disseminate relevant information to its stakeholders, including shareholders, analysts, suppliers, customers, employees and the society at large. It also conducts earnings calls with analysts and investors. An analysis of the various means of dissemination of information during the year under review is produced in Table 10.
3. WEBSITE: The primary source of information regarding operations of the Company is the corporate website: www.drreddys.com. All offi cial news, releases and presentations made to institutional investors and analysts are posted here. It contains a separate dedicated section called ‘Investors’, where the information for shareholders are available. The webcast of the proceedings of the Annual General
Meeting is also made available on the website. In addition, the Company maintains various portals such as www.customer2drl.com,www.vikreta2drl.com and www.housecallsindia.com, which have proved to be eff ective and widely appreciated tools for information dissemination.
4. ANNUAL REPORT: The Company’s annual report containing, inter alia, the Directors’ Report, Corporate Governance Report, Management’s Discussion and Analysis (MD&A) Report, Audited Annual Accounts, Consolidated Financial Statements, Auditors’ Report and other important information is circulated to shareholders and others so entitled. The annual report is also available on the website in a user-friendly and downloadable form.
5. CHAIRMAN’S SPEECH: Webcast of the speech is made available on the Company’s website.
6. REMINDER TO INVESTORS: Reminders to encash unclaimed dividend on shares or on account of debenture interest are sent to the relevant shareholders and debenture holders.
7. COMPLIANCES WITH STOCK EXCHANGES: The National Stock Exchange (NSE) and BSE Ltd. maintain separate online portals for electronic submission of information by listed companies. Various communications such as notices, press releases and the regular quarterly, half-yearly and annual compliances and disclosures are fi led electronically on these online portals. In addition, such disclosures and communications are also sent to the NSE and the BSE as hard copies.
8. DESIGNATED EXCLUSIVE EMAIL-ID: Dr. Reddy’s has designated an email-id exclusively for investor service: [email protected].
9. REGISTER TO RECEIVE ELECTRONIC COMMUNICATIONS: The Companyhas provided an option to the shareholders to register their email-id
TABLE 10 DETAILS OF COMMUNICATION MADE DURING FY2014
MEANS OF COMMUNICATION FREQUENCY
Press releases/statements 14
Earnings calls 4
Publication of results 4
72
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
online through the Company’s website to receive electronic communications. Shareholders who wish to receive electronic communications fromDr. Reddy’s may register at:www.drreddys.com/investors/shareholder-information.html
ADDITIONAL INFORMATION IN TERMS OF CLAUSE 49-IV-G OF THE LISTING AGREEMENT, ON DIRECTORS SEEKING RE-APPOINTMENT/APPOINTMENT AT THE ENSUING ANNUAL GENERAL MEETINGMR. ANUPAM PURIMr. Anupam Puri joined the Company’s Board in 2002. From 1970 to 2000, Mr. Puri was with McKinsey & Company, a leading management consultancy fi rm. He worked globally with corporate clients in several industries on strategy and organizational issues and also served several governments and multilateral institutions on public policy.
Mr. Puri spearheaded the development of McKinsey’s India practice, oversaw the Asian and Latin American offi ces and was an elected member of the Board. He is currently a management consultant. He is also on the Boards of: Mahindra & Mahindra Limited, Tech Mahindra Limited, Mumbai Mantra Media Limited and our wholly owned subsidiary, Dr. Reddy’s Laboratories Inc., USA.
In addition to the Committee chairmanship/membership in the Company, he also holds positions in the Board Committees of other Companies (Table 11).
Mr. Anupam Puri holds 21,300 ADRs in the Company as on 31 March 2014.
DR. BRUCE L A CARTERDr. Bruce L A Carter joined the Company’s Board in 2008. He was appointed the Chairman of the Board and CEO of ZymoGenetics Inc., USA in April 2005. From April 1998 to January 2009, he served as its CEO. Dr. Carter fi rst joined ZymoGenetics in 1986 as Vice President of R&D. In 1988, Novo Nordisk acquired ZymoGenetics and, in 1994, he was promoted to Corporate Executive Vice President and Chief Scientifi c Offi cer for Novo Nordisk A/S, the then parent company of ZymoGenetics. Dr. Carter then negotiated to establish ZymoGenetics as an independent company in 2000.
Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co. Limited from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He is also on the Board of Regulus Inc., Xencor Inc., Enanta Pharmaceutical Inc. and TB Alliance all in USA.
Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England and a Ph.D. in Microbiology from Queen Elizabeth College, University of London. His Committee positions in other companies is given in Table 12.
Dr. Carter holds 11,800 ADRs in the Company as on 31 March 2014.
MR. SRIDAR IYENGARMr. Sridar Iyengar joined the Company’s Board in 2011. He is an independent mentor investor in early stage start-ups and companies. For more than 35 years, he has worked in the UK, US and India with a large number of companies, advising them on strategy and other issues.
Earlier, Mr. Iyengar was a senior partner with KPMG in the US and UK and served for three years as the Chairman and CEO of KPMG’s operations in India. He is the former President of Foundation for Democratic Reforms in India, a US-based non-profi t organization. He is also an advisor to several venture and private equity funds in India.
Mr. Iyengar also holds directorship in ICICI Venture Funds Management Company Ltd., Rediff .com India Ltd., Mahindra Holidays and Resorts India Ltd., CL Educate Limited and Cleartrip Pvt. Ltd. in India, Cleartrip Inc., AverQ Inc., Kovair Software Inc., RediffHoldings Inc. and American India Foundation INc. in USA, iYogi Limited in Mauritius and our wholly owned subsidiary Dr. Reddy's Laboratories S.A., in Switzerland.
He holds a B.Com. (Hons.) degree from the University of Calcutta and is a Fellow of the Institute of Chartered Accountants in England and Wales. His Board and Committee positions in companies other than Dr. Reddy’s is given in Table 13.
Mr. Sridar Iyengar does not hold any shares/ADRs of the Company as on 31 March 2014.
DR. ASHOK S GANGULYDr. Ashok S Ganguly joined the Company’s Board in 2009. He is currently the Chairman of ABP Private Limited (Ananda Bazar Patrika Group) and was a Director on the Central Board of Reserve Bank of India from 2001 to 2009. He is a member of the Prime Minister’s Council on Trade and Industry as well as the Investment Commission, and the India-USA CEO Council set up by the Prime Minister of India and the President of the US. He is also a member of the National Knowledge Commission to the Prime Minister of India.
TABLE 11 CHAIRMANSHIP/MEMBERSHIP HELD BY MR. ANUPAM PURI IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Tech Mahindra Limited- Audit Committee
- Compensation Committee
Mumbai Mantra Media Limited - Audit Committee
Mahindra & Mahindra Limited -Strategic Investment Committee
TABLE 12 CHAIRMANSHIP/MEMBERSHIP HELD BY DR. BRUCE L A CARTER IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Regulus Inc., USA. Compensation Committee Audit Committee
Xencor Inc., USA. - Corporate Governance Committee
Enanta Pharmaceutical Inc., USA. Compensation Committee -
73
STATUTORY REPORTS/CORPORATE GOVERNANCE
He was the Chairman of Hindustan Lever Limited from 1980 to 1990, and member of the Unilever Board from 1990 to 1997 with responsibility for world-wide research and technology. He also serves as a Director on Board of Wipro Limited and as a member of Advisory Board of Diageo India Pvt. Limited.
He is a recipient of the ‘Padma Bhushan’ as well as ‘Padma Vibhushan’, two of India’s prestigious civilian honours. At present, he serves as a member of the Rajya Sabha, the upper house of the Parliament of India.
In addition to the Committee chairmanship/membership in the Company, he also holds positions in the Board Committees of other Companies as provided in Table 14.
Dr. Ashok S Ganguly holds 4,800 shares in the Company as on 31 March 2014.
DR. J P MOREAUDr. J P Moreau joined the Company’s Board in 2007. He founded Biomeasure Incorporated based near Boston and has been its President and CEO. Prior to that he was working as Executive Vice-President and Chief Scientifi c Offi cer of the IPSEN Group and was responsible for the Group’s Discovery and Innovation with facilities in Paris, London, Barcelona and Boston. He was the Vice-President, Research from
April 1994 and has been a member of the Executive Committee of IPSEN Group since that date. He has published over 50 articles in scientifi c journals and has more than 30 patents to his name. He is a regular speaker at scientifi c conferences and a member of Nitto Denko Scientifi c Advisory Board. Dr. Moreau was also responsible for establishing Kinerton Limited in Ireland in March, 1989, a wholesale manufacturer of therapeutic peptides. Dr. Moreau is also on the Board of Mulleris Therapeutics Inc. and ProteoThera Inc. in Delaware, USA.
Dr. Moreau has a degree in Chemistry from the University of Orleans and a D.Sc. in biochemistry. He has also conducted post-doctorate research at the École Polytechnique.
Apart from Committee memberships in Dr. Reddy’s, Dr. Moreau is not a member/chairman of any Committee in any other company.
Dr. Moreau does not hold any shares/ADRs in the Company as on 31 March 2014.
MS. KALPANA MORPARIAMs. Kalpana Morparia joined the Company’s Board in 2007. She is the Chief Executive Offi cer of J.P. Morgan, India, where she leads their Business Groups (investment banking,
asset management, treasury services and principal investment management) & Service Groups (global research, fi nance, technology and operations). She is also a member of J.P. Morgan’s global strategy team headquartered in New York and the J.P. Morgan Asia Pacifi c Executive Committee.
Prior to becoming CEO of J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group. She joined the ICICI Group in 1975 and was the Joint Managing Director of ICICI Group from 2001 to 2007. She was named one of ‘The 50 Most Powerful Women’ in ‘International Business’ by Fortune magazine in 2008; one of the 25 most powerful women in Indian business by Business Today, a leading Indian business magazine in 2004, 2005, 2006 and 2008; and one of ‘The 100 most Powerful Women’ by Forbes magazine in 2006. She also serves on the Boards of: Bennett, Coleman & Co. Limited, CMC Limited, J.P. Morgan Services India Private Limited, J.P. Morgan Asset Management India Private Limited and Philip Morris International Inc., USA. She is also a member of the Governing Board of Bharati Foundation.
A graduate in law from Bombay University, Ms. Morparia has served on several committees constituted by the Government of India. In addition to the Committee
TABLE 13 CHAIRMANSHIP/MEMBERSHIP HELD BY MR. SRIDAR IYENGAR IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Rediff.com India Limited Audit Committee -
CL Educate Limited Audit Committee -
Mahindra Holidays and Resorts India Limited Audit Committee Remuneration Committee
ICICI Venture Funds Management Company Limited - Compensation and Corporate Governance Committee
Cleartrip Private LimitedAudit Committee -
Compensation Committee -
Cleartrip Inc., Cayman IslandsAudit Committee Nominating & Governance Committee
Compensation Committee -
iYogi Limited, Mauritius Audit Committee -
TABLE 14 CHAIRMANSHIP/MEMBERSHIP HELD BY DR. ASHOK S GANGULY IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Wipro LimitedCorporate Governance Committee -
Nomination Committee -
74
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
chairmanship/membership in the Company, she also holds positions in the Board Committees of other Companies (see Table 15).
Ms. Morparia holds 10,800 shares in the Company as on 31 March 2014
DR. OMKAR GOSWAMIDr. Omkar Goswami joined the Company’s Board in 2000. Since April 2004, he has been the Founder and Chairman of CERG Advisory Private Limited, a consulting and advisory fi rm. He taught and researched Economics for 18 years at Oxford University, Delhi School of Economics, Harvard University, Tufts University, Jawaharlal Nehru University, Rutgers University and
at the Indian Statistical Institute. In March 1997, he moved away from formal academics to become the Editor of Business India, one of India’s leading business magazine. From August 1998 up to March 2004, Dr. Goswami served as the Chief Economist of the Confederation of Indian Industry–the premier apex industry association of India. He is also a Director on the Boards of: Infosys Ltd., Crompton Greaves Ltd., IDFC Ltd., Ambuja Cements Ltd., Cairn India Ltd., DSP Black Rock Investment Managers Private Ltd., Godrej Consumer Products Ltd., Bajaj Finance Ltd., Max Healthcare Institute Ltd. and Infosys BPO Ltd.
In addition to the Committee chairmanship/membership in the Company, he also holds
positions in the Board Committees of other Companies (see Table 16).
Dr. Goswami holds 22,800 shares in the Company as on 31 March 2014.
MR. RAVI BHOOTHALINGAMMr. Ravi Bhoothalingam joined the Company’s Board in 2000. Mr. Bhoothalingam has served as the President of The Oberoi Group of Hotels and was responsible for the Group’s worldwide operations. He has also served as Head of Personnel at British American Tobacco (BAT) Plc, Managing Director of VST Industries Limited and as a Director of ITC Limited. He is also a Director of Sona Koyo Steering Systems Limited.
TABLE 17 CHAIRMANSHIP/MEMBERSHIP HELD BY MR. RAVI BHOOTHALINGAM IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Sona Koyo Steering Systems Limited Audit Committee Remuneration Committee
TABLE 16 CHAIRMANSHIP/MEMBERSHIP HELD BY DR. OMKAR GOSWAMI IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Infosys LimitedInvestor Grievances Committee Risk Management Committee
- Compensation Committee
IDFC LimitedCompensation Committee Audit Committee
- Nomination Committee
Crompton Greaves Limited Audit and Risk Management Committee -
Ambuja Cements Limited- Compliance Committee
- Audit Committee
Cairn India LimitedInvestor Grievance Committee Audit Committee
- Remuneration Committee
Godrej Consumer Products Limited
- Audit Committee
- HR & Compensation Committee
- Nomination Committee
Infosys BPO Limited - Audit Committee
- Remuneration Committee
Bajaj Finance Limited
- Audit Committee
-Remuneration & Nomination / Compensation Committee
Max Healthcare Institute Limited Service Excellence Committee Remuneration Committee
TABLE 15 CHAIRMANSHIP/MEMBERSHIP HELD BY MS. KALPANA MORPARIA IN OTHER COMPANIES
NAME OF THE COMPANY AS CHAIRPERSON AS MEMBER
Bennett Coleman & Co. LtdAudit Committee -
Nomination & Remuneration Committee -
CMC Limited Governance Committee Executive Committee
Philip Morris International Inc.
Nominating and Corporate Governance Committee
Product Innovation and Regulatory Affairs Committee
- Finance Committee
75
STATUTORY REPORTS/CORPORATE GOVERNANCE
Mr. Bhoothalingam holds a Bachelor of Science degree in Physics from St. Stephens College, Delhi and Master’s degree in Experimental Psychology from Gonville and Caius College, Cambridge University.
In addition to the Committee chairmanship/membership in the Company, he also holds positions in the Board Committees of other Companies. (see Table 17).
Mr. Ravi Bhoothalingam holds 22,800 shares in the Company as on 31 March 2014.
COMPLIANCE REPORT ONTHE NYSE CORPORATE GOVERNANCE GUIDELINESPursuant to Section 303A.11 of the NYSE Listed Company Manual, Dr. Reddy’s which is a foreign private issuer as defi ned by SEC, must make its US investors aware of the signifi cant ways in which the corporate governance practices diff er from those required of domestic companies under NYSE listing standards. A detailed analysis of thisis posted on the Company’s website: www.drreddys.com
COMPLIANCE REPORT ON NON-MANDATORY REQUIREMENTS UNDER CLAUSE 491. THE BOARD: The Chairman of
Dr. Reddy’s is an Executive Directorand maintains the Chairman’s offi ce at the Company’s expenses.
2. REMUNERATION COMMITTEE:The Board of Directors has a Nomination, Governance and Compensation Committee, which comprises of only Independent Directors. This Committee also discharges the duties and responsibilities of Remuneration Committee as contemplated under the non-mandatory requirements of Clause 49. Details of the Committee and its
powers have been discussed in this chapter.
3. SHAREHOLDERS RIGHTS: The Company did not send half-yearly results to each household of the shareholders in FY2014. However, in addition to displaying its quarterly and half-yearly results on its website: www.drreddys.com and publishing in widely circulated newspapers, the quarterly fi nancial results are sent to the registered e-mail addresses of the shareholders.
4. AUDIT QUALIFICATIONS: Theauditors have not qualifi ed the fi nancial statements of the Company.
5. TRAINING OF BOARD MEMBERS: The Company believes that the Board be continuously empowered with the knowledge of the latest developments in the Company’s businesses and the external environment aff ecting the Company and the industry as a whole. To this end, the Directors were given presentations on the global business environment, as well as all business areas of the Company including business strategy, risks and opportunities. The Directors also visit manufacturing and research locations of the Company.
6. MECHANISM FOR EVALUATING NON-EXECUTIVE BOARD MEMBERS: A Director among the Independent Directors has been identifi ed to provide structured feedback to the Board on the functioning and performance of the Board and to encourage healthy discussions and openness amongst the members of the Board. The Company also conducted an independent review of its Board processes, functioning and contribution of individual Board members in enhancing overall Board’s eff ectiveness.
7. WHISTLE BLOWER POLICY: TheCompany has a whistle blower policy.
ADDITIONAL SHAREHOLDERS’ INFORMATIONThe chapter on Additional Shareholders’ Information forms a part of this annual report.
EXHIBIT 1DECLARATION OF THE CHIEF EXECUTIVE OFFICER ON COMPLIANCE WITH CODE OF BUSINESS CONDUCT AND ETHICSDr. Reddy’s Laboratories Limited has adopted a Code of Business Conduct and Ethics (the Code) which applies to all employees and Directors of the Company, its subsidiaries and affi liates. Under the Code, it is the responsibility of all employees and Directors to familiarize themselves with the Code and comply with its standards.
I hereby certify that the Board members and senior management personnel of Dr. Reddy’s have affi rmed compliance with the Code of the Company for the fi nancial year 2013-14.
G V PrasadChairman and Chief Executive Offi cer
Place HyderabadDate 13 May 2014
EXHIBIT 2REPORT OF THE AUDIT COMMITTEETo the shareholders of Dr. Reddy’s Laboratories Limited
The Audit Committee of the Board of Directors comprises of four Directors. Each member of the Committee is an Independent Director as defi ned under Indian laws, Clause 49 of the Listing Agreement and the New York Stock Exchange Corporate Governance Guidelines. The Committee operates under a written charter adopted by the Board of Directors and has been vested with all the powers necessary to eff ectively discharge its responsibilities.
Dr. Reddy’s management has primary responsibility for the fi nancial statements and reporting process, including the systems of internal controls. During 2013-14, the
76
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Audit Committee met fi ve times. It discussed with the Company’s internal auditors and statutory auditors the scope and plans for their respective audits. It also discussed the results of their examination, their evaluation of the Company’s internal controls, and overall quality of the Company’s fi nancial reporting.
In fulfi lling its oversight responsibilities, the Committee reviewed and discussed the Company’s quarterly unaudited and annual audited fi nancial statements with the management. B S R & Co. LLP, Chartered Accountants, the Company’s independent auditors for Indian GAAP and KPMG, the Company’s independent auditors for IFRS fi nancial statements, are responsible for expressing their opinion on the conformity of the Company’s audited fi nancial statements with Generally Accepted Accounting Principles.
Relying on the review and discussions with the management and the Independent auditors, the Audit Committee believes that the Company’s fi nancial statements are fairly presented in conformity with Generally Accepted Accounting Principles and the IFRS in all material aspects.
To ensure that the accounts of the Company are properly maintained and that accounting transactions are in accordance with the prevailing laws and regulations, the Committee reviewed the internal controls put in place by the Company and in conducting such reviews, the Committee found no material discrepancy or weakness in the Company’s internal control systems.
In 2005-06, the Company became the fi rst Indian manufacturing company to comply with Section 404 of the US Sarbanes-Oxley Act (SOX), in advance of the mandatory deadline of 31 March 2007, which was applicable to foreign private issuers.
The Committee has also reviewed the non-audited services being provided by the Statutory Auditors and concluded that such services were not in confl ict with the independence of the Statutory Auditors.
The Committee ensures that the Company’s Code of Business Conduct and Ethics has a mechanism such that no personnel intending to make a complaint relating to securities and fi nancial reporting shall be denied access to the Audit Committee.
The Audit Committee has recommended to the Board of Directors:1. That the audited Standalone and
Consolidated fi nancial statements prepared as per Indian GAAP of Dr. Reddy’s Laboratories Limited for the year ended 31 March 2014, be accepted by the Board as a true and fair statement of the fi nancial status of the Company.
2. That the fi nancial statements prepared as per IFRS as issued by International Accounting Standards Board for the year ended 31 March 2014, be accepted by the Board and included in the Company’s annual report on Form 20-F, to be fi led with the US Securities and Exchange Commission.
Further, the Committee has recommended to the Board the re-appointment of B S R & Co. LLP, Chartered Accountants as statutory Independent auditors under Indian GAAP for a period up to the fi scal year ending 31 March 2016 and KPMG, India, as statutory Independent auditors for IFRS for the fi scal year ending 31 March 2015.
Mr. Sridar IyengarChairman, Audit Committee
Place HyderabadDate 12 May 2014
EXHIBIT 3REPORT OF THE NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEETo the shareholders of Dr. Reddy’s Laboratories Limited
The Nomination, Governance and Compensation Committee of the Board of Directors comprises of four Directors. Each member of the Committee is an Independent
Director as defi ned under Indian laws, Clause 49 of the Listing Agreement and the New York Stock Exchange Corporate Governance Guidelines. The Committee operates under a written charter adopted by the Board of Directors, and has been vested with all the powers necessary to eff ectively discharge its responsibilities.
The Committee’s primary responsibilities are to:
Periodically examine the structure, composition and functioning of the Board and recommend changes, as necessary, to improve the Board’s eff ectiveness and oversee the evaluation
Assess the Company’s policies and processes in key areas of corporate governance and the impact of related signifi cant regulatory and statutory changes, if any, with a view to ensure that the Company is at the forefront of good corporate governance
Examine major aspects of the Company’s organizational health and recommend changes as necessary
Review and recommend the compensation and variable pay for Executive Directors to the Board; and
Establish, in consultation with the management, the compensation program for the Company, and recommend it to the Board for approval In that context:
Establish annual Key Result Areas (KRAs) for the Executive Directors and oversee the evaluation of their achievement
Review, discuss and provide guidance to the management, on the KRAs for members of the Management Council and their remuneration
Review the Company’s ESOP Schemes and oversee administration of the ESOP Schemes
As on 31 March 2014, the Company had 749,137 outstanding stock options, which amounts to 0.44 % of total equity capital. These stock options are held by 770 employees of the Company and its
77
STATUTORY REPORTS/CORPORATE GOVERNANCE
subsidiaries under Dr. Reddy’s Employees Stock Options Scheme, 2002 and Dr. Reddy’s Employees ADR Stock Options Scheme, 2007. Out of the total 749,137 stock options, 10,000 are exercisable at fair market value and 739,137 stock options are exercisable at par value i.e. `5.
The Committee met thrice during the fi nancial year. It had discussions around review of annual performance appraisal, grant of stock options, incentive plans for Proprietary Products & Biologics, gender diversity, and compensation and other human resource related matters.
The Committee devoted considerable time discussing the organization health, design and succession planning for critical positions within the Company. It also monitors the Company’s system for hiring, developing and retaining talent.
The Committee also focused on identifying and evaluating candidates for the Board.
The Nomination, Governance and Compensation Committee also recommends to the Board, changes in committee structure and membership and other steps that would improve the Board’s eff ectiveness in overseeing the Company.
Mr. Anupam PuriChairman, Nomination, Governance and Compensation Committee
Place HyderabadDate 12 May 2014
EXHIBIT 4REPORT OF THE SCIENCE, TECHNOLOGY AND OPERATIONS COMMITTEETo the Shareholders of Dr. Reddy’s Laboratories Limited
The Science, Technology and Operations Committee of the Board of Directors comprises of four Directors. Each member of the Committee is an Independent Director as
defi ned under Indian laws, Clause 49 of the Listing Agreement and the New York Stock Exchange Corporate Governance Guidelines. The Committee operates under a written charter adopted by the Board of Directors, and has been vested with all the powers necessary to eff ectively dischargeits responsibilities.
The Committee's primary responsibilitiesare to:
Advise the Board and management on scientifi c, medical and technical matters and operations involving the Company’s development and discovery programs (generic and proprietary), including major internal projects, business development opportunities, interaction with academic and other outside research organizations
Assist the Board and management to stay abreast of novel scientifi c and technology developments and innovations and anticipate emerging concepts and trends in therapeutic research and development, to help assure that the Company makes well-informed choices in committing its resources
Assist the Board and the managementin creation of valuable Intellectual Property (IP)
Review the status of non-infringement patent challenges
Assist the Board and the managementin building and nurturing science inthe organization in tune with itsbusiness strategy
The Committee met four times during the fi nancial year. The Science, Technology and Operations Committee apprised the Board on the key discussions and recommendations made at the Committee meetings.
Dr. Ashok S GangulyChairman, Science, Technology and Operations Committee
Place HyderabadDate 12 May 2014
EXHIBIT 5REPORT OF THE RISK MANAGEMENT COMMITTEETo the Shareholders of Dr. Reddy’s Laboratories Limited
The Risk Management Committee of the Board of Directors comprises four Directors. Each member of the Committee is an Independent Director as defi ned under Indian laws, Clause 49 of the Listing Agreement and the New York Stock Exchange Corporate Governance Guidelines. The Committee operates under a written charter adopted by the Board of Directors, and has been vested with all the powers necessary to eff ectively discharge its responsibilities.
The Committee believes that its primary responsibilities are to:
Discuss with senior management, the Company’s Enterprise Level Risks and provide oversight as may be needed
Ensure it is apprised of the most signifi cant risks and emerging issues, along with the action, the management is taking and how it is ensuring eff ective Enterprise Risk Management (ERM)
Reviewing risk disclosure statements in any public documents or disclosures
The Committee met thrice during the fi nancial year to review the enterprise wide risks, review the status of mitigation of the key risks, risk management initiatives (including review of insurance and self-insurance options), evaluate residual risk thereof and recommend interventions from time to time.
The Risk Management Committee also apprised the Board on the key discussions and recommendations made at the Committee meetings and shared information on enterprise-wide risks.
Dr. Bruce L A CarterChairman, Risk Management Committee
Place HyderabadDate 12 May 2014
78
HEALTHY FOREVERHEALTHY FOREVER
CORPORATE GOVERNANCE
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
AUDITORS’ CERTIFICATE ON CORPORATE GOVERNANCETo the members of Dr. Reddy’s Laboratories Limited
We have examined the compliance of conditions of Corporate Governance by Dr. Reddy’s Laboratories Limited ('the Company'), for the year ended on 31 March 2014, as stipulated in Clause 49 of the Listing Agreement of the Company with the stock exchanges.
The compliance of the conditions of the Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the fi nancial statements of the Company.
In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned Listing Agreement.
We further state that such compliance is neither an assurance as to the future viability of the Company nor the effi ciency or eff ectiveness with which the management has conducted the aff airs of the Company.
for B S R & CO. LLPCHARTERED ACCOUNTANTSFirm Registration No.: 101248W
Supreet SachdevPartnerMembership No.: 205385
Place HyderabadDate 13 May 2014
EXHIBIT 6CEO AND CFO CERTIFICATE TO THE BOARD PURSUANT TO CLAUSE 49 OF THE LISTING AGREEMENT OF THE SEBIWe, G V Prasad, Chairman and Chief Executive Offi cer and Saumen Chakraborty, President and Chief Financial Offi cer, to the best of our knowledge and belief, certify that:A. We have reviewed the fi nancial
statements including cash fl ow statement (standalone and consolidated) for the fi nancial year ended 31 March 2014 and that these statements:
i. do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
ii. together present a true and fair view of the Company’s aff airs and are in compliance with existing accounting standards, applicable laws and regulations.
B. There are no transactions entered into by the Company during the year, which are fraudulent, illegal or in violation of the Company’s Code of Business Conduct and Ethics.
C. We accept the responsibility for establishing and maintaining internal controls for fi nancial reporting and that we have evaluated the eff ectiveness of internal control systems of the Company pertaining to fi nancial reporting and have disclosed to the auditors and the Audit Committee, defi ciencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to address these defi ciencies.
D. We have disclosed, wherever applicable, to the auditors and the Audit Committee:
i. that there were no defi ciencies in the design or operations of internal controls that could adversely aff ect the Company's ability to record, process, summarize and report fi nancial data including any corrective actions;
ii. that there are no material weaknesses in the internal controls over fi nancial reporting;
i ii. that there are no signifi cant changes in internal control over fi nancial reporting during the year;
iv. all signifi cant changes in the accounting policies during the year, if any, and the same have been disclosed in the notes to the fi nancial statements; and
v. that there are no instances of signifi cant fraud of which we have become aware of and involvement therein of the management or an employee having a signifi cant role in the Company’s internal control system over fi nancial reporting.
G V PrasadChairman and Chief Executive Offi cer
Saumen ChakrabortyPresident and Chief Financial Offi cer
Place HyderabadDate 13 May 2014
79
Additional Shareholders’ Information
FY2014 represents fi scal year 2013-14, from 1 April 2013 to
31 March 2014. Analogously for FY2013 and previously such
labeled years.
CONTACT INFORMATIONREGISTERED AND CORPORATE OFFICEDr. Reddy’s Laboratories Limited8-2-337, Road No. 3, Banjara HillsHyderabad 500 034Andhra Pradesh, IndiaTel: +91-40-4900 2900Fax: +91-40-4900 2999website: www.drreddys.comCIN: L85195TG1984PLC004507E-mail ID: [email protected]
REPRESENTING OFFICERSCorrespondence to the following offi cers may be addressed at the registered and corporate offi ce of the Company.
COMPLIANCE OFFICER UNDERLISTING AGREEMENTSandeep PoddarCompany SecretaryTel: +91-40-4900 2222Fax: +91-40-4900 2999E-mail ID: [email protected]
ADR INVESTORS/INSTITUTIONALINVESTORS/FINANCIAL ANALYSTSKedar UpadhyeInvestor RelationsTel: +91-40-6683 4297Fax: +91-40-2373 1955E-mail ID: [email protected]
MEDIADharini MishraCorporate CommunicationsTel: +91-40-4900 2441Fax: +91-40-4900 2999E-mail ID: [email protected]
INDIAN RETAIL INVESTORSSandeep PoddarCompany SecretaryTel: +91-40-4900 2222Fax: +91-40-4900 2999E-mail ID: [email protected]
ANNUAL GENERAL MEETINGDate Thursday, 31 July 2014Time 9.30 AMVenue Grand Ball Room, Hotel Taj Krishna,
Road No. 1, Banjara Hills,Hyderabad 500 034
Last date for receipt of proxy forms: Tuesday, 29 July 2014 before 9.30 AM.
DIVIDENDThe Board of Directors of the Company has proposed a dividend of `18 per share on equity shares of `5 each. The dividend, if declared by the shareholders at the 30th Annual General Meeting scheduled to be held on 31 July 2014, will be paid on or after 7 August 2014.
BOOK CLOSURE DATEThe dates of book closure are from Tuesday,15 July 2014 to Friday, 18 July 2014 (both days inclusive) for the purpose of payment of dividend.
INTERNATIONAL SECURITIES IDENTIFICATION NUMBER (ISIN)ISIN is an unique identifi cation number of traded scrip. This number has to be quoted in each transaction relating to the dematerialised securities of the Company. The ISIN number of the equity shares of the Company is INE089A01023.
STATUTORY REPORTS/ADDITIONAL SHAREHOLDERS’ INFORMATION
80
HEALTHY FOREVERHEALTHY FOREVER
ADDITIONAL SHAREHOLDERS’ INFORMATION
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
LISTING ON STOCK EXCHANGES AND STOCK CODES
EQUITY SHARES ADRs
BSE Limited (BSE) 500124 -
National Stock Exchange of India Limited (NSE) DRREDDY-EQ -
New York Stock Exchange Inc. (NYSE) - RDY
Notes:
1. Listing fees to the Indian Stock Exchanges for listing of equity shares have been paid for the FY2015.
2. Listing fees to the NYSE for listing of ADRs has been paid for the CY2014.
3. The Stock Code on Reuters is REDY.NS and on Bloomberg is DRRD:IN.
FINANCIAL CALENDAR
TENTATIVE CALENDAR FOR DECLARATION OF FINANCIAL RESULTS IN FY2015
For the quarter ending 30 June 2014 Last week of July 2014
For the quarter and half-year ending 30 September 2014 Last week of October 2014
For the quarter and nine months ending 31 December 2014 Last week of January 2015
For the year ending 31 March 2015 First fortnight of May 2015
AGM for the year ending 31 March 2015 Second fortnight of July 2015
TABLE 1 PERSONS HOLDING 1% OR MORE OF THE SHARES IN THE COMPANY AS ON 31 MARCH 2014(1)
S. NO. NAME NO. OF SHARES %
1 Dr. Reddy’s Holdings Limited 39,729,284 23.35
2 First State Investments Management (UK) Limited, First State Investments International Limited and their Associates
14,056,799 8.26
3 Blackrock Institutional Trust Company and their Associates 3,585,440 2.11
4 ICICI Prudential Life Insurance Company Limited 3,531,404 2.08
5 Abu Dhabi Investment Authority 3,423,613 2.01
6 Government of Singapore 2,446,719 1.44
7 Life Insurance Corporation of India and its associates 2,008,098 1.18
(1)Does not include ADR holding.
CUSIP NUMBER FOR ADRSThe Committee on Uniform Security Identifi cation Procedures (CUSIP) of the American Bankers Association has developed a numbering system for securities. A CUSIP number uniquely identifi es a security and its issuer and this is recognized globally by organizations adhering to standards issued by the International Securities Organization. The Company’s ADRs carry the CUSIP number 256135203.
DEPOSITORIESOVERSEAS DEPOSITORY OF ADRsJ P Morgan Chase & Co.P.O. Box 64504, St. PaulMN 55164-0504Tel: +1-651-453 2128
INDIAN CUSTODIAN OF ADRsJP Morgan Chase Bank NAIndia Sub-Custody, 6th FloorParadigm B Wing, Mindspace, Malad (West)Mumbai 400 064Maharashtra, IndiaTel: +91-22-6649 2500Fax: +91-22-6649 2509/2880 1117E-mail ID: [email protected]
REGISTRAR FOR INDIAN SHARES (COMMON AGENCY FOR DEMAT AND PHYSICAL SHARES)Bigshare Services Private Limited306, Right Wing, 3rd Floor, Amrutha VilleOpp. Yashoda Hospital, Rajbhavan RoadHyderabad 500 082 Andhra Pradesh, IndiaTel: +91-40-2337 4967Fax: +91-40-2337 0295E-mail ID: [email protected]
PERSONS HOLDINGOVER 1% OF THE SHARESTable 1 gives the names of the persons who hold more than 1 per cent shares of the Company as on 31 March 2014.
EQUITY HISTORY OF THE COMPANYTable 2 lists equity history of the Company since incorporation of the Company up to 31 March 2014.
DESCRIPTION OF VOTING RIGHTSAll shares issued by the Company carry equal voting rights.
81
STATUTORY REPORTS/ADDITIONAL SHAREHOLDERS’ INFORMATION
TABLE 2 EQUITY HISTORY OF THE COMPANY SINCE INCORPORATION OF THE COMPANY UP TO 31 MARCH 2014
DATE/FINANCIAL YEAR PARTICULARS ISSUED CANCELLED CUMULATIVE
24 February 1984 Issue to Promoters 200 200
22 November 1984 Issue to Promoters 243,300 243,500
14 June 1986 Issue to Promoters 6,500 250,000
9 August 1986 Issue to Public 1,116,250 1,366,250
30 September 1988 Forfeiture of 100 shares 100 1,366,150
9 August 1989 Rights Issue 819,750 2,185,900
16 December 1991 Bonus Issue (1:2) 1,092,950 3,278,850
17January 1993 Bonus Issue (1:1) 3,278,850 6,557,700
10 May 1994 Bonus Issue (2:1) 13,115,400 19,673,100
10 May 1994 Issue to Promoters 2,250,000 21,923,100
26 July 1994 GDR underlying Equity Shares 4,301,076 26,224,176
29 September 1995 SEFL Shareholders on merger 263,062 26,487,238
30 January 2001 CDL Shareholders on merger 5,142,942 31,630,180
30 January 2001 Cancellation of shares held in CDL 41,400 31,588,780
11 April 2001 ADR underlying Equity Shares 6,612,500 38,201,280
9 July 2001 GDR conversion into ADR 38,201,280
24 September 2001 ARL Shareholders on merger 56,694 38,257,974
25 October 2001 Sub division of equity shares* 76,515,948
30 January 2004 Allotment pursuant to exercise of Stock Options 3,001 76,518,949
2005-06 Allotment pursuant to exercise of Stock Options 175,621 76,694,570
11 May 2006 Allotment pursuant to exercise of Stock Options 7,683 76,702,253
1 July 2006 Allotment pursuant to exercise of Stock Options 34,687 76,736,940
16 August 2006 Allotment pursuant to exercise of Stock Options 20,862 76,757,802
30 August 2006 Bonus Issue (1:1) 76,757,802 153,515,604
22 November 2006 ADR underlying Equity Shares 12,500,000 166,015,604
29 November 2006 ADR underlying Equity Shares (Green Shoe option) 1,800,000 167,815,604
19 December 2006 Allotment pursuant to exercise of Stock Options 13,958 167,829,562
16 February 2007 Allotment pursuant to exercise of Stock Options 70,782 167,900,344
20 March 2007 Allotment pursuant to exercise of Stock Options 11,836 167,912,180
2007-08 Allotment pursuant to exercise of Stock Options 260,566 168,172,746
2008-09Allotment pursuant to exercise of Stock Options 223,605
168,468,777Allotment pursuant to exercise of ADR Stock Options 72,426
2009-10Allotment pursuant to exercise of Stock Options 302,451
168,845,385Allotment pursuant to exercise of ADR Stock Options 74,157
2010-11Allotment pursuant to exercise of Stock Options 363,296
169,252,732Allotment pursuant to exercise of ADR Stock Options 44,051
2011-12Allotment pursuant to exercise of Stock Options 264,683
169,560,346Allotment pursuant to exercise of ADR Stock Options 42,931
2012-13Allotment pursuant to exercise of Stock Options 228,583
169,836,475Allotment pursuant to exercise of ADR Stock Options 47,546
2013-14Allotment pursuant to exercise of Stock Options 241,140
170,108,868Allotment pursuant to exercise of ADR Stock Options 31,253
*Sub-division of one equity share of `10 face value into two equity shares of `5 face value.
82
HEALTHY FOREVERHEALTHY FOREVER
ADDITIONAL SHAREHOLDERS’ INFORMATION
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
STOCK DATATable 3 gives the monthly high/low and the total number of shares/ADRs traded per month on the BSE, NSE and the NYSE during FY2014. Chart 1 gives the movement of the Company’s share price on NSE vis-à-vis CNX Nifty during FY2014. Chart 2 gives the movement of Dr. Reddy's ADR prices on NYSE vis-à-vis S&P ADR Index during FY2014 and Chart 3 gives premium in percent on ADR traded on NYSE compared to price quoted at NSE during FY2014.
SHAREHOLDING PATTERNAS ON 31 MARCH 2014Tables 4 and 5 gives the data on shareholding classifi ed on the basis of ownership and shareholders’ class, respectively.
DIVIDEND HISTORYChart 4 on page 84 shows the dividend history of the Company from FY2004 to FY2014.
NOMINATION FACILITYShareholders holding physical shares may, if they so desire, send their nominations in Form SH.13 of the Companies (Share Capital and Debentures) Rules, 2014 to the Registrars & Transfer Agent of the Company. Those holding shares in dematerialized form may contact their respective Depository Participant (DP) to avail nomination facility.
SHARE TRANSFER SYSTEMAll queries and requests relating to share transfers/transmissions may be addressed to our Registrar and Transfer Agent.
BIGSHARE SERVICES PRIVATE LIMITED306, Right Wing, 3rd Floor, Amrutha VilleOpp. Yashoda Hospital, Rajbhavan RoadHyderabad 500 082Tel: +91-40-2337 4967Fax: +91-40-2337 0295E-mail ID: [email protected]
CHART 3
PREMIUM ON ADR TRADED ON NYSE VERSUS PRICE QUOTED AT THE NSE
2
0
-4
-2
-6
4
6
8
APR
13
AUG
13
MAY
13
SEP
13
DEC
13
JUN
13
OCT
13
JAN
14
JUL
13
NOV
13
FEB
14
MAR
14
Note: Premium has been calculated on a daily basis using RBI reference exchange rate.
MOVEMENT OF THE COMPANY’S SHARE PRICE ON NSE AND CNX NIFTY INDEX
CHART 1
130
120
110
100
90
140
150
160
APR
13
AUG
13
MAY
13
SEP
13
DEC
13
JUN
13
OCT
13
JAN
14
JUL
13
NOV
13
FEB
14
MAR
14
S&P CNX NIFTY
DR. REDDY’S SHARE PRICE
Notes: 1. All values are indexed to 100 as on 1 April 2013.2. S&P CNX Nifty is a well diversifi ed 50 stock index accounting for 22 sectors of the Indian economy. It is owned and managed by India Index Services and Products Ltd. (IISL), India’s fi rst specialized company focused upon the index as a core product.
90
120
110
100
130
140
150
APR
13
AUG
13
MAY
13
SEP
13
DEC
13
JUN
13
OCT
13
JAN
14
JUL
13
NOV
13
FEB
14
MAR
14
S&P ADR INDEX
DR. REDDY’S ADR PRICE
MOVEMENT OF ADR PRICE AND S&P ADR INDEX
CHART 2
Notes: 1. All values are indexed to 100 as on 1 April 2013.2. The S&P ADR Index is based on the non-US stocks comprising the S&P Global 1200 traded in the US exchanges. For details of the methodology used to compute this index please visit www.adr.com.
83
STATUTORY REPORTS/ADDITIONAL SHAREHOLDERS’ INFORMATION
TABLE 3 HIGH, LOW AND NUMBER OF SHARES TRADED PER MONTH ON BSE, NSE AND NYSE DURING FY2014
MONTHBSE NSE NYSE
HIGH (`) LOW (`) NO. OF SHARES HIGH (`) LOW (`) NO. OF
SHARES HIGH (US$) LOW (US$) NO. OF ADRs(1)
April 2013 2,035.00 1,766.30 3,57,214 2,038.65 1,768.25 7,550,136 37.97 32.78 6,522,617
May 2013 2,150.90 1,970.25 9,67,775 2,152.00 1,970.00 9,411,954 38.74 36.44 4,505,490
June 2013 2,230.00 2,037.00 3,86,553 2,233.90 2,034.20 6,279,834 38.73 34.31 4,370,973
July 2013 2,400.75 2,136.35 6,08,259 2,404.80 2,135.80 8,992,642 39.95 35.97 5,127,385
August 2013 2,354.95 2,025.00 3,74,255 2,367.00 2,027.00 6,892,056 37.81 31.32 6,362,800
September 2013 2,471.70 2,161.00 4,38,526 2,474.40 2,194.20 5,434,164 39.20 32.22 4,825,279
October 2013 2,545.00 2,350.00 5,61,434 2,545.15 2,354.00 6,752,780 41.03 38.08 4,035,946
November 2013 2,498.70 2,313.00 3,15,915 2,500.00 2,377.10 4,620,603 40.79 38.00 3,735,027
December 2013 2,554.00 2,393.15 2,16,118 2,557.55 2,391.15 4,481,172 41.42 38.43 4,011,115
January 2014 2,690.00 2,460.00 3,88,446 2,691.95 2,460.20 5,888,449 43.81 39.39 4,386,417
February 2014 2,939.80 2,517.05 3,71,192 2,939.40 2,516.55 6,713,826 47.93 41.08 5,515,902
March 2014 2,890.00 2,548.00 6,13,453 2,878.00 2,546.40 8,693,816 46.99 42.76 6,566,912
(1)One ADR is equal to one equity share.
TABLE 4 DISTRIBUTION OF SHAREHOLDINGS ON THE BASIS OF OWNERSHIP
AS ON 31 MARCH 2014 AS ON 31 MARCH 2013% CHANGE
NO. OF SHARES % OF TOTAL NO. OF SHARES % OF TOTAL
Promoters’ Holding
– Individuals 3,688,528 2.17 3,688,528 2.17 0.00
– Companies 39,729,284 23.35 39,729,284 23.39 (0.04)(1)
Sub-Total 43,417,812 25.52 43,417,812 25.56 (0.04)
Indian Financial Institutions 2,279,143 1.34 8,011,645 4.72 (3.38)
Banks 102,681 0.06 253,670 0.15 (0.09)
Mutual Funds 8,319,959 4.89 10,477,307 6.17 (1.28)
Foreign holdings
– Foreign Institutional Investors 58,353,621 34.30 50,367,192 29.65 4.65
– Non Resident Indians 2,276,099 1.34 2,437,396 1.44 (0.10)
– ADRs/Foreign Nationals 30,648,384 18.02 28,622,630 16.85 1.17
Sub total 101,979,887 59.95 100,169,840 58.98 0.97
Indian Public and Corporates 24,711,169 14.53 26,248,823 15.46 (0.93)
Total 170,108,868 100.00 169,836,475 100.00 0.00(1)Change in percentage due to further ESOP allotment.
TABLE 5 DISTRIBUTION OF SHAREHOLDING ACCORDING TO SHAREHOLDERS' CLASS AS ON 31 MARCH 2014
SHARES HELD NO. OF SHAREHOLDERS % OF SHAREHOLDERS NO. OF SHARES HELD % OF SHAREHOLDING
1 – 5,000 66,294 94.83 5,407,566 3.18
5,001 – 10,000 1,303 1.86 1,914,852 1.13
10,001 – 20,000 946 1.35 2,772,749 1.63
20,001 – 30,000 334 0.48 1,688,833 1.00
30,001 – 40,000 199 0.28 1,378,733 0.81
40,001 – 50,000 109 0.16 995,017 0.58
50,001 – 100,000 250 0.36 3,506,577 2.06
100,001 and above 469 0.67 121,802,306 71.60
Total (Excluding ADRs) 69,904 100.00 139,466,633 81.99
Equity shares underlying ADRs(1) 1 0.00 30,642,235 18.01
Total 69,905 100.00 170,108,868 100.00(1)Held by benefi cial owners outside India.
84
HEALTHY FOREVERHEALTHY FOREVER
ADDITIONAL SHAREHOLDERS’ INFORMATION
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
The Company periodically reviews the operations of its Registrar and Transfer Agent. The number of shares transferred/transmitted in physical form during the last two fi nancial years are given in Table 6.
DEMATERIALIZATION OF SHARESThe Company’s scrip forms part of the compulsory dematerialization segment for all investors with eff ect from 15 February 1999. To facilitate easy access of the dematerialized system to the investors, the Company has signed up with both the depositories — namely the National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL) — and has established connectivity with the depositories through its Registrar and Transfer Agent, Bigshare Services Private Limited.
Chart 5 gives the breakup of dematerialized shares and shares in certifi cate form as on 31 March 2014 as compared with that as on 31 March 2013. Dematerialization of shares is done through Bigshare Services Private Limited and on an average the dematerialization process is completed within 10 days from the date of receipt of a valid dematerialization request along with the relevant documents.
SECRETARIAL AUDITFor each quarter of FY2014, a qualifi ed practicing Company Secretary carried out the reconciliation of share capital audit to reconcile the total admitted share capital with NSDL and CDSL, total issued and listed share capital. The reports confi rm that the total issued/paid up share capital is in agreement with the total number of shares in physical form and dematerialized form held with NSDL and CDSL.
In addition to the above, a Secretarial Audit for FY2014 was carried out by Dr. K R Chandratre, practicing Company Secretary, having more than 27 years of experience. The report of said Secretarial Audit forms a part of this annual report.
OUTSTANDING ADRS AND THEIR IMPACT ON EQUITY SHARESThe Company’s ADRs are traded in the US on New York Stock Exchange Inc. (NYSE) under the ticker symbol ‘RDY’. Each ADR is represented by one equity share. As on 31 March 2014, there were approximately 10,530 record holders of ADRs evidencing 30,642,235 ADRs.
QUERIES AND REQUESTS RECEIVED FROM SHAREHOLDERS IN FY2014Table 7 gives details of types of shareholder queries received and replied to during FY2014. Pending queries and requests were either received during the last week of March 2014, or were pending due to non-receipt of information/documents from the shareholders.
DATES AND VENUE OF LAST THREE ANNUAL GENERAL MEETINGSTable 8 gives the details of date, time, location and business transacted through special resolution at last three Annual General Meetings. There is no proposal to conduct postal ballot for any matter in the ensuing Annual General Meeting.
DISCLOSURE ON LEGAL PROCEEDINGS PERTAINING TO SHARESThere are fi ve pending cases relating to disputes over title of the shares of the Company, in which the Company has been made a party. These cases, however, are not material in nature.
UNCLAIMED DIVIDENDS/INTERESTPursuant to Section 205A of the Companies Act, 1956, unclaimed dividends up to and including for the FY2006 have been transferred to the general revenue account of the Central Government/Investor Education and Protection Fund.
The dividends and interest on debentures for the following years, which remain unclaimed for seven years will be transferred to Investor
DIVIDEND HISTORY
FY2004-FY2014IN PERCENT
CHART 4
FY20
10
FY20
09
FY20
08
FY20
07
FY20
06
FY20
05
FY20
04
FY20
11
FY20
12
FY20
13
FY20
143
60
30
0
27
5
22
5
22
5
125
75
75
100
100
100
(Pro
pose
d)
BREAK UP OF SHARES IN
ELECTRONIC AND PHYSICAL
FORM
IN PERCENT
CHART 5
ELECTRONIC FORM NSDL
ELECTRONIC FORM CDSL
PHYSICALFORM
2013
2014
97.4
1.21.4
97.3
1.11.6
85
STATUTORY REPORTS/ADDITIONAL SHAREHOLDERS’ INFORMATION
TABLE 6 SHARES TRANSFERRED/TRANSMITTED IN PHYSICAL FORM
FY2014 FY2013
Number of transfers/transmissions 107 74
Number of shares 62,776 14,298
TABLE 8 LAST THREE ANNUAL GENERAL MEETINGS
YEAR DATE AND TIME LOCATION SPECIAL RESOLUTION(S) PASSED
2010-11 21 July 2011 at 11.30 A.M. Grand Ball Room, Hotel Taj KrishnaRoad No. 1, Banjara HillsHyderabad 500 034
Re-appointment of Dr. K Anji Reddy as Whole-time Director designated as ChairmanPayment of commission and grant of stock options to Directors other than the Managing/Whole-time Directors
2011-12 20 July 2012 at 11.30 A.M. Grand Ball Room, Hotel Taj KrishnaRoad No. 1, Banjara HillsHyderabad 500 034
Extension of term of Dr. Reddy’s Employees Stock Option Scheme, 2002
2012-13 31 July 2013 at 10.30 A.M. Grand Ball Room, Hotel Taj KrishnaRoad No. 1, Banjara HillsHyderabad 500 034
No Special Resolution passed
TABLE 7 SHAREHOLDER QUERIES AND REQUESTS RECEIVED AND REPLIED TO IN FY2014S. NO. NATURE OF LETTERS OPENING
BALANCE RECEIVED REPLIED CLOSING BALANCE(1)
1 Change of address - 142 142 -
2 Revalidation and issue of duplicate dividend warrants 53 1,534 1,361 226
3 Sub-division of shares (Exchange) 4 123 113 14
4 Share transfers 1 111 110 2
5 Transmission of shares 13 12 22 3
6 Split/Consolidation of shares - 4 4 -
7 Stop transfers - 23 23 -
8 Power of attorney registration - - - -
9 Change of bank mandate - 116 112 4
10 Correction of name - 9 9 -
11 Dematerialization of Shares 4 478 473 9
12 Rematerialization of Shares - - - -
13 lssue of duplicate share certificates of Dr. Reddy’s 3 28 25 6
14 lssue of duplicate share certificates of ARL/SEFL/CDL - - - -
15 Letters & emails received from Shareholders 8 1,130 1,131 7
16 Complaints received from Stock Exchanges/SEBI etc. - 13 13 -
(1)The Company has since resolved all the shareholders' queries which were pending as on 31 March 2014. The above table does not include those shareholder's disputes, which are pending in various counts.
TABLE 9 DATES OF TRANSFER OF UNCLAIMED DIVIDEND ON SHARES/INTEREST AND REDEMPTION AMOUNT ON DEBENTURES
FINANCIAL YEAR TYPE OF PAYMENT DATE OFDECLARATION/PAYMENT
AMOUNT OUTSTANDINGAS ON 31 MARCH 2014
DUE FORTRANSFER ON
2006-07 Final Dividend 24 July 2007 2,138,355.00 30 August 2014
2007-08 Final Dividend 22 July 2008 1,969,777.50 28 August 2015
2008-09 Final Dividend 22 July 2009 3,124,100.50 28 August 2016
2009-10 Final Dividend 23 July 2010 5,194,597.50 29 August 2017
2010-11 Final Dividend 21 July 2011 5,536,766.25 27 August 2018
2011-12 1st Year Debenture Interest 24 March 2012 1,866,050.08 23 March 2019
2011-12 Final Dividend 20 July 2012 6,927,697.50 26 August 2019
2012-13 2nd Year Debenture Interest 23 March 2013 1,966,396.38 22 March 2020
2012-13 Final Dividend 31 July 2013 8,090,520.00 05 September 2020
2013-14Debenture Redemption and 3rd & Final year’s Interest
24 March 2014 45,908,231.50 23 March 2021
86
HEALTHY FOREVERHEALTHY FOREVER
ADDITIONAL SHAREHOLDERS’ INFORMATION
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Education and Protection Fund established by the Central Government under Section 205C of the Companies Act, 1956. Table 9gives the transfer dates in this regard. The Bonus Debentures, issued by the Company in 2011, matured on March 24, 2014. They were redeemed for cash at face value of `5 each along with third and fi nal year’s interest. Shareholders/Debenture holders who have not claimed these dividends/interest/redemption amount are, therefore, requested to do so before they are statutorily transferred to the Investor Education and Protection Fund.
Shareholders/Debenture holders who have not encashed their dividend/interest warrants nor claimed the redemption amount on matured debentures as specifi ed in Table 9 are requested to immediately approach M/s. Bigshare Services Private Limited, Hyderabad for the issue of duplicate warrant(s)/demand draft(s) in lieu of the original warrants.
NON-COMPLIANCE ON MATTERS RELATING TO CAPITAL MARKETSThere has been no instance of non-compliance by the Company relating to capital markets for the last three years.
FINANCIAL RESULTS ON COMPANY’S WEBSITEThe quarterly, half yearly and annual results of the Company are displayed on its website: www.drreddys.com. Presentations to analysts, as and when made, are immediately placed on the website for the benefi t of the shareholders and public at large. Apart from the above, the Company also regularly provides relevant information to the stock exchanges as per the requirements of the Listing Agreements.
INFORMATION ON DIRECTORS PROPOSED FOR RE-APPOINTMENTThe information is given in the chapter on Corporate Governance.
QUERIES AT ANNUALGENERAL MEETINGShareholders desiring any information with regard to the accounts are requested to write to the Company at an early date so as to enable the management to keep the information ready. The queries relating to operational and fi nancial performance may be raised at the Annual General Meeting.
The Company provides the facility of Investor-Helpdesk at the Annual General Meeting. Shareholders may post their queries relating to shares, dividends etc., at this Investor-Helpdesk.
PROCEDURE FOR CONVENINGAN EXTRAORDINARYGENERAL MEETINGPursuant to the provisions of Section 100 of the Companies Act, 2013 and the Companies (Management and Administration) Rules, 2014, an Extraordinary General Meeting of the Company may be called on the requisition of shareholders, either in writing or through electronic mode, at least clear twenty one days prior to the proposed date of such extraordinary general meeting. Such a requisition shall set out the matters of consideration for which the meeting is to be called on, signed by the requisitionists and sent to the registered offi ce of the Company.
Members entitled to make requisition for an Extraordinary General Meeting with regard to any matter, shall be those who hold not less than one-tenth of such of the paid up share capital of the Company as on the date of the requisition, carries the right of voting.
PROCEDURE FOR NOMINATINGA DIRECTOR ON THE BOARDPursuant to Section 160 of the Companies Act, 2013, any member, intending to propose a person for appointment on the Board of the Company, or the person himself, shall deposit a signed notice signifying candidature to the offi ce of a Director, along with a deposit of `100,000 (Rupees
One Lakh) at the registered offi ce of the Company, not less than fourteen days before the shareholders’ meeting. This amount shall be refunded to such person or the member, if the person proposed gets elected as a director or gets more than 25% of votes.
All nominations are considered by the Nomination, Governance and Compensation Committee of the Board of Directors of the Company which entirely comprises of Independent Directors.
INFORMATION ON MEMORANDUM AND ARTICLES OF ASSOCIATIONThe Memorandum and Articles of Association of the Company are available at the corporate website of the Company:www.drreddys.com.
CERTIFICATE FROM THECOMPANY SECRETARYI, Sandeep Poddar, Company Secretary of Dr. Reddy’s Laboratories Limited, hereby confi rm that as on date of this certifi cate, the Company has:a. Complied with the provisions of the
Listing Agreements with the Stock Exchanges, applicable rules and regulations framed by the Securities and Exchange Board of India and the Companies Act, 1956, as applicable, including Companies Act, 2013 implemented as on date, certain of which sections has signifi cantly progressed as per timelines permitted under the Act.
b. Complied with the provisions prescribed for Directors’ Identifi cation Number under the Companies Act, 1956 and Director Identifi cation Number Rules, 2006 as amended.
c. Maintained all books of account and statutory registers prescribed under the Companies Act, 1956.
d. Filed all forms and returns and furnished all necessary particulars to the Registrar of Companies and/or authorities as required under the Companies Act, 1956.
87
STATUTORY REPORTS/ADDITIONAL SHAREHOLDERS’ INFORMATION
e. Conducted the Board meetings and Annual General Meeting as per the Companies Act, 1956 and the minutes thereof were properly recorded in the minutes books.
f. Eff ected share/debenture transfers and despatched the certifi cates within the time limit prescribed by various authorities.
g. Not exceeded the borrowing or investment limits.
h. Paid dividend to the shareholders, interest and redemption amount to the debenture holders within the prescribed time limit, transferred the unpaid dividend to the Investor Education and Protection Fund within the time limit and has also complied with the provisions of the Investor Education and Protection Fund (uploading of information regarding unpaid and unclaimed amounts lying with companies) Rules, 2012.
The certifi cate is given by the undersigned according to the best of his knowledge and belief and based on information and records, knowing fully that on the faith and strength of what is stated above, full reliance will be placed on it by the shareholders of the Company.
Place Hyderabad Sandeep PoddarDate 13 May 2014 Company Secretary
88
HEALTHY FOREVERHEALTHY FOREVER
ADDITIONAL SHAREHOLDERS’ INFORMATION
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
FORMULATIONSSRIKAKULAM PLANT (SEZ)Sector No. 9-13 & 17-20Devunipalavalasa VillageRanastalam MandalSrikakulam District, Andhra PradeshPin: 532 409
BIOLOGICSSurvey No. 47, Bachupally VillageQutubullapur MandalRanga Reddy District, Andhra PradeshPin: 500 123
RESEARCH ANDDEVELOPMENT FACILITIES
INTEGRATED PRODUCT DEVELOPMENT ORGANIZATION (IPDO)Bachupally VillageQutubullapur MandalRanga Reddy District, Andhra PradeshPin: 500 123
AURIGENE DISCOVERY TECHNOLOGIES LIMITED (ADTL), BANGALORE39-40, KIADB Industrial AreaElectronic City Phase IIHosur RoadBangalore, KarnatakaPin: 560 100
ADTL, HYDERABADBollaram Road, MiyapurHyderabad, Andhra PradeshPin: 500 049
TECHNOLOGYDEVELOPMENT CENTRE HYDERABAD 1Bollaram Road, MiyapurHyderabad, Andhra PradeshPin: 500 049
TECHNOLOGYDEVELOPMENT CENTRE HYDERABAD 2Plot 31A IDA, JeedimetlaHyderabad, Andhra PradeshPin: 500 050
FACILITY LOCATIONS IN INDIAACTIVE PHARMACEUTICAL INGREDIENTS (API) FACILITIES
API HYDERABAD PLANT 1Plot No. 137 & 138IDA Bollaram, Jinnaram MandalMedak District, Andhra PradeshPin: 502 325
API HYDERABAD PLANT 2Plot No. 75B, 105, 110 & 111IDA Bollaram, Jinnaram MandalMedak District, Andhra PradeshPin: 502 325
API HYDERABAD PLANT 3Plot No. 116, 116A & 126C & SY No. 157IDA Bollaram, Jinnaram MandalMedak District, Andhra PradeshPin: 502 325
API HYDERABAD PLANT 4Plot No. 9/A, 9/B, 22A, 22B & 22CPhase – III, IDA JeedimetlaRanga Reddy District, Andhra PradeshPin: 500 055
API NALGONDA PLANTPeddadevulapallyTripuraram MandalNalgonda District, Andhra PradeshPin: 508 207
API SRIKAKULAM PLANTIDA PydibheemavaramRansthal MandalSrikakulam District, Andhra PradeshPin: 532 409
API SRIKAKULAM PLANT (SEZ)Sector No. 28 & 34Devunipalavalasa Village Ranastalam Mandal,Srikakulam District, Andhra PradeshPin: 532 409
FORMULATIONSMANUFACTURING FACILITIES
FORMULATIONS HYDERABAD PLANT 1Plot No. 146IDA Bollaram, Jinnaram MandalMedak District, Andhra PradeshPin: 502 320
FORMULATIONSHYDERABAD PLANT 2Survey No. 42, 45, 46 & 54Bachupally, Qutubullapur MandalRanga Reddy District, Andhra PradeshPin: 500 123
FORMULATIONS HYDERABAD PLANT 3Survey No. 41Bachupally, Qutubullapur MandalRanga Reddy District, Andhra PradeshPin: 500 123
FORMULATIONS YANAM PLANTWard-F, Block-4, AdavipolamYanam, PondicherryPin: 533 464
FORMULATIONS BADDI PLANT 1Khol, NalagarhSolan District, Nalagarh Road BaddiHimachal PradeshPin: 173 205
FORMULATIONS BADDI PLANT 2Village Mauja ThanaNalagarh Baddi Road, BaddiSolan District, Himachal PradeshPin: 173 205
FORMULATIONS VIZAG SEZ PLANT 1Plot No. P1-P9, Phase IIIDuvvada, VSEZ, VisakapatanamAndhra PradeshPin: 530 046
FORMULATIONS VIZAG SEZ PLANT 2Plot No. Q1 to Q5, Phase IIIDuvvada, VSEZ, VisakapatanamAndhra PradeshPin: 530 046
89
STATUTORY REPORTS/ADDITIONAL SHAREHOLDERS’ INFORMATION
FACILITY LOCATIONSOUTSIDE INDIA
KUNSHAN ROTAM REDDY PHARMACEUTICAL CO. LIMITEDNo.258, Huang Pu Jiang (M) RoadKunshan Development ZoneJiangsu Province, P. R. ChinaPin: 215 300
API CUERNAVACA PLANTIndustrias Quimicas Falcon de MexicoS.A. de C.V.Carretera Federal Cuernavaca-CuautlaKM 4.5 CIVAC, Jiutepec, MorelosMexico 62578
DR. REDDY’S LABORATORIES(UK) LIMITED6, Riverview RoadBeverly, East Yorkshire, HU 17 OLDUnited Kingdom
API MIRFIELD PLANTDR. REDDY’S LABORATORIES(EU) LTD.Steanard LaneMirfi eld, West YorkshireWF 14,8HZUnited Kingdom
TECHNOLOGYDEVELOPMENT CENTRECAMBRIDGE CHIROTECH TECHNOLOGY LIMITED410, Cambridge Science ParkMilton RoadCambridge, CB4 0PE United Kingdom
FORMULATIONSSHREVEPORT PLANTDr. Reddy’s Laboratories Louisiana LLC8800, Line AvenueShreveport, Louisiana 71106USA
FORMULATIONS BRISTOL PLANTDr. Reddy’s Laboratories Tennessee LLCP.O. Box 9002,201, Industrial Drive, BristolTennessee 37621-9002USA
API MIDDLEBURGH PLANTDR. REDDY’S LABORATORIES NEW YORK INC.1974, Route 145, P.O. Box 500Middleburgh, New York 12122USA
TECHNOLOGY DEVELOPMENT CENTRE LEIDEN OCTOPLUS N.V.Zernikedreef 12, 2333 CL LeidenThe Netherlands
TECHNOLOGY DEVELOPMENT CENTRE PRINCETON303, College Road East,Princeton, New Jersey 08540USA
90
HEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Five yearsat a Glance
` million
YEAR ENDED MARCH 31 2014 2013 2012 2011 2010
INCOME STATEMENT DATA
Revenues 1,32,170 1,16,266 96,737 74,693 70,277
Cost of revenues 56,369 55,687 43,432 34,430 33,937
Gross profit 75,801 60,579 53,305 40,263 36,340
as a % of revenues 57 52 55 54 52
OPERATING EXPENSES
Selling, general and administrative expenses* 38,783 34,272 29,907 23,689 31,108
Research and development expenses 12,402 7,674 5,911 5,060 3,793
Other Operating (income)/expenses, net (1,416) (2,479) (765) (1,115) (569)
Total operating expenses 49,769 39,467 35,053 27,634 34,332
Operating income 26,032 21,112 18,252 12,629 2,008
as a % of revenues 20 18 19 17 3
FINANCE COSTS, NET
Finance income 1,674 1,478 1,227 173 369
Finance expenses (1,274) (1,018) (1,067) (362) (372)
Finance (expense)/income, net 400 460 160 (189) (3)
Share of profit of equity accounted investees, net of income tax 174 104 54 3 48
Profit before income tax 26,606 21,676 18,466 12,443 2,053
Income tax benefit/(expense) (5,094) (4,900) (4,204) (1,403) (985)
Profit for the year 21,512 16,776 14,262 11,040 1,068
as a % of revenues 16 14 15 15 2
EARNINGS PER SHARE (`)
– Basic 126.52 98.82 84.16 65.28 6.33
– Diluted 126.04 98.44 83.81 64.95 6.30
Dividend declared per share (`) 18.00 15.00 13.75 11.25 11.25
BALANCE SHEET DATA
Cash and cash equivalents, net of bank overdraft 8,451 5,054 7,379 5,660 6,545
Operating working capital** 46,526 41,710 35,189 25,194 16,009
Total assets 1,70,223 1,42,369 1,19,477 95,005 80,330
Total long-term debt, excluding current portion 20,740 12,625 16,335 5,271 5,385
Total stockholders' equity# 90,801 72,805 57,287 45,803 42,915
ADDITIONAL DATA
NET CASH PROVIDED BY/(USED IN):
Operating activities 19,463 13,317 16,150 8,009 13,226
Investing activities (16,620) (13,944) (18,665) (8,658) (6,998)
Financing activities (217) (1,792) 3,735 (377) (5,307)
Effect of exchange rate changes on cash 771 94 499 141 246
Expenditure on property, plant and equipment & Intangibles (10,627) (7,336) (8,585) (11,606) (4,283)
* Includes impairment of goodwill and other intangibles and reversal of impairment. Figures are regrouped for previous years.
** Operating working capital = Trade receivables + inventories - Trade payables
# Restated to refl ect the adoption of revised IAS-19
91
CORPORATE OVERVIEW/FIVE YEARS AT A GLANCE AND KEY FINANCIAL RATIOS
Key FinancialRatios
YEAR ENDED MARCH 31 2014 2013 2012 2011 2010
PROFITABILITY RATIOS
EBITDA margin % 25% 24% 26% 22% 23%
Gross Margin % 57% 52% 55% 54% 52%
– Global Generics 66% 59% 63% 65% 60%
– PSAI 20% 32% 32% 26% 33%
Adjusted PAT* margin % 16% 15% 16% 14% 13%
ASSET PRODUCTIVITY RATIOS
Fixed Asset Turnover 3.2 3.3 3.1 2.9 3.2
Total Assets Turnover 0.8 0.9 0.9 0.9 0.9
WORKING CAPITAL RATIOS
Working Capital Days 165 154 154 134 130
Inventory Days 148 134 149 156 143
Debtors Days 90 90 81 72 69
Creditor Days 72 70 76 94 82
GEARING RATIO
Net Debt/Equity 0.12 0.20 0.24 0.39 0.10
VALUATION RATIOS
Earnings per share (`) 126.04 98.44 83.81 64.95 6.30
Book Value per share (`) 532 427 337 269 253
Dividend Payout % 14% 15% 16% 17% 179%
Trailing Price/Earnings Ratio 20.3 17.9 19.6 28.7 18.9
(1) Fixed Asset Turnover: Net Sales/Avg Net Fixed Assets (Property, plant and equipment)
(2) Total Asset Turnover: Net Sales/Avg Total Assets
(3) Working Capital Days: Inventory Days + Receivable Days – Payable Days
(4) Inventory Days: Average Inventory/Cost of Revenue * 365
(5) Receivable Day: Average Trade Receivables/Turnover * 365
(6) Payable Days: Average Trade Payables/Cost of Revenue * 365
(7) Book Value per share: Equity/Outstanding equity shares
(8) Dividend Payout: DPS/EPS
(9) Trailing price: Closing share price on the last working day of March
Adjusted for non-cash impairment charge and other non-recurring costs/income
92
HEALTHY FOREVERHEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
SecretarialAudit Report
THE BOARD OF DIRECTORS,Dr. Reddy’s Laboratories Limited8-2-337, Banjara Hills, Road No. 3Hyderabad 500 034
I have examined the registers, records and documents of Dr. Reddy’s Laboratories Limited (“the Company”) for the fi nancial year ended on 31 March 2014 according to the provisions of –
The Companies Act, 1956 and the Rules made under that Act;The Depositories Act, 1996 and the Regulations and Bye-laws framed under that Act;The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (‘SEBI Act’):
The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
The Securities Contracts (Regulation) Act, 1956 (‘SCRA’), the Rules made under that Act; and
The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008.
The Equity Listing Agreements with BSE Limited, National Stock Exchange of India Limited, Debt Listing Agreements with National Stock Exchange of India Limited and BSE Limited and Listed
Company Manual of New York Stock Exchange Inc.
1. Based on my examination and verifi cation of the registers, records and documents produced to me and according to the information and explanations given to me by the Company, I report that the Company has, in my opinion, complied with the provisions of the Companies Act, 1956 (“the Act”) and the Rules made under the Act and the Memorandum and Articles of Association of the Company, with regard to:
(a) maintenance of various statutory registers and documents and making necessary entries therein;
(b) closure of the Register of Members/Debenture holders;
(c) forms, returns, documents and resolutions required to be fi led with the Registrar of Companies and Central Government;
(d) service of documents by the Company on its Members, Debenture holders, Debenture Trustees, Auditors and the Registrar of Companies;
(e) notice of Board meetings and Committee meetings of Directors;
(f) the meetings of Directors and Committees of Directors including passing of resolutions by circulation;
(g) the 29th Annual General Meeting held on 31 July 2013;
(h) minutes of proceedings of General Meetings and of Board and its Committee meetings;
(i) approvals of the Members, the Board of Directors, the Committees of Directors and government authorities, wherever required;
(j) constitution of the Board of Directors/Committee(s) of Directors and appointment, retirement and re-
93
STATUTORY REPORTS/SECRETARIAL AUDIT REPORT
appointment of Directors including the Managing Director and Whole-time Director;
(k) payment of remuneration to the Directors including the Managing Director and Whole-time Director;
(l) appointment and remuneration of Auditors and Cost Auditors;
(m) transfers and transmissions of the Company’s shares and debentures, issue and allotment of shares and debentures and issue and delivery of original and duplicate certifi cates of shares and debentures;
(n) payment of interest on debentures and redemption of debentures;
(o) declaration and payment of dividends;(p) transfer of certain amounts as required
under the Act to the Investor Education and Protection Fund;
(q) borrowings and registration, modifi cation and satisfaction of charges;
(r) investment of the Company’s funds including inter corporate loans and investments and loans to others;
(s) giving guarantees in connection with loans taken by subsidiaries and associate companies;
(t) form of Balance Sheet and Profi t and Loss Account under the Act;
(u) Board’s Report;(v) contracts, common seal, registered
offi ce and publication of name of the Company; and
(w) generally, all other applicable provisions of the Act and the Rules made under that Act; and
(x) the Company has not accepted any fi xed deposits and hence provisions of Sections 58A and 58AA and Rules framed thereunder are not applicable to the Company.
2. I further report that:(a) the Directors have complied with
the requirements as to disclosure of interests and concerns in contracts and arrangements, shareholdings/debenture holdings and directorships in other companies and interests in other entities;
(b) the Directors have complied with the disclosure requirements in respect of
their eligibility of appointment, their being independent and compliance with the code of Business Conduct & Ethics for Directors and Management Personnel;
(c) the Company has obtained all necessary approvals under the various provisions of the Act; and
(d) there was no prosecution initiated and no fi nes or penalties were imposed during the year under review under the Companies Act, SEBI Act, SCRA, Depositories Act, Listing Agreement and Rules, Regulations and Guidelines framed under these Acts against/on the Company, its Directors and Offi cers.
3. I further report that the Company has complied with the provisions of the Depositories Act, 1996 and the Bye-laws framed there under by the Depositories with regard to dematerialization/rematerialization of securities and reconciliation of records of dematerialized securities with all securities issued by the Company.
4. I further report that:(a) the Company has complied with the
requirements under the Equity Listing Agreements entered into with the BSE Limited and the Debt Listing Agreements with National Stock Exchange of India Limited and BSE Limited and the Listed Company Manual of New York Stock Exchange Inc;
(b) the Company has complied with the provisions of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 including the provisions with regard to disclosures and maintenance of records required under the Regulations;
(c) the Company has complied with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 including the provisions with regard to disclosures and maintenance of records required under the Regulations; and
(d) the Company has complied with the provisions of the Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 and Debenture Trust Deed with regard to the disclosures under the Deed.
Dr. K R ChandratrePracticing Company SecretaryCertifi cate of Practice No. 5144
Dated 1 May 2014
94
HEALTHY FOREVERHEALTHY FOREVER
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
DEAR MEMBERS,Your Directors are pleased to present the 30th annual report for the year ended 31 March 2014.
FINANCIAL HIGHLIGHTSTable 1 gives the fi nancial highlights of the Company for FY2014 compared to the previous fi nancial year on Indian GAAP standalone basis.
DIVIDENDYour Directors are pleased to recommend a dividend of `18 on every equity share of `5 each (360%) for FY2014. The dividend, if approved at the 30th Annual General Meeting, will be paid to those shareholders whose names appear on the register of members of the Company as on 15 July 2014. The dividend is tax-free in the hands of the shareholders.
SHARE CAPITALThe paid-up share capital of your Company increased by `1.36 million in FY2014 due to the allotment of 272,393 equity shares on exercise of stock options by the eligible employees under Dr. Reddy’s Employees Stock Option Scheme, 2002 and Dr. Reddy’s Employees ADR Stock Option Scheme, 2007.
UNSECURED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (NCDS)The unsecured, redeemable, non-convertible debentures (NCDs) of `5 each issued by the Company in FY2011 as bonus debentures were due for maturity on 24 March 2014. These were redeemed at par and paid along with the third and fi nal year’s interest.
CORPORATE GOVERNANCE AND ADDITIONAL SHAREHOLDERS' INFORMATIONA detailed report on the corporate governance systems and practices of the Company is given in a separate chapter of the annual report 2013-14. Similarly, other
TABLE 1 FINANCIAL HIGHLIGHTS ` million
FY2014 FY2013
Total revenue 98,795 85,757Profit before depreciation and tax 28,349 20,660
Depreciation 3,805 3,128
Profit before tax 24,544 17,532
Tax expense 5,216 4,877
Net profit for the year 19,328 12,655Add: Surplus at the beginning of the year 43,614 36,049
Total available for appropriation 62,942 48,704Appropriations:Proposed dividend on equity shares 3,062 2,548
Tax on proposed dividend 520 433
Credit of dividend distribution tax (2) (4)
Dividend of previous years (including tax) 3 3
Debenture Redemption Reserve 827 845
Transfer to General Reserve 1,933 1,265
Balance carried forward 56,599 43,614
Directors’Report
detailed information for shareholders is given in chapter on Additional Shareholders’ Information.
MANAGEMENT DISCUSSION AND ANALYSISA detailed report on the ManagementDiscussion and Analysis is provided as a separate chapter in the annual report.
BUSINESS RESPONSIBILITY REPORTA detailed Business Responsibility Reportis given as a separate chapter in the annual report.
SUBSIDIARY COMPANIESThe Company has 51 subsidiaries as on 31 March 2014. During FY2014, two subsidiaries namely, Dr. Reddy’s Laboratories Canada Inc., USA and Dr. Reddy’s Singapore PTE. Ltd., Singapore were incorporated. Further, during FY2014, Reddy US Therapeutics Inc., USA ceased to be a subsidiary of the Company.
As per Section 212 of the Companies Act, 1956, the Company is required to attach the Directors’ Report, Balance Sheet and Statement of Profi t and Loss of the subsidiaries to the annual report. The Ministry of Corporate Aff airs, Government of India vide its circular No. 2/2011 dated 8 February 2011 has provided an exemption to the companies from complying with Section 212, provided such companies publish the audited consolidated fi nancial statements in their annual report.
Accordingly, the annual report 2013-14 does not contain the fi nancial statements of the subsidiaries. The audited annual accounts and related information of the subsidiaries,
FY2014 represents fi scal year 2013-14, from 1 April 2013 to 31 March 2014. Analogously for FY2013 and previously such labeled years.
95
STATUTORY REPORTS/DIRECTORS’ REPORT
where applicable, will be made available for inspection during business hours at our registered offi ce in Hyderabad, India. The same will also be published on the Company’s website: www.drreddys.com
The members, if they so desire, may write to the Company Secretary at Dr. Reddy’s Laboratories Limited, 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034, to obtain a copy of the fi nancials of the subsidiary companies.
The consolidated fi nancial statements, in terms of Section 129 of the Companies Act, 2013 and Clause 32 of the Listing Agreement and prepared in accordance with Accounting Standard 21 as specifi ed in the Companies (Accounting Standards) Rules, 2006 also forms a part of this annual report.
DIRECTORSSub-section (10) of Section 149 of the Companies Act, 2013 (eff ective 1 April 2014) provides that an Independent Director shall hold offi ce for a term of up to fi ve consecutive years on the Board of a Company; and shall be eligible for re-appointment on passing of a special resolution by the shareholders of the Company. Sub-section (11) of the same section states that no Independent Director shall be eligible for more than two consecutive terms of up to fi ve years each. In addition, sub-section 13 of Section 149 states that the provisions of retirement by rotation as defi ned in sub-sections (6) and (7) of Section 152 of the Act, shall not apply to such Independent Directors.
The new Clause 49 notifi ed by the SEBI on April 17, 2014, most of which comes into eff ect from 1 October 2014, states in sub-clause II (B)(2) that any Independent Director “who has already served fi ve years or more in a listed company as on 1 October 2014, shall be eligible for appointment, on completion of his present term, for one more term of up to fi ve years only.”
The appointment of Non-Executive Directors — whose sub-set comprise Independent Directors — under the Companies Act, 1956 was a de facto term of three years because one third of such fi duciaries were eligible for retirement by rotation. Therefore, it stands to reason that those Independent Directors who would complete their present three-year term at the ensuing AGM of the Company in July 2014, and are eligible for re-appointment, may be considered by the shareholders for re-appointment for a term of up to fi ve years.
Therefore, the Board recommends to re-appoint the retiring Directors, Mr. Anupam Puri for an additional period of four years and Dr. Bruce L A Carter and Mr. Sridar Iyengar, for an additional period of fi ve years each, respectively.
Further, the Board also recommends the appointment of Dr. Ashok S Ganguly, Dr. J P Moreau, Ms. Kalpana Morparia, Dr. Omkar Goswami and Mr. Ravi Bhoothalingam as Independent Directors under the provisions of the Companies Act, 2013 and Clause 49 of the Listing Agreement, not liable to retire by rotation and to hold offi ce for the period as stated in their respective resolutions and the explanatory statement forming part of the Notice of the AGM.
The brief profi le of all the Independent Directors is given in the Corporate Governance section of the annual report for reference of the shareholders.
The Board of Directors at their meeting held on 13 May 2014 has re-designated Mr. Satish Reddy as Chairman and Mr. G V Prasad as Co-Chairman, Managing Director and Chief Executive Offi cer of the Company.
Further, pursuant to the provisions of Section 152 of the Companies Act, 2013 (eff ective 1 April 2014), one-third of the retiring Board members (other than Independent Directors), shall retire every year and if eligible, can be re-appointed, by the shareholders at their meeting.
Hence, approval of shareholders is also being sought for variation in terms of appointment of Mr. G V Prasad and Mr. Satish Reddy, Executive Directors for making their offi ce liable to retire by rotation. All other terms and conditions of their appointment shall remain unchanged.
The respective resolutions to the above-referred matters are included in the notice convening the 30th Annual General Meeting scheduled on 31 July 2014.
DIRECTORS’ RESPONSIBILITY STATEMENTIn terms of Section 217(2AA) of the Companies Act, 1956, your Directors confi rm as under:
1. In preparation of annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
2. Accounting policies have been selected and applied consistently and judgments and estimates made, are reasonable and prudent so as to give a true and fair view of the state of aff airs of the Company at the end of the FY2014 and of profi t of the Company for that period;
3. Proper and suffi cient care has been taken to maintain adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. Annual accounts have been prepared on a going concern basis.
STATUTORY AUDITORSThe statutory auditors of the Company, B S R & Co. LLP, Chartered Accountants, retire at the ensuing Annual General Meeting and have confi rmed their eligibility and willingness to accept offi ce of the statutory auditors, if re-appointed.
96
HEALTHY FOREVERHEALTHY FOREVER
DIRECTORS’ REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
Section 139(2) of the Companies Act, 2013 (eff ective 1 April 2014), mandates that a listed company or such other prescribed classes of companies shall not appoint or re-appoint an audit fi rm as Statutory Auditors for more than two terms of fi ve consecutive years each.
Further, the companies as aforesaid, whose Statutory Auditors has held offi ce for a period of ten years or more are required to comply with these provisions, within three years from the date of commencement of these provisions i.e. 1 April 2014. For this purpose, the term of the audit fi rm before the commencement of these provisions shall be taken into account for calculating the period of ten consecutive years.
Our auditors, M/s. B S R & Co. LLP, Chartered Accountants, are holding the offi ce as Statutory Auditors since FY2003. Hence, they can only be re-appointed for a period up to three years, i.e. up to FY2017.
The Audit Committee and the Board of Directors recommend the re-appointment of M/s. B S R & Co. LLP, Chartered Accountants as statutory auditors of the Company up to FY2016, for shareholders’ approval.
COST AUDITThe Central Government, in exercise of its powers conferred under sub-section (1) of Section 148 of the Companies Act, 2013 (eff ective 1 April 2014) has directed an audit of cost accounting records in respect of pharmaceuticals. The audit needs to be conducted by a Cost Accountant in Practice appointed for this purpose and whose appointment needs to be approved by the Board. The provisions also require that the remuneration of such cost auditor shall be ratifi ed by the shareholders.
Based on the recommendations of the Audit Committee, the Board of Directors appointed M/s. Sagar & Associates as cost auditors of the Company for FY2015. The
cost audit report would be fi led with the Central Government as per the stipulated timeline. As a matter of record, relevant cost audit reports for FY2013 were fi led on 27 September 2013, three days before thedue date.
SECRETARIAL AUDIT REPORTA secretarial audit for FY2014 was carried out by Dr. K R Chandratre, practicing Company Secretary. This forms a part of the annual report. It confi rms that the Company has complied with all the applicable provisions of the Companies Act, 1956, Depositories Act, 1996, Equity and Debt Listing Agreements with the Stock Exchanges, Debenture Trust Deed, Securities Contracts (Regulation) Act, 1956 and all the regulations of Securities and Exchange Board of India (SEBI) as applicable to the Company, including the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and the SEBI (Prohibition of Insider Trading) Regulations, 1992.
TRANSFER OF UNPAID AND UNCLAIMED AMOUNTS TO IEPFPursuant to the provisions of Section 205A(5) of the Companies Act, 1956, the declared dividends, which remained unpaid or unclaimed for a period of seven years, have been transferred by the Company to the Investor Education and Protection Fund (IEPF) established by the Central Government pursuant to Section 205C of the said Act.
EMPLOYEES STOCK OPTION SCHEMESThe details of stock options as on 31 March 2014 under the ‘Dr. Reddy’s Employees Stock Option Scheme, 2002’ and the ‘Dr. Reddy’s Employees ADR Stock Option Scheme, 2007’, in terms of Guideline 12 of the Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, as amended, are set out in the Annexure 1 to the Directors’ Report.
PARTICULARS OF EMPLOYEESIn terms of the provisions of Section 217(2A) of the Companies Act, 1956, read with the Companies (Particulars of Employees) Rules, 1975, as amended, the names and other particulars of the employees are set out in the annexure to the Directors’ Report. Having regard to the provisions of Section 219(1)(b)(iv) of the said Act, the annual report excluding the aforesaid information is being sent to the members of the Company. Any member interested in obtaining such particulars may write to the Company Secretary of the Company.
CONSERVATION OF ENERGY, RESEARCH AND DEVELOPMENTS, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGOThese particulars as prescribed under Section 217(1)(e) of the Companies Act, 1956, read with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988 are set out in the Annexure 2 to the Directors’ Report.
ACKNOWLEDGEMENTYour Directors place on record their sincere appreciation for the signifi cant contribution made by the employees through their dedication, hard work and commitment and the trust reposed on us by the medical fraternity and the patients. We also acknowledge the support and wise counsel extended to us by analysts, bankers, government agencies, shareholders and investors at large. We look forward to having the same support in our endeavor to help people lead healthier lives.
For Dr. Reddy’s Laboratories Limited,
G V PrasadChairman and Chief Executive Offi cer
Place HyderabadDate 13 May 2014
97
STATUTORY REPORTS/DIRECTORS’ REPORT
ANNEXURE – 1Pursuant to the provisions of Guideline 12 of the Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme), Guidelines, 1999, as amended, the details of stock options as on 31 March 2014 under the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007 are as under:
EMPLOYEES STOCK OPTION SCHEMES
S. NO. DESCRIPTION
DETAILS
DR. REDDY’S EMPLOYEES STOCK OPTION SCHEME, 2002
DR. REDDY’S EMPLOYEES ADR STOCK OPTION SCHEME, 2007
1 Total Options granted 6,851,606 572,918
2 Pricing formula Dr. Reddy’s Employees Stock Option Scheme, 2002
provides for the grant of options in two categories:
Dr. Reddy’s Employees ADR Stock Option Scheme,
2007 provides for the grant of options in two
categories:
Category A: 505,939 stock options out of the total
of 4,349,102 reserved for grant of options having an
exercise price equal to the fair market value of the
underlying equity shares on the date of grant; and
Category A: 382,695 stock options out of the total
of 1,530,779 reserved for grant of options having an
exercise price equal to the fair market value of the
underlying equity shares on the date of grant; and
Category B: 3,843,163 stock options out of the total
of 4,349,102 reserved for grant of options having an
exercise price equal to the par value of the underlying
equity shares (i.e. `5 per option).
Category B: 1,148,084 stock options out of the total
of 1,530,779 reserved for grant of options having an
exercise price equal to the par value of the underlying
equity shares (i.e. `5 per option).
The fair market value of a share on each grant date
falling under Category A above is defined as the
weighted average closing price of the company’s
equity shares for 30 days prior to the grant, in the
stock exchange where there is highest trading
volume during that period.
The fair market value of a share on each grant date
falling under Category A above is defined as the
closing price of the Company’s equity shares on the
trading day immediately preceding the date of grant,
in the stock exchange where there is highest trading
volume during that period.
3 Options vested as at 31 March 2014 60,818 7,265
4 Total Options exercised 2,464,608 312,364
5Total number of shares arising as a
result of exercise of options2,464,608 312,364
6 Total Options lapsed 3,735,324 163,091
7 Variation of terms of Options 1. Members of the Company approved the
amendment in Dr. Reddy’s Employees Stock Option
Scheme, 2002 at the Annual General Meeting held on
28 July 2004. The amendment enabled the Company
to grant Stock Options in two categories of par value
and fair market value. Before this amendment, the
Scheme provided for grant of options at fair market
value only.
1. Members of the Company approved the
amendment in Dr. Reddy’s Employees ADR Stock
Option Scheme, 2007, at the Annual General Meeting
held on 22 July 2008, to exercise the right to recover
from the relevant employees, the fringe benefit tax, in
respect of options granted to or vested or exercised
by the eligible employees under provisions of the
Income Tax Act, 1961.
2. Members of the Company further approved the
amendment in Dr. Reddy’s Employees Stock Option
Scheme, 2002 at the Annual General meeting held on
27 July 2005. The amendment enabled the Company
to grant options in the following categories:
Category A: 300,000 stock options out of the total
of 2,295,478 reserved for grant of options having an
exercise price equal to the fair market value of the
underlying equity shares on the date of grant; and
98
HEALTHY FOREVERHEALTHY FOREVER
DIRECTORS’ REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
EMPLOYEES STOCK OPTION SCHEMES (CONTINUED)
S. NO. DESCRIPTION
DETAILS
DR. REDDY’S EMPLOYEES STOCK OPTION SCHEME, 2002
DR. REDDY’S EMPLOYEES ADR STOCK OPTION SCHEME, 2007
Category B: 1,995,478 stock options out of the total
of 2,295,478 reserved for grant of options having an
exercise price equal to the par value of the underlying
equity shares (i.e. `5 per option).
3. Members of the Company further approved the
amendment in Dr. Reddy’s Employees Stock Option
Scheme, 2002, at the Annual General Meeting held
on 22 July 2008, to exercise the right to recover
from the relevant employees, the fringe benefit tax, in
respect of options granted to or vested or exercised
by the eligible employees under provisions of the
Income Tax Act, 1961. Further, pursuant to changes
in the work levels in the organization structure of the
Company, the Members of the Company approved
removing the grades and designations prescribed in
the scheme.
The Government of India has abolished fringe benefit
tax through the Finance Act 2009. Under this Act
the fringe benefit tax payable by the employer as a
result of share based payments would be replaced
by an income tax payable by the employees as a
“perquisite” (as defined in the Indian Income Tax Act,
1961) based on the value of the underlying share as
on the date of exercise of the options. Consequent
to this abolishment and in furtherance of the
resolution passed by the Company on 22 July 2008,
management resolved to absorb the consequent
perquisite tax for the options granted on or prior to
18 May 2008.
8 Total Money realised by exercise of
options`164,094,214 `1,561,820
9 Total number of options in force 651,674 97,463
10 Employee wise details of options
granted during the year to
(i) Senior managerial PersonnelNAME
EXERCISE PRICE
NO. OF OPTIONS
NAMEEXERCISE
PRICENO. OF
OPTIONS
Mr. Abhijit Mukherjee Par Value 6,000 Dr. Raghav Chari Par Value 3,500
Mr. Saumen Chakraborty Par Value 3,500
Mr. Umang Vohra Par Value 4,000
Dr. Cartikeya Reddy Par Value 3,500
Dr. R Ananthanarayanan Par Value 4,500
Mr. M V Ramana Par Value 4,000
Mr. Samiran Das Par Value 3,300
Dr. Amit Biswas Par Value 3,300
Dr. K V S Ram Rao Par Value 1,600
Mr. Alok Sonig Par Value 2,200
(ii) Any other employee who receives
a grant in any one year of option
amounting to 5% or more of option
granted during that year.
None None
99
STATUTORY REPORTS/DIRECTORS’ REPORT
EMPLOYEES STOCK OPTION SCHEMES (CONTINUED)
S. NO. DESCRIPTION
DETAILS
DR. REDDY’S EMPLOYEES STOCK OPTION SCHEME, 2002
DR. REDDY’S EMPLOYEES ADR STOCK OPTION SCHEME, 2007
(iii) Identified employees who were
granted option, during any one year,
equal to or exceeding 1% of the
issued capital (excluding outstanding
warrants and conversions) of the
Company at the time of grant;
None None
11 Diluted Earnings Per Share (EPS)
pursuant to issue of shares on
exercise of option calculated in
accordance with Accounting Standard
(AS) 20 ‘Earnings Per Share’
`113.13
12 The difference between the employee
compensation cost computed under
Intrinsic Value Method and the
employee compensation cost that
shall have been recognized if the
Company had used the Fair Value
Methods and its impact on profits and
on EPS of the Company
The employee Compensation Cost on account of ESOP in the financial year 2013-14 based on Intrinsic Value
Method is `472 million. Had the Company used the Fair Value Method, the ESOP cost in the financial year
would have been `436 million, which would have a consequential impact on profit.
However, there would not have been any significant adverse effect on the Profit and EPS, on using fair value
method of accounting.
13 Weighted-average exercise prices
and weighted-average fair values of
options for options whose exercise
price either equals or exceeds or
is less than the market price of the
stock
Weighted average exercise price and weighted average fair value of the outstanding Fair Market Value options
as on 31 March 2014 was `448 and `210, respectively.
Weighted average exercise price and weighted average fair value of the outstanding Par Value options as on
31 March 2014 was `5 and `1,724, respectively.
14 Description of the method and
significant assumptions used during
the year to estimate the fair values of
options:
The Company has opted Intrinsic Value Method for accounting of Compensation Cost arising out of ESOP.
However for disclosures in para 12 above the following assumptions have been used:
(i) Risk-free interest rate 7.38% – 7.51%
(ii) Expected life 12 months to 48 months
(iii) Expected volatility 18.87% – 23.88%
(iv) Expected dividends 0.72%
(v) The price of the underlying share in
market at the time of option grant`2,077.30
100
HEALTHY FOREVERHEALTHY FOREVER
DIRECTORS’ REPORT
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
ANNEXURE – 2FORM FOR DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY
FORM A POWER AND FUEL CONSUMPTION
1. ELECTRICITY FY2014 FY2013
Purchased
Unit 271,595,729 219,220,958
Total amount (`) 1,736,359,312 1,359,301,040
Rate/unit (`) 6.39 6.20
Own generation – through diesel generator set
Unit 11,536,089 44,386,029
Units per ltr. of diesel oil 3.46 3.56
Rate/unit (`) 17.83 13.56
2. COAL (USED IN BOILER)
Quantity (tonnes) 65,351 72,806
Total Cost (`) 341,481,183 405,895,221
Average rate (`) 5,225 5,575
3. FURNACE OIL
Quantity (K Ltrs.) 7,416 6,990
Total Cost (`) 342,350,802 312,771,412
Rate/unit (`) 46,167 44,747
TABLE 1 EXPENDITURE ON R&D
FY2014 FY2013
Capital (` million) 724 391
Recurring (` million) 9,982 6,509
Total (` million) 10,706 6,900
Total R&D expenditure as a percentage of total turnover 11.10% 8.37%
FORM BRESEARCH AND DEVELOPMENT (R&D)1 Specifi c areas in which R&D activities were carried out by the Company are:Our research and development activities can be classifi ed into several categories, which run parallel to the activities in our principal areas of operations:
Global Generics, where our research and development activities are directed at the development of product formulations, process validation, bioequivalence testing and other data needed to develop the drugs that are equivalent to brand name products for sale in the emerging markets or whose patents and regulatory exclusivity periods have expired or are nearing expiration in the highly regulated markets of the United States and Europe. Global Generics also include our biologics business, where research and development activities are directed at the development of biologics products for the emerging as well as highly regulated markets.
Our new biologics research and development facility caters to the highest development standards, including cGMP, Good Laboratory Practices and bio-safety level IIA.
Pharmaceutical Services and Active Ingredients, where our research and development activities concentrate on development of chemical processes for the synthesis of Active Pharmaceutical Ingredients and intermediates (API) for use in our Global Generics segment and for sales in the emerging and developed markets to third parties. Our research and development activities also support our custom pharmaceutical services business and enable us to leverage the strength of our process chemistry and fi nished dosage development expertise to target innovator as well as emerging pharmaceutical companies. The research and development is directed towards providing services to support the entire pharmaceutical value chain – from discovery all the way to the market.
Proprietary Products, where we are actively developing drugs based on Diff erentiated Formulations and discovery and development of new molecules, sometimes also referred to as 'New Chemical Entity' or 'NCEs'. Our research and development programs focus on the following therapeutic areas:
Neurology Dermatology Pain and Anti-infectives
We are focusing on an integrated research and development strategy to build sustainable mix of proprietary and branded Research and development portfolio of products in the above chosen Therapeutic areas.
2 Benefi ts derived as a result of the R&D
Development of new products Modifi cation of existing manufacturing
processes to achieve savings in cost of production
Modifi cation of existing manufacturing processes to reduce the time cycle
101
STATUTORY REPORTS/DIRECTORS’ REPORT
Indian patents and US patents fi lings for protection of Intellectual Property generated during R&D
3 Future plan of actionCommercialization of new products forwhich the products are under trials at development stage. Several new products have been identifi ed after a thorough studyof the market and the processes to manufacture these products will be developed in the R&D lab.
4 Expenditure on R&DExpenditure on R&D is given in Table 1.
TECHNOLOGY, ABSORPTION, ADAPTATION AND INNOVATIONTable 2 contains the details of technology absorption, adaptation and innovation.
FORM CFOREIGN EXCHANGE EARNINGS AND OUTGOPlease refer information given in the Note nos. 2.33 and 2.34 – Notes to the accounts.
TABLE 2 TECHNOLOGY ABSORPTION, ADAPTATION AND INNOVATION
1 Efforts, in brief, made towards technology
absorption, adaptation and innovation
The Company has a full-fledged R&D division
continuously engaged in research on new
products and on process development of existing
products. The Company has developed indigenous
technology in respect of the products manufactured
by it. As soon as the technology is developed for a
product, it is tested in a Pilot Plant and thereafter
commercial production is taken up. It is our
philosophy to continuously upgrade the technology.
2 Benefits derived as a result of the above
efforts, e.g., product improvement, cost
reduction, product development, import
substitution, etc.
Product quality improvements, cost reduction,
product development, import substitution etc.
The continuous upgradation and adoption of new
technology has benefited the Company in the form
of better production process, better yields, better
quality of the end product and cost reduction.
3 In case of imported technology (imported
during the last 5 years reckoned from the
beginning of the financial year), following
information may be furnished:
a) Technology imported
b) Year of import
c) Has technology been fully absorbed
d) If not fully absorbed, areas where this
has not taken place, reasons therefore and
future plans of action.
No Imported technology
102 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
This page has been intentionally left blank
IGAAP STANDALONE FINANCIAL STATEMENTS
103
IGAAP StandaloneFinancial Statements
AUDITORS’ REPORT 104
BALANCE SHEET 108
STATEMENT OF PROFIT AND LOSS 109
CASH FLOW STATEMENT 110
NOTES TO FINANCIAL STATEMENTS 111
104 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
To the members of Dr. Reddy’s Laboratories Limited
Report on the Financial Statements
We have audited the accompanying fi nancial statements of Dr. Reddy’s Laboratories Limited (‘the Company’) which comprises the balance sheet as at 31 March 2014, the
statement of profi t and loss and the cash fl ow statement for the year then ended and a summary of signifi cant accounting policies and other explanatory information.
Management’s Responsibility for the Financial Statements
Management is responsible for the preparation of these fi nancial statements that give a true and fair view of the fi nancial position, fi nancial performance and cash fl ows of the
Company in accordance with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Companies Act, 1956 (“the Act”). This responsibility includes the
design, implementation and maintenance of internal control relevant to the preparation and presentation of the fi nancial statements that give a true and fair view and are free
from material misstatement, whether due to fraud or error.
Auditors’ Responsibility
Our responsibility is to express an opinion on these fi nancial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued
by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable
assurance about whether the fi nancial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the fi nancial statements. The procedures selected depend on the
auditor’s judgment, including the assessment of the risks of material misstatement of the fi nancial statements, whether due to fraud or error. In making those risk assessments,
the auditor considers internal control relevant to the Company’s preparation and fair presentation of the fi nancial statements in order to design audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the
appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the
fi nancial statements.
We believe that the audit evidence we have obtained is suffi cient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion and to the best of our information and according to the explanations given to us, the fi nancial statements give the information required by the Act in the manner
so required and give a true and fair view in conformity with the accounting principles generally accepted in India:
(i) in the case of the balance sheet, of the state of affairs of the Company as at 31 March 2014;
(ii) in the case of the statement of profi t and loss, of the profi t for the year ended on that date; and
(iii) in the case of the cash fl ow statement, of the cash fl ows for the year ended on that date.
Report on Other Legal and Regulatory Requirements
1. As required by the Companies (Auditor’s Report) Order, 2003 (“the Order”), as amended, issued by the Central Government of India in terms of sub-section (4A) of
Section 227 of the Act, we give in the Annexure a statement on the matters specifi ed in paragraphs 4 and 5 of the Order.
2. As required by Section 227(3) of the Act, we report that:
(a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
(b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
(c) the balance sheet, the statement of profi t and loss and the cash fl ow statement dealt with by this Report are in agreement with the books of account;
(d) in our opinion, the balance sheet, the statement of profi t and loss and the cash fl ow statement comply with the Accounting Standards referred to in sub-section (3C) of
Section 211 of the Companies Act, 1956, to the extent applicable; and
(e) on the basis of written representations received from the directors as on 31 March 2014, and taken on record by the Board of Directors, none of the directors is
disqualifi ed as on 31 March 2014, from being appointed as a director in terms of clause (g) of sub-section (1) of Section 274 of the Companies Act, 1956.
for B S R & Co LLP.Chartered AccountantsFirm registration No: 101248W
Supreet SachdevPartner
Membership No: 205385
Place : Hyderabad
Date : 13 May 2014
INDEPENDENT AUDITORS’ REPORT
IGAAP STANDALONE FINANCIAL STATEMENTS
105
The Annexure referred to in the auditors’ report to the members of Dr. Reddy’s Laboratories Limited (“the Company”) for the year ended 31 March 2014.
We report that:
i. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fi xed assets.
(b) The Company has a regular programme of physical verifi cation of its fi xed assets by which all fi xed assets are verifi ed in a phased manner over a period of 3 years.
In our opinion, this periodicity of physical verifi cation is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies
were noticed on such verifi cation.
(c) Fixed assets disposed off during the year were not substantial and therefore do not affect the going concern assumption.
ii. (a) Inventories, except goods-in-transit and stocks lying with third parties have been physically verifi ed by the management during the year. In our opinion, the
frequency of such verifi cation is reasonable. For stocks lying with third parties at the year-end, written confi rmations have been obtained.
(b) In our opinion, the procedures of physical verifi cation of inventories followed by the management are reasonable and adequate in relation to the size of the Company
and the nature of its business.
(c) The Company is maintaining proper records of inventory. The discrepancies noticed on verifi cation between the physical stocks and the book records were not
material.
iii. (a) The Company has granted loans to nine subsidiary companies (of which 5 loans are interest free) covered in the register maintained under Section 301 of the
Companies Act, 1956. The maximum amount outstanding during the year was ` 6,142 millions and the year-end balance of such loans was ` 4,856 millions.
(b) In our opinion, the rate of interest and other terms and conditions on which loans have been granted to companies listed in the register maintained under Section
301 of the Companies Act, 1956 are not, prima facie, prejudicial to the interest of the Company.
(c) In the case of loans granted to the companies listed in the register maintained under Section 301, where stipulations have been made, the borrowers have been
regular in repaying the principal amounts as stipulated and in the payment of interest, wherever applicable.
(d) There is no overdue amount of more than ` one lakh in respect of loans granted to any of the companies, fi rms or other parties listed in the register maintained
under Section 301 of the Companies Act, 1956.
(e) The Company has not taken loans secured or unsecured from any companies, fi rms and other parties covered in the register maintained under Section 301 of the
Companies Act, 1956.
iv. In our opinion and according to the information and explanations given to us, and having regard to the explanation that purchases of certain items of inventories are
for the Company’s specialized requirements and similarly certain goods sold are for the specialized requirements of the buyers and suitable alternative sources are not
available to obtain comparable quotations, there is an adequate internal control system commensurate with the size of the Company and the nature of its business with
regard to purchase of inventories and fi xed assets and with regard to the sale of goods and services. We have not observed any major weakness in the internal control
system during the course of the audit.
v. (a) In our opinion and according to the information and explanations given to us, the particulars of contracts or arrangements referred to in Section 301 of the
Companies Act, 1956 have been entered in the register required to be maintained under that section.
(b) In our opinion, and according to the information and explanations given to us, the transactions made in pursuance of contracts and arrangements referred to in
point (a) above and exceeding the value of ` 5 lakh with any party during the year, have been made at prices which are reasonable having regard to the prevailing
market prices at the relevant time except for the purchases of certain items of inventories which are for Company’s specialized requirements and similarly for sale of
certain goods for the specialized requirements of the buyers and for which suitable alternative sources are not available to obtain comparable quotations. However,
on the basis of information and explanations provided, the same appear reasonable.
vi. In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of Section 58A, Section 58AA or other
relevant provisions of the Companies Act, 1956 and the rules framed there under/the directives issued by the Reserve Bank of India (as applicable) with regard to deposits
accepted from the public. Accordingly, there have been no proceedings before the Company Law Board or National Company Law Tribunal (as applicable) or Reserve
Bank of India or any Court or any other Tribunal in this matter and no order has been passed by any of the aforesaid authorities.
vii. In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
viii. We have broadly reviewed the books of account maintained by the Company pursuant to the rules prescribed by the Central Government for the maintenance of
cost records under Section 209 (1) (d) of the Companies Act, 1956, and are of the opinion that prima facie the prescribed accounts and records have been made and
maintained. However, we have not made a detailed examination of the records.
ix. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the
books of account in respect of undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees’ State Insurance, Income
tax, Sales tax, Wealth tax, Service tax, Customs duty, Excise duty and other material statutory dues have been generally regularly deposited during the year by the
Company with the appropriate authorities.
ANNEXURE TO THE INDEPENDENT AUDITORS’ REPORT
106 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
(b) According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Investor Education and Protection Fund,
Employees’ State Insurance, Income tax, Sales tax, Wealth tax, Service tax, Customs duty, Excise duty and other material statutory dues were in arrears as at 31
March 2014 for a period of more than six months from the date they became payable.
(c) According to the information and explanations given to us, the dues set out in Appendix - 1 in respect of Income tax, Sales tax, Service tax, Customs duty and
Excise duty have not been deposited with the appropriate authorities on account of disputes.
x. The Company does not have any accumulated losses at the end of the fi nancial year and has not incurred cash losses during the fi nancial year and in the immediately
preceding fi nancial year.
xi. In our opinion and according to the information and explanations given to us, the Company, has not defaulted in repayment of dues to its bankers or to any fi nancial
institutions, or to debenture holders during the year.
xii. The Company has not granted loans and advances on the basis of security by way of pledge of shares, debentures and other securities.
xiii. In our opinion and according to the information and explanations given to us, the Company is not a chit fund/nidhi/mutual fund/society.
xiv. According to the information and explanations given to us, the Company is not dealing or trading in shares, securities, debentures and other investments. Accordingly,
clause 4(xiv) of the Order is not applicable.
xv. In our opinion and according to the information and explanations given to us, the terms and conditions on which the Company has given guarantees for loans taken by
others from banks or fi nancial institutions are not prejudicial to the interests of the Company.
xvi. In our opinion and according to the information and explanations given to us by the management, term loans availed by the Company were applied for the purposes for
which the loans were obtained, other than for temporary deployment of funds pending application.
xvii. According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we are of the opinion that funds raised
on short-term basis have not been used for long term investment.
xviii. The Company has not made any preferential allotment of shares to companies, fi rms or parties covered in the register maintained under Section 301 of the Companies
Act, 1956.
xix. During the year ended 31 March 2011, the Company had issued unsecured debentures in accordance with the scheme of arrangement approved by the High Court of
Andhra Pradesh, India. No security or charge in respect of such debentures was created. During the year ended 31 March 2014, the Company has redeemed all of such
unsecured debentures at par value aggregating to ` 5,078 million as per the terms of the aforesaid scheme.
xx. During the year, the Company has not raised any money through public issue.
xxi. According to the information and explanations given to us, no material fraud on or by the Company has been noticed or reported during the course of our audit.
for B S R & Co LLP.Chartered AccountantsFirm registration No: 101248W
Supreet SachdevPartner
Membership No: 205385
Place : Hyderabad
Date : 13 May 2014
ANNEXURE TO THE INDEPENDENT AUDITORS’ REPORT (CONTINUED)
IGAAP STANDALONE FINANCIAL STATEMENTS
107
Appendix 1 as referred to in paragraph ix (c) of annexure to the Independent Auditors’ Report
Name of the Statute Nature of duesAmount in` millions
Forum where the dispute is pendingPeriod to which
the amount relates
Income Tax Act, 1961 Tax and interest
447 Income Tax Appellate Tribunal 2005-2009
86 Commissioner Appeals 2011-2012
9 High Court 1990-1994
Central Excise Act, 1944 Duty
1,568 Appellate Authority – upto Commissioners 2001-2013
83 CESTAT 2003-2013
36 High Court 2003-2012
98 Revenue Authority 2012-2013
218 CESTAT and High Court 2011-2012
Customs Act,1962
Duty26 Appellate Authority – upto Commissioners 2003-2009
18 Supreme Court 1992-1999
Penalty
0.1 Appellate Authority – upto Commissioners 2007
16 Supreme Court 1992-1999
0.4 CESTAT 2004
Finance Act, 1994CENVAT Credit of
Service Tax
498 CESTAT 2006-2012
208 Appellate Authority – upto Commissioners 2004-2013
13 High Court 2005-2008
Central Sales Tax Act and Sales Tax Acts of
various states
Tax
1 Sales Tax Appellate Tribunal 2008-2009
139 Appellate Authority – upto Commissioners 2005-2013
143 Sales Tax Tribunal 2002-2011
2 High Court 2006-2008
Penalty46 Appellate Authority – upto Commissioners 2008-13
13 Sales Tax Tribunal 2006-11
Out of the total disputed dues, an amount of ` 309 million has been paid under protest for sales tax related matters, ` 57 million has been paid under protest for service tax
related matters, ` 18 million has been paid for customs related matters, ` 237 million has been paid for excise related matters and ` 10 million has been paid for income tax
related matters.
ANNEXURE TO THE INDEPENDENT AUDITORS’ REPORT (CONTINUED)
108 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
PARTICULARS NOTE AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
EQUITY AND LIABILITIES
Shareholders’ funds
Share capital 2.1 851 849
Reserves and surplus 2.2 92,439 76,985
93,290 77,834
Non current liabilities
Long term borrowings 2.3 9,015 63
Deferred tax liabilities, net 2.25 1,252 937
Other long term liabilities 2.4 47 28
Long term provisions 2.5 335 298
10,649 1,326
Current liabilities
Short term borrowings 2.3 17,630 15,828
Trade payables 2.6 8,423 7,678
Other current liabilities 2.4 10,294 13,011
Short term provisions 2.5 4,795 4,214
41,142 40,731
TOTAL 145,081 119,891
ASSETS
Non current assets
Fixed assets
Tangible assets 2.7 26,937 23,355
Intangible assets 2.7 546 515
Capital work-in-progress 5,761 4,232
Non current investments 2.8 17,401 21,826
Long term loans and advances 2.9 5,358 3,752
Other non current assets 2.15 - 209
56,003 53,889
Current assets
Current investments 2.10 10,664 1,966
Inventories 2.11 15,921 15,265
Trade receivables 2.12 45,615 29,639
Cash and bank balances 2.13 6,651 9,191
Short term loans and advances 2.14 8,287 8,634
Other current assets 2.15 1,940 1,307
89,078 66,002
TOTAL 145,081 119,891
Signifi cant accounting policies 1
The accompanying notes are an integral part of fi nancial statements
BALANCE SHEET (All amounts in Indian Rupees millions, except share data and where otherwise stated)
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited
Chartered Accountants
Firm Registration No.: 101248W
Supreet Sachdev
Partner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
IGAAP STANDALONE FINANCIAL STATEMENTS
109
STATEMENT OF PROFIT AND LOSS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
PARTICULARS NOTEFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
INCOME
Sales, gross 95,777 81,462
Less: Excise duty (820) (718)
Sales, net 94,957 80,744
Service income 335 388
License fees 1,176 1,315
Other operating revenue 2.16 812 1,893
Revenue from operations 97,280 84,340
Other income 2.17 1,515 1,417
Total revenue 98,795 85,757
EXPENSES
Cost of material consumed (including packing material consumed) 21,918 22,773
Purchase of stock-in-trade (traded goods) 4,690 3,931
Changes in inventories of fi nished goods,work-in-progress and stock-in-trade 2.18 (1,706) (1,006)
Conversion charges 785 592
Excise duty 562 636
Employee benefi ts expense 2.19 11,849 11,381
Finance costs 2.20 783 614
Depreciation and amortization expense 2.7 3,805 3,128
Research and development expenses 2.21 9,982 6,509
Other expenses 2.22 21,583 19,667
Total expenses 74,251 68,225
Profi t before exceptional and extraordinary items and tax 24,544 17,532
Exceptional items - -
Profi t before extraordinary items and tax 24,544 17,532
Extraordinary Items - -
Profi t before tax 24,544 17,532
Tax expense 2.23
Current tax expense 4,901 4,140
Deferred tax expense 315 737
Profi t for the year 19,328 12,655
Earnings per share 2.26
Basic - Par value ` 5/- per share 113.67 74.54
Diluted - Par value ` 5/- per share 113.13 74.17
Number of shares used in computing earnings per share
Basic 170,044,518 169,778,214
Diluted 170,857,689 170,617,880
Signifi cant accounting policies 1
The accompanying notes are an integral part of fi nancial statements
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited
Chartered Accountants
Firm Registration No.: 101248W
Supreet Sachdev
Partner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
110 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
CASH FLOW STATEMENT (All amounts in Indian Rupees millions, except share data and where otherwise stated)
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014FOR THE YEAR ENDED
31 MARCH 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Profi t before taxation 24,544 17,532
Adjustments:
Depreciation and amortization expense 3,805 3,128
Provision for wealth tax 2 3
Stock compensation expense, net 472 421
Foreign exchange (gain) / loss, net 4,151 264
Profi t on sale of current investments, net (213) (212)
Loss on de-recognition of intangible assets 86 -
Provision for decline in the value of non current investments 245 223
Dividend from subsidiary (12) (28)
Loss on sale of non current investments 166 6
Interest income (1,022) (933)
Finance costs 783 614
(Profi t) / Loss on sale of fi xed assets, net (28) 9
Allowance for sales returns 782 829
Provision for inventory obsolescence 1,318 1,328
Provision for doubtful debts, net 29 45
Provision / (reversal of provision) for doubtful advances, net (382) 1,155
Operating cash fl ows before working capital changes 34,726 24,384 Changes in operating assets and liabilities
Trade receivables (18,274) (10,571)
Inventories (1,974) (3,326)
Trade payables 746 355
Other assets and liabilties, net (739) (4,196)
Cash generated from operations 14,485 6,646 Income taxes paid, net (5,430) (3,758)
Net cash provided by operating activities 9,055 2,888 CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES
Purchase of fi xed assets (8,718) (5,802)
Proceeds from sale of fi xed assets 273 20
(Increase) / decrease in deposit accounts (having original maturity of more than three months)
and other bank balances 2,941 (1,540)
Purchase of investments (35,810) (11,865)
Proceeds from sale of investments 31,069 12,626
Dividend from subsidiary 12 28
Loans and advances repaid by subsidiaries 539 416
Interest received 886 928
Net cash used in investing activities (8,808) (5,189)CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES
Proceeds from issue of share capital 2 1
Redemption of 9.25% redeemable non-convertible debentures of ` 5/- each (5,078) -
Proceeds from long term borrowings 9,089 -
Repayment of short term borrowings (35,230) (25,165)
Proceeds from short term borrowings 35,306 30,265
Interest paid (828) (875)
Dividend paid (2,979) (2,708)
Net cash from fi nancing activities 282 1,518 Net increase / (decrease) in cash and cash equivalents 529 (783)
Cash and cash equivalents at the beginning of the year (refer note 2.13) 561 1,400
Effect of foreign exchange gain / (loss) on cash and cash equivalents 66 (56)
Cash and cash equivalents at the end of the year (refer note 2.13) 1,156 561 Notes to the cash fl ow statement:Cash and cash equivalents at the end of the year (refer note 2.13) 1,156 561
Other bank balances (refer note 2.13) 5,495 8,630
Cash and bank balances at the end of the year (refer note 2.13) 6,651 9,191
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories LimitedChartered AccountantsFirm Registration No.: 101248W
Supreet SachdevPartner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
IGAAP STANDALONE FINANCIAL STATEMENTS
111
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES
a) Basis of preparation
The fi nancial statements of Dr. Reddy’s Laboratories Limited (“DRL” or “the Company”) have been prepared and presented in accordance with Indian Generally Accepted
Accounting Principles (IGAAP) under historical cost convention on an accrual basis. Pursuant to circular 15/2013 dated 13 September 2013 read with circular 08/2014
dated 4 April 2014 issued by the Ministry of Corporate Affairs, the existing accounting standards notifi ed under the Companies Act, 1956 shall apply till the standards
of accounting or any addendum thereto are prescribed by the Central Government in consultation and recommendation of the National Financial Reporting Authority.
Consequently, these fi nancial statements have been prepared to comply in all material aspects with accounting standards notifi ed by the Central Government of India
under Section 211 (3C) of the Companies Act, 1956, other pronouncements of the Institute of Chartered Accountants of India, the relevant provisions of the Companies
Act, 1956 and guidelines issued by the Securities and Exchange Board of India (SEBI) (Collectively referred to as “IGAAP”). The fi nancial statements are presented in Indian
rupees rounded off to the nearest million.
b) Use of estimates
The preparation of the fi nancial statements in conformity with IGAAP requires the Company’s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent liabilities on the date of the fi nancial statements and reported amounts of revenues and expenses for the
year. Examples of such estimates include estimation of useful life of tangible and intangible assets, assessment of recoverable amounts of deferred tax assets, provision
for obligations relating to employees, provisions against litigations and impairment of assets. Actual results could differ from these estimates. Estimates and underlying
assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognised prospectively in the current and future periods.
c) Current and non current classifi cation
All the assets and liabilities have been classifi ed as current or non current as per the Company’s normal operating cycle and other criteria set out in the Revised Schedule
VI to the Companies Act, 1956.
Assets:
An asset is classifi ed as current when it satisfi es any of the following criteria:
a) it is expected to be realised in, or is intended for sale or consumption in, the Company’s normal operating cycle;
b) it is held primarily for the purpose of being traded;
c) it is expected to be realised within 12 months after the reporting date; or
d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.
Liabilities:
A liability is classifi ed as current when it satisfi es any of the following criteria:
a) it is expected to be settled in the Company’s normal operating cycle;
b) it is held primarily for the purpose of being traded;
c) it is due to be settled within 12 months after the reporting date; or
d) the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at
the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classifi cation.
Current assets / liabilities include the current portion of non current fi nancial assets / liabilities respectively. All other assets / liabilities are classifi ed as non current.
d) Tangible fi xed assets and depreciation
Fixed assets are carried at the cost of acquisition or construction less accumulated depreciation. The cost of fi xed assets includes non refundable taxes, duties, freight
and other incidental expenses related to the acquisition and installation of the respective assets.
Subsequent expenditure related to an item of tangible fi xed asset is capitalised only if it increases the future benefi ts from the existing assets beyond its previously
assessed standards of performance.
Advances paid towards acquisition of tangible fi xed assets outstanding at each balance sheet date are shown under long term loans and advances. Cost of assets not
ready for intended use, as on the balance sheet date, is shown as capital work-in-progress.
Depreciation on tangible fi xed assets is provided using the straight-line method at the rates specifi ed in Schedule XIV to the Companies Act, 1956 or based on the useful
life of the assets as estimated by the Company’s management, whichever is higher. Depreciation is calculated on a pro-rata basis from the date of installation till the
date the assets are sold or disposed. Individual assets costing less than ` 5,000/- are depreciated in full in the year of acquisition. Assets acquired on fi nance leases are
depreciated over the period of the lease agreement or the useful life whichever is shorter. Leasehold improvements are depreciated over their estimated useful life, or the
remaining period of lease, whichever is shorter.
112 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
The Management’s estimates of the useful lives for various categories of fi xed assets are given below:
Years
Buildings
- Factory and administrative buildings 20 to 30
- Ancillary structures 3 to 10
Plant and machinery 3 to 15
Electrical equipment 5 to 15
Laboratory equipment 5 to 15
Furniture, fi xtures and offi ce equipment 4 to 8
Vehicles 4 to 5
Gains or losses from disposal of tangible fi xed assets are recognised in the statement of profi t and loss.
e) Borrowing costs
General and specifi c borrowing costs directly attributable to acquisition or construction of those fi xed assets which necessarily take a substantial period of time to get
ready for their intended use are capitalised. Borrowing costs are interest and other costs incurred by the Company in connection with the borrowing of funds. All other
borrowing costs are recognised in the statement of profi t and loss in the period in which they are incurred.
f) Intangible assets and amortisation
Intangible assets are recorded at the consideration paid for acquisition including any import duties and other taxes (other than those subsequently recoverable by the
enterprise from the taxing authorities), and any directly attributable expenditure in making the asset ready for its intended use.
Intangible assets are amortised on a systematic basis over the best estimate of their useful lives, commencing from the date the asset is available to the Company for its
use.
The Company’s management estimates the useful lives for the various intangible assets as follows:
Years
Customer contracts 2 to 5
Technical know-how 10
Non-Compete fee 1.5 to 10
Product related intangibles 5 to 10
Copyrights and Patents (including marketing / distribution rights) 3 to 10
An intangible asset is derecognised on disposal or when no future economic benefi ts are expected from its use and disposal. Gains or losses arising from the disposal
of intangible assets are recognised in the statement of profi t and loss.
g) Investments
Investments that are readily realisable and are intended to be held for not more than 12 months from the date, on which such investments are made, are classifi ed as
current investments. All other investments are classifi ed as non current investments.
Current investments are carried at the lower of cost and fair value. The comparison of cost and fair value is done separately in respect of each category of investment.
Non current investments are carried at cost less any other-than-temporary diminution in value, determined separately for each individual investment. The reduction in the
carrying amount is reversed when there is a rise in the value of the investment or if the reasons for the reduction no longer exist. Any reduction in the carrying amount and
any reversal in such reductions are charged or credited to the statement of profi t and loss.
h) Inventories
Inventories are valued at the lower of cost and net realisable value. Net realisable value (NRV) is the estimated selling price in the ordinary course of the business, less the
estimated costs of completion and the estimated costs necessary to make the sale. Cost of inventories comprises all cost of purchase, cost of conversion and other costs
incurred in bringing the inventories to their present location and condition. The cost of all categories of inventory is determined using weighted average cost method.
i) Research and development
Expenditure on research activities undertaken with the prospect of gaining new scientifi c or technical knowledge and understanding is recognized as expense in the
statement of profi t and loss when incurred.
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
IGAAP STANDALONE FINANCIAL STATEMENTS
113
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only
if the enterprise can demonstrate all of the following:
a) the product or the process is technically and commercially feasible;
b) future economic benefi ts are probable and ascertainable;
c) the Company intends to and has suffi cient resources to complete development of the product and has the ability to use or sell the asset; and
d) development costs can be measured reliably.
j) Employee benefi ts
Defi ned benefi t plans
The liability in respect of defi ned benefi t plans and other post-employment benefi ts is calculated using the projected unit credit method and spread over the period during
which the benefi t is expected to be derived from employees’ services, consistent with the advice of qualifi ed actuaries. The long term obligations are measured at present
value of estimated future cash fl ows discounted at rates refl ecting the yields on risk free government bonds that have maturity dates approximating the terms of the
Company’s obligations. Short term employee benefi t obligations are measured on an undiscounted basis and are expensed as the related service is provided.
All actuarial gains and losses arising during the year are recognized in the statement of profi t and loss.
Defi ned contribution plans
The Company’s contributions to defi ned contribution plans are charged to profi t or loss as and when the services are received from the employees.
Compensated leave of absence
The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized
compensated absences and utilize it in future periods or receive cash in lieu thereof as per Company policy. The Company records an obligation for compensated
absences in the period in which the employee renders the services that increases this entitlement. The measurement of such obligation is based on actuarial valuation as
at the balance sheet date carried out by a qualifi ed actuary.
Employee stock option schemes
In accordance with the SEBI guidelines, the cost is calculated based on intrinsic value method i.e., the excess of the market price of shares, at the date prior to the day
of grant of options under the Employee stock option schemes, over the exercise price is treated as employee compensation and amortised over the vesting period.
k) Foreign currency transactions and balances
Foreign currency transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign
currency transactions settled during the year are recognised in the statement of profi t and loss.
Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are reported using the foreign exchange rates as at the balance sheet date.
The resultant exchange differences are recognised in the statement of profi t and loss. Non monetary assets and liabilities are carried at the rates prevailing on the date of
transaction.
Exchange differences arising on a monetary item that, in substance, forms part of the Company’s net investment in a non integral foreign operation are accumulated in a
foreign currency translation reserve in the Company’s fi nancial statements. Such exchange differences are recognized in the statement of profi t and loss in the event of
disposal of the net investment.
l) Derivative instruments and hedge accounting
The Company uses forward contracts, option contracts and swap contracts (derivatives) to mitigate its risk of changes in foreign currency exchange rates and interest
rates. The Company does not use derivatives for trading or speculative purposes.
The premium or discount on foreign exchange forward contracts is amortized as income or expense over the life of the contract. The exchange difference is calculated
and recorded in accordance with AS-11 (revised) in the statement of profi t and loss. The changes in the fair value of foreign currency option contracts and swap contracts
are recognized in the statement of profi t and loss as they arise. Fair value of such option and swap contracts is determined based on the appropriate valuation techniques
considering the terms of the contract.
Pursuant to ICAI Announcement “Accounting for Derivatives” on the early adoption of Accounting Standard AS-30 “Financial Instruments: Recognition and Measurement”,
the Company has adopted the Standard, to the extent that the adoption does not confl ict with existing mandatory accounting standards and other authoritative
pronouncements, Company law and other regulatory requirements.
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
114 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
Cashfl ow hedges
The Company classifi es its derivative contracts that hedge foreign currency risk associated with highly probable forecasted transactions as cash fl ow hedges and
measures them at fair value. The effective portion of such cash fl ow hedges is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and
re-classifi ed into the statement of profi t and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion is
immediately recorded in the statement of profi t and loss.
The Company also designates certain non derivative fi nancial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign
currency risk associated with highly probable forecasted transactions and, accordingly, applies cash fl ow hedge accounting for such relationships. Re-measurement gain/
loss on such non derivative fi nancial liabilities is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classifi ed in the statement of
profi t and loss as revenue in the period corresponding to the occurrence of the forecasted transactions.
If the hedging instrument no longer meets the criteria for hedge accounting, gets expired or is sold, terminated or exercised before the occurrence of the forecasted
transaction, the hedge accounting on such transaction is discontinued prospectively. The cumulative gain or loss previously recognized in hedging reserve continues to
remain there until the forecasted transaction occurs. If the forecasted transaction is no longer expected to occur, the balance in hedging reserve is recognized immediately
in the statement of profi t and loss.
m) Revenue recognition
Sale of goods
Revenue is recognized when the signifi cant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is reasonably certain, the
associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods and the amount of revenue can
be measured reliably.
Revenue from the sale of goods includes excise duty and is net of returns, sales tax and applicable trade discounts and allowances.
Revenue includes shipping and handling costs billed to the customer.
Sales returns
The Company accounts for sales returns by recording an allowance for sales returns concurrent with the recognition of revenue at the time of a product sale. This
allowance is based on the Company’s estimate of expected sales returns. The estimate of sales returns is determined primarily by the Company’s historical experience in
the markets in which the Company operates.
Profi t share revenues
The Company from time to time enters into marketing arrangements with certain business partners for the sale of its products in certain markets. Under such arrangements,
the Company sells its products to the business partners at a non-refundable base purchase price agreed upon in the arrangement and is also entitled to a profi t share
which is over and above the base purchase price.
Revenue in an amount equal to the base purchase price is recognized in these transactions upon delivery of products to the business partners. An additional amount
representing the profi t share component is recognized as revenue in the period which corresponds to the ultimate sales of the products made by business partners only
when the collectability of the profi t share becomes probable and a reliable measurement of the profi t share is available.
Service Income
Service income is recognised as per the terms of contracts with customers when the related services are performed, or the agreed milestones are achieved.
License fee
The Company enters into certain dossier sales, licensing and supply arrangements with various parties. Income from licensing arrangements is generally recognised over
the term of the contract. Some of these arrangements include certain performance obligations by the Company. Revenue from such arrangements is recognized in the
period in which the Company completes all its performance obligations.
Dividend and interest income
Dividend income is recognised when the unconditional right to receive the income is established. Income from interest on deposits, loans and interest bearing securities
is recognised on a time proportion basis.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
115
Export incentives
Export entitlements are recognised as reduction from cost of material consumed when the right to receive credit as per the terms of the scheme is established in respect
of the exports made and where there is no signifi cant uncertainty regarding the ultimate collection of the relevant export proceeds.
n) Income tax expense
Income tax expense comprises current tax and deferred tax charge or credit.
Current tax
The current charge for income taxes is calculated in accordance with the relevant tax regulations applicable to the Company.
Deferred tax
Deferred tax charge or credit refl ects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or
credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet
date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed
depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets.
Deferred tax assets are reviewed at each balance sheet date and are written-down or written-up to refl ect the amount that is reasonably/virtually certain (as the case may
be) to be realised.
o) Earnings per share
The basic earnings per share (“EPS”) is computed by dividing the profi t after tax for the year by the weighted average number of equity shares outstanding during the
year. For the purpose of calculating diluted earnings per share, profi t after tax for the year and the weighted average number of shares outstanding during the year are
adjusted for the effects of all dilutive potential equity shares. The dilutive potential equity shares are deemed converted as of the beginning of the period, unless they have
been issued at a later date. The diluted potential equity shares have been adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e., the
average market value of the outstanding shares).
p) Provisions and contingent liabilities and contingent assets
A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outfl ow of resources embodying economic
benefi ts will be required to settle the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the balance
sheet date.
Contingent liabilities and contingent assets
A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outfl ow of resources.
Where there is a possible obligation or a present obligation in respect of which the likelihood of outfl ow of resources is remote, no provision or disclosure is made.
Contingent assets are not recognised in the fi nancial statements. However, contingent assets are assessed continually and if it is virtually certain that an infl ow of economic
benefi ts will arise, the asset and related income are recognised in the period in which the change occurs.
q) Impairment of assets
The Company assesses at each balance sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates
the recoverable amount of the asset.
For the purpose of impairment testing, assets are grouped together into the smallest group of assets (Cash Generating Unit or CGU) that generates cash infl ows from
continuing use that are largely independent of the cash infl ows of other assets or CGUs.
The recoverable amount of an asset or CGU is the greater of its value in use and its net selling price. Value in use is the present value of the estimated future cash fl ows
expected to arise from the continuing use of an asset and from its disposal at the end of its useful life.
If such recoverable amount of the asset or the recoverable amount of the CGU to which the asset belongs is less than its carrying amount, the carrying amount is reduced
to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the statement of profi t and loss. If at the balance sheet date there is an
indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is refl ected at the recoverable amount subject
to a maximum of amortised historical cost.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
116 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
r) Leases
The lease arrangement is classifi ed as either a fi nance lease or an operating lease, at the inception of the lease, based on the substance of the lease arrangement.
Finance leases
A fi nance lease is a lease that transfers substantially all the risks and rewards incident to ownership of an asset. A fi nance lease is recognized as an asset and a liability
at the commencement of the lease, at the lower of the fair value of the asset and the present value of the minimum lease payments. Initial direct costs, if any, are also
capitalized and, subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Minimum lease payments
made under fi nance leases are apportioned between the fi nance expense and the reduction of the outstanding liability. The fi nance expense is allocated to each period
during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Operating leases
Other leases are operating leases, and the leased assets are not recognized on the Company’s balance sheet. Payments made under operating leases are recognized in
the statement of profi t and loss on a straight-line basis over the term of the lease.
s) Cash and cash equivalents
Cash and cash equivalents consist of cash on hand, demand deposits and short term, highly liquid investments that are readily convertible into known amounts of cash
and which are subject to insignifi cant risk of changes in value. For this purpose, “short term” means investments having maturity of three months or less from the date of
investment.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
117
NOTE 2: NOTES TO FINANCIAL STATEMENTS
2.1: SHARE CAPITAL
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Authorised
240,000,000 (previous year: 240,000,000) equity shares of ` 5/- each 1,200 1,200
Issued
170,109,068 (previous year: 169,836,675) equity shares of ` 5/- each fully paid-up 851 849
Subscribed and fully paid-up
170,108,868 (previous year: 169,836,475) equity shares of ` 5/- each fully paid-up 851 849
Add: Forfeited share capital (e) - 851 - 849
851 849
(a) Reconciliation of the equity shares outstanding is set out below:
PARTICULARS
AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
NO. OF EQUITY SHARES
AMOUNTNO. OF EQUITY
SHARESAMOUNT
Number of shares outstanding at the beginning of the year 169,836,475 849 169,560,346 848
Add: Equity shares issued pursuant to employee stock option plan 272,393 2 276,129 1
Number of shares outstanding at the end of the year 170,108,868 851 169,836,475 849
(b) Terms / rights attached to the equity shares
The Company has only one class of equity shares having a par value of ` 5 per share. Each holder of equity shares is entitled to one vote per share. The Company
declares and pays dividends in Indian rupees. During the year ended 31 March 2014, the amount of per share dividend recognized as distributions to equity
shareholders is ` 18 (previous year: `15). The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual
General Meeting.
(c) Details of shareholders holding more than 5% shares in the Company
PARTICULARS
AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
NO. OF EQUITY
SHARES HELD
% OF EQUITY
SHARES HELD
NO. OF EQUITY
SHARES HELD
% OF EQUITY
SHARES HELD
Dr. Reddy’s Holdings Limited 39,729,284 23.35 39,729,284 23.39
First State Investments Management (UK) Limited, First State Investments International
Limited and their associates 14,056,799 8.26 9,667,791 5.69
(d) 651,674 (previous year: 695,259) stock options are outstanding to be issued by the Company on exercise of the vested stock options in accordance with the
terms of exercise under the “Dr. Reddy’s Employees Stock Option Plan, 2002” and 97,463 (previous year: 98,608) stock options are outstanding to be issued by
the Company on exercise of the vested stock options in accordance with the terms of exercise under the “Dr. Reddy’s Employees ADR Stock Option Plan 2007”.
(Refer note 2.30)
(e) Represents 200 (previous year: 200) equity shares of ` 5/- each, amount paid-up ` 500/- (rounded off in millions in the note above) forfeited due to non-payment
of allotment money.
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
118 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.2: RESERVES AND SURPLUS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Capital reserveBalance at the beginning of the year 267 267
Movement during the year - -
267 267 Securities premium accountBalance at the beginning of the year 18,815 18,532
Add: Employee stock options exercised during the year 342 283
19,157 18,815 Employee stock options outstanding* Balance at the beginning of the year 685 547
Add : Amortization during the year, net of forfeiture 472 421
Less : Employee stock options exercised during the year (342) (283)
815 685 * Net of deferred employee stock compensation of ` 482 (previous year: ` 446)
General reserveBalance at the beginning of the year 11,117 9,852
Add: Transferred from surplus 1,933 1,265
Add: Transferred from debenture redemption reserve 2,539 -
15,589 11,117 Foreign currency translation reserve (a)Balance at the beginning of the year 373 219
Movement during the year (356) 154
17 373 Hedging reserve
Balance at the beginning of the year 402 (3)
Movement during the year (407) 405
(5) 402 Debenture redemption reserve
Balance at the beginning of the year 1,712 867
Add: Transferred from surplus 827 845
Less: Transferred to general reserve (2,539) -
- 1,712 SurplusBalance at the beginning of the year 43,614 36,049
Add: Current year profi t 19,328 12,655
Amount available for appropriation 62,942 48,704 Less: Appropriations:
Proposed dividend on equity shares 3,062 2,548
Tax on proposed dividend 520 433
Dividend of previous years 3 3
Credit of dividend distribution tax (b) (2) (4)
Transferred to debenture redemption reserve 827 845
Transferred to general reserve 1,933 1,265
Balance carried forward 56,599 43,614
92,439 76,985
(a) The foreign currency translation reserve comprises exchange difference on loans and advances that in substance form part of net investment in Industrias Quimicas
Falcon de Mexico S.A. de C.V. (Mexico), a non-integral foreign operation as defi ned in Accounting Standard (AS) - 11 (Revised 2003) on “Accounting for the Effects
of Changes in foreign Exchange Rates”. These exchange differences will be recognised in the statement of profi t and loss in the event of disposal of such net
investments.
(b) Credit of dividend distribution tax pertains to the availment of dividend distribution tax paid by Aurigene Discovery Technologies Limited, a subsidiary company on
payment of dividend on preference shares to the Company.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
119
2.3: BORROWINGS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Long term borrowings
Secured
Long term maturities of fi nance lease obligations (a) 13 35
Unsecured
Sales tax deferment loan from the Government of Andhra Pradesh (interest free) (b) 15 28
Long term loans from banks (c) 8,987 -
9,015 63
B) Short term borrowings
Unsecured
Packing credit loans (d) 17,630 15,786
Bank overdraft - 42
17,630 15,828
(a) Finance lease obligations are towards lease rentals payable for the vehicles leased by the Company. Lease rentals are paid in monthly instalment, with the last
instalment due in April 2018.
(b) Sales tax deferment loan is repayable in 8 instalments, with the last instalment due on 31 March 2019.
(c) External Commercial Borrowings of USD 150 million carrying interest rate of LIBOR plus 179 bps and is repayable in fi ve equal quarterly instalments ending in
February 2019. As part of the arrangement, the Company is required to comply with certain fi nancial covenants and the Company was in compliance with such
covenants as of 31 March 2014.
(d) Packing credit loans for the current year comprised of USD and EUR denominated loans carrying interest rates of LIBOR plus 20 - 85 bps, RUB denominated loans
carrying interest rate of Moscow Prime Offered Rate plus 60 bps, RUB denominated loans carrying fi xed interest rate of 7.20% - 7.75% per annum and INR denom-
inated loans carrying fi xed interest rate of 9.50% - 10%, and are repayable within 1 to 6 months from the date of drawdown. Packing Credit loans for the previous
year comprised of USD and EUR denominated loans carrying interest rates of LIBOR plus 50 - 125 bps and RUB denominated loans carrying fi xed interest rate of
7.25% - 8.00% per annum and are repayable within 1 to 6 months from the date of drawdown.
2.4: OTHER LIABILITIES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Other long term liabilities
Deferred revenue 47 28
47 28
B) Other current liabilities
Current maturities of long term borrowings
Finance lease obligations 4 12
Sales tax deferment loan from the Government of Andhra Pradesh (interest free) 13 19
9.25% Redeemable Non-convertible Debentures of ` 5/- each (a) - 5,078
Due to capital creditors 1,714 1,231
Payable to subsidiary companies including step down subsidiaries 2,306 1,218
Interest accrued but not due on loan 41 19
Unclaimed dividends, debentures and debenture interest (b) 83 38
Accrued expenses 4,259 3,977
Salary and bonus payable 1,027 973
Derivative fi nancial instrument liability 148 109
Due to statutory authorities 193 121
Trade and security deposits received 166 62
Others 340 154
10,294 13,011
(a) During the year ended 31 March 2014, the Company redeemed 9.25% unsecured, non-convertible, redeemable debentures at par value of ` 5,078.
(b) Unclaimed amounts are transferred to Investor Protection and Education Fund after seven years from the due date.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
120 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.5: PROVISIONS
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Long term provisions
Provision for employee benefi ts
Compensated absences 255 209
Long service award benefi t plan 80 89
335 298
B) Short term provisions
Provision for employee benefi ts
Gratuity 132 168
Compensated absences 157 109
Long service award benefi t plan 11 13
Other provisions
Allowance for sales returns (a) 600 562
Proposed dividend 3,062 2,548
Tax on proposed dividend 518 433
Others 315 381
4,795 4,214
(a) Details of changes in allowance for sales returns during the year are as follows:
Balance at the beginning of the year 562 404
Provision made during the year 782 829
Provision utilised during the year (744) (671)
Balance at the end of the year 600 562
2.6: TRADE PAYABLES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Payable to third parties
Due to micro, small and medium enterprises 97 236
Others 6,654 6,725
Payable to subsidiary companies including step down subsidiaries 1,672 717
8,423 7,678
(a) The principal amount remaining unpaid as at 31 March 2014 in respect of enterprises covered under the “Micro, Small and Medium Enterprises Development Act,
2006” (MSMDA) is ` 97 (previous year: ` 236). The interest amount computed based on the provisions under Section 16 of the MSMDA of ` 0.03 (previous year:
` 0.02) is remaining unpaid as of 31 March 2014. The interest amount of ` 0.02 that remained unpaid as at 31 March 2013 was paid fully during the current year.
(b) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without
adding the interest specifi ed under this Act is ` Nil (previous year: ` Nil).
(c) The list of undertakings covered under MSMDA was determined by the Company on the basis of information available with the Company and has been relied upon
by the auditors.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
121
2.7:
FIX
ED
AS
SE
TS
GR
OS
S B
LOC
KD
EP
RE
CIA
TIO
N /
AM
OR
TIZ
ATIO
NN
ET
BLO
CK
DE
SC
RIP
TIO
NA
S A
T
1 A
PR
IL 2
013
AD
DIT
ION
S
DE
LET
ION
SA
S A
T
31 M
AR
CH
20
14
AS
AT
1
AP
RIL
201
3F
OR
TH
E
YE
AR
D
ELE
TIO
NS
A
S A
T
31 M
AR
CH
20
14
AS
AT
31
MA
RC
H
2014
AS
AT
31
MA
RC
H
2013
Tang
ible
ass
ets
Land
1,1
75
85
4
1,2
56
-
-
-
-
1,2
56
1
,17
5
Build
ings
9,3
68
1,8
37
29
11,1
76
1,5
97
392
23
1
,96
6
9,2
10
7
,77
1
Pla
nt
and
machin
ery
20,5
77
3,8
03
162
24,2
18
10,2
45
2,2
01
1
36
1
2,3
10
1
1,9
08
1
0,3
32
Ele
ctr
ical e
quip
ment
3,0
80
480
5
3,5
55
1,4
50
338
5
1,7
83
1
,77
2
1,6
30
Lab
ora
tory
eq
uip
ment
3,8
00
698
69
4,4
29
2,1
58
400
60
2
,49
8
1,9
31
1
,64
2
Furn
iture
and
fi x
ture
s 7
84
86
9
861
509
91
9
5
91
2
70
2
75
Offi
ce e
quip
ment
1,4
20
386
30
1,7
76
1,0
43
220
30
1
,23
3
54
3
37
7
Vehic
les
Ow
ned
403
11
238
176
307
52
2
14
1
45
3
1
96
Leased
95
161
222
34
38
26
4
6
18
1
6
57
Tota
l tan
gib
le a
sset
s (A
) 4
0,70
2 7
,547
7
68
47,
481
17,
347
3,7
20
523
2
0,54
4 2
6,93
7 2
3,35
5
Inta
ngib
le a
sset
s
Custo
mer
contr
acts
243
-
-
243
243
-
-
24
3
-
-
Technic
al k
now
how
459
-
-
459
459
-
-
45
9
-
-
Non-c
om
pete
fees
228
-
228
-
228
-
22
8
-
-
-
Pro
duct
rela
ted
inta
ngib
le 5
14
202
85
631
-
85
-
8
5
54
6
51
4
Cop
yrig
hts
and
pate
nts
(in
clu
din
g
mark
eting /
dis
trib
ution r
ights
) 1
84
-
1
183
183
-
-
18
3
-
1
Tota
l int
ang
ible
ass
ets
(B)
1,6
28
202
3
14
1,5
16
1,1
13
85
228
9
70
546
5
15
Tota
l (A
+B
) 4
2,33
0 7
,749
1
,082
4
8,99
7 1
8,46
0 3
,805
7
51
21,
514
27,
483
23,
870
Pre
vious y
ear
35,0
78
8,0
59
807
42,3
30
16,1
10
3,1
28
77
8
18
,46
0
23
,87
0
Note
:a)
Dep
recia
tion for
the y
ear
inclu
des d
ep
recia
tion a
mounting to `
409 (p
revi
ous y
ear:
` 4
38) on a
ssets
used
for
researc
h a
nd
deve
lop
ment.
During
the y
ear, C
om
pany
incurr
ed
` 7
24
(p
revi
ousye
ar
` 3
91
) to
ward
s
cap
ital e
xp
end
iture
for
researc
h a
nd
deve
lop
ment
(Refe
r note
2.4
1).
b)
The C
om
pany
has c
ap
italis
ed
borr
ow
ing c
ost
of
` 77 d
uring t
he y
ear
end
ed
31 M
arc
h 2
014.
NOTE
2: N
OT
ES
TO
FIN
AN
CIA
L S
TAT
EM
EN
TS
(CO
NTIN
UE
D)
NOTE
S TO
FIN
ANCI
AL S
TATE
MEN
TS
(All
amou
nts
in In
dian
Rup
ees
milli
ons,
exc
ept s
hare
dat
a an
d w
here
oth
erw
ise
stat
ed)
122 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.8: NON CURRENT INVESTMENTS
PARTICULARS AS AT
31 MARCH 2014 AS AT
31 MARCH 2013
Non current investments at cost
I. QUOTED INVESTMENTS
(a) Equity shares (fully paid-up)
12,000 (previous year: 12,000) equity shares of ` 10/- each of State Bank of India (a) 3 3
TOTAL QUOTED NON CURRENT INVESTMENTS (I) 3 3
II. UNQUOTED INVESTMENTS
Trade
In Subsidiary Companies
Equity shares (fully paid up)
105,640,410 (previous year: 75,640,410) ordinary shares of CHF 1 each of Dr. Reddy’s Laboratories SA,
Switzerland 13,514 2,951
2,377,826 (previous year: 2,377,826) equity shares of ` 10/- each of Idea2Enterprises India Private Limited, India 1,447 1,447
90,544,104 (previous year: 90,544,104) equity shares of ` 10/- each of Aurigene Discovery Technologies Limited,
India 974 974
140,526,270 (previous year: 140,526,270) Series “A” shares of Peso 1 each of Industrias Quimicas Falcon de
Mexico S.A. de C.V., Mexico 709 709
26,699,230 (previous year: 26,699,230) shares of Real $ 1 each of Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil 634 634
9,066,000 (previous year: 5,566,000) ordinary shares of Euro 1 each of Reddy Pharma Iberia SA, Spain 566 321
34,022,070 (previous year: 34,022,070) equity shares of ` 10/- each of Dr. Reddy’s Bio-sciences Limited, India 266 266
1,131,646 (previous year: 1,131,646) equity shares of US $ 1 each of Reddy Antilles N.V., Netherlands 52 52
2,500 (previous year: 2,500) ordinary shares of FF 100 each of Reddy Cheminor S.A., France 2 2
134,513 (previous year: 134,513) equity shares of ` 10/- each of Cheminor Investments Limited, India 1 1
50,000 (previous year: 50,000) equity shares of ` 1/- each of Dr. Reddy’s Pharma SEZ Limited 1 1
50,000 (previous year: 50,000) equity shares of ` 10/- each of DRL Impex Limited, India 1 1
Nil (previous year: 16,033) equity shares of Euro 1 each of Lacock Holdings Limited, Cyprus (c) - 16,146
Nil (previous year: 100) ordinary shares of Rand 1 each of Dr. Reddy’s Laboratories (Proprietary) Limited, South
Africa (c) - 512
Nil (previous year: 400,750) ordinary shares of US $ 10 each of Dr. Reddy’s Laboratories Inc, U.S.A. (c) - 175
Equity shares of OOO Dr. Reddy’s Laboratories Limited, Russia (b & c) - 72
Nil (previous year: 1,000,000) ordinary shares of Aus $ 1 each of Dr. Reddy’s Laboratories (Australia) Pty. Limited.,
Australia (c) - 36
18,167 24,300
Less: Provision for decline, other than temporary, in the value of non current investments:
Reddy Pharma Iberia SA, Spain (566) (321)
Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil (633) (633)
Lacock Holdings Limited, Cyprus (c) - (2,100)
TOTAL UNQUOTED TRADE INVESTMENTS IN EQUITY SHARES OF SUBSIDIARY COMPANIES, NET (A) 16,968 21,246
Preference shares (fully paid up)
Nil (previous year: 14,750,000) 8% cumulative redeemable preference shares of ` 10/- each of Aurigene
Discovery Technologies Limited, India (d) - 147
TOTAL UNQUOTED TRADE INVESTMENTS IN PREFERENCE SHARES OF SUBSIDIARY COMPANIES (B) - 147
In joint venture
Equity shares held in Kunshan Rotam Reddy Pharmaceutical Co. Limited, China (b) 429 429
TOTAL UNQUOTED TRADE INVESTMENTS IN EQUITY SHARES OF JOINT VENTURE COMPANIES (C) 429 429
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
123
2.8: NON CURRENT INVESTMENTS (CONTINUED)
PARTICULARS AS AT
31 MARCH 2014 AS AT
31 MARCH 2013
Unquoted trade investments (continued)
In other companies
Equity shares (fully paid-up)
Ordinary shares of Roubles 1,000 each of Biomed Russia Limited, Russia (b) 66 66
200,000 (previous year: 200,000) ordinary shares of ` 10/- each of Altek Engineering Limited, India 2 2
8,859 (previous year: 8,859) equity shares of ` 100/- each of Jeedimetla Effl uent Treatment Limited, India 1 1
24,000 (previous year: 24,000) equity shares of ` 100/- each of Progressive Effl uent Treatment Limited, India 2 2
20,250 (previous year: 20,250) equity shares of ` 10/- each of Shivalik Solid Waste Management Limited, India (e) - -
71 71
Less: Provision for decline, other than temporary, in the value of non current investments (70) (70)
TOTAL UNQUOTED TRADE INVESTMENTS IN EQUITY SHARES OF OTHER COMPANIES, NET (D) 1 1
TOTAL UNQUOTED NON CURRENT INVESTMENTS ( II ) (A+B+C+D) 17,398 21,823
TOTAL NON CURRENT INVESTMENTS, NET (I + II) 17,401 21,826
Aggregate amount of quoted investments 3 3
Aggregate amount of unquoted investments 18,667 24,947
Market value of quoted investments 23 25
(a) In respect of shares of State Bank of India, the share certifi cates were misplaced during transfer/lost in transit. The Company has initiated necessary legal action at
the appropriate courts.
(b) Shares held in Kunshan Rotam Reddy Pharmaceutical Co. Limited, China , OOO Dr. Reddy’s Laboratories Limited, Russia, and Biomed Russia Limited, Russia are
not denominated in number of shares as per the laws of the respective countries.
(c) During the year ended 31 March 2014, the Company disposed its investment in Lacock Holdings Limited, Dr. Reddy’s Laboratories Inc., Dr. Reddy’s Laboratories
(Australia) Pty. Limited, Dr. Reddy’s Laboratories (Proprietary) Limited and OOO Dr. Reddy’s Laboratories Limited to its wholly owned subsidiary Dr. Reddy’s
Laboratories SA, Switzerland. The aggregate loss on such disposal of investment recorded under “Other expenses” is ` 166.
(d) Preference shares held by the Company in Aurigene Discovery Technologies Limited, India were redeemed during the year ended 31 March 2014.
(e) Rounded off in millions in the note above.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
124 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.9: LONG TERM LOANS AND ADVANCES
PARTICULARS AS AT
31 MARCH 2014AS AT
31 MARCH 2013
(Unsecured)
Considered good
Loans and advances to wholly owned subsidiaries (a) 3,990 2,722
Advance income tax (net of provisions ` 22,146; previous year: ` 17,246) 903 251
Capital advances for purchase of fi xed assets 67 384
Security Deposits 391 382
Other advances 7 13
Considered doubtful
Loans and advances to wholly owned subsidiaries (a) 866 1,224
Others 8 8
6,232 4,984
Less: Provision for doubtful loans and advances (b, c & d) (874) (1,232)
5,358 3,752
(a) Loans and advances to wholly owned subsidiaries comprise:
PARTICULARSBALANCE AS AT
MAXIMUM AMOUNT OUTSTANDING AT ANY TIME DURING
THE YEAR ENDED
31 MARCH 2014 31 MARCH 2013 31 MARCH 2014 31 MARCH 2013
DRL Impex Limited, India 2,045 2,593 2,603 2,593
Reddy Antilles N.V., Netherlands 311 282 353 282
Dr. Reddy’s Laboratories (Australia) Pty Limited, Australia - 541 644 541
Dr Reddy’s Laboratories Romania SRL, Romania 26 22 29 22
Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil 290 263 329 263
Reddy Pharma Iberia SA, Spain (Advance towards investment) (c) - 245 245 245
Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico (e) 2,184 - 2,184 1,848
Cheminor Investments Limited, India (f) - - - -
Dr. Reddy’s Bio-sciences Limited, India (f) - - - -
Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa (f) - - - 10
4,856 3,946
(b) Consequent to the increase in expected cash fl ows of some of the products forming part of product related intangibles pertaining to Company’s Global Generics
segment, the Company assessed the recoverability of money advanced to one of its subsidiaries which had funded the acquisition of such product related
intangibles and reversed ` 280 of provision for doubtful advances during the year.
(c) In the previous year, the Company had advanced a sum of ` 245 towards investment in Reddy Pharma Iberia SA. As the shares were not alloted by the end of
previous year, the said amount was classifi ed as “Advance towards Investment”. Further, the advance was provided for as not recoverable and recorded as other
expenditure. In the current period, shares were issued to the Company and accordingly the earlier provision for advance is reclassifi ed as provision for permanent
diminution in the value of investments with an equivalent reversal in “other expenses”.
(d) The Company assessed the recoverability of money advanced to Reddy Antilles N.V. and has created a provision for doubtful advances of `147 during the year.
(e) During the current year, the Company has advanced a sum of ` 2,184 as working capital loan to Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico, its
wholly owned subsidiary.
(f) Rounded off in millions in the note above.
(g) The settlement of loans and advances to wholly owned subsidiaries is neither planned nor likely to occur in the next twelve months. Loans given to Reddy Antilles
N.V., Netherlands, Dr. Reddy’s Laboratories Romania SRL, Romania, Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil, Cheminor Investments Limited, India and Dr.
Reddy’s Bio-sciences Limited, India are interest free. Other loans carry the following rates of interest:
Loan to Interest rate per annum
DRL Impex Limited, India 1.75%
Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 9%
Dr. Reddy’s Laboratories (Australia) Pty Limited, Australia 6%
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
125
2.10: CURRENT INVESTMENTS
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Current investments at cost or fair value whichever is lower
Quoted investments
In Mutual Funds
63,475,942.62 (previous year: Nil) units of IDFC Money Manager Fund Investment Plan 1,250 -
45,050,321.21 (previous year: Nil) units of HDFC Floating Rate Income Fund Long Term Plan Direct Plan 1,000 -
42,988,185.11 (previous year: Nil) units of IDFC Money Manager Fund Treasury Plan Direct Plan G 868 -
68,985,181.98 (previous year: Nil) units of IDFC Banking Debt Fund-Direct Plan-Growth 750 -
18,519,257.18 (previous year: 10,061,940.12) units of Kotak Scheme Plan A-Growth 638 340
50,000,000 (previous year: Nil) units of DSP Black Rock FMP Series 151-12M 500 -
10,000,000 (previous year: Nil) units of DSP Black Rock FMP Series 153-12M 100 -
24,988,298.82 (previous year: Nil) units of Sundaram Flexible Fund STP Direct Plan 503 -
35,464,262.66 (previous year: Nil) units of DWS Treasury Fund - Investment Direct Plan Growth 500 -
36,328,760.75 (previous year: Nil) units of HDFC Short Term Opportunities Fund Direct Plan 500 -
24,958,817.95 (previous year: Nil) units of Reliance FRF - ST - Direct Plan 500 -
390,092.53 (previous year: Nil) units of Axis Banking Debt Fund - Direct Plan - Growth 452 -
30,384,875.08 (previous year: Nil) units of SBI Dynamic Bond Fund Direct Plan Growth 450 -
14,169,825.36 (previous year: Nil) units of Kotak Banking & PSU Debt Fund Direct Growth 400 -
40,000,000 (previous year: Nil) units of Reliance Fixed Horizon Fund XXV Series 32 - Direct Plan 400 -
224,838.91 (previous year: 137,543.89) units of IDFC Cash Fund Growth Regular Plan 350 195
1,704,068.54 (previous year: Nil) units of Birla SL Cash Plus 350 -
30,000,000 (previous year: Nil) units of SDFS A – 12 - Direct Plan 300 -
12,547,051.44 (previous year: 21,802,761.32) units of Birla Sun Life Dynamic Bond Fund Retail Growth Direct Plan 250 400
25,000,000 (previous year: Nil) units of IDFC Fixed Term Plan Series – 85 - Direct Plan 250 -
15,000,000 (previous year: Nil) units of JP Morgan India Fixed Maturity Plan 150 -
15,000,000 (previous year: Nil) units of HDFC FMP 366D March 2014 (1) - Direct Plan 150 -
25,070.76 (previous year: Nil) units of Reliance Liquid Fund -Cash Plan-Direct Plan-Growth 51 -
68,941.48 (previous year: Nil) units of HDFC FRIF-STF-Direct Plan-Growth 2 -
Nil (previous year: 25,173,517.46) units of IDFC Dynamic Bond Plan - 350
Nil (previous year: 15,060,265.96) units of UTI - 191
Nil (previous year: 19,176,190.84) units of Reliance Dynamic Bond Fund - 300
Nil (previous year: 94,755.81) units of SBI Magnum Insta Cash Fund Liquid Floater Growth - 190
Total quoted current investments 10,664 1,966
Market value of quoted investments 10,762 2,010
2.11: INVENTORIES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Valued on weighted average basis)
Raw materials (Includes in transit ` 50; previous year: ` 6) 5,040 6,266
Work-in-progress 6,007 5,149
Finished goods 2,696 2,062
Stock-in-trade (goods acquired for trading) 940 726
Stores and spares 529 404
Packing materials 709 658
15,921 15,265
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
126 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.12: TRADE RECEIVABLES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Unsecured)
Outstanding for a period exceeding six months
Considered good 1,133 796
Considered doubtful 218 190
1,351 986
Less: Provision for doubtful debts (218) (190)
1,133 796
Others
Considered good 44,482 28,843
45,615 29,639
2.13: CASH AND BANK BALANCES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Cash on hand 2 4
Bank balances
In current accounts 913 557
In EEFC accounts 3 -
In term deposit accounts (original maturity less than 3 months) 238 -
Cash and cash equivalents (A) 1,156 561
In unclaimed dividend accounts 33 28
In unclaimed fractional share pay order accounts 1 1
In unclaimed debentures and debenture interest account 50 10
In term deposit accounts (original maturity more than 3 months) 5,411 8,591
Other bank balances (B) 5,495 8,630
Total cash and bank balances (A+B) 6,651 9,191
2.14: SHORT TERM LOANS AND ADVANCES
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Unsecured)
Considered good
Balances with statutory / government authorities 6,960 5,470
Prepaid expenses 269 241
Loans and advances to a wholly owned subsidiary company (a) - 1,848
Other advances 1,058 1,075
Considered doubtful
Other advances recoverable in cash or in kind or for value to be received 37 56
8,324 8,690
Less: Provision for doubtful loans and advances (37) (56)
8,287 8,634
(a) Loan given to Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico, Company’s wholly owned subsidiary at an interest rate of MXN TIIE 28d plus 1.5% per
annum, which was repaid by the subsidiary on 4 April 2013.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
127
2.15: OTHER ASSETS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Non current assets
In term deposit accounts (maturity more than 12 months) - 209
- 209
B) Current assets
Considered good
Claims receivable 161 50
Interest accrued but not due on term deposits 175 39
Derivative fi nancial asset 580 544
Other receivables from wholly owned subsidiary companies and step down subsidiary companies:
Aurigene Discovery Technologies Limited, India - 7
Reddy Antilles N.V., Netherlands 19 16
Dr. Reddy’s Bio-sciences Limited, India 70 68
Dr. Reddy’s Laboratories, Inc., USA 8 14
Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 4 5
Dr. Reddy’s Laboratories SA, Switzerland 332 331
Dr. Reddy’s Laboratories (Australia) Pty Limited, Australia - 92
Betapharm Arzneimittel GmbH, Germany 534 118
Idea2Enterprises (India) Private Limited, India 3 3
Dr. Reddy’s Srl, Italy - 20
OctoPlus Development B.V. 1 -
Dr. Reddy’s Laboratories (EU) Limited 1 -
Chirotech Technology Limited, U.K. 1 -
Others 51 -
1,940 1,307
2.16: OTHER OPERATING REVENUE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Sale of spent chemicals 481 588
Scrap sales 135 122
Income from settlement of litigation (a) 162 1,112
Miscellaneous income 34 71
812 1,893
(a) For the year ended 31 March 2013, income from settlement of litigation represents money received on settlement of ongoing litigation for breach of service
obligations by Nordion. (Refer note 2.39)
2.17: OTHER INCOME
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Interest income
On fi xed deposits 870 690
On loans to subsidiaries and joint venture 132 230
On other deposits 20 13
Dividend from subsidiaries and joint venture (a) 12 28
Profi t on sale of fi xed assets, net 28 -
Profi t on sale of current investments, net 213 212
Miscellaneous income 240 244
1,515 1,417
(a) Preference dividend received from Aurigene Discoveries Technologies Limited, India.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
128 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.18: CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening
Work-in-progress 5,149 4,462
Finished goods 2,062 1,938
Stock-in-trade 726 7,937 531 6,931
Closing
Work-in-progress 6,007 5,149
Finished goods 2,696 2,062
Stock-in-trade 940 9,643 726 7,937
(1,706) (1,006)
2.19: EMPLOYEE BENEFITS EXPENSE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Salaries, wages and bonus 9,804 9,438
Contribution to provident and other funds 552 567
Staff welfare expenses 1,128 955
Stock compensation expense, net 365 421
11,849 11,381
2.20: FINANCE COSTS
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Interest on long term borrowings 124 -
Interest on other borrowings 930 655
Gain on interest rate swaps, net (283) (41)
Loss on fair valuation of current investments 12 -
783 614
2.21: RESEARCH AND DEVELOPMENT EXPENSES
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Personnel costs 2,243 1,579
Clinical trial expenses 1,808 1,200
Materials / consumables / spares 2,089 1,825
Legal and professional charges 232 192
Power and fuel 147 153
Stock compensation expense, net 107 -
Other expenses 3,356 1,560
9,982 6,509
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
129
2.22: OTHER EXPENSES
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Consumption of stores and spare parts 946 1,015
Advertisments 233 866
Commission on sales 176 181
Carriage outward 2,494 2,492
Other selling expenses 6,087 4,130
Repairs and maintenance
Buildings 155 150
Plant and machinery 567 519
Others 1,037 712
Power and fuel 2,581 2,826
Legal and professional 2,347 2,107
Travel and conveyance 838 836
Non executive directors’ remuneration 80 60
Foreign exchange loss, net 1,287 308
Rent 313 249
Rates and taxes 216 147
Donations 183 175
Insurance 299 215
Loss on sale of fi xed assets, net - 9
Loss on sale of non current investments (Refer note 2.8) 166 6
Auditors’ remuneration (Refer note 2.28) 14 14
Provision for other than temporary diminution in the value of non current investments (Refer note 2.42) 245 223
Provision for doubtful debts, net 29 45
Provision / (reversal of provision) for doubtful advances, net (382) 1,155
Other general expenses 1,672 1,227
21,583 19,667
2.23: TAX EXPENSE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Current tax expense
Domestic taxes 4,901 4,140
4,901 4,140
Deferred tax expense
Domestic taxes 315 737
315 737
(a) Pursuant to a favourable order from Income Tax Appellate Tribunal, Hyderabad over a previously litigated matter, the Company has reversed a tax provision of
` 684 during the year.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
130 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.24: CONTINGENT LIABILITIES AND COMMITMENTS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Contingent liabilities:
Guarantees:
(a) Issued by the Company on behalf of subsidiaries, associates and joint ventures 13,836 16,274
Claims against the Company not acknowledged as debts in respect of:
(a) Income tax matters, under dispute 1,264 446
(b) Excise matters (including service tax), under dispute 633 301
(c) Sales tax matters, under dispute 319 379
(d) DPCO matters
The Company has received demands for payment to the credit of the Drug Prices Equalisation Account under Drugs (Price Control) Order, 1995 for few of its
products which are being contested. Based on its best estimate, the Company has made a provision for the potential liability related to the overcharged amount
including the interest thereon and believes that the possibility of any liability that may arise on account of penalty on this demand is not probable. In the event the
Company is unsuccessful in its litigation in the Supreme Court, it will be required to remit the sale proceeds in excess of the notifi ed selling prices to the Government
of India with interest and including penalties, if any, which amounts are not readily ascertainable.
(e) Fuel surcharge adjustment
The Andhra Pradesh Electricity Regulatory Commission (the “APERC”) has passed various orders approving the levy of Fuel Surcharge Adjustment (“FSA”) charges
for the period from 1 April 2008 to 31 March 2013 by power distribution companies from all the consumers of electricity in the state of Andhra Pradesh, India. The
Company fi led separate Writs of Mandamus before the High Court of Andhra Pradesh (the “High Court”) challenging and questioning the validity and legality of this
levy of FSA charges by the APERC for various periods.
The Company, after taking into account all of the available information and legal provisions, has recorded an amount of ` 215 as the potential liability towards FSA
charges. The total amount approved by APERC for collection by the power distribution companies from the Company in respect of FSA charges for the period
from 1 April 2008 to 31 March 2013 is approximately ` 473. As of 31 March 2014, the Company has paid, under protest, an amount of ` 267 demanded by the
power distribution companies as part of monthly electricity bills. The Company remains exposed to additional fi nancial liability should the orders passed by the
APERC be upheld by the Courts.
(f) Land pollution
The Indian Council for Environmental Legal Action fi led a writ in 1989 under Article 32 of the Constitution of India against the Union of India and others in the
Supreme Court of India for the safety of people living in the Patancheru and Bollarum areas of Medak district of Andhra Pradesh. The Company has been named in
the list of polluting industries. In 1996, the Andhra Pradesh District Judge proposed that the polluting industries compensate farmers in the Patancheru, Bollarum
and Jeedimetla areas for discharging effl uents which damaged the farmers’ agricultural land. The compensation was fi xed at ` 0.0013 per acre for dry land and
` 0.0017 per acre for wet land. Accordingly, the Company has paid a total compensation of ` 3. The Company believes that the possibility of additional liability
is remote. The Andhra Pradesh High Court disposed of the writ petition on 12 February 2013 and transferred the case to the National Green Tribunal (“NGT”),
Chennai, India. The interim orders passed in the writ petitions will continue until the matter is decided by the NGT.
(g) Water pollution and air pollution
During the three months ended 31 December 2011, the Company, along with 14 other companies, received a notice from the Andhra Pradesh Pollution Control
Board (“APP Control Board”) to show cause as to why action should not be initiated against them for violations under the Indian Water Pollution Act and the Indian
Air Pollution Act. Furthermore, the APP Control Board issued orders to the Company to (i) stop production of all new products at the Company’s manufacturing
facilities in Hyderabad, India without obtaining a “Consent for Establishment”, (ii) cease manufacturing products at such facilities in excess of certain quantities
specifi ed by the APP Control Board and (iii) furnish a bank guarantee (similar to a letter of credit) to assure compliance with the APP Control Board’s orders.
The Company appealed the APP Control Board orders to the Andhra Pradesh Pollution Appellate Board (“the APP Appellate Board”). The APP Appellate Board,
on the basis of a report of a fact-fi nding advisory committee, recommended to the Andhra Pradesh Government to allow expansion of units fully equipped with
Zero-Liquid Discharge (“ZLD”) facilities and otherwise found no fault with the Company (on certain conditions). The APP Appellate Board’s decision was challenged
by one of the petitioners in the National Green Tribunal and the matter is currently pending before it.
Separately, the Andhra Pradesh Government, following recommendations of the APP Appellate Board, published a notifi cation in July 2013 that allowed expansion
of production of all types of existing bulk drug and bulk drug intermediate manufacturing units subject to the installation of ZLD facilities and the outcome of cases
pending in the National Green Tribunal. Importantly, the notifi cation directed pollution load of industrial units to be assessed at the point of discharge (if any) as
opposed to point of generation.
In September 2013, the Ministry of Environment and Forests, based on the revised Comprehensive Environment Pollution Index issued a notifi cation that re-
imposed a moratorium on expansion of industries in certain areas where some of the Company’s manufacturing facilities are located. This notifi cation overrides the
Andhra Pradesh Government’s notifi cation that conditionally permitted expansion.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
131
2.24: CONTINGENT LIABILITIES AND COMMITMENTS (CONTINUED)
(h) Assessable value of products supplied by a vendor to the Company
During the year ended 31 March 2003, the Central Excise Authorities of India (“the Central Excise Authorities”) issued a demand notice to a vendor of the Company
regarding the assessable value of products supplied by this vendor to the Company. The Company has been named as a co-defendant in this demand notice.
The Central Excise Authorities demanded payment of ` 176 from the vendor, including penalties of ` 90. Through the same notice, the Central Excise Authorities
issued a penalty claim of ` 70 against the Company. During the year ended 31 March 2005, the Central Excise Authorities issued an additional notice to this vendor
demanding ` 226 from the vendor, including a penalty of ` 51. Through the same notice, the Central Excise Authorities issued a penalty claim of ` 7 against the
Company. Furthermore, during the year ended 31 March 2006, the Central Excise Authorities issued an additional notice to this vendor demanding ` 34. The
Company fi led appeals against these notices with the Customs, Excise and Service Tax Appellate Tribunal (the “CESTAT”). In October 2006, the CESTAT passed an
order in favour of the Company setting aside all of the above demand notices. In July 2007, the Central Excise Authorities appealed against CESTAT’s order in the
Supreme Court of India, New Delhi. The matter is pending in the Supreme Court of India, New Delhi.
(i) Distribution of input service tax credits
The Central Excise Authorities have issued various show cause notices to the Company objecting to the Company’s methodology of distributing input service tax
credits claimed for one of the Company’s facilities. The below table shows the details of each of such show cause notices and the consequential actions on and
status of the same.
PERIOD COVERED UNDER THE NOTICE AMOUNT DEMANDED STATUS AS ON 31 MARCH 2014
March 2008 to September 2009 ` 102 plus 100% penalty
and interest thereon
The Company fi led an appeal with the CESTAT against the Central Excise
Commissioner’s order. In July 2013, the Company received an order from the
CESTAT remanding the matter back to the Central Excise Commissioner for
reconsideration of the input service tax credit eligibility. The CESTAT also ordered
the Company to make an interim deposit of ` 50. The Company made the
requisite deposit and is awaiting a hearing with the Central Excise Commissioner.
October 2009 to March 2011 ` 125 plus penalties of
` 100 and interest thereon
The Company has fi led an appeal with the CESTAT against the Central Excise
Commissioner’s order and awaits a hearing before the CESTAT.
April 2011 to March 2012 ` 51 plus interest and
penalties
The Company has responded to such show cause notice and is currently awaiting
a hearing with the Central Excise Commissioner.
April 2012 to March 2013 ` 54 plus interest and
penalties
The Company is in the process of responding to such notice.
The Company believes that the possibility of any liability that may arise on account of the alleged inappropriate distribution of input service tax credits is not probable.
(j) Direct tax matter
During the year ended 31 March 2014, the Indian Income Tax authorities disallowed for tax purposes certain business transactions entered into by the parent company
with its wholly owned subsidiaries. The associated tax impact is ` 658. The Company believes that such business transactions are allowed for tax deduction under
Indian Income Tax laws and has accordingly fi led an appeal with the Income Tax Appellate Tribunal, Hyderabad. The Company further believes that the probability of
succeeding in this matter is more likely than not and therefore no provision was made in the fi nancial statements.
(k) Additionally, the Company is involved in other disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings,
including patent and commercial matters that arise from time to time in the ordinary course of business. Except as discussed above, the Company does not believe
that there are any such contingent liabilities that are expected to have any material adverse effect on its fi nancial statements.
Commitments:
Estimated amount of contracts remaining to be executed on capital account and not provided for (net
of advances)2,652 2,783
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
132 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.25: DEFERRED TAXATION
Deferred tax liability, net included in the balance sheet comprises of the following:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Deferred tax assets
Trade receivables 89 80
Other long term liabilities and current liabilities 127 227
Short term loans and advances 15 18
231 325
Deferred tax liability
Excess of depreciation allowable under Income tax law over depreciation provided in accounts (1,483) (1,262)
(1,483) (1,262)
Deferred tax liability, net (1,252) (937)
2.26: EARNINGS PER SHARE (EPS)
The computation of EPS is set out below:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Earnings
Profi t for the year 19,328 12,655
Shares
Number of shares at the beginning of the year 169,836,475 169,560,346
Add: Equity shares issued on exercise of vested stock options 272,393 276,129
Total number of equity shares outstanding at the end of the year 170,108,868 169,836,475
Weighted average number of equity shares outstanding during the year – Basic 170,044,518 169,778,214
Add: Weighted average number of equity shares arising out of outstanding stock options (net of the stock
options forfeited) that have dilutive effect on the EPS813,171 839,666
Weighted average number of equity shares outstanding during the year – Diluted 170,857,689 170,617,880
Earnings per share of par value ` 5/- – Basic (`) 113.67 74.54
Earnings per share of par value ` 5/- – Diluted (`) 113.13 74.17
2.27: RELATED PARTY DISCLOSURES
a. List of all subsidiaries and joint ventures:
Subsidiaries including step down subsidiaries
1. Aurigene Discovery Technologies (Malaysia) SDN BHD;
2. Aurigene Discovery Technologies Inc., USA;
3. Aurigene Discovery Technologies Limited, India;
4. beta Institut gemeinnützige GmbH, Germany;
5. betapharm Arzneimittel GmbH, Germany;
6. Cheminor Investments Limited, India;
7. Chienna B.V., Netherlands (from 15 February 2013);
8. Chirotech Technology Limited, UK;
9. Dr. Reddy’s Bio-sciences Limited, India;
10. Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil;
11. Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia;
12. Dr. Reddy’s Laboratories (EU) Limited, UK;
13. Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa;
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
133
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
14. Dr. Reddy’s Laboratories Inc., USA;
15. Dr. Reddy’s Laboratories International SA, Switzerland;
16. Dr. Reddy’s Laboratories Lousiana LLC, USA;
17. Dr. Reddy’s Laboratories Romania SRL, Romania;
18. Dr. Reddy’s Laboratories SA, Switzerland;
19. Dr. Reddy’s New Zealand Limited, New Zealand;
20. Dr. Reddy’s Pharma SEZ Limited, India;
21. Dr. Reddy’s Singapore PTE Limited, Singapore (from 22 October 2013)
22. Dr. Reddy’s Srl, Italy (formerly Jet Generici Srl);
23. Dr. Reddy’s Laboratories New York, Inc., USA;
24. Dr. Reddy’s Laboratories Canada Inc., Canada (from 29 August 2013);
25. Dr. Reddy’s Laboratories (UK) Limited, UK;
26. Dr. Reddy’s Laboratories ILAC TICARET Limited SIRKETI, Turkey (till 04 December 2012);
27. Dr. Reddy’s Laboratories Tennessee LLC, USA;
28. Dr. Reddy’s Laboratories LLC, Ukraine;
29. Dr. Reddy’s Venezuela C.A., Venezuela;
30. DRL Impex Limited, India;
31. Eurobridge Consulting B.V., Netherlands;
32. Idea2Enterprises (India) Private Limited, India;
33. Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico;
34. I-Ven Pharma Capital Limited, India (under liquidation);
35. Lacock Holdings Limited, Cyprus;
36. OctoPlus Development B.V., Netherlands (from 15 February 2013);
37. OctoPlus N.V., Netherlands (from 15 February 2013);
38. OctoPlus PolyActive Sciences B.V., Netherlands (from 15 February 2013);
39. OctoPlus Sciences B.V., Netherlands (from 15 February 2013);
40. OctoPlus Technologies B.V., Netherlands (from 15 February 2013);
41. OctoShare B.V., Netherlands (from 15 February 2013);
42. OOO Alfa, Russia (till 16 July 2012);
43. OOO Dr. Reddy’s Laboratories Limited, Russia;
44. OOO DRS LLC, Russia;
45. Promius Pharma LLC, USA;
46. Reddy Antilles N.V., Netherlands;
47. Reddy Specialities GmbH, Germany (formerly Reddy beta GmbH);
48. Reddy Cheminor S.A., France (under liquidation);
49. Reddy Holding GmbH, Germany;
50. Reddy Netherlands B.V., Netherlands;
51. Reddy Pharma Iberia SA, Spain;
52. Reddy Pharma Italia S.p.A, Italy;
53. Reddy Pharmaceuticals Hong Kong Limited, Hong Kong (till 19 October 2012 );
54. Reddy US Therapeutics Inc., USA; (till 03 July 2013 ) and
55. Trigenesis Therapeutics Inc., USA (till 04 December 2012).
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
134 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
Joint ventures
Kunshan Rotam Reddy Pharmaceutical Company Limited (“Reddy Kunshan”),
China
Enterprise over which the Company exercises joint control with other joint venture
partners and holds 51.33% of equity shares
DRANU LLC, USA (from 9 July 2012)Enterprise over which the Company’s step down subsidiary exercises joint control
with other joint venture partner and holds 50% of equity shares
b. List of other related parties with whom transactions have taken place during the current and/or previous year:
Dr. Reddy’s Research Foundation Enterprise over which the principal shareholders have signifi cant infl uence
Dr. Reddy's Institute of Life Sciences Enterprise over which principal shareholders have signifi cant infl uence
Ecologic Chemicals Limited Enterprise controlled by principal shareholders
Stamlo Hotels Private Limited Enterprise controlled by principal shareholders
Green Park Hotels and Resorts Limited Enterprise controlled by relative of a director
K Samrajyam Mother of Vice Chairman and Managing Director
G Anuradha Spouse of Chairman and Chief Executive Offi cer
Deepti Reddy Spouse of Vice Chairman and Managing Director
G. Mallika Reddy Daughter of Chairman and Chief Executive Offi cer
G V Sanjana Reddy Daughter of Chairman and Chief Executive Offi cer
Dr. Reddy’s Foundation Enterprise where principal shareholders are trustees
Pudami Educational Society Enterprise where principal shareholders are trustees
A. R. Life Sciences Private Limited* Enterprise in which relative of a director has signifi cant infl uence
* A.R. Life Sciences Private Limited (“ARLS”) was a related party of the Company only for the year ended 31 March 2013. Accordingly, transactions with ARLS for the
year ended 31 March 2014 are not considered for reporting in the related party transactions summary.
c. List of Key Management Personnel of the Company
G V Prasad (whole-time director);
K Satish Reddy (whole-time director);
Abhijit Mukherjee;
Alok Sonig;
Dr. Amit Biswas;
Dr. R Ananthanarayanan;
Dr. Cartikeya Reddy;
Dr. Chandrasekhar Sripada;
Dr. Raghav Chari;
Dr. KVS Ram Rao;
M V Ramana;
Samiran Das;
Saumen Chakraborty;
Umang Vohra; and
Late Dr. K Anji Reddy (whole-time director till 15 March 2013)
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
135
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
d. Particulars of related party transactions
The following is a summary of signifi cant related party transactions:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31MARCH 2013
i. Revenues from:
Subsidiaries including step down subsidiaries:
Dr. Reddy’s Laboratories Inc., USA 37,695 23,953
OOO Dr. Reddy’s Laboratories Limited, Russia 12,062 10,358
Dr. Reddy’s Laboratories SA, Switzerland 5,289 6,811
Others 6,365 6,064
Total 61,411 47,186
Other related parties:
Ecologic Chemicals Limited 49 4
A.R. Life Sciences Private Limited - 724
Total 49 728
ii. Sale of assets to Ecologic Chemicals Limited 14 -
iii. Interest income from subsidiaries including step down subsidiaries:
Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 74 127
DRL Impex Limited, India 43 49
Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia 16 37
Others - 17
Total 133 230
iv. Service income from subsidiaries including step down subsidiaries:
Dr. Reddy’s Laboratories Inc., USA 21 15
Dr. Reddy’s Laboratories SA, Switzerland 6 10
Chirotech Technology Limited, UK 14 14
Aurigene Discovery Technologies Limited, India 1 -
Total 42 39
v. Licence fees from subsidiaries including step down subsidiaries:
betapharm Arzneimittel GmbH, Germany 785 326
Dr. Reddy’s Laboratories SA, Switzerland 313 816
Dr. Reddy’s Laboratories Inc., USA 38 63
Total 1,136 1,205
vi. Commission on guarantee from subsidiaries including step down subsidiaries:
Dr. Reddy’s Laboratories SA, Switzerland 145 121
Dr. Reddy’s Laboratories Inc., USA - 25
betapharm Arzneimittel GmbH, Germany 11 31
Lacock Holdings Limited, Cyprus 20 -
Total 176 177
vii. Rent from Aurigene Discovery Technologies Limited, India 14 15
viii. Reimbursement of operating and other expenses by subsidiary and step down subsidiary:
Dr. Reddy’s Laboratories SA, Switzerland 2 171
Aurigene Discovery Technologies Limited, India 40 302
Others 50 84
Total 92 557
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
136 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
ix. Purchases and services from:
Subsidiaries including step down subsidiaries:
Reddy Netherlands B.V., Netherlands 992 -
Dr. Reddy’s Laboratories Inc., USA 956 1,127
OOO Dr. Reddy’s Laboratories Limited, Russia 870 559
Chirotech Technology Limited, UK 448 43
Others 257 228
Total 3,523 1,957
Other related parties:
Ecologic Chemicals Limited 40 47
Dr. Reddy’s Institute of Life Sciences 96 66
A.R. Life Sciences Private Limited - 1,309
Total 136 1,422
x. Purchase of assets from Ecologic Chemicals Limited (Refer note 2.43) 1,264 -
xi. Royalty paid/payable to:
I-VEN Pharma Capital Limited, India 361 376
DRL Impex Limited, India 137 -
Total 498 376
xii. Contributions for social development:
Dr. Reddy’s Foundation 143 107
Pudami Educational Society 27 24
Total 170 131
xiii. Hotel expenses paid/payable to:
Green Park Hotels & Resorts Limited 20 17
Stamlo Hotels Private Limited 11 7
Total 31 24
xiv. Rent paid/payable to:
Key management personnel:
K Satish Reddy 14 14
Others:
G Anuradha 13 13
Deepti Reddy 3 3
K Samrajyam 2 1
G. Mallika Reddy 2 -
G V Sanjana Reddy 2 -
Total 22 17
xv. Rental deposit paid to:
Others:
G. Mallika Reddy 2 -
G V Sanjana Reddy 2 -
Total 4 -
xvi. Remuneration to key management personnel 405 421
(Note: The above amounts do not include the remuneration of key management personnel employed by Company’s subsidiaries. The above amounts do not include
stock based compensation.)
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
137
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
xvii. Investment made/(disposed) in subsidiaries during the year:
Dr. Reddy’s Laboratories SA, Switzerland 10,564 -
Reddy Pharma Iberia SA, Spain 245 7
Lacock Holdings Limited, Cyprus (16,146) -
Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa (512) -
Dr. Reddy’s Laboratories Inc., USA (175) -
OOO Dr. Reddy’s Laboratories Limited, Russia (72) -
Dr. Reddy’s Laboratories (Australia) Pty. Limited (36) -
Reddy Pharmaceuticals Hong Kong Limited, Hong Kong (dissolved) - (58)
Dr. Reddy’s Laboratories (EU) Limited, UK - (658)
Trigenesis Therapeutics Inc, USA (dissolved) - (497)
OOO Alfa, Russia - (7)
Total (6,132) (1,213)
xviii. Provision made for other than temporary diminution in the value of non current investments:
Reddy Pharma Iberia SA, Spain 245 -
Trigenesis Therapeutics Inc, USA - 222
Others - 1
Total 245 223
xix. Investments in / (redemption of) preference shares:
Aurigene Discovery Technologies Limited, India (147) -
xx. Loans and advances given to/(repaid by) subsidiaries and step down subsidiaries (including interest charged):
Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil - 15
Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa - (9)
Lacock Holdings Limited, Cyprus - (652)
Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 696 80
Reddy Pharma Iberia SA, Spain (245) 245
Dr. Reddy’s Laboratories (Australia) Pty Limited, Australia (442) 33
DRL Impex Limited, India (548) 44
Total (539) (244)
xxi. Trade advances given to / (settled by) Ecologic Chemicals Limited (2) 2
xxii. Provision made / (reversed) for loans given to subsidiary and associate:
Dr. Reddy’s Farmaceutica Do Brasil Ltda, Brazil - 123
DRL Impex Limited, India (280) 775
Reddy Pharma Iberia SA, Spain (245) 245
Reddy Antilles N.V, Netherlands 147 -
Total (378) 1,143
xxiii. Guarantee given / (released) on behalf of subsidiary and step down subsidiary:
Dr. Reddy’s Laboratories SA, Switzerland (407) 896
Reddy Holding GmbH, Germany (3,266) -
Dr. Reddy’s Laboratories Inc., USA (75) (2,628)
betapharm Arzneimittel GmbH, Germany - 212
Effect of changes in the foreign exchange rates 1,309 756
Total (2,439) (764)
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
138 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
d. The Company has the following amounts due from / to related parties:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
i. Due from related parties:
Subsidiaries including step down subsidiaries (included in trade receivables):
Dr. Reddy’s Laboratories Inc., USA 21,224 8,202
OOO Dr. Reddy’s Laboratories Limited, Russia 9,918 7,567
Others 6,693 5,651
Total 37,835 21,420
Other related parties (included in trade receivables):
Ecologic Chemicals Limited - 8
A.R. Life Sciences Private Limited - 163
Total - 171
Rental deposit to key management personnel and their relatives 8 5
ii.Provision outstanding at the end of the year towards dues from subsidiaries including step down subsidiaries (included in trade receivables):
Reddy Cheminor S.A., France 5 5
OOO Dr. Reddy’s Laboratories Limited, Russia 7 7
Total 12 12
iii. Due to related parties:
Subsidiaries including step down subsidiaries (included in trade payables and other current liabilities):
OOO Dr. Reddy’s Laboratories Limited, Russia 1,620 671
Reddy Netherlands B.V., Netherlands 992 -
Dr. Reddy’s Laboratories Inc., USA 429 439
Dr. Reddy’s Laboratories SA, Switzerland 314 369
I-VEN Pharma Capital Limited, India - 330
Others 605 127
Total 3,960 1,936
Others (included in trade payables and other current liabilities):
Dr. Reddy’s Research Foundation 18 19
Ecologic Chemicals Limited - 4
Total 18 23
Equity held in subsidiaries, associates and joint venture has been disclosed under “Non current investments” (Note 2.8). Loans and advances to subsidiaries, joint venture
and associates have been disclosed under “Long term loans and advances” and “Short term loans and advances” (Notes 2.9 and 2.14). Other receivables from subsidiaries,
associates and joint venture have been disclosed under “Other current assets” (Note 2.15).
2.28: AUDITOR’S REMUNERATION
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
a) Audit fees 11 10
b) Other charges
Taxation matters* - -
Other matters 1 1
c) Reimbursement of out of pocket expenses 2 3
14 14
*represents amount of ` 400 thousands, rounded off in millions above.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
139
2.29: INTEREST IN JOINT VENTURE
The Company has 51.33 percent interest in Kunshan Rotam Reddy Pharmaceutical Co. Limited (KRRP), a joint venture in China. KRRP is engaged in manufacturing and
marketing of active pharmaceutical ingredients and intermediates and formulations in China. The contractual arrangement between shareholders of KRRP indicates joint
control as the minority shareholders, along with the Company, have signifi cant participating rights such that they jointly control the operations of KRRP.
The aggregate amount of assets, liabilities, income and expenses related to the Company’s share in KRRP are given below:
Balance Sheet (extract)
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Fixed assets 157 139
Deferred tax assets, net 2 7
Inventories 195 124
Trade receivables 216 160
Cash and bank balances 271 126
Short term loans and advances 223 96
Trade payables 273 133
Other current liabilities 189 151
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances) 5 4
Statement of Profi t and Loss
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Income
Sales 1,428 983
Other income 6 6
Expenditure
Material costs 359 255
Employee benefi ts expense 312 226
Operating and other expenses 497 380
Research and development 10 8
Finance costs - 2
Depreciation 19 9
Profi t before taxation 240 109
Provision for taxation
- Current tax expense 34 16
- Deferred tax expense 6 -
Profi t after taxation 200 93
2.30: EMPLOYEE STOCK OPTION SCHEME
Dr. Reddy’s Employees Stock Option Plan-2002 (“the DRL 2002 Plan”): The Company instituted the DRL 2002 Plan for all eligible employees in pursuance of the special
resolution approved by the shareholders in the Annual General Meeting held on 24 September 2001. The DRL 2002 Plan covers all employees of DRL and its subsidiaries and
directors (excluding promoter directors) of DRL and its subsidiaries (collectively, “eligible employees”). Under the Scheme, the Nomination, Governance and Compensation
Committee of the Board (‘the Committee’) shall administer the Scheme and grant stock options to eligible directors and employees of the Company and its subsidiaries. The
Committee shall determine the employees eligible for receiving the options, the number of options to be granted, the exercise price, the vesting period and the exercise period.
The vesting period is determined for the options issued on the date of the grant. The options issued under the DRL 2002 Plan options vest in periods ranging between one
and four years and generally have a maximum contractual term of fi ve years.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
140 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.30: EMPLOYEE STOCK OPTION SCHEME (CONTINUED)
The DRL 2002 Plan was amended on 28 July 2004 at the Annual General Meeting of shareholders to provide for stock options grants in two categories:
Category A: 1,721,700 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the fair market value of the underlying equity
shares on the date of grant; and
Category B: 573,778 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the par value of the underlying equity shares
(i.e., ` 5 per option).
The DRL 2002 Plan was further amended on 27 July 2005 at the Annual General Meeting of shareholders to provide for stock option grants in two categories:
Category A: 300,000 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the fair market value of the underlying equity
shares on the date of grant; and
Category B: 1,995,478 stock options out of the total of 2,295,478 reserved for grant of options having exercise price equal to the par value of the underlying equity shares
(i.e., ` 5 per option).
The fair market value of a share on each grant date falling under Category A above is defi ned as the average closing price (after adjustment of Bonus issue) for 30 days prior
to the grant, in the stock exchange where there was highest trading volume during that period. Notwithstanding the foregoing, the Committee may, after getting the approval
of the shareholders in the Annual General Meeting, grant options with a per share exercise price other than fair market value and par value of the equity shares.
After the issue of bonus shares by the Company in August 2006, the DRL 2002 Plan provides for stock options granted in the above two categories as follows:
PARTICULARS NUMBER OF OPTIONS
UNDER CATEGORY A NUMBER OF OPTIONS
UNDER CATEGORY B TOTAL
Options reserved under original plan 300,000 1,995,478 2,295,478
Options exercised prior to stock dividend date (A) 94,061 147,793 241,854
Balance of shares that can be allotted on exercise of options (B) 205,939 1,847,685 2,053,624
Options arising from stock dividend (C) 205,939 1,847,685 2,053,624
Options reserved after stock dividend (A+B+C) 505,939 3,843,163 4,349,102
In the case of termination of employment, all unvested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the
time prescribed under each option agreement by the Committee or if no time limit is prescribed, within three months of the date of employment termination, failing which they
would stand cancelled.
The term of the DRL 2002 Plan expired on 29 January 2012. Consequently, the Board of Directors of the Company, based on the recommendation of the Nomination,
Governance and Compensation Committee, resolved to extend the term of the DRL 2002 Plan for a period of 10 years with effect from 29 January 2012, subject to the
approval of shareholders. A resolution to this effect was approved by the shareholders at the Company’s Annual General Meeting held on 20 July 2012.
During the current year, the Company under the DRL 2002 Plan has issued 258,870 Catagory B options to eligible employees. The vesting period for the options granted
varies from 12 to 48 months.
The date of grant, number of options granted, exercise price fi xed by the Nomination, Governance and Compensation Committee for respective options and the market price
of the shares of the Company on the day prior to the date of grant are given below:
DATE OF GRANT NUMBER OF OPTIONS GRANTED EXERCISE PRICE `MARKET PRICE `
(AS PER SEBI GUIDELINES)
13 May 2013 258,870 5.00 2,091.70
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
141
2.30: EMPLOYEE STOCK OPTION SCHEME (CONTINUED)
Stock option activity under the DRL 2002 Plan for the two categories of options was as follows:
CATEGORY A – FAIR MARKET VALUE OPTIONS YEAR ENDED 31 MARCH 2014
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICESWEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 11,000 ` 373.50-448.00 ` 441.23 52
Granted during the year - - - -
Expired / forfeited during the year (1,000) ` 373.50 ` 373.50 -
Exercised during the year - - - -
Outstanding at the end of the year 10,000 ` 448.00 ` 448.00 44
Exercisable at the end of the year 10,000 ` 448.00 ` 448.00 44
CATEGORY A – FAIR MARKET VALUE OPTIONS YEAR ENDED 31 MARCH 2013
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF
EXERCISE PRICES WEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 11,000 ` 373.50-448.00 ` 441.23 65
Granted during the year - - - -
Expired / forfeited during the year - - - -
Exercised during the year - - - -
Outstanding at the end of the year 11,000 ` 373.50-448.00 ` 441.23 52
Exercisable at the end of the year 11,000 ` 373.50-448.00 ` 441.23 52
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2014
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICESWEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 684,259 ` 5.00 ` 5.00 71
Granted during the year 258,870 5.00 5.00 90
Forfeited during the year (60,315) 5.00 5.00 -
Exercised during the year (241,140) 5.00 5.00 -
Outstanding at the end of the year 641,674 ` 5.00 ` 5.00 78
Exercisable at the end of the year 50,818 ` 5.00 ` 5.00 42
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2013
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICES WEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 643,156 ` 5.00 ` 5.00 70
Granted during the year 335,110 5.00 5.00 90
Forfeited during the year (65,424) 5.00 5.00 -
Exercised during the year (228,583) 5.00 5.00 -
Outstanding at the end of the year 684,259 ` 5.00 ` 5.00 71
Exercisable at the end of the year 60,296 ` 5.00 ` 5.00 38
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
142 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.30: EMPLOYEE STOCK OPTION SCHEME (CONTINUED)
Dr. Reddy’s Employees ADR Stock Option Plan-2007 (“the DRL 2007 Plan”): The Company instituted the DRL 2007 Plan for all eligible employees in pursuance of
the special resolution approved by the shareholders in the Annual General Meeting held on 27 July 2005. The DRL 2007 Plan came into effect on approval of the Board of
Directors on 22 January 2007. The DRL 2007 Plan covers all employees of DRL and its subsidiaries and directors (excluding promoter directors) of DRL and its subsidiaries
(collectively, “eligible employees”). Under the DRL 2007 Plan, the Nomination, Governance and Compensation Committee of the Board (‘the Committee’) shall administer
the DRL 2007 Plan and grant stock options to eligible employees of the Company and its subsidiaries. The Nomination, Governance and Compensation Committee shall
determine the employees eligible for receiving the options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting
period is determined for all options issued on the date of the grant. The options issued under the DRL 2007 Plan vest in periods ranging between one and four years and
generally have a maximum contractual term of fi ve years.
The Committee may, after obtaining the approval of the shareholders in the Annual General Meeting, grant options with a per share exercise price other than fair market value
and par value of the equity shares.
During the current year, the Company under the DRL 2007 Plan has issued 44,240 Category B options to eligible employees. The vesting period for the options granted varies
from 12 to 48 months.
The date of grant, number of options granted, exercise price fi xed by the Committee for respective options and the market price of the shares of the Company on the day
prior to the date of grant is given below:
DATE OF GRANT NUMBER OF OPTIONS GRANTED EXERCISE PRICE `MARKET PRICE `
(AS PER SEBI GUIDELINES)
13 May 2013 44,240 5.00 2,091.70
Stock option activity under the DRL 2007 Plan was as follows:
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2014
PARTICULARSSHARES ARISING OUT OF OPTIONS
RANGE OF EXERCISE PRICES
WEIGHTED-AVERAGE EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING CONTRACTUAL
LIFE (MONTHS)
Outstanding at the beginning of the year 98,608 ` 5.00 ` 5.00 73
Granted during the year 44,240 5.00 5.00 90
Forfeited during the year (14,132) 5.00 5.00 -
Exercised during the year (31,253) 5.00 5.00 -
Outstanding at the end of the year 97,463 ` 5.00 ` 5.00 79
Exercisable at the end of the year 7,265 ` 5.00 ` 5.00 44
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2013
PARTICULARSSHARES ARISING OUT OF OPTIONS
RANGE OF EXERCISE PRICES
WEIGHTED-AVERAGE EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING CONTRACTUAL
LIFE (MONTHS)
Outstanding at the beginning of the year 117,899 ` 5.00 ` 5.00 73
Granted during the year 58,140 5.00 5.00 90
Forfeited during the year (29,885) 5.00 5.00 -
Exercised during the year (47,546) 5.00 5.00 -
Outstanding at the end of the year 98,608 ` 5.00 ` 5.00 73
Exercisable at the end of the year 4,328 ` 5.00 ` 5.00 47
The Company has not granted any options under Category A of “the DRL 2007 Plan”.
The Company has followed intrinsic method of accounting based on which a compensation expense of ` 472 (previous year: ` 421) has been recognized in the statement of
profi t and loss.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
143
2.31: DETAILS OF IMPORTED AND INDIGENOUS RAW MATERIALS, SPARE PARTS, CHEMICALS, PACKING MATERIALS AND COMPONENTS CONSUMED
PARTICULARS
FOR THE YEAR ENDED31 MARCH 2014
FOR THE YEAR ENDED31 MARCH 2013
VALUE% OF TOTAL
CONSUMPTIONVALUE
% OF TOTAL CONSUMPTION
Raw material, packing material and chemicals
Imported 8,119 37% 6,885 30%
Indigenous 13,798 63% 15,888 70%
21,917 22,773
Stores and spares
Imported 64 7% 83 8%
Indigenous 882 93% 932 92%
946 1,015
2.32: CIF VALUE OF IMPORTS
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Raw materials 11,031 8,837
Capital equipment (including spares and components) 1,931 2,650
12,962 11,487
2.33: EARNINGS IN FOREIGN CURRENCY
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Exports on FOB basis 74,059 61,004
Interest on loan to subsidiaries 90 181
Service income and license fees 1,495 1,684
Guarantee commission 176 177
Litigation settlement 162 1,220
Others 25 24
76,007 64,290
2.34: EXPENDITURE IN FOREIGN CURRENCY
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Legal and professional 1,358 988
Bio-studies expenses 1,001 688
Interest on loans 604 402
Travel 185 161
Others 9,500 6,399
12,648 8,638
2.35: HEDGES OF FOREIGN CURRENCY RISK AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, British pounds sterling, Russian roubles
and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros.
The Company uses forward contracts, option contracts and swap contracts (derivatives) to mitigate its risk of changes in foreign currency exchange rates. Further, the
Company also uses non derivative fi nancial instruments as part of its foreign currency exposure risk mitigation strategy.
The Company had a net asset of ` 431 as of 31 March 2014 as compared to a net asset of ` 436 as of 31 March 2013 towards these derivative fi nancial instruments.
In respect of the aforesaid foreign exchange derivative contracts, the Company has recorded, as part of foreign exchange gains and losses, a net loss of ` 297 and a net gain
of ` 158 for the year ended 31 March 2014 and 2013, respectively.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
144 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.35: HEDGES OF FOREIGN CURRENCY RISK AND DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)
Hedges of highly probable forecasted transactions
The Company classifi es its derivative contracts that hedge foreign currency risk associated with highly probable forecasted transactions as cash fl ow hedges and measures
them at fair value. The effective portion of such cash fl ow hedges is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classifi ed in the
statement of profi t and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion is immediately recorded in the
statement of profi t and loss.
The Company also designates certain non derivative fi nancial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign
currency risk associated with highly probable forecasted transactions and, accordingly, applies cash fl ow hedge accounting for such relationships. Re-measurement gain/loss
on such non derivative fi nancial liabilities is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classifi ed in the statement of profi t and
loss as revenue in the period corresponding to the occurrence of the forecasted transactions.
In respect of the aforesaid hedges of highly probable forecasted transactions, the Company has recorded, in reserves and surplus, a net loss of ` 407 and a net profi t of ` 405
for the year ended 31 March 2014 and 2013, respectively. The Company also recorded, as part of revenue, a net loss of ` 946 and ` 352 during the year ended 31 March
2014 and 2013, respectively.
The net carrying amount of the Company’s “hedging reserve” was a loss of ` 5 as at 31 March 2014, as compared to a gain of ` 402 as at 31 March 2013.
The table below summarises the periods when the forecasted cash fl ows associated with derivative hedging instruments that are classifi ed as cash fl ow hedges, are expected
to occur:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Cash fl ows in U.S. Dollars (fi gures in equivalent rupee millions)
Not later than one month 1,797 2,171
Later than one month and not later than three months 3,595 4,343
Later than three months and not later than six months 5,392 6,514
Later than six months and not later than two years 5,992 11,400
16,776 24,428
Cash fl ows in Euro (fi gures in equivalent rupee millions)
Not later than one month - -
Later than one month and not later than three months - 208
Later than three months and not later than six months - 313
Later than six months and not later than one year - 626
- 1,147
Hedges of recognised assets and liabilities
Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied are
recognised in the statement of profi t and loss. The changes in fair value of such derivative contracts as well as the foreign exchange gains and losses relating to the monetary
items are recognised as part of foreign exchange gains and losses.
Fair values of foreign exchange derivative contracts are determined under the Modifi ed Black Scholes technique by using inputs from market observable data and other
relevant terms of the contract with counter parties which are banks or fi nancial institutions.
The following are the outstanding foreign exchange derivative contracts for hedges of recognized assets and liabilities:
As at 31 March 2014
CATEGORY CURRENCY CROSS CURRENCYAMOUNTS IN
MILLIONSBUY / SELL PURPOSE
Forward Contract USD INR USD 10 Buy Hedging
Forward Contract USD INR USD 467.5 Sell Hedging
Forward Contract EUR USD EUR 28 Sell Hedging
Option Contract USD INR USD 235 Sell Hedging
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
145
2.35: HEDGES OF FOREIGN CURRENCY RISK AND DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)
As at 31 March 2013
CATEGORY CURRENCY CROSS CURRENCYAMOUNTS IN
MILLIONSBUY / SELL PURPOSE
Forward Contract USD INR USD 23 Buy Hedging
Forward Contract USD INR USD 140.7 Sell Hedging
Option Contract USD INR USD 595 Sell Hedging
Swap Contract USD INR USD 64.7 Sell Hedging
Swap Contract EUR INR EUR 16.5 Sell Hedging
Derivative fi nancial instruments valuation:
The Company enters into derivative fi nancial instruments with various counterparties, principally fi nancial institutions and banks. Derivatives valued using valuation techniques
with market observable inputs are mainly interest rate swaps, foreign exchange forward contracts and foreign exchange option contracts. The most frequently applied valuation
techniques include forward pricing, swap models and Black Scholes models (for option valuation), using present value calculations.
The year-end signifi cant foreign currency exposures that have not been hedged by a derivative instrument or otherwise are given below:
Un-hedged signifi cant foreign currency exposure as at 31 March 2014
CURRENCY FOREIGN CURRENCY IN MILLIONS EXCHANGE RATE ` MILLIONS
RUB 1,070 1.69 1,808
EUR (20) 82.69 (1,654)
ZAR 84 5.65 475
MXN 114 4.59 523
Un-hedged signifi cant foreign currency exposure as at 31 March 2013
CURRENCY FOREIGN CURRENCY IN MILLIONS EXCHANGE RATE ` MILLIONS
RUB 1,100 1.74 1,914
EUR (7) 69.50 (487)
ZAR 78 5.87 458
MXN 33 4.39 145
2.36: FINANCIAL RISK MANAGEMENT
The Company’s activities expose it to a variety of fi nancial risks, including market risk, credit risk and liquidity risk. The Company’s primary risk management focus is to
minimize potential adverse effects of market risk on its fi nancial performance. The Company’s risk management assessment and policies and processes are established to
identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment
and management policies and processes are reviewed regularly to refl ect changes in market conditions and the Company’s activities. The Board of Directors and the Audit
Committee are responsible for overseeing Company’s risk assessment and management policies and processes.
a. Credit risk
Credit risk is the risk of fi nancial loss to the Company if a customer or counterparty to a fi nancial instrument fails to meet its contractual obligations, and arises principally
from the Company’s receivables from customers. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness
of customers to which the Company grants credit terms in the normal course of business. The Company establishes an allowance for doubtful debts and impairment that
represents its estimate of incurred losses in respect of trade and other receivables.
Trade receivables
The Company’s exposure to credit risk is infl uenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of
the industry and country, in which the customer operates, also has an infl uence on credit risk assessment. As at 31 March 2014 and 31 March 2013 the maximum exposure
to credit risk in relation to trade and other receivables is ` 45,615 and ` 29,639 respectively (net of allowances).
Trade receivables that are neither past due nor impaired
Trade receivables amounting to ` 30,673 and ` 23,557 were neither past due nor impaired as at 31 March 2014 and 31 March 2013 respectively.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
146 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.36: FINANCIAL RISK MANAGEMENT (CONTINUED)
Trade receivables that are past due but not impaired
The Company’s credit period for customers generally ranges from 20 – 180 days. The age analysis of the trade receivables has been considered from the due date of the
invoice. The ageing of trade receivables that are past due but not impaired is given below:
PERIOD (IN DAYS)AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
1-30 8,617 3,219
31-90 1,938 1,192
91-180 3,254 875
More than 180 1,133 796
Total 14,942 6,082
Trade receivables that are impaired
The age analysis of the trade receivables that are impaired is given below:
PERIOD (IN DAYS)AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
1-30 - -
31-90 - -
91-180 - -
More than 180 218 190
Total 218 190
Reconciliation of the allowance account for credit losses
The details of changes in provision for doubtful debts during the year ended 31 March 2014 and 31 March 2013 are as follows:
PARTICULARS 2013-14 2012-13
Balance as at 1 April 190 202
Provision made during the year 33 45
Trade receivables written off during the year (1) (37)
Provision reversed during the year (4) (20)
Balance as at 31 March 218 190
Loans and advances
Loans and advances are predominantly given to subsidiaries for the purpose of working capital and capital expansions.
The details of changes in provision for doubtful loans and advances to subsidiaries during the year ended 31 March 2014 and 31 March 2013 are as follows:
PARTICULARS 2013-14 2012-13
Balance as at 1 April 1,232 87
Provision made during the year 147 1,143
Loans and advances written off during the year - -
Provision reversed during the year (525) (3)
Effect of change in the foreign exchange rates 20 5
Balance as at 31 March 874 1,232
b. Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its fi nancial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as
possible, that it will always have suffi cient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to
the Company’s reputation.
As at 31 March 2014 and 2013, the Company had unutilized credit limits from banks of ` 13,565 and ` 20,364, respectively.
As at 31 March 2014, the Company had working capital of ` 47,936 including cash and bank balances of ` 6,651 and current investments of ` 10,664. As at 31 March 2013,
the Company had working capital of ` 25,271 including cash and bank balances of ` 9,191 and current investments of ` 1,966.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
147
2.36: FINANCIAL RISK MANAGEMENT (CONTINUED)
The table below provides details regarding the contractual maturities of signifi cant fi nancial liabilities (other than provisions for employee benefi ts expense which have been
disclosed in Note 2.5, obligations under Bonus Debentures which have been disclosed in Note 2.40 and fi nance leases which have been disclosed in Note 2.45).
As at 31 March 2014
PARTICULARS 2015 2016 2017 2018 THEREAFTER TOTAL
Trade payables 8,423 - - - - 8,423
Long term borrowings - - - 1,797 7,190 8,987
Short term borrowings 17,630 - - - - 17,630
Other liabilities and provisions 10,378 - - - - 10,378
As at 31 March 2013
PARTICULARS 2014 2015 2016 2017 THEREAFTER TOTAL
Trade payables 7,678 - - - - 7,678
Short term borrowings 15,828 - - - - 15,828
Other liabilities and provisions 8,197 - - - - 8,197
Financial guarantees
Financial guarantees disclosed in Note 2.24 have been provided as counter corporate guarantees to fi nancial institutions and banks that have extended credits and other
fi nancial assistance to the Company’s subsidiaries. In this regard, the Company does not foresee any signifi cant credit risk exposure.
c. Market risk
Market risk is the risk of loss of future earnings or fair values or future cash fl ows that may result from a change in the price of a fi nancial instrument. The value of a fi nancial
instrument may change as a result of changes in the interest rates, foreign currency exchange rates and other market changes that affect market risk-sensitive instruments.
Market risk is attributable to all market risk-sensitive fi nancial instruments including foreign currency receivables and payables and long term debt. The Company is exposed to
market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company’s exposure to market risk is a function
of investing and borrowing activities and revenue generating and operating activities in foreign currencies.
Foreign exchange risk
The Company’s exchange risk arises from its foreign operations, foreign currency revenues and expenses, (primarily in U.S. dollars, British pounds sterling, Roubles and Euros)
and foreign currency borrowings (in U.S. dollars, Euros and Roubles). A signifi cant portion of the Company’s revenues are in these foreign currencies, while a signifi cant portion
of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Company’s fi nancial performance gets adversely
impacted. The exchange rate between the Indian rupee and these foreign currencies has fl uctuated substantially in recent periods and may continue to fl uctuate substantially
in the future. Consequently, the Company uses derivative fi nancial instruments, such as foreign exchange forward contracts, option contracts and swap contracts, to mitigate
the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted cash fl ows and trade receivables.
The details in respect of the outstanding foreign exchange forward contracts, option contracts and swap contracts are given in Note 2.35 above.
In respect of the Company’s derivative contracts, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such contracts would have
resulted in an approximately ` 1,254/(945) increase/(decrease) in the Company’s hedging reserve and an approximately ` 2,745/(2,892) increase/(decrease) in the Company’s
net profi t as at 31 March 2014.
In respect of the Company’s derivative contracts, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such contracts would
have resulted in an approximately ` 2,219/(1,751) increase/(decrease) in the Company’s hedging reserve and an approximately ` 1,642/(1,640) increase/(decrease) in the
Company’s net profi t as at 31 March 2013.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
148 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.36: FINANCIAL RISK MANAGEMENT (CONTINUED)
The following table analyzes foreign currency risk from fi nancial instruments as at 31 March 2014:
(All fi gures in equivalent rupees millions)
PARTICULARS U.S. DOLLARS EURO ROUBLES OTHERS(1) TOTAL
Assets:
Cash and bank balances 88 13 43 273 417
Trade receivables 29,710 914 9,910 2,209 42,743
Long term, short term loans and advances and other current assets 732 553 14 2,274 3,573
Total 30,530 1,480 9,967 4,756 46,733
Liabilities:
Trade payables 1,453 1,435 - 256 3,144
Long term borrowings 9,000 - - - 9,000
Short term borrowings 7,519 1,282 6,179 - 14,980
Other liabilities and provisions 2,084 564 1,759 278 4,685
Total 20,056 3,281 7,938 534 31,809
(1) Others include currencies such as British pounds sterling, Australian dollars, Mexican pesos, South African rand, Venezuela bolivars, etc.
The following table analyzes foreign currency risk from fi nancial instruments as at 31 March 2013:
(All fi gures in equivalent rupees millions)
PARTICULARS U.S. DOLLARS EURO ROUBLES OTHERS(1) TOTAL
Assets:
Cash and bank balances - - - 51 51
Trade receivables 15,456 1,693 7,558 1,138 25,845
Long term, short term loans and advances and other current assets 1,962 287 94 696 3,039
Total 17,418 1,980 7,652 1,885 28,935
Liabilities:
Trade payables 1,599 116 - 43 1,758
Short term borrowings 7,274 2,676 5,836 - 15,786
Other liabilities and provisions 1,593 121 865 589 3,168
Total 10,466 2,913 6,701 632 20,712
(1) Others include currencies such as British pounds sterling, Australian dollars, Mexican pesos, South African rand, Venezuela bolivars, etc.
For the year ended 31 March 2014 and 2013, every 10% depreciation/appreciation in the exchange rate between the Indian rupee and the respective currencies in the above
mentioned fi nancial assets/liabilities would affect the Company’s net profi t by approximately ` 1,492 and ` 822 respectively, from such fi nancial assets/liabilities.
Interest rate risk
As of 31 March 2014, the Company had foreign currency loans of ` 17,219 carrying a fl oating interest rate of LIBOR plus 20-179 bps and ` 846 carrying a fl oating interest
rate of Moscow Prime Offered Rate plus 60 bps whereas as of 31 March 2013 foreign currency loans were ` 8,104 carrying a fl oating interest rate of LIBOR plus 100-150
bps. These loans expose the Company to risk of changes in interest rates. The Company’s treasury department monitors the interest rate movement and manages the interest
rate risk based on its policies, which include entering into interest rate swaps as considered necessary. An increase or decrease of 10% in the fl oating interest rate component
applicable to its loans and borrowings would affect the Company’s net profi t by approximately ̀ 10 and ̀ 1 for the year ended 31 March 2014 and 31 March 2013, respectively.
The Company’s investments in time deposits with banks and short term liquid mutual funds are for short durations, and therefore do not expose the Company to signifi cant
interest rates risk.
Commodity rate risk
Exposure to market risk with respect to commodity prices primarily arises from the Company’s purchases and sales of active pharmaceutical ingredients, including the raw
material components for such active pharmaceutical ingredients. These are commodity products, whose prices may fl uctuate signifi cantly over short periods of time. The
prices of the Company’s raw materials generally fl uctuate in line with commodity cycles, although the prices of raw materials used in the Company’s active pharmaceutical
ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company’s operating expenses. Commodity price risk exposure is
evaluated and managed through operating procedures and sourcing policies. The Company has historically not entered into any material derivative contracts to hedge
exposure to fl uctuations in commodity prices.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
149
2.37: EMPLOYEE BENEFIT PLANS
2.37.1 Gratuity Plan of Dr. Reddy’s Laboratories Limited
In accordance with applicable Indian laws, the Company provides for a lump sum payment to eligible employees, at retirement or termination of employment based on the last
drawn salary and years of employment with the Company. Effective September 1, 1999, the Company established the Dr. Reddy’s Laboratories Gratuity Fund (the “Gratuity
Fund”). Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund. Amounts
contributed to the Gratuity Fund are primarily invested in Indian government bonds and corporate debt securities. A small portion of the fund is also invested in Indian equities.
The following table set out the status of the aforesaid funded gratuity plan as required under AS-15 (Revised):
Reconciliation of the present value of the defi ned benefi t obligation
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening defi ned benefi t obligation 875 646
Current service cost 116 86
Interest cost 74 59
Actuarial losses / (gains) 45 135
Benefi ts paid (70) (51)
Closing defi ned benefi t obligation 1,040 875
Change in the fair value of assets
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening fair value of plan assets 707 624
Expected return on plan assets 56 54
Actuarial gains / (losses) 14 7
Contributions by employer 201 73
Benefi ts paid (70) (51)
Closing fair value of plan assets 908 707
Amount recognized in the balance sheet
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Present value of funded obligations 1,040 875
Fair value of plan assets (908) (707)
Net Liability 132 168
Expense recognized in the statement of profi t and loss
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Current service cost 116 86
Interest on defi ned benefi t obligation 74 59
Expected return on plan assets (56) (54)
Net actuarial losses / (gains) recognized in the year 31 128
Amount included in employee benefi ts expense 165 219
Actual return on plan assets 70 61
Contributions : The Company expects to contribute ` 100 to the Gratuity Plan during the year ending 31 March 2015.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
150 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.37: EMPLOYEE BENEFIT PLANS (CONTINUED)
Asset information
CATEGORY OF ASSETSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Government of India securities - -
Corporate bonds - -
Insurer managed funds 99% 99%
Others 1% 1%
Total 100% 100%
Summary of actuarial assumptions
Financial assumptions at the valuation date:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Discount Rate 9% p.a. 7.95% p.a.
Expected rate of return on plan assets 9% p.a. 7.95% p.a.
Salary escalation rate
11% p.a. for fi rst two
years and 10% p.a.
thereafter
10% p.a. for fi rst two
years and 9% p.a.
thereafter
Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.
Expected rate of return on plan assets: This is based on the expectation of the average long term rate of return expected on investments of the fund during the estimated
term of the obligations.
Salary escalation rate: The estimate of future salary increases considered takes into account the infl ation, seniority, promotion and other relevant factors.
Experience adjustments
PARTICULARSFOR THE YEAR ENDED 31 MARCH
2014 2013 2012 2011 2010
Defi ned Benefi t Obligation 1,040 875 646 584 452
Plan Assets 908 707 624 490 449
Surplus / (Defi cit) (132) (168) (22) (94) (3)
Experience Adjustment on Plan Liabilities 42 26 23 28 27
Experience Adjustment on Plan Assets 15 7 6 5 27
2.37.2 Other benefi ts
Provident fund benefi ts
Certain categories of employees of the Company receive benefi ts from a provident fund, a defi ned contribution plan. Both the employee and employer each make monthly
contributions to a government administered fund equal to 12% of the covered employee’s qualifying salary. The Company has no further obligations under the plan beyond its
monthly contributions. The Company contributed ` 391 and ` 331 to the provident fund plan during the year ended 31 March 2014 and 2013 respectively.
Superannuation benefi ts
The senior offi cers of the Company participate in superannuation, a defi ned contribution plan administered by the Life Insurance Corporation of India. The Company makes
annual contributions based on a specifi ed percentage of each covered employee’s salary. The Company has no further obligations under the plan beyond its annual
contributions. The Company contributed ` 62 and ` 56 to the superannuation plan during the year ended 31 March 2014 and 2013 respectively.
Compensated leave of absence
The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized
compensated absences and utilize it in future periods or receive cash in lieu thereof as per Company policy. The Company records an obligation for compensated absences
in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this benefi t was ` 412 and ` 331
as at 31 March 2014 and 2013 respectively.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
151
2.38: DIVIDEND REMITTANCE IN FOREIGN CURRENCY
The Company does not make any direct remittances of dividends in foreign currencies to American Depository Receipts (ADRs) holders. The Company remits the equivalent
of the dividends payable to the ADR holders in Indian Rupees to the custodian, which is the registered shareholder on record for all owners of the Company’s ADRs. The
custodian purchases the foreign currencies and remits it to the depository bank which inturn remits the dividends to the ADR holders.
2.39: SETTLEMENT AGREEMENT WITH NORDION
During March 2013, the Company entered into an agreement with Nordion Inc. (formerly known as MDS Inc.) to settle its ongoing litigation for alleged breach of service
obligations by Nordion Inc. during the years 2000 to 2004. As part of the settlement, the Company received a total amount of `1,220 (USD 22.5 million) from Nordion Inc. out
of which `108 (USD 2 million) was towards reimbursement of research and development cost and the same was recorded as reduction in such cost. The balance `1,112 (USD
20.5 million) was towards ‘lost profi ts’ and the same was recorded as part of other operating revenue.
2.40: ISSUANCE OF BONUS DEBENTURES
The Company had, on 24 March 2011, allotted 1,015,516,392, 9.25% unsecured, non-convertible, redeemable bonus debentures aggregating to ` 5,078. The interest is
payable at the end of 12, 24 and 36 months from the initial date of issuance. The bonus debentures are redeemable at the end of 36 months from the initial date of issuance.
These debentures have been listed on the Bombay Stock Exchange Limited and National Stock Exchange of India Limited.
As per the requirements of the Companies Act, 1956, the Company created a Debenture Redemption Reserve aggregating to ` 2,539 and ` 1,712 as at 24 March 2014 and
31 March 2013 respectively.
On 24 March 2014, the Company redeemed 9.25% unsecured, non-convertible, redeemable bonus debentures at par value of ` 5,078. Consequently the amount of ` 2,539
representing Debenture Redemption Reserve has been transferred to General Reserve upon redemption of debentures.
2.41: RESEARCH AND DEVELOPMENT FIXED ASSETS (INCLUDED IN NOTE 2.7)
DESCRIPTION
GROSS BLOCK DEPRECIATION NET BLOCK
AS AT1 APRIL
2013
ADDITIONS(a)
DELETIONS (b)
AS AT31 MARCH
2014
AS AT1 APRIL
2013
FOR THE YEAR (a)
DELETIONS (b)
AS AT31 MARCH
2014
AS AT31 MARCH
2014
AS AT31 MARCH
2013
Land 70 - - 70 - - - - 70 70
Buildings 860 44 - 904 203 32 - 235 669 657
Plant and machinery 1,332 166 39 1,459 848 129 28 949 510 484
Electrical equipment 237 22 - 259 151 24 - 175 84 86
Laboratory equipment 1,988 435 77 2,346 1,236 187 66 1,357 989 752
Furniture and fi xtures 184 23 4 203 149 15 4 160 43 35
Offi ce equipment 177 34 4 207 139 22 4 157 50 38
Grand total 4,848 724 124 5,448 2,726 409 102 3,033 2,415 2,122
Previous year 4,577 391 119 4,848 2,400 438 112 2,726 2,122
(a) Includes gross block of ` 34 (previous year: ` 6) and accumulated depreciation of ` 13 (previous year: ` 4) towards transfers from non research and development to
research and development fi xed assets during the year.
(b) Includes gross block of ` 28 (previous year: ` 14) and accumulated depreciation of ` 19 (previous year: ` 8) towards transfers from research and development to non
research and development fi xed assets during the year.
2.42: PROVISION FOR OTHER THAN TEMPORARY DIMINUTION IN THE VALUE OF LONG TERM INVESTMENTS
For the year ended 31 March 2014:
Investment in Reddy Pharma Iberia SA
In the previous year, the Company had advanced a sum of ` 245 towards investment in Reddy Pharma Iberia SA. As the shares were not alloted by the end of previous year,
the said amount was classifi ed as “Advance towards Investment” within long term loans and advances. Further, the advance was provided for as not recoverable and recorded
as other expenditure. In the current period, shares were issued to the Company and accordingly the earlier provision for advance is reclassifi ed as provision for permanent
diminution in the value of investments with an equivalent reversal in other expenditure.
For the year ended 31 March 2013:
Investment in Trigenesis Therapeutics Inc.
Following the Company’s decision to discontinue its research and development on terbinafi ne nail lacquer, the Company assessed the recoverability of money invested in its
subsidiary, Trigenesis Therapeutics Inc. and has created a provision of ` 223 for diminution in the value of long term investments for the year ended 31 March 2013.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
152 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.43: ASSET PURCHASE AGREEMENT WITH ECOLOGIC CHEMICALS LIMITED
During the year ended 31 March 2014, the Company entered into an asset purchase agreement with Ecologic Chemicals Limited (“Ecologic”), where in two directors of the
Company have equity interests. The Company has paid ` 1,264 excluding taxes and duties for purchase of fi xed and current assets. The consideration was arrived at based
on valuation from independent valuers. The acquisition of these assets will help augment the Company’s manufacturing capacity in meeting the future business requirements
of its PSAI segment.
The acquisition has been accounted for as a purchase of assets. The total purchase consideration has been allocated to the acquired assets as of 13 September 2013 based
on a fair valuation carried out by the Company’s management as tabulated below:
CATEGORY AMOUNT
Land 66
Buildings 382
Plant and machinery 702
Inventories 113
Other current assets 1
Total ` 1,264
2.44: SEGMENT INFORMATION
In accordance with AS-17 “Segment Reporting”, segment information has been given in the consolidated fi nancial statements of Dr. Reddy’s Laboratories Limited and
therefore no separate disclosure on segment information is given in these fi nancial statements.
2.45: FINANCE LEASE
The Company has taken vehicles on fi nance lease. The future minimum lease payments and their present values as at 31 March 2014 are as follows:
PARTICULARSPRESENT VALUE OF
MINIMUM LEASE PAYMENTS
FUTURE INTERESTMINIMUM LEASE
PAYMENTS
Not later than one year 4 9 13
Later than one year and not later than fi ve years 13 11 24
Total 17 20 37
The future minimum lease payments and their present values as at 31 March 2013 were as follows:
PARTICULARSPRESENT VALUE OF
MINIMUM LEASE PAYMENTS
FUTURE INTERESTMINIMUM LEASE
PAYMENTS
Not later than one year 12 26 38
Later than one year and not later than fi ve years 35 38 73
Total 47 64 111
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP STANDALONE FINANCIAL STATEMENTS
153
2.46: OPERATING LEASE
The Company has taken offi ces and vehicles under operating lease agreements. Total expense recognised in statement of profi t and loss on account of operating leases during
the year amounts to ` 380 (previous year: ` 309)
The total future minimum lease payments under non cancellable leases are as follows:
PARTICULARS 31 MARCH 2014 31 MARCH 2013
Not later than one year 72 67
Later than one year and not later than fi ve years 85 82
Total 157 149
2.47: COMPARATIVE FIGURES
Previous year’s fi gures have been regrouped / reclassifi ed wherever necessary, to conform to current year’s classifi cation.
NOTE 2: NOTES TO FINANCIAL STATEMENTS (CONTINUED)
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited
Chartered Accountants
Firm Registration No.: 101248W
Supreet Sachdev
Partner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
154 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
This page has been intentionally left blank
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
155
IGAAP ConsolidatedFinancial Statements
AUDITORS’ REPORT 156
CONSOLIDATED BALANCE SHEET 157
CONSOLIDATED STATEMENT OF PROFIT AND LOSS 158
CONSOLIDATED CASH FLOW STATEMENT 159
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 160
156 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
To the Board of Directors of Dr. Reddy’s Laboratories Limited
We have audited the accompanying consolidated fi nancial statements of Dr. Reddy’s Laboratories Limited (“DRL” or the “parent company”) and its subsidiaries, associates
and joint ventures (collectively referred to as “the Company” or “the Group”), which comprise the consolidated balance sheet as at 31 March 2014, the consolidated statement
of profi t and loss and the consolidated cash fl ow statement for the year then ended, and a summary of signifi cant accounting policies and other explanatory information.
Management’s responsibility for the Consolidated Financial Statements
Management is responsible for the preparation of these consolidated fi nancial statements that give a true and fair view of the consolidated fi nancial position, consolidated
fi nancial performance and consolidated cash fl ows of the Company in accordance with the applicable fi nancial reporting framework. This responsibility includes the design,
implementation and maintenance of internal control relevant to the preparation and presentation of the consolidated fi nancial statements that give a true and fair view and are
free from material misstatement, whether due to fraud or error.
Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated fi nancial statements based on our audit. We conducted our audit in accordance with the Standards on
Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain
reasonable assurance about whether the consolidated fi nancial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated fi nancial statements. The procedures selected
depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated fi nancial statements, whether due to fraud or error. In
making those risk assessments, the auditor considers internal control relevant to the Company’s preparation and presentation of the consolidated fi nancial statements in order
to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control.
An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as
evaluating the overall presentation of the consolidated fi nancial statements.
We believe that the audit evidence we have obtained is suffi cient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion and to the best of our information and according to the explanations given to us, the consolidated fi nancial statements give a true and fair view in conformity
with the accounting principles generally accepted in India:
(i) in the case of the consolidated balance sheet, of the state of affairs of the group as at 31 March 2014;
(ii) in the case of consolidated statement of profi t and loss, of the profi t for the year ended on that date; and
(iii) in the case of consolidated cash fl ow statement, of the cash fl ows for the year ended on that date.
Other matters
We did not audit the fi nancial statements of certain subsidiaries, whose fi nancial statements refl ect total assets of ` 8,278 millions as at 31 March 2014, total revenue of
` 16,301 millions and net cash outfl ows amounting to ` (70) millions for the year then ended. These fi nancial statements have been audited by other auditors whose reports
have been furnished to us, and our opinion is based solely on the report of other auditors. Our opinion is not qualifi ed in this matter.
for B S R & Co LLP.Chartered AccountantsFirm registration No: 101248W
Supreet SachdevPartner
Membership No: 205385
Place : Hyderabad
Date : 13 May 2014
INDEPENDENT AUDITORS’ REPORT ON CONSOLIDATED FINANCIAL STATEMENTS
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
157
PARTICULARS NOTE AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
EQUITY AND LIABILITIES
Shareholders’ funds
Share capital 2.1 851 849
Reserves and surplus 2.2 77,801 62,842
78,652 63,691
Non current liabilities
Long term borrowings 2.3 20,755 12,659
Deferred tax liabilities, net 2.28 1,241 1,070
Other long term liabilities 2.4 1,181 350
Long term provisions 2.5 563 514
23,740 14,593
Current liabilities
Short term borrowings 2.3 20,607 18,986
Trade payables 2.6 8,932 9,657
Other current liabilities 2.4 20,208 21,204
Short term provisions 2.5 8,157 6,741
57,904 56,588
TOTAL 160,296 134,872
ASSETS
Non current assets
Fixed assets
Tangible assets 2.7 37,496 31,416
Intangible assets 2.7 8,912 9,090
Capital work-in-progress 6,388 5,653
Non current investments 2.8 4 4
Deferred tax assets, net 2.28 1,917 1,742
Long term loans and advances 2.9 2,322 1,491
Other non current assets 2.15 - 209
57,039 49,605
Current assets
Current investments 2.10 10,664 1,966
Inventories 2.11 24,188 21,707
Trade receivables 2.12 33,253 31,804
Cash and bank balances 2.13 23,006 20,171
Short term loans and advances 2.14 10,989 8,613
Other current assets 2.15 1,157 1,006
103,257 85,267
TOTAL 160,296 134,872
Signifi cant accounting policies 1
The accompanying notes are an integral part of consolidated fi nancial statements
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited
Chartered Accountants
Firm Registration No.: 101248W
Supreet Sachdev
Partner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
CONSOLIDATED BALANCE SHEET (All amounts in Indian Rupees millions, except share data and where otherwise stated)
158 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
PARTICULARS NOTEFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
INCOME
Sales, gross 131,715 114,933
Less: Excise duty (820) (718)
Sales, net 130,895 114,215
Service income 1,632 2,070
License fees 280 533
Other operating revenues 2.16 1,346 2,138
Revenue from operations 134,153 118,956
Other income 2.17 1,697 1,499
Total revenue 135,850 120,455
EXPENSES
Cost of material consumed (including packing material consumed) 28,407 28,166
Purchase of stock-in-trade (traded goods) 7,398 8,057
Changes in inventories of fi nished goods,work-in-progress and stock-in-trade 2.18 (3,196) (1,685)
Conversion charges 2,207 1,880
Excise duty 562 630
Employee benefi ts expense 2.19 22,130 19,287
Finance costs 2.20 1,267 1,003
Depreciation and amortization expense 2.7 6,475 5,502
Research and development cost 12,632 7,915
Other expenses 2.21 31,505 27,511
Total expenses 109,387 98,266
Profi t before exceptional and extraordinary items and tax 26,463 22,189
Exceptional items
- Impairment of goodwill 2.36 - 505
- Impairment of intangibles 2.36 - 37
Profi t before extraordinary items and tax 26,463 21,647
Extraordinary items - -
Profi t before tax 26,463 21,647
Tax expense 2.22
Current tax expense 6,568 6,570
Deferred tax expense/ (benefi t) 263 (191)
Profi t for the year 19,632 15,268
Earnings per share 2.29
Basic - Par value ` 5/- per share 115.45 89.93
Diluted - Par value ` 5/- per share 114.90 89.48
Number of shares used in computing earnings per share
Basic 170,044,518 169,778,214
Diluted 170,857,689 170,617,880
Signifi cant accounting policies 1
The accompanying notes are an integral part of consolidated fi nancial statements
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited
Chartered Accountants
Firm Registration No.: 101248W
Supreet Sachdev
Partner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
CONSOLIDATED STATEMENT OF PROFIT AND LOSS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
159
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014FOR THE YEAR ENDED
31 MARCH 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Profi t before taxation 26,463 21,647
Adjustments:
Depreciation and amortization expense 6,475 5,502
Provision for wealth tax 2 3
Profi t on sale of current investments, net (213) (212)
Foreign exchange (gain) / loss, net (1,107) 105
Impairment of goodwill and intangibles - 542
Loss on de-recognition of intangibles 86 -
Stock compensation expense, net 468 421
Allowance for sales returns 2,451 2,068
Interest income (1,085) (900)
Finance costs 1,267 1,003
(Profi t) / Loss on sale of fi xed assets, net (24) 34
Provision for inventory obsolescence 1,941 1,887
Provision for doubtful debts, net 168 108
Provision / (reversal of provision) for doubtful advances, net (2) 67
Operating cash fl ows before working capital changes 36,890 32,275 Changes in operating assets and liabilities
Trade receivables (261) (6,310)
Inventories (4,047) (3,898)
Trade payables (1,019) 1,817
Other assets and liabilties, net (4,723) (4,553)
Cash generated from operations 26,840 19,331 Income taxes paid, net (7,143) (5,552)
Net cash from operating activities 19,697 13,779 CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES
Purchase of fi xed assets (10,831) (7,557)
Proceeds from sale of fi xed assets 85 52
(Increase)/ decrease in deposit accounts (having original maturity of more than 3 months) and
other bank balances 1,361 (6,268)
Purchase of investments (25,091) (11,561)
Proceeds from sale of investments 16,594 11,882
Interest received 965 846
Cash paid for acquisition, net of cash acquired - (1,746)
Acquisition of minority interest (24) (111)
Net cash used in investing activities (16,941) (14,463)CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES
Proceeds from issuance of share capital 2 1
Proceeds from long term borrowings 10,100 -
Redemption of 9.25% redeemable non-convertible debentures of ` 5 each (5,078) -
Repayment of other long term borrowings (207) (36)
Proceeds / (repayment) from short term borrowings, net (917) 2,439
Interest paid (1,162) (1,257)
Dividend paid (2,980) (2,715)
Net cash used in fi nancing activities (242) (1,568)Net increase / (decrease) in cash and cash equivalents 2,514 (2,252)
Cash and cash equivalents at the beginning of the year (refer note 2.13) 5,204 7,362
Effect of foreign exchange gain on cash and cash equivalents 906 94
Cash and cash equivalents at the end of the year (refer note 2.13) 8,624 5,204
Notes to the cash fl ow statement:Cash and cash equivalents at the end of the year (refer note 2.13) 8,624 5,204
Other bank balances (refer note 2.13) 14,382 14,967
Cash and bank balances at the end of the year (refer note 2.13) 23,006 20,171
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories LimitedChartered AccountantsFirm Registration No.: 101248W
Supreet SachdevPartner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
CONSOLIDATED CASH FLOW STATEMENT (All amounts in Indian Rupees millions, except share data and where otherwise stated)
160 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
a) Basis of preparation of consolidated fi nancial statements
The consolidated fi nancial statements have been prepared and presented in accordance with the Indian Generally Accepted Accounting Principles (“IGAAP”) under
historical cost convention on an accrual basis. Pursuant to circular 15/2013 dated 13 September 2013 rea d with circular 08/2014 dated 4 April 2014 issued by the
Ministry of Corporate Affairs, the existing accounting standards notifi ed under the Companies Act, 1956 shall apply till the standards of accounting or any addendum
thereto are prescribed by the Central Government in consultation and recommendation of the National Financial Reporting Authority. Consequently, these fi nancial
statements have been prepared to comply in all material aspects with accounting standards notifi ed by the Central Government of India under Section 211 (3C) of the
Companies Act, 1956, other pronouncements of the Institute of Chartered Accountants of India, the relevant provisions of the Companies Act, 1956 and guidelines
issued by the Securities and Exchange Board of India (SEBI) (Collectively referred to as “IGAAP”). The fi nancial statements are presented in Indian rupees rounded off to
the nearest million.
b) Use of estimates
The preparation of the fi nancial statements in conformity with IGAAP requires the Company’s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent liabilities on the date of the fi nancial statements and reported amounts of revenues and expenses for the
year. Examples of such estimates include estimation of useful life of tangible and intangible assets, assessment of recoverable amounts of deferred tax assets, provision
for obligations relating to employees, provisions against litigations and impairment of assets. Actual results could differ from these estimates. Estimates and underlying
assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognised prospectively in the current and future periods.
c) Current and non-current classifi cation
All the assets and liabilities have been classifi ed as current or non-current as per the Company’s normal operating cycle and other criteria set out in the Revised Schedule
VI to the Companies Act, 1956.
Assets:
An asset is classifi ed as current when it satisfi es any of the following criteria:
a) it is expected to be realised in, or is intended for sale or consumption in, the Company’s normal operating cycle;
b) it is held primarily for the purpose of being traded;
c) it is expected to be realised within 12 months after the reporting date; or
d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.
Liabilities:
A liability is classifi ed as current when it satisfi es any of the following criteria:
a) it is expected to be settled in the Company’s normal operating cycle;
b) it is held primarily for the purpose of being traded;
c) it is due to be settled within 12 months after the reporting date; or
d) the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at
the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classifi cation.
Current assets/ liabilities include the current portion of non-current fi nancial assets/ liabilities respectively. All other assets/ liabilities are classifi ed as non-current.
d) Principles of consolidation
The consolidated fi nancial statements include the fi nancial statements of Dr. Reddy’s Laboratories Limited (“DRL” or the “parent company”), and all of its subsidiaries
(collectively referred to as “the Company” or “the Group”), in which the parent company has more than one-half of the voting power of an enterprise or where the parent
company controls the composition of the board of directors. In accordance with AS 27 – “Financial Reporting of Interests in Joint Ventures”, issued under Companies
(Accounting Standards) Rules, 2006, the Company has accounted for its proportionate share of interest in joint venture by the proportionate consolidation method. The
consolidated fi nancial statements have been prepared on the following basis:
The fi nancial statements of the parent company and the subsidiaries have been combined on a line-by-line basis by adding together the book values of like items of
assets, liabilities, income and expenses after eliminating intra-group balances / transactions and resulting unrealised profi ts in full. Unrealised losses resulting from
intra-group transactions have also been eliminated except to the extent that recoverable value of related assets is lower than their cost to the Company. The amounts
shown in respect of reserves comprise the amount of the relevant reserves as per the balance sheet of the parent company and its share in the post-acquisition
increase in the relevant reserves of the subsidiaries.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
161
The proportionate share of Company’s interest in Joint Ventures is combined on a line-by-line basis by adding together the book values of like items of assets,
liabilities, income and expenses after eliminating intra-group transactions and resulting unrealised profi ts, to the extent it pertains to the Company.
The excess / defi cit of cost to the parent company of its investment in the subsidiaries, joint ventures and associates over its portion of equity at the respective dates
on which investment in such entities were made is recognised in the fi nancial statements as goodwill / capital reserve.
The consolidated fi nancial statements are presented, to the extent possible, in the same format as that adopted by the parent company for its separate fi nancial
statements.
The consolidated fi nancial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances.
e) Tangible fi xed assets and depreciation
Tangible fi xed assets are carried at the cost of acquisition or construction less accumulated depreciation. The cost of tangible fi xed assets includes non-refundable taxes,
duties, freight and other incidental expenses related to the acquisition and installation of the respective assets.
Subsequent expenditure related to an item of tangible fi xed asset is capitalised only if it increases the future benefi ts from the existing assets beyond its previously
assessed standards of performance.
Advances paid towards acquisition of tangible fi xed assets outstanding at each balance sheet date are shown under long-term loans and advances. Cost of assets not
ready for intended use, as on the balance sheet date, is shown as capital work-in-progress.
Depreciation on tangible fi xed assets is provided using the straight-line method at the rates specifi ed in Schedule XIV to the Companies Act, 1956 or based on the useful
life of the assets as estimated by Management, whichever is higher. Depreciation is calculated on a pro-rata basis from the date of installation till the date the assets are
sold or disposed. Individual assets costing less than ` 5,000/- are depreciated in full in the year of acquisition. Assets acquired on fi nance leases are depreciated over the
period of the lease agreement or the useful life whichever is shorter. Leasehold improvements are depreciated over their estimated useful life, or the remaining period of
lease, whichever is shorter.
Land is not depreciated.
The Management’s estimates of the useful lives for various categories of fi xed assets are given below:
Years
Buildings
Factory and administrative buildings 20 to 50
Ancillary structures 3 to 15
Plant and machinery 3 to 15
Electrical equipment 5 to 15
Laboratory equipment 5 to 15
Furniture, fi xtures and offi ce equipment 3 to10
Vehicles 4 to 5
Depreciation methods, useful lives and residual values are reviewed at each reporting date.
Gains or losses from disposal of tangible fi xed assets are recognised in the statement of profi t and loss.
f) Borrowing costs
General and specifi c borrowing costs directly attributable to acquisition or construction of those fi xed assets which necessarily take a substantial period of time to get
ready for their intended use are capitalised. Borrowing costs are interest and other costs incurred by the Company in connection with the borrowing of funds. All other
borrowing costs are recognised in the statement of profi t and loss in the period in which they are incurred.
g) Intangible assets and amortization
Intangible assets are recorded at the consideration paid for acquisition including any import duties and other taxes (other than those subsequently recoverable by the
enterprise from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use.
Intangible assets are amortised on a systematic basis over the best estimate of their useful lives, commencing from the date the asset is available to the Company for its
use.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
162 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
The Company’s management estimates the useful lives for various categories of intangible assets as follows:
Years
Goodwill 5 to 20
Customer related intangibles 2 to 11
Patents, trademarks, etc. (including marketing/ distribution rights) 3 to 16
Technology related intangibles 3 to 13
Product related intangibles 5 to 15
The amortisation period and the amortisation method for intangible assets are reviewed at each fi nancial year-end.
An intangible asset is derecognised on disposal or when no future economic benefi ts are expected from its use and disposal. Gains or losses arising from the disposal of
intangible asset are recognised in the statement of profi t and loss.
h) Investments
Investments that are readily realisable and are intended to be held for not more than one year from the date on which such investments are made are classifi ed as current
investments. All other investments are classifi ed as non-current investments.
Non-current investments are carried at cost less any other-than-temporary diminution in value, determined separately for each individual investment. The reduction in the
carrying amount is reversed when there is a rise in the value of the investment or if the reasons for the reduction no longer exist. Any reduction in the carrying amount and
any reversal in such reductions are charged or credited to the statement of profi t and loss.
Current investments are carried at the lower of cost and fair value. The comparison of cost and fair value is done separately in respect of each category of investment.
i) Inventories
Inventories are valued at the lower of cost and net realisable value. Net realisable value (NRV) is the estimated selling price in the ordinary course of the business, less
the estimated costs of completion and the estimated costs necessary to make the sale. Cost of inventories comprises all cost of purchase, cost of conversion and other
costs incurred in bringing the inventories to their present location and condition.
The cost of all categories of inventory is determined using weighted average cost method.
j) Research and development
Expenditure on research activities undertaken with the prospect of gaining new scientifi c or technical knowledge and understanding is recognized in the statement of profi t
and loss when incurred.
Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only
if the enterprise can demonstrate all of the following:
a. the product or the process is technically and commercially feasible;
b. future economic benefi ts are probable and ascertainable;
c. the Company intends to and has suffi cient resources to complete development of the product and has the ability to use or sell the asset; and
d. development costs can be measured reliably.
k) Employee benefi ts
Defi ned benefi t plans
The liability in respect of defi ned benefi t plans and other post-employment benefi ts is calculated using the projected unit credit method and spread over the period during
which the benefi t is expected to be derived from employees’ services, consistent with the advice of qualifi ed actuaries. The long term obligations are measured at present
value of estimated future cash fl ows discounted at rates refl ecting the yields on risk free government bonds that have maturity dates approximating the terms of the
Company’s obligations. Short-term employee benefi t obligations are measured on an undiscounted basis and are expensed as the related service is provided.
All actuarial gains and losses arising during the year are recognized in the statement of profi t and loss.
Defi ned contribution plan
The Company’s contributions to defi ned contribution plans are charged to statement of profi t and loss as and when the services are received from the employees.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
163
Termination benefi ts
Termination benefi ts are recognized as an expense when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan
to either terminate employment before the normal retirement date, or to provide termination benefi ts as a result of an offer made to encourage voluntary redundancy.
Termination benefi ts for voluntary redundancies are recognized as an expense if the Company has made an offer encouraging voluntary redundancy, it is probable that
the offer will be accepted, and the number of acceptances can be estimated reliably.
Compensated leave of absence
The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized
compensated absences and utilize it in future periods or receive cash in lieu thereof as per Company policy. The Company records an obligation for compensated
absences in the period in which the employee renders the services that increases this entitlement. The measurement of such obligation is based on actuarial valuation as
at the balance sheet date carried out by a qualifi ed actuary.
Employee stock option schemes
In accordance with the SEBI guidelines, the cost is calculated based on intrinsic value method i.e. the excess of the market price of shares, at the date prior to the day of
grant of options under the Employee stock option schemes, over the exercise price is treated as employee compensation and amortised over the vesting period.
l) Foreign currency transactions, balances and translation of fi nancial statements of foreign operations
Foreign currency transactions
Foreign currency transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign
currency transactions settled during the year are recognised in the statement of profi t and loss.
Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are reported using the foreign exchange rates as at the balance sheet date.
The resultant exchange differences are recognised in the statement of profi t and loss. Non-monetary assets and liabilities are carried at the rates prevailing on the date of
transaction.
Exchange differences arising on a monetary item that, in substance, forms part of Company’s net investment in a non-integral foreign operation are accumulated in a
foreign currency translation reserve in the Company’s fi nancial statements. Such exchange differences are recognized in the statement of profi t and loss in the event of
disposal of the net investment.
Foreign operations
The fi nancial statements of the foreign integral subsidiaries, representative offi ces and branches collectively referred to as the ‘foreign integral operations’ are translated
into Indian rupees as follows:
Items of income and expenditure are translated at the respective monthly average rates;
Monetary items are translated using the closing rate;
Non-monetary items are translated using the monthly average rate which is expected to approximate the actual rate on the date of transaction; and
The net exchange difference resulting from the translation of items in the fi nancial statements of foreign integral operations is recognised as foreign exchange gain/
loss.
The fi nancial statements of non-integral foreign operations are translated into Indian rupees as follows:
All assets and liabilities, both monetary and non-monetary, are translated using the closing rate;
Items of income and expenditure are translated at the respective monthly average rates; and
The resulting net exchange difference is credited or debited to a foreign currency translation reserve.
m) Derivative instruments and hedge accounting
The Company uses forward contracts, option contracts and swap contracts (derivatives) to mitigate its risk of changes in foreign currency exchange rates and interest
rates. The Company does not use derivatives for trading or speculative purposes.
The premium or discount on foreign exchange forward contracts is amortized as income or expense over the life of the contract. The exchange difference is calculated
and recorded in accordance with AS-11 (revised) in the statement of profi t and loss. The changes in the fair value of foreign currency option contracts and swap contracts
are recognised in the statement of profi t and loss as they arise. Fair value of such option contracts and swap contracts is determined based on the appropriate valuation
techniques considering the terms of the contract.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
164 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
Pursuant to the ICAI Announcement “Accounting for Derivatives” on the early adoption of Accounting Standard-30 “Financial Instruments: Recognition and Measurement”,
the Company has adopted the Standard, to the extent that the adoption does not confl ict with existing mandatory accounting standards and other authoritative
pronouncements, the Companies Act, 1956 and other regulatory requirements.
Cash fl ow hedges
The Company classifi es its derivative contracts that hedge foreign currency risk associated with highly probable forecasted transactions as cash fl ow hedges and
measures them at fair value. The effective portion of such cash fl ow hedges is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and
re-classifi ed into the statement of profi t and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion is
immediately recorded in the statement of profi t and loss.
The Company also designates certain non-derivative fi nancial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign
currency risk associated with highly probable forecasted transactions and, accordingly, applies cash fl ow hedge accounting for such relationships. Re-measurement gain/
loss on such non-derivative fi nancial liabilities is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classifi ed in the statement of
profi t and loss as revenue in the period corresponding to the occurrence of the forecasted transactions.
If the hedging instrument no longer meets the criteria for hedge accounting, gets expired or is sold, terminated or exercised before the occurrence of the forecasted
transaction, the hedge accounting on such transaction is discontinued prospectively. The cumulative gain or loss previously recognized in hedging reserve continues to
remain there until the forecasted transaction occurs. If the forecasted transaction is no longer expected to occur, the balance in hedging reserve is recognized immediately
in the statement of profi t and loss.
n) Revenue recognition
Sale of goods
Revenue is recognized when the signifi cant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is reasonably certain, the
associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods and the amount of revenue can
be measured reliably.
Revenue from the sale of goods includes excise duty and is net of returns, sales tax and applicable trade discounts and allowances.
Revenue includes shipping and handling costs billed to the customer.
Provision for chargeback, rebates and discounts
Accrual for chargeback, rebates, discounts and medicaid payments are estimated and provided for in the year of sales and recorded as reduction of revenue. A
chargeback claim is a claim made by the wholesaler for the difference between the price at which the product is initially invoiced to the wholesaler and the net price at
which it is agreed to be procured from the Company. Accrual for such chargeback is made considering the factors such as historical average chargeback rate actually
claimed over a period of time, current contract prices with wholesalers / other customers and estimated inventory holding by the wholesaler.
Sales returns
The Company accounts for sales returns by recording an allowance for sales returns concurrent with the recognition of revenue at the time of a product sale. This
allowance is based on the Company’s estimate of expected sales returns. The estimate of sales returns is determined primarily by the Company’s historical experience
in the markets in which the Company operates.
Profi t share revenues
From time to time the Company enters into various marketing arrangements with its business partners for the sale of its products. Under such arrangements, the
Company sells its products to the business partners at a price agreed upon in the arrangement and is also entitled to a profi t share which is over and above the agreed
price. Revenue in an amount equal to the agreed price is recognized on these transactions upon delivery of products to the business partners. The additional amount
representing the profi t share component is recognized as revenue in the period which corresponds to the ultimate sales made by business partners only when the
collectability of the profi t share becomes probable and a reliable measure of the profi t share is available.
Service Income
Revenue from services rendered, which primarily relate to contract research, is recognized in the statement of profi t and loss as the underlying services are performed.
Upfront non-refundable payments received under these arrangements are deferred and recognised as revenue over the expected period over which the related services
are expected to be performed.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
165
License fee
The Company enters into certain dossier sales, licensing and supply arrangements with various parties. Income from licensing arrangements is generally recognised over
the term of the contract. Some of these arrangements include certain performance obligations by the Company. Revenue from such arrangements is recognized in the
period in which the Company completes all its performance obligations.
Dividend and interest income
Dividend income is recognised when the unconditional right to receive the income is established. Income from interest on deposits, loans and interest bearing securities
is recognised on a time proportion basis.
Export incentives
Export incentives are recognised as reduction from cost of material consumed when the right to receive credit as per the terms of the scheme is established in respect
of the exports made and where there is no signifi cant uncertainty regarding the ultimate collection of the relevant export proceeds.
o) Income tax expense
Income tax expense comprises current tax and deferred tax charge or credit. Total tax expense is the aggregate of the amounts of tax expense appearing in the separate
fi nancial statements of the parent company and its subsidiaries. Accordingly, tax expense is not adjusted for consolidation adjustments such as elimination of unrealized
intra-group profi ts.
Current tax
The current charge for income taxes is calculated in accordance with the relevant tax regulations applicable to the entities in the Company.
Deferred tax
Deferred tax charge or credit refl ects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or
credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet
date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed
depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets.
Deferred tax assets are reviewed at each balance sheet date and are written-down or written-up to refl ect the amount that is reasonably/virtually certain (as the case may
be) to be realised.
Offsetting
Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the
asset and the liability on a net basis. Deferred tax assets and liabilities are offset where the Company has a legally enforceable right to set-off assets against liabilities
representing current tax, and where such deferred tax assets and liabilities relate to taxes on income levied by the same governing taxation laws.
p) Earnings per share
The basic earnings per share (“EPS”) is computed by dividing the net profi t after tax for the year by the weighted average number of equity shares outstanding during the
year. For the purpose of calculating diluted earnings per share, net profi t after tax for the year and the weighted average number of shares outstanding during the year are
adjusted for the effects of all dilutive potential equity shares. The dilutive potential equity shares are deemed converted as of the beginning of the year, unless they have
been issued at a later date. The diluted potential equity shares have been adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. the
average market value of the outstanding shares).
q) Impairment of assets
The Company assesses at each balance sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates
the recoverable amount of the asset.
For the purpose of impairment testing, assets are grouped together into the smallest group of assets (Cash Generating Unit or CGU) that generates cash infl ows from
continuing use that are largely independent of the cash infl ows of other assets or CGUs.
The recoverable amount of an asset or CGU is the greater of its value in use and its net selling price. Value in use is the present value of the estimated future cash fl ows
expected to arise from the continuing use of an asset and from its disposal at the end of its useful life.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
166 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying
amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the statement of profi t and loss. If at the balance sheet
date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is refl ected at the recoverable
amount subject to a maximum of amortised historical cost.
r) Provisions, contingent liabilities and contingent assets
A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outfl ow of resources embodying economic
benefi ts will be required to settle the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the balance
sheet date.
Onerous contracts
A contract is considered as onerous when the expected economic benefi ts to be derived by the Company from the contract are lower than the unavoidable cost of
meeting its obligations under the contract. The provision for an onerous contract is measured at the lower of the expected cost of terminating the contract and the
expected net cost of continuing with the contract. Before a provision is established, the Company recognises any impairment loss on the assets associated with that
contract.
Contingent liabilities and contingent assets
A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outfl ow of resources.
Where there is possible obligation or a present obligation in respect of which the likelihood of outfl ow of resources is remote, no provision or disclosure is made. Contingent
assets are not recognised in the fi nancial statements. However, contingent assets are assessed continually and if it is virtually certain that an infl ow of economic benefi ts
will arise, the asset and related income are recognised in the period in which the change occurs.
s) Government grants
The Company recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be
received. Government grants received in relation to assets are presented as a reduction from the carrying amount of the related asset. Revenue Grants are deducted in
reporting the related expense.
t) Leases
The lease arrangement is classifi ed as either a fi nance lease or an operating lease, at the inception of the lease, based on the substance of the lease arrangement.
Finance leases
A fi nance lease is a lease that transfers substantially all the risks and rewards incident to ownership of an asset. A fi nance lease is recognized as an asset and a liability
at the commencement of the lease, at the lower of the fair value of the asset and the present value of the minimum lease payments. Initial direct costs, if any, are also
capitalized and, subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Minimum lease payments
made under fi nance leases are apportioned between the fi nance expense and the reduction of the outstanding liability. The fi nance expense is allocated to each period
during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Operating leases
Other leases are operating leases, and the leased assets are not recognized on the Company’s balance sheet. Payments made under operating leases are recognized in
the statement of profi t and loss on a straight-line basis over the term of the lease.
u) Cash and cash equivalents
Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash
and which are subject to insignifi cant risk of changes in value. For this purpose, “short-term” means investments having maturity of three months or less from the date of
investment.
NOTE 1: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
167
2.1: SHARE CAPITAL
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Authorised
240,000,000 (previous year: 240,000,000) equity shares of ` 5/- each 1,200 1,200
Issued
170,109,068 (previous year: 169,836,675) equity shares of ` 5/- each fully paid-up 851 849
Subscribed and fully paid-up
170,108,868 (previous year: 169,836,475) equity shares of ` 5/- each fully paid-up 851 849
Add: Forfeited share capital (e) - 851 - 849
851 849
(a) Reconciliation of the equity shares outstanding is set out below:
PARTICULARS
AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
NO. OF EQUITY
SHARESAMOUNT
NO. OF EQUITY
SHARESAMOUNT
Number of shares outstanding at the beginning of the year 169,836,475 849 169,560,346 848
Add: Equity shares issued pursuant to employee stock option plan 272,393 2 276,129 1
Number of shares outstanding at the end of the year 170,108,868 851 169,836,475 849
(b) Terms / rights attached to the equity shares
The Company has only one class of equity shares having a par value of ` 5 per share. Each holder of equity shares is entitled to one vote per share. The Company
declares and pays dividends in Indian rupees. During the year ended 31 March 2014, the amount of per share dividend recognized as distributions to equity
shareholders is ` 18 (previous year: ` 15). The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual
General Meeting.
(c) Details of shareholders holding more than 5% shares in the Company
PARTICULARS
AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
NO. OF EQUITY
SHARES HELD
% OF EQUITY
SHARES HELD
NO. OF EQUITY
SHARES HELD
% OF EQUITY
SHARES HELD
Dr. Reddy’s Holdings Limited 39,729,284 23.35 39,729,284 23.39
First State Investments Management (UK) Limited, First State Investments International
Limited and their associates 14,056,799 8.26 9,667,791 5.69
(d) 651,674 (previous year: 695,259) stock options are outstanding to be issued by the Company on exercise of the vested stock options in accordance with the terms
of exercise under the “Dr. Reddy’s Employees Stock Option Plan, 2002” and 97,463 (previous year: 98,608) stock options are outstanding to be issued by the
Company on exercise of the vested stock options in accordance with the terms of exercise under the “Dr. Reddy’s Employees ADR Stock Option Plan 2007”. (Refer
note 2.32)
(e) Represents 200 (previous year: 200) equity shares of ` 5/- each, amount paid-up ` 500/- (rounded off in millions in the note above) forfeited due to non-payment of
allotment money.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
168 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.2: RESERVES AND SURPLUS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Capital reserve
Balance at the beginning of the year 267 274
Movement during the year - (7)
267 267
Capital Redemption reserve
Balance at the beginning of the year - -
Movement during the year (a) 148 -
148 -
Securities premium account
Balance at the beginning of the year 18,815 18,532
Add: Additions during the year on exercise of employee stock options 342 283
19,157 18,815
Employee stock options outstanding*
Balance at the beginning of the year 689 551
Add: Amortization during the year, net of forfeiture 468 421
Less: Options exercised during the year (342) (283)
815 689
* Net of deferred employee stock compensation of ` 482 (previous year: ` 446)
General reserve
Balance at the beginning of the year 11,189 9,924
Add: Transferred from surplus 1,933 1,265
Add: Transferred from debenture redemption reserve 2,539 -
15,661 11,189
Foreign currency translation reserve
Balance at the beginning of the year 3,810 3,673
Movement during the year (37) 137
3,773 3,810
Hedging reserve
Balance at the beginning of the year (391) (1,356)
Movement during the year (1,519) 965
(1,910) (391)
Debenture redemption reserve
Balance at the beginning of the year 1,712 867
Add: Transferred from surplus 827 845
Less: Transferred to general reserve (2,539) -
- 1,712
Surplus
Balance at the beginning of the year 26,751 16,577
Add: Current year profi t 19,632 15,268
Amount available for appropriations 46,383 31,845
Less: Appropriations:
Proposed dividend on equity shares 3,062 2,548
Tax on proposed dividend 520 433
Dividend of previous years 3 3
Transferred to debenture redemption reserve 827 845
Capital redemption reserve 148 -
Transferred to general reserve 1,933 1,265
Balance carried forward 39,890 26,751
77,801 62,842
(a) Capital redemption reserve represents reserve created during the year on account of redemption of preference shares in Aurigene Discovery Technologies Limited.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
169
2.3: BORROWINGS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Long term borrowings
Secured
Long term maturities of fi nance lease obligations (a) 947 802
Unsecured
Sales tax deferment loan from the Government of Andhra Pradesh (interest free) (b) 15 28
Long term loans from banks (c) 19,793 11,829
20,755 12,659
B) Short term borrowings
Unsecured
Packing credit loans (d) 17,630 15,786
Other short term loans (e) 2,977 3,118
Bank overdraft - 82
20,607 18,986
(a) Finance lease obligations represent lease rentals payable for buildings, plant and machinery and vehicles leased by the Company.
(b) Sales tax deferment loan is repayable in 8 instalments, with the last instalment due in March 2019.
(c) The balance of long term loans comprises of:
(i) External Commercial Borrowings of USD 150 million carrying interest rate of LIBOR plus 179 bps and is repayable in fi ve equal quarterly instalments ending
in February 2019;
(ii) Term loan of USD 220 million carrying interest rate of LIBOR plus 100 bps and is repayable in eight equal quarterly instalments ending in September 2016.
The fi gure refl ected in above table is excluding the current portion of USD 55 million which is classifi ed under “other current liabilities”; and
(iii) Term loan of GBP 10 million carrying interest rate of LIBOR plus 130 bps and is repayable in September 2016.
As part of the aforesaid loan arrangements, the Company is required to comply with certain fi nancial covenants and the Company was in compliance with such
covenants as of 31 March 2014 and 31 March 2013.
(d) Packing credit loans for the current year comprised of USD and EUR denominated loans carrying interest rates of LIBOR plus 20 - 85 bps, RUB denominated loans
carrying interest rate of Moscow Prime Offered Rate plus 60 bps and fi xed interest rate of 7.20% - 7.75% per annum and INR denominated loans carrying fi xed
interest rate of 9.50% - 10%, and are repayable within 1 to 6 months from the date of drawdown. Packing Credit loans for the previous year comprised of USD and
EUR denominated loans carrying interest rates of LIBOR plus 50 - 125 bps and RUB denominated loans carrying fi xed interest rate of 7.25% - 8.00% per annum
and are repayable within 1 to 6 months from the date of drawdown.
(e) Other short term loans for the current year comprises of loan of EUR 36 million carrying interest rate of LIBOR plus 90 bps. Previous year other short term loans
included borrowings of EUR 45 million carrying interest rate of LIBOR plus 110 bps, which has been repaid during the current fi nancial year.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
170 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.4: OTHER LIABILITIES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Other long term liabilities
Deferred revenue 959 217
Others 222 133
1,181 350
B) Other current liabilities
Current maturities of long term borrowings
Long term loans from banks (a) 3,295 -
Finance lease obligations 100 80
Sales tax deferment loan from the Government of Andhra Pradesh (interest free) 13 19
9.25% Redeemable Non-convertible Debentures of ` 5/- each (b) - 5,078
Due to capital creditors 1,844 1,394
Interest accrued but not due on loans 45 23
Unclaimed dividends and debenture interest (c) 83 38
Accrued expenses 9,286 9,869
Salary and bonus payable 1,835 1,641
Derivative fi nancial instrument liability 339 114
Due to statutory authorities 487 233
Trade and security deposits received 296 206
Others 2,585 2,509
20,208 21,204
(a) Comprises of USD 55 million, representing current portion of term loan of USD 220 million carrying interest rate of LIBOR plus 100 bps. The amount is payable in
two equal instalments of USD 27.5 million each in December 2014 and in March 2015.
(b) During the year ended 31 March 2014, the Company redeemed 9.25% unsecured, non-convertible, redeemable debentures at par value of ` 5,078.
(c) Unclaimed amounts are transferred to Investor Protection and Education Fund after seven years from the due date.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
171
2.5: PROVISIONS
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Long term provisions
Provision for employee benefi ts
Long service award benefi t plan 79 89
Pension, seniority and severence indemnity plans 167 204
Compensated absences 282 221
Others 35 -
563 514
B) Short term provisions
Provision for employee benefi ts
Gratuity 133 169
Long service award benefi t plan 12 13
Pension, seniority and severence indemnity plans 7 7
Compensated absences 181 123
Other provisions
Taxation, net of advance taxes 1,421 1,155
Allowance for sales returns (a) 2,504 1,906
Proposed dividend 3,062 2,548
Tax on proposed dividend 518 433
Others 319 387
8,157 6,741
(a) Details of changes in allowance for sales returns during the year is as follows:
Balance at the beginning of the year 1,906 1,341
Provision made during the year 2,451 2,068
Provision utilised during the year (1,853) (1,503)
Balance at the end of the year 2,504 1,906
2.6: TRADE PAYABLES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Trade payables
Due to micro, small and medium enterprises 97 236
Others 8,835 9,421
8,932 9,657
(a) The principal amount remaining unpaid as at 31 March 2014 in respect of enterprises covered under the “Micro, Small and Medium Enterprises Development Act,
2006” (MSMDA) is ` 97 (previous year: ` 236). The interest amount computed based on the provisions under Section 16 of the MSMDA of ` 0.03 (previous year: `
0.02) is remaining unpaid as of 31 March 2014. The interest amount of ` 0.02 that remained unpaid as at 31 March 2013 was paid fully during the current year.
(b) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without
adding the interest specifi ed under this Act is ` Nil (previous year: ` Nil).
(c) The list of undertakings covered under MSMDA was determined by the Company on the basis of information available with the Company and has been relied upon
by the auditors.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
172 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
NOTE
S TO
THE
CON
SOLI
DATE
D FI
NANC
IAL
STAT
EMEN
TS
(All
amou
nts
in In
dian
Rup
ees
milli
ons,
exc
ept s
hare
dat
a an
d w
here
oth
erw
ise
stat
ed)
2.7:
FIX
ED
AS
SE
TS
GR
OS
S B
LOC
KD
EP
RE
CIA
TIO
N /
AM
OR
TIZ
ATIO
N /
IMP
AIR
ME
NT
NE
T B
LOC
K
DE
SC
RIP
TIO
NA
S A
T
1 A
PR
IL
2013
AD
DIT
ION
SD
ELE
TIO
NS
FO
RE
IGN
E
XC
HA
NG
E
AD
JUS
TM
EN
TS
(a)
AS
AT
31
MA
RC
H
2014
AS
AT
1
AP
RIL
20
13
DE
PR
EC
IAT
ION
/
AM
OR
TIZ
ATIO
N
FO
R T
HE
YE
AR
IMP
AIR
ME
NT (b)
DE
LET
ION
SF
OR
EIG
N
EX
CH
AN
GE
A
DJU
ST
ME
NT
S (a
)
AS
AT
31
MA
RC
H
2014
AS
AT
31
MA
RC
H
2014
AS
AT
31
MA
RC
H
2013
Tang
ible
ass
ets
Land
3,6
52
94
4
57
3,7
99
-
-
-
-
-
-
3,7
99
3
,65
2
Build
ings
Ow
ned
11,4
04
2,4
66
39
211
14,0
42
2,1
67
486
-
25
5
9
2,6
87
1
1,3
55
9
,23
7
Assets
taken o
n fi
nance le
ase
886
-
-
79
965
88
80
-
-
1
16
9
79
6
79
8
Leasehold
imp
rove
ments
-
439
-
-
439
-
31
-
-
-
31
4
08
-
Pla
nt
and
machin
ery
Ow
ned
25,3
93
4,9
83
166
424
30,6
34
12,3
39
2,6
74
-
13
9
15
3
15
,02
7
15
,60
7
13
,05
4
Assets
taken o
n fi
nance le
ase
104
-
94
3
13
3
18
-
16
-
5
8
1
01
Ele
ctr
ical e
quip
ment
2,8
25
523
10
7
3,3
45
1,3
01
354
-
8
2
1,6
49
1
,69
6
1,5
24
Lab
ora
tory
eq
uip
ment
Ow
ned
4,4
47
1,0
02
94
33
5,3
88
2,5
56
518
-
83
1
0
3,0
01
2
,38
7
1,8
91
Assets
taken o
n fi
nance le
ase
56
-
51
-
5
-
5
-
-
-
5
-
56
Furn
iture
, fi x
ture
s a
nd
offi
ce
eq
uip
ment
Ow
ned
3,1
11
681
59
66
3,7
99
2,2
09
435
-
56
4
6
2,6
34
1
,16
5
90
2
Assets
taken o
n fi
nance le
ase
1
-
-
-
1
-
1
-
-
-
1
-
1
Vehic
les
Ow
ned
485
28
252
2
263
354
76
-
23
0
1
20
1
62
1
31
Assets
taken o
n fi
nance le
ase
110
365
221
-
254
41
46
-
46
-
4
1
21
3
69
Tota
l tan
gib
le a
sset
s (A
)52
,474
10
,581
9
90
882
62,9
47
21,0
58
4,72
4 -
6
03
272
25
,451
37
,496
31
,416
Inta
ngib
le a
sset
s
Good
will
32,5
11
24
-
5,1
48
37,6
83
26,3
19
1,0
74
-
-
4,3
42
3
1,7
35
5
,94
8
6,1
92
Custo
mer
contr
acts
701
-
-
45
746
677
13
-
-
40
7
30
1
6
24
Cop
yrig
hts
and
pate
nts
(inclu
din
g m
ark
eting /
dis
trib
ution r
ights
)
13,7
93
-
4
2,3
30
16,1
19
11,5
14
529
-
3
2,0
85
1
4,1
25
1
,99
4
2,2
79
Technic
al k
now
ho
w 6
73
-
-
-
673
592
25
-
-
-
61
7
56
8
1
Pro
duct
rela
ted
inta
ngib
le 5
14
547
87
8
982
-
110
-
-
-
11
0
87
2
51
4
No-c
om
petition a
rrangem
ents
2
28
- 2
28
-
-
228
-
-
22
8
-
-
-
-
Oth
er
inta
ngib
les
-
26
-
-
26
-
-
-
-
-
-
26
-
Tota
l int
ang
ible
ass
ets
(B)
48,4
20
597
319
7
,531
56
,229
39
,330
1,
751
-
231
6
,467
47
,317
8,
912
9,09
0
Tota
l (A
+B
)10
0,89
4 11
,178
1,
309
8,41
3 11
9,17
6 60
,388
6,
475
-
834
6,7
39
72,7
68
46,4
08
40,5
06
Pre
vious y
ear
88,4
23
12,0
54
985
1,4
02
100,8
94
54,3
06
5,5
02
542
89
8
93
6
60
,38
8
40
,50
6
(a)
Fore
ign e
xchange a
dju
stm
ents
rep
resents
exchang
e d
iffere
nces r
esultin
g fro
m t
ransla
tion o
f fi x
ed
assets
rela
ting t
o n
on-inte
gra
l fore
ign o
pera
tio
ns.
(b)
The d
eta
ils o
f im
pairm
ent
losses h
ave
been s
et
out
in t
he N
ote
2.3
6.
(c)
The C
om
pany
has c
ap
italis
ed
borr
ow
ing c
ost
of
` 77 d
uring t
he y
ear
end
ed
31 M
arc
h 2
014.
NOTE
2: N
OT
ES
TO
TH
E C
ON
SO
LID
AT
ED
FIN
AN
CIA
L S
TAT
EM
EN
TS
(CO
NTIN
UE
D)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
173
2.8: NON CURRENT INVESTMENTS
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Non current investments at cost
I. QUOTED INVESTMENTS
(a) Equity shares (fully paid-up)
12,000 (previous year: 12,000) equity shares of ` 10/- each in State Bank of India (a) 3 3
TOTAL QUOTED LONG TERM INVESTMENTS (I) 3 3
II. UNQUOTED INVESTMENTS
Trade
In other companies
Ordinary shares of Roubles 1,000 each in Biomed Russia Limited, Russia (b) 66 66
200,000 (previous year: 200,000) ordinary shares of ` 10/- each in Altek Engineering Limited, India 2 2
8,859 (previous year: 8,859) equity shares of ` 100/- each in Jeedimetla Effl uent Treatment Limited, India 1 1
24,000 (previous year: 24,000) equity shares of ` 100/- each in Progressive Effl uent Treatment Limited, India 2 2
20,250 (previous year: 20,250) equity shares of ` 10/- each in Shivalik Solid Waste Management Limited, India (c) - -
71 71
Less: Provision for decline, other than temporary, in the value of long term investments (70) (70)
TOTAL UNQUOTED LONG TERM INVESTMENTS (II), NET 1 1
TOTAL NON CURRENT INVESTMENTS, NET (I + II) 4 4
Aggregate amount of quoted investments 3 3
Aggregate amount of unquoted investments 71 71
Market value of quoted investments 23 25
(a) In respect of shares in State Bank of India, the share certifi cates were misplaced during transfer/lost in transit. The Company has initiated necessary legal action at
the appropriate courts.
(b) Shares held in Biomed Russia Limited, Russia are not denominated in number of shares as per the laws of the country.
(c) Rounded off in millions in the note above.
2.9: LONG TERM LOANS AND ADVANCES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Unsecured)
Considered good
Advance income tax, net of provision 1,603 643
Capital advances for purchase of fi xed assets 279 406
Security deposits 440 442
Considered doubtful
Others - 8
2,322 1,499
Less: Provision for doubtful loans and advances - (8)
2,322 1,491
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
174 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.10: CURRENT INVESTMENTS
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Current investments at cost or fair value whichever is lower
Quoted investments
In Mutual Funds
63,475,942.62 (previous year: Nil) units of IDFC Money Manager Fund Investment Plan 1,250 -
45,050,321.21 (previous year: Nil) units of HDFC Floating Rate Income Fund Long Term Plan Direct Plan 1,000 -
42,988,185.11 (previous year: Nil) units of IDFC Money Manager Fund Treasury Plan Direct Plan G 868 -
68,985,181.98 (previous year: Nil) units of IDFC Banking Debt Fund-Direct Plan-Growth 750 -
18,519,257.18 (previous year: 10,061,940.12) units of Kotak Scheme Plan A-Growth 638 340
50,000,000 (previous year: Nil) units of DSP Black Rock FMP Series 151-12M 500 -
10,000,000 (previous year: Nil) units of DSP Black Rock FMP Series 153-12M 100 -
24,988,298.82 (previous year: Nil) units of Sundaram Flexible Fund STP Direct Plan 503 -
35,464,262.66 (previous year: Nil) units of DWS Treasury Fund - Investment Direct Plan Growth 500 -
36,328,760.75 (previous year: Nil) units of HDFC Short Term Opportunities Fund Direct Plan 500 -
24,958,817.95 (previous year: Nil) units of Reliance FRF - ST - Direct Plan 500 -
390,092.53 (previous year: Nil) units of Axis Banking Debt Fund - Direct Plan - Growth 452 -
30,384,875.08 (previous year: Nil) units of SBI Dynamic Bond Fund Direct Plan Growth 450 -
14,169,825.36 (previous year: Nil) units of Kotak Banking & PSU Debt Fund Direct Growth 400 -
40,000,000 (previous year: Nil) units of Reliance Fixed Horizon Fund XXV Series 32 - Direct Plan 400 -
224,838.91 (previous year: 137,543.89) units of IDFC Cash Fund Growth Regular Plan 350 195
1,704,068.54 (previous year: Nil) units of Birla SL Cash Plus 350 -
30,000,000 (previous year: Nil) units of SDFS A – 12 - Direct Plan 300 -
12,547,051.44 (previous year: 21,802,761.32) units of Birla Sun Life Dynamic Bond Fund Retail Growth Direct Plan 250 400
25,000,000 (previous year: Nil) units of IDFC Fixed Term Plan Series – 85 - Direct Plan 250 -
15,000,000 (previous year: Nil) units of JP Morgan India Fixed Maturity Plan 150 -
15,000,000 (previous year: Nil) units of HDFC FMP 366D March 2014 (1) - Direct Plan 150 -
25,070.76 (previous year: Nil) units of Reliance Liquid Fund -Cash Plan-Direct Plan-Growth 51 -
68,941.48 (previous year: Nil) units of HDFC FRIF-STF-Direct Plan-Growth 2 -
Nil (previous year: 25,173,517.46) units of IDFC Dynamic Bond Plan - 350
Nil (previous year: 15,060,265.96) units of UTI - 191
Nil (previous year: 19,176,190.84) units of Reliance Dynamic Bond Fund - 300
Nil (previous year: 94,755.81) units of SBI Magnum Insta Cash Fund Liquid Floater Growth - 190
Total quoted current investments 10,664 1,966
Market value of quoted investments 10,762 2,010
2.11: INVENTORIES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Valued on weighted average basis)
Raw materials (Includes in transit ` 57; previous year: ` 38) 6,151 7,086
Work-in-progress 6,690 5,638
Finished goods 8,054 6,108
Stock-in-trade (goods acquired for trading) 1,663 1,465
Stores and spares 693 568
Packing materials 937 842
24,188 21,707
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
175
2.12: TRADE RECEIVABLES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Unsecured)
Outstanding for a period exceeding six months
Considered good 239 586
Considered doubtful 690 582
929 1,168
Less: Provision for doubtful debts (690) (582)
239 586
Others
Considered good 33,014 31,218
33,253 31,804
2.13: CASH AND BANK BALANCES
PARTICULARS AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Cash on hand 3 5
Bank balances
In current accounts 4,731 4,479
In EEFC accounts 26 -
In term deposit accounts (original maturity less than 3 months) 3,864 720
Cash and cash equivalents (A) 8,624 5,204
In unclaimed dividend accounts 33 28
In unclaimed fractional share pay order accounts 1 1
In unclaimed debenture interest account 50 10
In term deposit accounts (original maturity more than 3 months) 14,298 14,928
Other bank balances (B) 14,382 14,967
Total cash and bank balances (A+B) 23,006 20,171
2.14: SHORT TERM LOANS AND ADVANCES
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
(Unsecured)
Considered good
Balances with statutory / government authorities 7,985 6,423
Prepaid expenses 547 644
Others 2,457 1,546
Considered doubtful
Other advances recoverable in cash or in kind or for value to be received 46 173
11,035 8,786
Less: Provision for doubtful loans and advances (46) (173)
10,989 8,613
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
176 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.15: OTHER ASSETS
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
A) Non current assets
In term deposit accounts (maturity more than 12 months) - 209
- 209
B) Current assets
Considered good
Claims receivable 204 95
Interest accrued but not due on term deposits 208 99
Derivative fi nancial asset 580 562
Others 165 250
1,157 1,006
2.16: OTHER OPERATING REVENUE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Sale of spent chemicals 481 588
Scrap sales 152 140
Royalty income 4 54
Income from settlement of litigation (a) 577 1,112
Miscellaneous income 132 244
1,346 2,138
(a) Income from settlement of litigation includes:
(i) ` 415 (CAD 6.75 million) for the year ended 31 March 2014 towards resolution of erstwhile litigation associated with Company’s sales of Olanazapine in North
America and
(ii) ` 1,112 (USD 20.5 million) for the year ended 31 March 2013 on settlement of ongoing litigation for breach of service obligations by Nordion Inc. (Refer note
2.42)
2.17: OTHER INCOME
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Interest income
On fi xed deposits 1,054 877
Others 31 23
Profi t on sale of fi xed assets, net 24 -
Profi t on sale of current investments, net 213 212
Foreign exchange gain, net 354 334
Miscellaneous income 21 53
1,697 1,499
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
177
2.18: CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening
Work-in-progress 5,638 4,986
Finished goods 5,992 2,196
Stock-in-trade 1,581 13,211 4,344 11,526
Closing
Work-in-progress 6,690 5,638
Finished goods 8,054 5,992
Stock-in-trade 1,663 16,407 1,581 13,211
(3,196) (1,685)
2.19: EMPLOYEE BENEFITS EXPENSE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Salaries, wages and bonus 18,742 16,544
Contribution to provident and other funds 1,229 955
Staff welfare expenses 1,794 1,367
Stock compensation expense, net 365 421
22,130 19,287
2.20: FINANCE COSTS
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Interest on long term borrowings 410 272
Interest on other borrowings 1,104 772
Gain on interest rate swaps, net (259) (41)
Loss on fair valuation of current investments 12 -
1,267 1,003
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
178 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.21: OTHER EXPENSES
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Consumption of stores and spare parts 1,728 1,648
Advertisements 1,598 1,406
Commission on sales 177 290
Carriage outward 3,047 3,630
Other selling expenses 7,826 5,865
Legal and professional 3,717 3,005
Power and fuel 3,199 3,354
Repairs and maintenance
Buildings 203 227
Plant and machinery 1,987 1,897
Others 1,345 846
Insurance 499 450
Travel and conveyance 1,878 1,687
Rent 749 535
Rates and taxes 671 459
Donations 188 176
Provision for doubtful debts, net 168 108
Provision for doubtful advances, net (2) 67
Non Executive Directors’ remuneration 80 60
Auditors’ remuneration (Refer note 2.27) 14 15
Loss on sale of fi xed assets, net - 34
Other general expenses 2,433 1,752
31,505 27,511
2.22: TAX EXPENSE
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Current tax expense
Domestic taxes 5,090 4,434
Foreign taxes 1,478 2,136
6,568 6,570
Deferred tax expense/ (benefi t)
Domestic taxes 295 173
Foreign taxes (32) (364)
263 (191)
(a) Pursuant to a favourable order from Income Tax Appellate Tribunal, Hyderabad over a previously litigated matter, the company has reversed a tax provision of
` 684 during the year.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
179
2.23: DESCRIPTION OF THE GROUP
Dr. Reddy’s Laboratories Limited (“DRL” or the “parent company”) together with its subsidiaries (collectively, “the Company” or “the Group”) is a leading India-based
pharmaceutical company headquartered and having its registered offi ce in Hyderabad, Andhra Pradesh, India. Through its three businesses - Pharmaceutical Services
and Active Ingredients, Global Generics and Proprietary Products – the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients
(“APIs”), Custom Pharmaceutical Services (“CPS”), generics, biosimilars, differentiated formulations and New Chemical Entities (“NCEs”). The Company’s principal research
and development facilities are located in Andhra Pradesh, India; Cambridge, United Kingdom; and Leiden, the Netherlands; its principal manufacturing facilities are located
in Andhra Pradesh, India; Himachal Pradesh, India; Cuernavaca-Cuautla, Mexico; Mirfi eld, United Kingdom; Louisiana, United States and Tennessee, United States; and its
principal markets are in India, Russia, the United States, the United Kingdom and Germany. The Company’s shares trade on the Bombay Stock Exchange and the National
Stock Exchange in India and, since 11 April 2001, also on the New York Stock Exchange in the United States.
Subsidiaries, step-down subsidiaries and joint venture of the parent company are listed below:
ENTITY COUNTRY OF INCORPORATIONPERCENTAGE
OF HOLDING (%)
Subsidiaries
Aurigene Discovery Technologies Limited A Company organised under the laws of India 100
Cheminor Investments Limited A Company organised under the laws of India 100
Dr. Reddy’s Bio-sciences Limited A Company organised under the laws of India 100
Dr. Reddy’s Farmaceutica Do Brasil Ltda. A Company organised under the laws of Brazil 100
Dr. Reddy’s Pharma SEZ Limited A Company organised under the laws of India 100
Dr. Reddy’s Laboratories SA A Company organised under the laws of Switzerland 100
DRL Impex Limited A Company organised under the laws of India 100
Idea2Enterprises (India) Private Limited A Company organised under the laws of India 100
Industrias Quimicas Falcon de Mexico S.A. de C.V A Company organised under the laws of Mexico 100
Reddy Antilles N.V. A Company organised under the laws of Netherlands 100
Reddy Cheminor S.A. (under liquidation) A Company organised under the laws of France 100
Reddy Pharma Iberia SA A Company organised under the laws of Spain 100
Dr. Reddy’s Laboratories ILAC TICARET Limited SIRKETI (until 4
December 2012)A Company organised under the laws of Turkey 100
Trigenesis Therapeutics Inc. (until 4 December 2012) A Company organised under the laws of USA 100
Reddy Pharmaceuticals Hong Kong Limited (until 19 October 2012) A Company organised under the laws of Hong Kong 100
OOO Alfa (until 16 July 2012) A Company organised under the laws of Russia 100
Step-down subsidiaries
Aurigene Discovery Technologies (Malaysia) SDN BHDA subsidiary of Aurigene Discovery Technologies Limited organised under
the laws of Malaysia100
Aurigene Discovery Technologies Inc. A subsidiary of Aurigene Discovery Technologies Limited organised under
the laws of USA100
beta Institut gemeinnützige GmbH A subsidiary of Reddy Holding GmbH organised under the laws of
Germany100
betapharm Arzneimittel GmbHA subsidiary of Reddy Holding GmbH organised under the laws of
Germany100
Chienna B.V. (from 15 February 2013) A subsidiary of OctoPlus N.V. organised under the laws of Netherlands 100
Chirotech Technology Limited A subsidiary of Dr. Reddy’s Laboratories (EU) Limited organised under the
laws of United Kingdom100
Dr. Reddy’s Laboratories (Australia) Pty. LimitedA subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Australia100
Dr. Reddy’s Laboratories (Proprietary) LimitedA subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
the Republic of South Africa100
Dr. Reddy’s SrlA subsidiary of Reddy Pharma Italia S.p.A organised under the laws of
Italy100
Dr. Reddy’s Laboratories (EU) Limited A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
the United Kingdom100
Dr. Reddy’s Laboratories (UK) Limited A subsidiary of Dr. Reddy’s Laboratories (EU) Limited organised under the
laws of the United Kingdom100
Dr. Reddy’s Laboratories Canada, Inc. (from 29 August 2013)A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Canada100
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
180 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.23: DESCRIPTION OF THE GROUP (CONTINUED)
ENTITY COUNTRY OF INCORPORATIONPERCENTAGE
OF HOLDING (%)
Dr. Reddy’s Singapore PTE Limited, Singapore (from 22 October 2013)A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
Singapore100
Dr. Reddy’s Laboratories Inc. A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of USA100
Dr. Reddy’s Laboratories International SAA subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
Switzerland 100
Dr. Reddy’s Laboratories New York, Inc. A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of USA100
Dr. Reddy’s Laboratories, LLC Ukraine A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Ukraine100
Dr. Reddy’s New Zealand Limited A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
New Zealand100
Dr. Reddy’s Laboratories Louisiana LLCA subsidiary of Dr. Reddy’s Laboratories Inc. organised under the laws
of USA100
Dr. Reddy’s Laboratories Romania S.R.L. A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Romania 100
Dr. Reddy’s Laboratories Tennessee, LLC A subsidiary of Dr. Reddy’s Laboratories Inc. organised under the laws
of USA100
Dr. Reddy’s Venezuela, C.A. A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
Venezuela 100
Eurobridge Consulting B.V.A subsidiary of Reddy Antilles N.V. organised under the laws of
Netherlands100
I-VEN Pharma Capital Limited (under liquidation) A subsidiary of DRL Impex Limited organised under the laws of India 100
Lacock Holdings Limited A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Cyprus100
OOO Dr. Reddy’s Laboratories LimitedA subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Russia 100
OctoPlus N.V. (from 15 February 2013)A subsidiary of Reddy Netherlands B.V. organised under the laws of
Netherlands100
OctoPlus Development B.V. (from 15 February 2013) A subsidiary of OctoPlus N.V. organised under the laws of Netherlands 100
OctoPlus Sciences B.V. (from 15 February 2013) A subsidiary of OctoPlus N.V. organised under the laws of Netherlands 100
OctoPlus PolyActive Sciences B.V. (from 15 February 2013)A subsidiary of OctoPlus Sciences B.V. organised under the laws of
Netherlands 100
OctoPlus Technologies B.V. (from 15 February 2013) A subsidiary of OctoPlus N.V. organised under the laws of Netherlands 100
OctoShare B.V. (from 15 February 2013) A subsidiary of OctoPlus N.V. organised under the laws of Netherlands 100
OOO DRS LLCA subsidiary of Eurobridge Consulting B.V. organised under the laws of
Russia100
Promius Pharma LLC A subsidiary of Dr. Reddy’s Laboratories Inc. organised under the laws
of USA100
Reddy Specialities GmbH, (formerly Reddy beta GmbH)A subsidiary of Reddy Holding GmbH organised under the laws of
Germany100
Reddy Holding GmbH A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws
of Germany100
Reddy Netherlands B.V.A subsidiary of Dr. Reddy’s Laboratories SA organised under the laws of
Netherlands100
Reddy Pharma Italia S.p.A A subsidiary of Lacock Holdings Limited organised under the laws of Italy 100
Reddy US Therapeutics Inc. (until 3 July 2013) A subsidiary of Reddy Antilles N.V. organised under the laws of USA 100
Joint Venture
Kunshan Rotam Reddy Pharmaceutical Company Limited A joint venture of Dr. Reddy’s Laboratories Limited organised under the
laws of China51.33
DRANU LLC (from 9 July 2012)A joint venture of Dr. Reddy’s Laboratories Inc. organised under the laws
of USA50
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
181
2.24: CONTINGENT LIABILITIES AND COMMITMENTS
PARTICULARSAS AT
31 MARCH 2014AS AT
31 MARCH 2013
Contingent liabilities:
Claims against the Company not acknowledged as debts in respect of:
(a) Income tax matters, under dispute 1,264 446
(b) Excise matters (including service tax), under dispute 633 301
(c) Sales tax matters, under dispute 319 379
(d) DPCO matters
The Company has received demands for payment to the credit of the Drug Prices Equalisation Account under Drugs (Price Control) Order, 1995 for few of its products
which are being contested. Based on its best estimate, the Company has made a provision for the potential liability related to the overcharged amount including
the interest thereon and believes that the possibility of any liability that may arise on account of penalty on this demand is not probable. In the event the Company is
unsuccessful in its litigation in the Supreme Court, it will be required to remit the sale proceeds in excess of the notifi ed selling prices to the Government of India with
interest and including penalties, if any, which amounts are not readily ascertainable.
(e) Olanzapine, Canada litigation
The Company supplies certain generic products, including olanzapine tablets (the generic version of Eli Lilly’s Zyprexa® tablets) to Pharmascience, Inc. for sale in
Canada. The Company’s agreement with Pharmascience includes a provision pursuant to which the Company shares a portion of all cost and expense incurred as a
result of settling lawsuits or paying damages that arise as a consequence of selling the products.
In November 2011, the Canadian Federal Court found the Eli Lilly Zyprexa patent invalid. This decision was upheld by the Canadian Federal Court of Appeal on 10
September 2012. On 8 November 2012, Eli Lilly fi led an application for leave to appeal with Supreme Court of Canada. On 16 May 2013, the Supreme Court of
Canada denied leave to appeal the Federal Court of Appeal decision.
(f) Ibandronate Sodium United States litigation
In June 2012, the Company launched its ibandronate sodium 150 mg tablet product, a generic version of Boniva® tablets, which are marketed and distributed by
Genentech USA, Inc., a member of the Roche Group.
The Company is defending patent infringement actions brought by Hoffmann-La Roche Inc. and Genentech USA, Inc., (collectively, “Roche”) in the United States
District Court for the District of New Jersey with respect to this product. These actions were fi rst commenced in September 2007 and over time expanded to
assert infringement of four patents – one formulation patent (U.S. patent number 6,294,196) and three method of use patents (numbers 7,192,938, 7,410,957 and
7,718,634). Claims regarding U.S. patent numbers 6,294,196 and 7,192,938 were dismissed in December 2008 and April 2010, respectively.
On 7 May 2012, the Court granted the Company’s motion for summary judgment that U.S. patent number 7,718,634 was invalid based on obviousness. In June 2012,
the Company launched its ibandronate sodium 150 mg tablet product. On 1 October 2012, the Court granted summary judgment in the Company’s favor fi nding U.S.
patent number 7,410,957 invalid.
On 15 November 2012, the Court issued a fi nal judgment in favor of the Company. Roche fi led a motion for reconsideration on 16 November 2012 which was denied
by the Court on 25 January 2013. Roche has appealed both of the Court’s summary judgment decisions. Argument of the appeal was heard on 6 December 2013,
and on 1 April 2014, the Court of Appeals affi rmed that the U.S. patent numbers 7,718,634 and 7,410,957 are invalid as obvious. A petition for rehearing and rehearing
en banc was fi led by Roche on 12 May 2014.
(g) Nexium United States litigations
Five federal antitrust class action lawsuits have been brought on behalf of direct purchasers of Nexium, and ten federal class action lawsuits have been brought under
both state and federal law on behalf of end-payors of Nexium. These actions have been fi led against various generic manufacturers, including the Company and its
U.S. subsidiary Dr. Reddy’s Laboratories, Inc. These actions have been consolidated in the United States District Court for the District of Massachusetts.
The complaints allege that, beginning in 2005, AstraZeneca sued various generic manufacturers, including the Company, for infringement with respect to patents
purporting to cover AstraZeneca’s branded drug, Nexium.
Plaintiffs allege that AstraZeneca’s settlement agreements with these various generic manufacturers, including the Company, violated federal and state antitrust laws,
as well as state unfair competition laws. The complaints seek unspecifi ed damages for class members as a result of an alleged delay in the entry of generic versions
of Nexium.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
182 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.24: CONTINGENT LIABILITIES AND COMMITMENTS (CONTINUED)
The Company believes that each of these complaints lacks merit and that the Company’s conduct complied with all applicable laws and regulations. All of the
defendants, including the Company, fi led motions to dismiss the complaints, which motions were denied in April 2013. The defendants also fi led motions for summary
judgment. Arguments regarding these motions were heard on 21 January 2014.
On 12 February 2014, the Court issued an order granting the Company’s motion in part, fi nding that the plaintiffs have failed to demonstrate that the Company’s
settlement of patent litigation with AstraZeneca included a large and unjustifi ed reverse payment. The Court refused, however, to grant the portion of the Company’s
motion related to the plaintiffs’ conspiracy theory. A trial is likely to be conducted in late 2014.
(h) Reclast and Zometa United States litigation
In January 2013, Novartis AG (“Novartis”) brought patent infringement actions against the Company and a number of other generic companies in the United States
District Court for the District of New Jersey. Novartis asserted that the Company’s ANDA for Reclast® would infringe Novartis’ U.S. Patent No. 8,052,987 and that the
Company’s ANDA for Zometa® would infringe Novartis’ U.S. Patent No. 8,324,189. In February 2013, Novartis sought a temporary restraining order and a preliminary
injunction prohibiting the Company and the other generic defendants from launching their generic Reclast® and Zometa® products. On 1 March 2013, the Court
denied Novartis’ motion for a temporary restraining order.
Later in March 2013, the Company launched its generic version of Novartis’ Zometa® Injection (zoledronic acid, 4 mg/5ml product) and in April 2013, the Company
launched its generic version of Novartis’ Reclast® Injection (zoledronic acid, 5 mg/100ml product). After the Company launched its products, Novartis withdrew its
application for a preliminary injunction. The Company believes that the asserted patents are either invalid or not infringed by the Company’s products. If Novartis
is ultimately successful in its patent infringement case, the Company could be required to pay damages related to the sale of its generic Reclast® and Zometa®
products.
i) Child resistant packaging matter
In May 2012, the Consumer Product Safety Commission (“CPSC”) requested that Dr. Reddy’s Laboratories Inc., a wholly owned subsidiary of the Company in the
United States, provide certain information with respect to compliance with requirements of special packaging for child resistant blister packs for 6 products sold by
the Company in the United States during the period commencing in 2002 through 2011. The Company provided the requested information. The CPSC subsequently
alleged, in a letter dated 30 April 2014, that the Company has violated the Consumer Product Safety Act and the Poison Prevention Packaging Act and intends to seek
civil penalties. Simultaneously, the Department of Justice is also currently investigating a complaint related to these issues under the Federal False Claims Act. At this
stage of the proceedings, the Company cannot conclude that the likelihood of an unfavourable outcome is either probable or remote in connection with this matter.
Accordingly, no provision is made in the fi nancial statements as of 31 March 2014. An unfavourable outcome in this matter that requires any signifi cant payment by
the Company could have a material adverse effect on its fi nancial statements.
(j) Land pollution, India
The Indian Council for Environmental Legal Action fi led a writ in 1989 under Article 32 of the Constitution of India against the Union of India and others in the Supreme
Court of India for the safety of people living in the Patancheru and Bollarum areas of Medak district of Andhra Pradesh. The Company has been named in the list
of polluting industries. In 1996, the Andhra Pradesh District Judge proposed that the polluting industries compensate farmers in the Patancheru, Bollarum and
Jeedimetla areas for discharging effl uents which damaged the farmers’ agricultural land. The compensation was fi xed at ` 0.0013 per acre for dry land and ` 0.0017
per acre for wet land. Accordingly, the Company has paid a total compensation of ` 3. The Company believes that the possibility of additional liability is remote. The
Andhra Pradesh High Court disposed of the writ petition on 12 February 2013 and transferred the case to the National Green Tribunal (“NGT”), Chennai, India. The
interim orders passed in the writ petitions will continue until the matter is decided by the NGT.
(k) Water pollution and air pollution, India
During the three months ended 31 December 2011, the Company, alongwith 14 other companies, received a notice from the Andhra Pradesh Pollution Control
Board (“APP Control Board”) to show cause as to why action should not be initiated against them for violations under the Indian Water Pollution Act and the Indian Air
Pollution Act. Furthermore, the APP Control Board issued orders to the Company to (i) stop production of all new products at the Company’s manufacturing facilities
in Hyderabad, India without obtaining a “Consent for Establishment”, (ii) cease manufacturing products at such facilities in excess of certain quantities specifi ed by the
APP Control Board and (iii) furnish a bank guarantee (similar to a letter of credit) to assure compliance with the APP Control Board’s orders.
The Company appealed the APP Control Board orders to the Andhra Pradesh Pollution Appellate Board (the “APP Appellate Board”). The APP Appellate Board, on the
basis of a report of a fact-fi nding advisory committee, recommended to the Andhra Pradesh Government to allow expansion of units fully equipped with Zero-Liquid
Discharge (“ZLD”) facilities and otherwise found no fault with the Company (on certain conditions). The APP Appellate Board’s decision was challenged by one of the
petitioners in the National Green Tribunal and the matter is currently pending before it.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
183
2.24: CONTINGENT LIABILITIES AND COMMITMENTS (CONTINUED)
Separately, the Andhra Pradesh Government, following recommendations of the APP Appellate Board, published a notifi cation in July 2013 that allowed expansion
of production of all types of existing bulk drug and bulk drug intermediate manufacturing units subject to the installation of ZLD facilities and the outcome of cases
pending in the National Green Tribunal. Importantly, the notifi cation directed pollution load of industrial units to be assessed at the point of discharge (if any) as opposed
to point of generation.
In September 2013, the Ministry of Environment and Forests, based on the revised Comprehensive Environment Pollution Index issued a notifi cation that re-imposed
a moratorium on expansion of industries in certain areas where some of the Company’s manufacturing facilities are located. This notifi cation overrides the Andhra
Pradesh Government notifi cation that conditionally permitted expansion.
(l) Fuel surcharge adjustment
The Andhra Pradesh Electricity Regulatory Commission (the “APERC”) has passed various orders approving the levy of Fuel Surcharge Adjustment (“FSA”) charges
for the period from 1 April 2008 to 31 March 2013 by power distribution companies from all the consumers of electricity in the state of Andhra Pradesh, India. The
Company fi led separate Writs of Mandamus before the High Court of Andhra Pradesh (the “High Court”) challenging and questioning the validity and legality of this
levy of FSA charges by the APERC for various periods.
The Company, after taking into account all of the available information and legal provisions, has recorded an amount of ` 219 as the potential liability towards FSA
charges. The total amount approved by APERC for collection by the power distribution companies from the Company in respect of FSA charges for the period from
1 April 2008 to 31 March 2013 is approximately ` 482. As of 31 March 2014, the Company has paid, under protest, an amount of ` 272 demanded by the power
distribution companies as part of monthly electricity bills. The Company remains exposed to additional fi nancial liability should the orders passed by the APERC be
upheld by the Courts.
(m) Assessable value of products supplied by a vendor to the Company
During the year ended 31 March 2003, the Central Excise Authorities of India (“the Central Excise Authorities”) issued a demand notice to a vendor of the Company
regarding the assessable value of products supplied by this vendor to the Company. The Company has been named as a co-defendant in this demand notice. The
Central Excise Authorities demanded payment of ` 176 from the vendor, including penalties of ` 90. Through the same notice, the Central Excise Authorities issued a
penalty claim of ` 70 against the Company. During the year ended 31 March 2005, the Central Excise Authorities issued an additional notice to this vendor demanding
` 226 from the vendor, including a penalty of ` 51. Through the same notice, the Central Excise Authorities issued a penalty claim of ` 7 against the Company.
Furthermore, during the year ended 31 March 2006, the Central Excise Authorities issued an additional notice to this vendor demanding ` 34.
The Company fi led appeals against these notices with Customs, Excise and Service Tax Appellate Tribunal (the “CESTAT”). In October 2006, the CESTAT passed an
order in favour of the Company setting aside all of the above demand notices. In July 2007, the Central Excise Authorities appealed against CESTAT’s order in the
Supreme Court of India, New Delhi. The matter is pending in the Supreme Court of India, New Delhi.
(n) Distribution of input service tax credits
The Central Excise Authorities have issued various show cause notices to the Company objecting to the Company’s methodology of distributing input service tax
credits claimed for one of the Company’s facilities. The below table shows the details of each of such show cause notices and the consequential actions on and status
of the same.
PERIOD COVERED UNDER THE NOTICE AMOUNT DEMANDED STATUS AS ON 31 MARCH 2014
March 2008 to September 2009 ` 102 plus 100% penalty
and interest thereon
The Company fi led an appeal with the CESTAT against the Central Excise Com-
missioner’s order. In July 2013, the Company received an order from the CESTAT
remanding the matter back to the Central Excise Commissioner for reconsider-
ation of the input service tax credit eligibility. The CESTAT also ordered the Com-
pany to make an interim deposit of ` 50. The Company made the requisite deposit
and is awaiting a hearing with the Central Excise Commissioner.
October 2009 to March 2011 ` 125 plus penalties of
` 100 and interest thereon
The Company has fi led an appeal with the CESTAT against the Central Excise
Commissioner’s order and awaits a hearing before the CESTAT.
April 2011 to March 2012 ` 51 plus interest and
penalties
The Company has responded to such show cause notice and is currently awaiting
a hearing with the Central Excise Commissioner.
April 2012 to March 2013 ` 54 plus interest and
penalties
The Company is in the process of responding to such notice.
The Company believes that the possibility of any liability that may arise on account of the alleged inappropriate distribution of input service tax credits is not probable.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
184 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.24: CONTINGENT LIABILITIES AND COMMITMENTS (CONTINUED)
(o) Direct taxes related matters
During the year ended 31 March 2014, the Indian Income Tax authorities disallowed for tax purposes certain business transactions entered into by the parent company
with its wholly owned subsidiaries. The associated tax impact is ` 658. The Company believes that such business transactions are allowed for tax deduction under
Indian Income Tax laws and has accordingly fi led an appeal with the Income Tax Appellate Tribunal, Hyderabad. The Company further believes that the probability of
succeeding in this matter is more likely than not and therefore no provision was made in the fi nancial statements.
(p) Additionally, the Company is involved in other disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings,
including patent and commercial matters that arise from time to time in the ordinary course of business. Except as discussed above, the Company does not believe
that there are any such contingent liabilities that are expected to have any material adverse effect on its fi nancial statements.
Commitments:
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of
advances)2,925 2,912
2.25: ACCOUNTING FOR INTEREST IN A JOINT VENTURE (JV)
Kunshan Rotam Reddy Pharmaceuticals Company Limited (“KRRP”)
The Company has 51.33 % interest in KRRP, a joint venture (JV) in China. KRRP is engaged in manufacturing and marketing of active pharmaceutical ingredients and
intermediates and formulations in China. The contractual arrangement between shareholders of KRRP indicates joint control as the minority shareholders, along with the
Company, have signifi cant participating rights such that they jointly control the fi nancial and operating policies of KRRP in the ordinary course of business.
The Company has, in accordance with Accounting Standard 27 “Financial Reporting of Interests in Joint Ventures” issued under the Companies (Accounting Standards) Rules
2006, accounted for its 51.33% interest in the JV by the proportionate consolidation method. Thus the Company’s statement of profi t and loss, balance sheet and cash fl ow
statement incorporate the Company’s share of income, expenses, assets, liabilities and cash fl ows of the JV on a line-by-line basis.
The aggregate amount of the assets, liabilities, income and expenses related to the Company’s share in the JV included in these fi nancial statements as of and for the year
ended 31 March 2014 and 31 March 2013 are given below:
Balance Sheet (extract)
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Fixed assets, net 157 139
Deferred tax assets, net 2 7
Inventories 195 124
Trade receivables 216 160
Cash and bank balances 271 126
Short term loans and advances 223 96
Trade payables 273 133
Current liabilities 189 151
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances) 5 4
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
185
2.25: ACCOUNTING FOR INTEREST IN A JOINT VENTURE (JV) (CONTINUED)
Statement of Profi t and Loss
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Income
Sales 1,428 983
Other income 9 6
Expenditure
Material costs 359 255
Employee benefi ts expense 312 226
Operating and other expenses 497 380
Research and development 10 8
Finance costs - 2
Depreciation 19 9
Profi t before taxation 240 109
Provision for taxation
- Current tax expense 34 16
- Deferred tax expense / (benefi t) 6 -
Profi t after taxation 200 93
2.26: ACQUISITIONS
OctoPlus N.V.
On 15 February 2013, the Company, through its wholly owned subsidiary Reddy Netherlands B.V., acquired 93.1% of the outstanding equity shares of OctoPlus N.V.
(‘OctoPlus’). OctoPlus is a specialty pharmaceutical company founded in 1995 and is headquartered in Leiden, Netherlands. OctoPlus’ provides pharmaceutical development
services, controlled release drug delivery technologies and cGMP manufacturing of fi nal products.
The aggregate purchase consideration is ` 1,772. The total purchase consideration has been allocated to acquired assets and liabilities at book values on the date of
acquisition as follows:
PARTICULARS Amount in ` Millions
Fixed assets net of accumulated depreciation 894
Current assets 220
Intangibles net of accumulated amortisation 86
Less: Current liabilities (769)
Less: Non current liabilities (510)
Net assets (79)
Goodwill 1,851
Purchase consideration 1,772
The total amount of goodwill of ` 1,851 is primarily attributable to the acquired employee workforce and expected synergies.
During the period from 16 February 2013 to 31 March 2013, the Company acquired further equity shares totaling 5.8% of the total share capital of OctoPlus at a price of Euro
0.52 per share through a combination of open market purchases as well as acceptance of shares tendered during the post-acquisition offer period.
Further, during the year ended 31 March 2014, the Company acquired equity shares totaling 1.1% of the total share capital of OctoPlus at a price of Euro 0.52 per share.
Consequently, OctoPlus became a wholly owned subsidiary of the Company.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
186 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.27: AUDITOR’S REMUNERATION
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
a) Audit fees 11 11
b) Other charges
Taxation matters* - -
Other matters 1 1
c) Reimbursement of out of pocket expenses 2 3
14 15
* represents amount of ` 400 thousands, rounded off in millions above.
2.28: DEFERRED TAXATION
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Deferred tax asset / (liability)
Tax losses carried forward 281 435
Provisions 29 250
Inventories 211 207
Trade receivables 870 387
Other current assets 170 214
Current liabilities 682 594
Stock based compensation cost (207) (158)
Excess of depreciation allowable under Income tax law over depreciation provided in accounts (1,360) (1,257)
Net deferred tax asset 676 672
The net deferred tax asset of ` 676 (previous year: ` 672) has the following breakdown:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Deferred tax asset 1,917 1,742
Deferred tax liability (1,241) (1,070)
Net deferred tax asset 676 672
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
187
2.29: EARNINGS PER SHARE (EPS)
The computation of EPS is set out below:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Earnings
Profi t for the year 19,632 15,268
Shares
Number of shares at the beginning of the year 169,836,475 169,560,346
Add: Equity shares issued on exercise of vested stock options 272,393 276,129
Total number of equity shares outstanding at the end of the year 170,108,868 169,836,475
Weighted average number of equity shares outstanding during the year – Basic 170,044,518 169,778,214
Add: Weighted average number of equity shares arising out of outstanding stock options (net of the stock
options forfeited) that have dilutive effect on the EPS813,171 839,666
Weighted average number of equity shares outstanding during the year – Diluted 170,857,689 170,617,880
Earnings per share of par value ` 5/- – Basic (`) 115.45 89.93
Earnings per share of par value ` 5/- – Diluted (`) 114.90 89.48
2.30: RELATED PARTY DISCLOSURES
a. Related parties with whom transactions have taken place during the current and/or previous year:
NAME OF THE RELATED PARTY NATURE OF RELATIONSHIP
Dr. Reddy’s Institute of Life Sciences Enterprise over which principal shareholders have signifi cant infl uence
Ecologic Chemicals Limited Enterprise controlled by principal shareholders
Stamlo Hotels Private Limited Enterprise controlled by principal shareholders
Green Park Hotels and Resorts Limited Enterprise controlled by relative of a director
K Samrajyam Mother of Vice Chairman and Managing Director
G Anuradha Spouse of Chairman and Chief Executive Offi cer
Deepti Reddy Spouse of Vice Chairman and Managing Director
G. Mallika Reddy Daughter of Chairman and Chief Executive Offi cer
G V Sanjana Reddy Daughter of Chairman and Chief Executive Offi cer
Dr. Reddy’s Foundation Enterprise where principal shareholders are trustees
Pudami Educational Society Enterprise where principal shareholders are trustees
A. R. Life Sciences Private Limited * Enterprise in which relative of a director has signifi cant infl uence
* A.R. Life Sciences Private Limited (“ARLS”) was a related party of the Company only for the year ended 31 March 2013. Accordingly, transactions with ARLS for the
year ended 31 March 2014 are not considered for reporting in the related party transactions summary.
b. List of Key Management Personnel of the Company
G V Prasad (whole-time director);
K Satish Reddy (whole-time director);
Abhijit Mukherjee;
Alok Sonig;
Dr. Amit Biswas
Dr. R Ananthanarayanan;
Dr. Cartikeya Reddy;
Dr. Chandrasekhar Sripada;
Dr. Raghav Chari;
Dr. KVS Rama Rao;
M V Ramana;
Samiran Das;
Saumen Chakraborty;
Umang Vohra ; and
Late Dr. K Anji Reddy (whole-time director till 15 March 2013).
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
188 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.30: RELATED PARTY DISCLOSURES (CONTINUED)
c. Particulars of related party transactions
The following is a summary of signifi cant related party transactions:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
i. Sales to:
Ecologic Chemicals Limited 49 4
A.R. Life Sciences Private Limited - 724
Total 49 728
ii. Sale of assets to Ecologic Chemicals Limited 14 -
iii. Purchases and services from:
Ecologic Chemicals Limited 91 47
Dr. Reddy’s Institute of Life Sciences 96 66
A.R. Life Sciences Private Limited - 1,309
Total 187 1,422
iv. Contributions for social development:
Dr. Reddy’s Foundation 143 107
Pudami Educational Society 27 24
Total 170 131
v. Purchase of assets from Ecologic Chemicals Limited (refer note 2.40) 1,264 -
vi. Hotel expenses paid / payable to:
Green Park Hotel and Resorts Limited 20 17
Stamlo Hotels Private Limited 11 7
Total 31 24
vii. Rent paid / payable to:
Key management personnel
K Satish Reddy 14 14
Others
G Anuradha 13 13
Deepti Reddy 3 3
K Samrajyam 2 1
G. Mallika Reddy 2 -
G V Sanjana Reddy 2 -
Total 22 17
viii. Trade advances given to / (settled by) Ecologic Chemicals Limited (2) 2
ix. Remuneration to key management personnel 476 475
(Note: The above amounts do not include stock based compensation.)
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
189
2.30: RELATED PARTY DISCLOSURES (CONTINUED)
d. The Company has the following dues from / to related parties:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
i. Due from related parties:
Rental deposit to key management personnel and their relatives 8 5
Others (included in trade receivables):
Ecologic Chemicals Limited - 8
A.R. Life Sciences Private Limited - 163
Total - 171
ii. Due to related parties (included in trade payables):
Dr. Reddy’s Research Foundation 18 19
Ecologic Chemicals Limited - 4
Total 18 23
2.31: SEGMENT REPORTING
The primary and secondary reportable segments are business and geographic segments, respectively.
Business segments:
The Company is organised on a worldwide basis into the following businesses which are reportable segments:
Pharmaceutical Services and Active Ingredients (“PSAI”);
Global Generics; and
Proprietary Products.
Pharmaceutical Services and Active Ingredients: This segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical
products or bulk drugs, which are the principal ingredients for fi nished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become fi nished
pharmaceutical products when the dosages are fi xed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This
segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specifi c customer
requirements.
Global Generics: This segment consists of fi nished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations)
or as generic fi nished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company’s biologics business.
Proprietary Products: This segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The
Company’s differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or effi cacy by modifying pharmacokinetics
of existing medicines. This segment also includes the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and
co-developed dermatology products.
Geographic segments:
The Company’s business is organised into fi ve key geographic segments viz. India, North America, Russia and other CIS countries, Europe and Others. Revenues are
attributable to individual geographic segments based on the location of the customer.
Segment revenues and expenses: All segment revenues and expenses are directly attributable to the segments.
Segment assets and liabilities: As certain assets of the Company including manufacturing facilities, development facilities, and treasury assets and liabilities are often
deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment.
Inter-segment transfers: Segment revenue, segment expenses and segment result include transfers between business segments. Inter-segment transfers are accounted for
at cost to the transferring segment. Such transfers are eliminated on consolidation.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
190 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.31: SEGMENT REPORTING (CONTINUED)
Accounting policies: The accounting policies consistently used in the preparation of the fi nancial statements are also applied to items of revenues and expenditure in individual
segments.
Un-allocable and Head offi ce expenses: General administrative expenses, head-offi ce expenses, and other expenses that arise at the corporate level and relate to the
Company as a whole, are shown as un-allocable items.
Segment information for the year ended 31 March 2014
PARTICULARS PSAIGLOBAL
GENERICS
PROPRIETARY
PRODUCTSOTHERS ELIMINATIONS
UN-
ALLOCABLE
ITEMS
TOTAL
External sales (Gross) 23,580 106,356 1,779 - - - 131,715
Inter-segment sales 5,601 - - - (5,601) - -
Less: Excise duty on sales (271) (549) - - - - (820)
Segment sales 28,910 105,807 1,779 - (5,601) - 130,895
Income from services 394 - - 1,238 - - 1,632
License fees - 263 - 17 - - 280
Other operating revenues 644 673 1 28 - - 1,346
Segment revenues 29,948 106,743 1,780 1,283 (5,601) - 134,153
Interest income - - - - - 1,085 1,085
Other un-allocable income - - - - - 612 612
Total Revenues 135,850
Segment result 2,069 30,813 (2,028) 973 - - 31,827
Un-allocated expense, net (5,193) (5,193)
Finance charges, net (171) (171)
Profi t before taxation 26,463
Income tax expense (6,831) (6,831)
Profi t for the year 19,632
Segment information for the year ended 31 March 2013
PARTICULARS PSAIGLOBAL
GENERICS
PROPRIETARY
PRODUCTSOTHERS ELIMINATIONS
UN-
ALLOCABLE
ITEMS
TOTAL
External sales (Gross) 30,131 83,334 1,468 - - - 114,933
Inter-segment sales 5,584 - - - (5,584) - -
Less: Excise duty on sales (309) (409) - - - - (718)
Segment sales 35,406 82,925 1,468 - (5,584) - 114,215
Income from services 516 - - 1,554 - - 2,070
License fees 55 466 - 12 - - 533
Other operating revenues 854 1,234 12 38 - - 2,138
Segment revenues 36,831 84,625 1,480 1,604 (5,584) - 118,956
Interest income - - - - - 900 900
Other un-allocable income - - - - - 599 599
Total Revenues 120,455
Segment result 6,841 19,367 (2,542) 457 - - 24,123
Un-allocated expense, net (1,683) (1,683)
Finance charges, net (793) (793)
Profi t before taxation 21,647
Income tax expense (6,379) (6,379)
Profi t for the year 15,268
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
191
2.31: SEGMENT REPORTING (CONTINUED)
Analysis of depreciation and amortization by business segments
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
PSAI 2,348 1,672
Global Generics 3,508 3,284
Proprietary Products 401 341
Others 113 119
Un-allocated 105 86
Total 6,475 5,502
Sales by geographic markets (Gross of excise duties)
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
India 18,182 17,521
North America 61,362 45,679
Russia and other CIS countries 19,819 16,908
Europe 16,287 20,096
Others 16,065 14,729
Total 131,715 114,933
Assets by geography
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
India 90,509 74,238
North America 25,364 21,373
Russia and other CIS countries 9,055 9,079
Europe 29,364 24,907
Others 6,004 5,275
Total 160,296 134,872
Cost of tangible and intangible fi xed assets (including capital work in progress) acquired by geography
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
India 9,337 6,200
North America 1,123 1,138
Russia and other CIS countries 308 21
Europe 714 3,228
Others 96 35
Total 11,578 10,622
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
192 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.32: EMPLOYEE STOCK OPTION SCHEME
Dr. Reddy’s Employees Stock Option Plan-2002 (“the DRL 2002 Plan”):
The Company instituted the DRL 2002 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on
24 September 2001. The DRL 2002 Plan covers all employees of DRL and its subsidiaries and directors (excluding promoter directors) of DRL and its subsidiaries (collectively,
“eligible employees”). Under the Scheme, the Nomination, Governance and Compensation Committee of the Board (‘the Committee’) shall administer the Scheme and grant
stock options to eligible directors and employees of the Company and its subsidiaries. The Committee shall determine the employees eligible for receiving the options, the
number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for the options issued on the date of the grant.
The options issued under the DRL 2002 Plan vests in periods ranging between one and four years and generally have a maximum contractual term of fi ve years.
The DRL 2002 Plan was amended on 28 July 2004 at the Annual General Meeting of shareholders to provide for stock options grants in two categories:
Category A: 1,721,700 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the fair market value of the underlying equity
shares on the date of grant; and
Category B: 573,778 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the par value of the underlying equity shares
(i.e., ` 5/- per option).
The DRL 2002 Plan was further amended on 27 July 2005 at the Annual General Meeting of shareholders to provide for stock option grants in two categories:
Category A: 300,000 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the fair market value of the underlying equity
shares on the date of grant; and
Category B: 1,995,478 stock options out of the total of 2,295,478 reserved for grant of options having an exercise price equal to the par value of the underlying equity shares
(i.e., ` 5/- per option).
The fair market value of a share on each grant date falling under Category A above is defi ned as the average closing price (after adjustment of Bonus issue) for 30 days prior
to the grant, in the stock exchange where there is highest trading volume during that period. Notwithstanding the foregoing, the Committee may, after getting the approval of
the shareholders in the Annual General Meeting, grant options with a per share exercise price other than fair market value and par value of the equity shares.
After the issue of bonus shares by the Company in August 2006, the DRL 2002 Plan provides for stock options granted in the above two categories as follows:
PARTICULARSNUMBER OF OPTIONS
UNDER CATEGORY ANUMBER OF OPTIONS
UNDER CATEGORY BTOTAL
Options reserved under original plan 300,000 1,995,478 2,295,478
Options exercised prior to stock dividend date (A) 94,061 147,793 241,854
Balance of shares that can be allotted on exercise of options (B) 205,939 1,847,685 2,053,624
Options arising from stock dividend (C) 205,939 1,847,685 2,053,624
Options reserved after stock dividend (A+B+C) 505,939 3,843,163 4,349,102
In the case of termination of employment, all unvested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the
time prescribed under each option agreement by the Committee or if no time limit is prescribed, within three months of the date of employment termination, failing which they
would stand cancelled.
The term of the DRL 2002 Plan expired on 29 January 2012. Consequently, the Board of Directors of the Company, based on the recommendation of the Committee, resolved
to extend the term of the DRL 2002 Plan for a period of 10 years with effect from 29 January 2012, subject to the approval of shareholders. A resolution to this effect was
approved by the shareholders at the Company’s Annual General Meeting held on 20 July 2012.
During the current year, the Company under the DRL 2002 Plan has issued 258,870 Catagory B options to eligible employees. The vesting period for the options granted
varies from 12 to 48 months.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
193
2.32: EMPLOYEE STOCK OPTION SCHEME (CONTINUED)
The date of grant, number of options granted, exercise price fi xed by the Committee for respective options and the market price of the shares of the Company on the day
prior to the date of grant is given below:
DATE OF GRANT NUMBER OF OPTIONS GRANTED EXERCISE PRICE (`)MARKET PRICE (`)
(AS PER SEBI GUIDELINES)
13 May 2013 258,870 5.00 2,091.70
Stock option activity under the DRL 2002 Plan for the two categories of options was as follows:
CATEGORY A – FAIR MARKET VALUE OPTIONS YEAR ENDED 31 MARCH 2014
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICESWEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 11,000 ` 373.50-448.00 ` 441.23 52
Granted during the year - - - -
Expired / forfeited during the year (1,000) ` 373.50 ` 373.50 -
Exercised during the year - - - -
Outstanding at the end of the year 10,000 ` 448.00 ` 448.00 44
Exercisable at the end of the year 10,000 ` 448.00 ` 448.00 44
CATEGORY A – FAIR MARKET VALUE OPTIONS YEAR ENDED 31 MARCH 2013
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICES WEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 11,000 ` 373.50-448.00 ` 441.23 65
Granted during the year - - - -
Expired / forfeited during the year - - - -
Exercised during the year - - - -
Outstanding at the end of the year 11,000 ` 373.50-448.00 ` 441.23 52
Exercisable at the end of the year 11,000 ` 373.50-448.00 ` 441.23 52
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2014
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICESWEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 684,259 ` 5.00 ` 5.00 71
Granted during the year 258,870 5.00 5.00 90
Forfeited during the year (60,315) 5.00 5.00 -
Exercised during the year (241,140) 5.00 5.00 -
Outstanding at the end of the year 641,674 ` 5.00 ` 5.00 78
Exercisable at the end of the year 50,818 ` 5.00 ` 5.00 42
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2013
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICES WEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 643,156 ` 5.00 ` 5.00 70
Granted during the year 335,110 5.00 5.00 90
Forfeited during the year (65,424) 5.00 5.00 -
Exercised during the year (228,583) 5.00 5.00 -
Outstanding at the end of the year 684,259 ` 5.00 ` 5.00 71
Exercisable at the end of the year 60,296 ` 5.00 ` 5.00 38
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
194 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.32: EMPLOYEE STOCK OPTION SCHEME (CONTINUED)
Dr. Reddy’s Employees ADR Stock Option Plan-2007 (“the DRL 2007 Plan”):
The Company instituted the DRL 2007 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held
on 27 July 2005. The DRL 2007 Plan came into effect on approval of the Board of Directors on 22 January 2007. The DRL 2007 Plan covers all employees of DRL and its
subsidiaries and directors (excluding promoter directors) of DRL and its subsidiaries (collectively “eligible employees”). Under the DRL 2007 Plan, Nomination, Governance
and Compensation Committee of the Board (“the Committee”) shall administer the DRL 2007 Plan and grant stock options to eligible employees of the Company and its
subsidiaries. The Committee shall determine the employees eligible for receiving the options, the number of options to be granted, the exercise price, the vesting period and the
exercise period. The vesting period is determined for all options issued on the date of the grant. The options issued under the DRL 2007 Plan vest in periods ranging between
one and four years and generally have a maximum contractual term of fi ve years.
The Committee may, after obtaining the approval of the shareholders in the Annual General Meeting, grant options with a per share exercise price other than fair market value
and par value of the equity shares.
During the current year, the Company under the DRL 2007 Plan has issued 44,240 Category B options to eligible employees. The vesting period for the options granted varies
from 12 to 48 months.
The date of grant, number of options granted, exercise price fi xed by the Committee for respective options and the market price of the shares of the Company on the day
prior to the date of grant is given below:
DATE OF GRANT NUMBER OF OPTIONS GRANTED EXERCISE PRICE (`)MARKET PRICE (`)
(AS PER SEBI GUIDELINES)
13 May 2013 44,240 5.00 2,091.70
Stock option activity under the DRL 2007 Plan was as follows:
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2014
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICES WEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED-AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 98,608 ` 5.00 ` 5.00 73
Granted during the year 44,240 5.00 5.00 90
Forfeited during the year (14,132) 5.00 5.00 -
Exercised during the year (31,253) 5.00 5.00 -
Outstanding at the end of the year 97,463 ` 5.00 ` 5.00 79
Exercisable at the end of the year 7,265 ` 5.00 ` 5.00 44
CATEGORY B – PAR VALUE OPTIONS YEAR ENDED 31 MARCH 2013
PARTICULARSSHARES ARISING OUT
OF OPTIONSRANGE OF EXERCISE
PRICES WEIGHTED-AVERAGE
EXERCISE PRICE
WEIGHTED- AVERAGE REMAINING
CONTRACTUAL LIFE (MONTHS)
Outstanding at the beginning of the year 117,899 ` 5.00 ` 5.00 73
Granted during the year 58,140 5.00 5.00 90
Forfeited during the year (29,885) 5.00 5.00 -
Exercised during the year (47,546) 5.00 5.00 -
Outstanding at the end of the year 98,608 ` 5.00 ` 5.00 73
Exercisable at the end of the year 4,328 ` 5.00 ` 5.00 47
The Company has not granted any options under Category A of “the DRL 2007 Plan”.
The Company has followed intrinsic method of accounting based on which a compensation expense of ` 468 (previous year: ` 421) has been recognized in the statement of
profi t and loss.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
195
2.33: OPERATING LEASE
The Company has leased offi ces and vehicles under various operating lease agreements that are renewable on a periodic basis at the option of both the lessor and the lessee.
Rental expense under those leases was ` 749 (previous year: ` 535).
The schedule of future minimum rental payments in respect of non-cancellable operating leases is set out below:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Not later than one year 359 209
Later than one year and not later than fi ve years 1,007 244
Beyond fi ve years 937 121
2,303 574
During the year ended 31 March 2014, the Company entered into a non-cancellable operating lease for an offi ce and laboratory facility in the United States of America. The
future minimum rental payments in respect of this lease are ` 1,556 (USD 26 million) as of 31 March 2014.
2.34: FINANCE LEASE
The Company has taken buildings, vehicles and plant and machinery under fi nance lease. Future minimum lease payments under fi nance leases as at 31 March 2014 are as
follows:
PARTICULARS
PRESENT VALUE
OF MINIMUM LEASE
PAYMENTS
FUTURE INTERESTMINIMUM LEASE
PAYMENTS
Not later than one year 100 122 222
Later than one year and not later than fi ve years 263 272 535
Beyond fi ve years 684 206 890
1,047 600 1,647
Future minimum lease payments under fi nance leases as at 31 March 2013 are as follows:
PARTICULARS
PRESENT VALUE OF
MINIMUM LEASE
PAYMENTS
FUTURE INTERESTMINIMUM LEASE
PAYMENTS
Not later than one year 80 78 158
Later than one year and not later than fi ve years 191 226 417
Beyond fi ve years 605 212 817
876 516 1,392
2.35: EMPLOYEE BENEFIT PLANS
2.35.1 Gratuity Plan of Dr. Reddy’s Laboratories Limited and Aurigene Discovery Technologies Limited
In accordance with applicable Indian laws, the Company provides for a lump sum payment to eligible employees, at retirement or termination of employment based on the last
drawn salary and years of employment with the Company. Effective 1 September 1999, the Company established the Dr. Reddy’s Laboratories Gratuity Fund (the “Gratuity
Fund”). Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund. Trustees
administer the contributions made to the Gratuity Fund. Amounts contributed to the Gratuity Fund are primarily invested in Indian government bonds and corporate debt
securities. A small portion of the fund is also invested in Indian equities.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
196 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.35: EMPLOYEE BENEFIT PLANS (CONTINUED)
The following table sets out the status of the aforesaid funded gratuity plan as required under AS-15 (Revised):
Reconciliation of the present value of the defi ned benefi t obligation
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening defi ned benefi t obligation 914 674
Current service cost 123 91
Interest cost 77 62
Actuarial losses / (gains) 49 140
Benefi ts paid (76) (53)
Closing defi ned benefi t obligation 1,087 914
Change in the fair value of assets:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening fair value of plan assets 743 624
Expected return on plan assets 59 54
Actuarial gains / (losses) 16 8
Contributions by employer 212 110
Benefi ts paid (76) (53)
Closing fair value of plan assets 954 743
Amount recognized in the balance sheet
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Present value of funded obligations 1,087 914
Fair value of plan assets (954) (743)
Net liability 133 171
Expense recognized in the statement of profi t and loss
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Current service cost 123 91
Interest on defi ned benefi t obligation 77 62
Expected return on plan assets (59) (54)
Net actuarial losses / (gains) recognized in the year 34 132
Amount included in employee benefi t expense 175 231
Actual return on plan assets 74 62
Contributions: The Company expects to contribute ` 108 to the Gratuity Plan during the year ending 31 March 2015.
Asset information
CATEGORY OF ASSETSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Government of India securities - -
Corporate bonds - -
Insurer managed funds 99% 99%
Others 1% 1%
Total 100% 100%
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
197
2.35: EMPLOYEE BENEFIT PLANS (CONTINUED)
Summary of Actuarial Assumptions
Financial assumptions at the valuation date:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Discount rate 9.00%p.a. 7.95% p.a.
Expected rate of return on plan assets 9.00%p.a. 7.95% p.a.
Salary escalation rate
11% p.a. for fi rst two
years & 10% p.a.
thereafter
10% p.a. for fi rst
two years & 9% p.a.
thereafter
Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.
Expected rate of return on plan assets: This is based on the expectation of the average long term rate of return expected on investments of the fund during the estimated
term of the obligations.
Salary escalation rate: The estimate of future salary increases considered takes into account the infl ation, seniority, promotion and other relevant factors.
Experience adjustments
PARTICULARSFOR THE YEAR ENDED 31 MARCH
2014 2013 2012 2011 2010
Defi ned benefi t obligation 1,087 914 674 609 473
Plan assets 954 743 624 490 449
Surplus / (defi cit) (133) (171) (50) (119) (24)
Experience Adjustment on Plan Liabilities 46 27 23 28 29
Experience Adjustment on Plan Assets 15 8 6 5 27
2.35.2 Employee Benefi t plan of Industrias Quimicas Falcon de Mexico S.A. de C.V.
Pension, seniority and severance plans
All employees of the Company’s Mexican subsidiary, Industrias Quimicas Falcon de Mexico S.A. de C.V. (“Falcon”), are entitled to a pension benefi t in the form of a defi ned
benefi t pension plan. The Falcon pension plan provides for payment to vested employees at retirement or termination of employment. Liabilities in respect of the pension plan
are determined by an actuarial valuation, based on which the Company makes contributions to the pension plan fund. This fund is administered by a third party, who is provided
guidance by a technical committee formed by senior employees of Falcon.
Falcon also provides its employees with termination benefi ts in the form of seniority premiums, paid from a funded defi ned benefi t plan covering certain categories of
employees, and severance pay, paid from an unfunded defi ned benefi t plan applicable to the employees who are terminated from the services of Falcon.
The disclosure particulars of aforesaid pension, seniority and severance plan are shown in the below tables:
Reconciliation of opening and closing balance of the present value of the defi ned benefi t obligation
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening defi ned benefi t obligation - funded and unfunded 348 316
Current service cost 22 19
Interest cost 25 26
Actuarial losses / (gains) (68) 62
Benefi ts paid (46) (108)
Foreign exchange differences 16 33
Closing defi ned benefi t obligation - funded and unfunded 297 348
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
198 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.35: EMPLOYEE BENEFIT PLANS (CONTINUED)
Reconciliation of opening and closing balance of the fair value of plan assets
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Opening fair value of plan assets 137 197
Expected return on plan assets 14 20
Actuarial gains / (losses) (3) 2
Contributions by employer 15 10
Benefi ts paid (46) (108)
Foreign exchange differences 6 16
Closing fair value of plan assets 123 137
Amount recognized in the balance sheet
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Present value of funded obligations 269 319
Present value of unfunded obligations 28 29
Total present value of obligations 297 348
Fair value of plan assets (123) (137)
Net liability / (asset) 174 211
Expense recognized in the statement of profi t and loss
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Current service cost 22 19
Interest on defi ned benefi t obligation 25 26
Expected return on plan assets (14) (20)
Net actuarial losses / (gains) recognized in the year (65) 60
Amount included in employee benefi t expense (32) 85
Actual return on plan assets 11 24
Contributions: The Company expects to contribute ` 50 to the Falcon defi ned benefi t plans during the year ending 31 March 2015.
Asset information
CATEGORY OF ASSETSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Corporate bonds 51% 50%
Equity shares of listed companies 49% 50%
Total 100% 100%
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
199
2.35: EMPLOYEE BENEFIT PLANS (CONTINUED)
Summary of actuarial assumptions
Financial assumptions at the valuation date:
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
Discount rate 8.00% p.a. 6.50% p.a.
Expected rate of return on plan assets 8.00% p.a. 8.50% p.a.
Salary escalation rate 4.50% p.a. 4.50% p.a.
Discount rate: The discount rate is based on the market yields prevailing in Mexico as at the balance sheet date for the estimated term of the obligations.
Expected rate of return on plan assets: This is based on our expectation of the average long term rate of return expected on investments of the fund during the estimated
term of the obligations.
Salary escalation rate: The estimate of future salary increases considered takes into account the infl ation, seniority, promotion and other relevant factors.
Experience adjustments
PARTICULARSFOR THE YEAR ENDED 31 MARCH
2014 2013 2012 2011 2010
Defi ned benefi t obligation, funded and unfunded 297 348 316 346 307
Plan assets 123 137 197 259 248
Surplus / (defi cit) (174) (211) (119) (87) (59)
Experience Adjustment on Plan Liabilities (20) 27 (20) 11 (2)
Experience Adjustment on Plan Assets (3) 2 (9) (23) 35
2.35.3 Other Benefi ts
Provident fund benefi ts
In India, certain categories of employees of the Company receive benefi ts from a provident fund, a defi ned contribution plan. Both the employee and employer each make
monthly contributions to a government administered fund equal to 12% of the covered employee’s qualifying salary. The Company has no further obligations under the plan
beyond its monthly contributions. The Company contributed ` 411 and ` 349 to the provident fund plan during the year ended 31 March 2014 and 2013, respectively.
Superannuation benefi ts
The senior offi cers of the Company participate in superannuation, a defi ned contribution plan administered by the Life Insurance Corporation of India. The Company makes
annual contributions based on a specifi ed percentage of each covered employee’s salary. The Company has no further obligations under the plan beyond its annual
contributions. The Company contributed ` 63 and ` 56 to the superannuation plan during the year ended 31 March 2014 and 2013, respectively.
Compensated leave of absence
The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized
compensated absences and utilize it in future periods or receive cash in lieu thereof as per Company policy. The Company records an obligation for compensated absences
in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this benefi t was ` 463 and ` 344
as at 31 March 2014 and 2013, respectively.
2.36: EXCEPTIONAL ITEM - IMPAIRMENT OF GOODWILL AND INTANGIBLES
Year ended 31 March 2013
Product portfolio
During the year ended 31 March 2013, the Company determined that there was a decrease in expected cash fl ows of a product portfolio primarily due to higher than expected
price erosion and increased competition leading to lower volumes. Consequently, the Company reassessed the recoverable amount of goodwill associated with such product
portfolio using value-in-use approach and determined that the carrying amount of goodwill was higher than its recoverable amount. Accordingly, an impairment loss of ` 427
for such goodwill was recorded for the year ended 31 March 2013. For this purpose, the pre-tax cash fl ows have been discounted based on a pre-tax discount rate of 5.52%.
The above impairment loss relates to the Company’s Global Generics segment.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
200 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.36: EXCEPTIONAL ITEM - IMPAIRMENT OF GOODWILL AND INTANGIBLES (CONTINUED)
Dr. Reddy’s Srl
Based on the business performance and expected cash fl ows from its business in Italy, the Company carried out an impairment test of Dr. Reddy’s Srl’s cash-generating unit
and recorded an impairment loss of goodwill and intangibles amounting to ` 78 and ` 17, respectively during the year ended 31 March 2013.
Terbinafi ne
Following the Company’s decision to discontinue its research and development on terbinafi ne nail lacquer, the Company recorded an impairment loss on intangible of ` 20
during the year ended 31 March 2013.
2.37: HEDGES OF FOREIGN CURRENCY RISKS, INTEREST RATE RISKS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company is exposed to exchange rate which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, British pounds sterling, Russian roubles
and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros.
The Company uses forwards contracts, options contracts and swap contracts (derivatives) to mitigate its risk of changes in foreign currency exchange rates. Further, the
Company also uses non-derivative fi nancial instruments as part of its foreign currency exposure risk mitigation strategy.
Hedges of highly probable forecasted transactions
The Company classifi es its derivative contracts that hedge foreign currency risk associated with highly probable forecasted transactions as cash fl ow hedges and measures
them at fair value. The effective portion of such cash fl ow hedges is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classifi ed in the
statement of profi t and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion is immediately recorded in the
statement of profi t and loss.
The Company also designates certain non-derivative fi nancial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign
currency risk associated with highly probable forecasted transactions and, accordingly, applies cash fl ow hedge accounting for such relationships. Re-measurement gain/loss
on such non-derivative fi nancial liabilities is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classifi ed in the statement of profi t and
loss as revenue in the period corresponding to the occurrence of the forecasted transactions.
In respect of the aforesaid hedges of highly probable forecasted transactions, the Company has recorded, in reserves and surplus, a net loss of ` 1,651 and ` 1,683 for the
year ended 31 March 2014 and 2013, respectively. The Company also recorded, as part of revenue, a net loss of ` 1,093 and a net loss of ` 2,576 during the year ended 31
March 2014 and 2013, respectively.
The net carrying amount of the Company’s “hedging reserve” in reserves and surplus before adjusting for tax impact was a loss of ` 1,904 as at 31 March 2014, as compared
to a loss of ` 253 as at 31 March 2013.
The table below summarizes the periods when the forecasted cash fl ows associated with derivative hedging instruments that are classifi ed as cash fl ow hedges, are expected
to occur:
PARTICULARSAS AT
31 MARCH 2014
AS AT
31 MARCH 2013
Cash fl ows in U.S. Dollars (fi gures in equivalent rupee millions)
Not later than one month 1,797 2,714
Later than one month and not later than three months 3,595 5,429
Later than three month and not later than six months 5,392 6,514
Later than six months and not later than two year 5,992 11,400
16,776 26,057
Cash fl ows in Euro (fi gures in equivalent rupee millions)
Not later than one month - -
Later than one month and not later than three months - 208
Later than three month and not later than six months - 313
Later than six months and not later than two year - 626
- 1,147
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
201
2.37: HEDGES OF FOREIGN CURRENCY RISKS, INTEREST RATE RISKS AND DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)
Hedges of recognized assets and liabilities
Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied are
recognized in the statement of profi t and loss. The changes in fair value of such derivative contracts as well as the foreign exchange gains and losses relating to the monetary
items are recognized as part of foreign exchange gains and losses.
Fair values of foreign exchange derivative contracts are determined under the Modifi ed Black Scholes technique by using inputs from market observable data and other
relevant terms of the contract with counter parties which are banks or fi nancial institutions.
In respect of all of its foreign exchange derivative contracts, the Company has recorded, as part of foreign exchange gains and losses, a net loss of ` 430 and a net gain of
` 501 for the year ended 31 March 2014 and 2013, respectively.
The following are the outstanding foreign exchange derivative contracts for hedges of recognized assets and liabilities:
As at 31 March 2014
CATEGORY CURRENCY CROSS CURRENCYAMOUNTS IN
MILLIONSBUY / SELL PURPOSE
Forward contract USD INR USD 10 Buy Hedging
Forward contract USD INR USD 422.5 Sell Hedging
Forward contract USD RON USD 13 Buy Hedging
Forward contract EUR USD EUR 170 Sell Hedging
As at 31 March 2013
CATEGORY CURRENCY CROSS CURRENCYAMOUNTS IN
MILLIONSBUY / SELL PURPOSE
Forward contract USD INR USD 23 Buy Hedging
Forward contract USD INR USD 125.7 Sell Hedging
Forward contract USD RON USD 13 Buy Hedging
Forward contract EUR USD EUR 30.5 Sell Hedging
Option contract USD INR USD 130 Sell Hedging
Swap contract USD INR USD 64.70 Sell Hedging
Hedges of changes in the interest rates:
Consistent with its risk management policy, the Company uses interest rate swaps (including cross currency interest rate swaps) to mitigate the risk of changes in the interest
rates. The Company does not use them for trading or speculative purposes.
The changes in fair value of such interest rate swaps (including cross currency interest rate swaps) are recognized as part of fi nance cost. Accordingly, the Company has
recorded, as part of fi nance cost, a net gain of ` 259 and of ` 41 for the year ended 31 March 2014 and 2013, respectively.
As on 31 March 2014, the Company has outstanding interest rate swap arrangements that hedge a portion of interest rate risk arising from fl oating rate, dollar denominated
foreign currency borrowing of USD 220 million.
Derivative fi nancial instrument valuations:
The Company enters into derivative fi nancial instruments with various counterparties, principally fi nancial institutions and banks. Derivatives valued using valuation techniques
with market observable inputs are mainly interest rate swaps, foreign exchange forward contracts and foreign exchange option contracts. The most frequently applied valuation
techniques include forward pricing, swap models and Black Scholes models (for option valuation), using present value calculations.
The Company had derivative fi nancial assets and derivative fi nancial liabilities of ` 580 and `339, respectively, as of 31 March 2014 as compared to derivative fi nancial assets
and derivative fi nancial liabilities of ` 562 and ` 114, respectively, as of 31 March 2013, towards these derivative fi nancial instruments.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
202 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.38: FINANCIAL RISK MANAGEMENT
The Company’s activities expose it to a variety of fi nancial risks, including market risk, credit risk and liquidity risk. The Company’s primary risk management focus is to
minimize potential adverse effects of market risk on its fi nancial performance. The Company’s risk management assessment and policies and processes are established to
identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment
and management policies and processes are reviewed regularly to refl ect changes in market conditions and the Company’s activities. The Board of Directors and the Audit
Committee is responsible for overseeing Company’s risk assessment and management policies and processes.
a. Credit risk
Credit risk is the risk of fi nancial loss to the Company if a customer or counterparty to a fi nancial instrument fails to meet its contractual obligations, and arises principally
from the Company’s receivables from customers. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness
of customers to which the Company grants credit terms in the normal course of business. The Company establishes an allowance for doubtful debts and impairment that
represents its estimate of incurred losses in respect of trade and other receivables.
Trade receivables
The Company’s exposure to credit risk is infl uenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of
the industry and country, in which the customer operates, also has an infl uence on credit risk assessment. As at 31 March 2014 and 31 March 2013 the maximum exposure
to credit risk in relation to trade and other receivables is ` 33,253 and ` 31,804, respectively (net of allowances).
Trade receivables that are neither past due nor impaired
Trade receivables amounting to ` 24,422 and ` 23,085 were neither past due nor impaired as at 31 March 2014 and 31 March 2013, respectively.
Trade receivables that are past due but not impaired
The Company’s credit period for customers generally ranges from 20 – 180 days. The age analysis of the trade receivables has been considered from the due date of the
invoice. The ageing of trade receivables that are past due, but not impaired, is given below:
PERIOD (IN DAYS)AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
0 - 30 6,007 5,526
31 - 90 1,709 1,858
91 - 180 876 749
More than 180 239 586
Total 8,831 8,719
Trade receivables that are impaired
The age analysis of the trade receivables that are impaired is given below:
PERIOD (IN DAYS)AS AT
31 MARCH 2014
AS AT
31 MARCH 2013
0 - 30 - -
31 - 90 - -
91 - 180 - -
More than 180 690 582
Total 690 582
Reconciliation of the allowance account for credit losses
The details of changes in provision for bad debts during the year ended 31 March 2014 and 31 March 2013 are as follows:
PARTICULARS 2013-14 2012-13
Balance as at 1 April 582 537
Provision made during the year 168 108
Trade receivables written off during the year (60) (63)
Balance as at 31 March 690 582
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
203
2.38: FINANCIAL RISK MANAGEMENT (CONTINUED)
b. Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its fi nancial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as
possible, that it will always have suffi cient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to
the Company’s reputation.
As at 31 March 2014 and 2013, the Company had unutilized credit limits from banks of ` 14,596 and ` 20,364, respectively.
As at 31 March 2014, the Company had working capital of ` 45,354 including cash and bank balances of ` 23,006 and current investments of ` 10,664. As at 31 March 2013,
the Company had working capital of ` 28,679 including cash and bank balances of ` 20,171 and current investments of ` 1,966.
The table below provides details regarding the contractual maturities of signifi cant fi nancial liabilities (other than obligations under fi nance leases which have been disclosed in
Note 2.34 and provision for employee benefi ts which have been disclosed in Note 2.5)
As at 31 March 2014
PARTICULARS 2015 2016 2017 2018 THEREAFTER TOTAL
Trade payables 8,932 - - - - 8,932
Long term borrowings 3,295 6,591 4,293 1,797 7,190 23,166
Short term borrowings 20,607 - - - - 20,607
Other liabilities and provisions 18,056 29 29 28 27 18,169
As at 31 March 2013
PARTICULARS 2014 2015 2016 2017 THEREAFTER TOTAL
Trade payables 9,657 - - - - 9,657
Long term borrowings - 2,986 5,971 2,986 - 11,943
Short term borrowings 18,986 - - - - 18,986
Other liabilities and provisions 21,178 31 26 26 50 21,311
c. Market risk
Market risk is the risk of loss of future earnings or fair values or future cash fl ows that may result from a change in the price of a fi nancial instrument. The value of a fi nancial
instrument may change as a result of changes in the interest rates, foreign currency exchange rates and other market changes that affect market risk-sensitive instruments.
Market risk is attributable to all market risk-sensitive fi nancial instruments including foreign currency receivables and payables and long term debt. The Company is exposed to
market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company’s exposure to market risk is a function
of investing and borrowing activities and revenue generating and operating activities in foreign currencies.
Foreign exchange risk
The Company’s exchange risk arises from its foreign operations, foreign currency revenues and expenses, (primarily in U.S. dollars, British pounds sterling, Roubles and
Euros) and foreign currency borrowings (in U.S. dollars, Euros and Roubles). A signifi cant portion of the Company’s revenues are in these foreign currencies, while a signifi cant
portion of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Company’s fi nancial performance may
get adversely impacted. The exchange rate between the Indian rupee and these foreign currencies has changed substantially in recent periods and may continue to fl uctuate
substantially in the future. Consequently, the Company uses derivative fi nancial instruments, such as foreign exchange forward contracts, option contracts and swap contracts
to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted transactions and recognized assets and liabilities.
The details in respect of the outstanding foreign exchange forward contracts, option contracts and swap contracts are given in Note 2.37 above.
In respect of the Company’s derivative contracts, a 10% decrease / increase in the respective exchange rates of each of the currencies underlying such contracts would
have resulted in an approximately ` 1,254 / (945) increase/(decrease) in the Company’s hedging reserve and an approximately ` 3,856 / (4,004) increase / (decrease) in the
Company’s net profi t as at 31 March 2014.
In respect of the Company’s derivative contracts, a 10% decrease / increase in the respective exchange rates of each of the currencies underlying such contracts would have
resulted in an approximately ` 2,381 / (1,854) increase / (decrease) in the Company’s hedging reserve and an approximately ` 1,478 / (1,535) increase / (decrease) in the
Company’s net profi t as at 31 March 2013.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
204 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.38: FINANCIAL RISK MANAGEMENT (CONTINUED)
The following table analyzes foreign currency risk from fi nancial instruments as at 31 March 2014:
(All fi gures in equivalent rupees millions)
PARTICULARS U.S. DOLLARS EURO ROUBLES OTHERS(1) TOTAL
Assets:
Cash and bank balances 4,341 109 345 1,283 6,078
Trade receivables 18,080 1,558 5,772 2,982 28,392
Long term, short term loans and advances and other current assets 221 1 212 181 615
Total 22,642 1,668 6,329 4,446 35,085
Liabilities:
Trade payables 1,688 490 144 213 2,535
Long term borrowings 22,185 - 124 - 22,309
Short term borrowings 7,519 4,258 6,179 - 17,956
Other liabilities and provisions 5,694 252 1,497 905 8,348
Total 37,086 5,000 7,944 1,118 51,148
(1) Others include currencies such as British pounds sterling, Swiss franc, South African rand, Mexican pesos, Venezuela bolivars, etc.
The following table analyzes foreign currency risk from fi nancial instruments as at 31 March 2013:
(All fi gures in equivalent rupees millions)
PARTICULARS U.S. DOLLARS EURO ROUBLES OTHERS(1) TOTAL
Assets:
Cash and bank balances 6,962 143 372 740 8,217
Trade receivables 15,910 1,602 6,349 2,657 26,518
Long term, short term loans and advances and other current assets 714 106 141 273 1,234
Total 23,586 1,851 6,862 3,670 35,969
Liabilities:
Trade payables 1,918 147 214 462 2,741
Long term borrowings 11,948 - 45 - 11,993
Short term borrowings 7,274 2,676 5,836 - 15,786
Other liabilities and provisions 3,759 137 1,516 1,200 6,612
Total 24,899 2,960 7,611 1,662 37,132
(1) Others include currencies such as British pounds sterling, Swiss franc, South African rand, Mexican pesos, Venezuela bolivars, etc.
For the year ended 31 March 2014 and 2013, every 10% depreciation / appreciation in the exchange rate between the Indian rupee and the respective currencies in the above
mentioned fi nancial assets / liabilities would affect the Company’s net profi t by approximately ` 1,606 and ` 116, respectively, from such fi nancial assets / liabilities.
Interest rate risk
As of 31 March 2014, the Company had foreign currency loans of ` 34,375 carrying a fl oating interest rate of LIBOR plus 20-179 bps and ` 846 carrying a fl oating interest
rate of Moscow Prime Offered Rate plus 60 bps whereas as of 31 March 2013 foreign currency loans were ` 23,174 carrying a fl oating interest rate of LIBOR plus 50-145 bps.
These loans expose the Company to risk of changes in interest rates. The Company’s treasury department monitors the interest rate movement and manages the interest
rate risk based on its policies, which include entering into interest rate swaps as considered necessary. An increase or decrease of 10% in the fl oating interest rate component
applicable to its loans and borrowings would affect the Company’s net profi t by ` 13 and `4 for the year ended 31 March 2014 and 31 March 2013, respectively.
The Company’s investments in time deposits with banks and short term liquid mutual funds are for short durations, and therefore do not expose the Company to signifi cant
interest rates risk.
Commodity rate risk
Exposure to market risk with respect to commodity prices primarily arises from the Company’s purchases and sales of active pharmaceutical ingredients, including the raw
material components for such active pharmaceutical ingredients. These are commodity products, whose prices may fl uctuate signifi cantly over short periods of time. The
prices of the Company’s raw materials generally fl uctuate in line with commodity cycles, although the prices of raw materials used in the Company’s active pharmaceutical
ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company’s operating expenses. Commodity price risk exposure is
evaluated and managed through operating procedures and sourcing policies. The Company has historically not entered into any material derivative contracts to hedge
exposure to fl uctuations in commodity prices.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
205
2.39: ISSUANCE OF BONUS DEBENTURES
The Company had, on 24 March 2011, allotted 1,015,516,392, 9.25% unsecured, non-convertible, redeemable bonus debentures aggregating to ` 5,078. The interest is
payable at the end of 12, 24 and 36 months from the initial date of issuance. The bonus debentures are redeemable at the end of 36 months from the initial date of issuance.
These debentures have been listed on the Bombay Stock Exchange Limited and National Stock Exchange of India Limited.
As per the requirements of the Companies Act, 1956, the Company created a Debenture Redemption Reserve aggregating to ` 2,539 and ` 1,712 as at 24 March 2014 and
31 March 2013, respectively.
On 24 March 2014, the Company redeemed 9.25% unsecured, non-convertible, redeemable bonus debentures at par value of ` 5,078. Accordingly, the amount of ` 2,539
representing Debenture Redemption Reserve has been transferred to General Reserve upon redemption of debentures.
2.40: ASSET PURCHASE AGREEMENT WITH ECOLOGIC CHEMICALS LIMITED
During the year ended 31 March 2014, the Company entered into an asset purchase agreement with Ecologic Chemicals Limited (“Ecologic”), where in two directors of the
company have equity interests. The Company has paid ` 1,264 excluding taxes and duties for purchase of fi xed and current assets. The consideration was arrived at based
on valuation from independent valuers. The acquisition of these assets will help augment the Company’s manufacturing capacity in meeting the future business requirements
of its PSAI segment.
The acquisition has been accounted for as a purchase of assets. The total purchase consideration has been allocated to the acquired assets as of 13 September 2013 based
on a fair valuation carried out by the Company’s management as tabulated below:
Category Amount
Land 66
Buildings 382
Plant and machinery 702
Inventories 113
Other current assets 1
Total ` 1,264
2.41: AGREEMENT WITH PIERRE FABRE
On 11 February 2014, Aurigene Discovery Technologies Limited (“Aurigene”), a wholly owned subsidiary of Dr. Reddy’s Laboratories Limited, entered into a collaborative
license, development and commercialization agreement granting Pierre Fabre, the third largest French pharmaceutical company, global worldwide rights (excluding India) to
a new immune checkpoint modulator, AUNP-12.
AUNP-12 offers a breakthrough mechanism of action in the PD-1 pathway compared to other molecules currently in development in the highly promising immune therapy
cancer space. AUNP-12 is the only peptide therapeutic in this pathway and could offer more effective and safer combination opportunities with emerging and established
treatment regimens. AUNP-12 will be in development for numerous cancer indications.
Under the terms of this agreement, Aurigene received a non-refundable upfront payment from Pierre Fabre. Such non-refundable upfront consideration is recognised as
revenue over the period in which the Company has continuing performance obligations. Aurigene will also receive additional milestone payments based upon the continued
development, regulatory progresses and commercialization of AUNP-12.
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
206 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
2.42: SETTLEMENT AGREEMENT WITH NORDION
During March 2013, the Company entered into an agreement with Nordion Inc. (formerly known as MDS Inc.) to settle its ongoing litigation for alleged breach of service
obligations by Nordion Inc. during the years 2000 to 2004. As part of the settlement, the Company received a total amount of ` 1,220 (USD 22.5 million) from Nordion Inc. out
of which ` 108 (USD 2 million) is towards reimbursement of research and development cost and the same is recorded as reduction in such cost. The balance ` 1,112 (USD
20.5 million) is towards ‘lost profi ts’ and the same is recorded as part of other operating revenue.
2.43: COMPARATIVE FIGURES
Previous year’s fi gures have been regrouped / reclassifi ed wherever necessary, to conform to current year’s classifi cation.
As per our report of even date attached
for B S R & Co. LLP for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited
Chartered Accountants
Firm Registration No.: 101248W
Supreet Sachdev
Partner G V Prasad Chairman & Chief Executive Offi cer
Membership No.: 205385 K Satish Reddy Vice Chairman & Managing Director
Place : Hyderabad Saumen Chakraborty President & Chief Financial Offi cer
Date : 13 May 2014 Sandeep Poddar Company Secretary
NOTE 2: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated)
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
207
IFRS ConsolidatedFinancial Statements
CONSOLIDATED STATEMENT OF FINANCIAL POSITION 208
CONSOLIDATED INCOME STATEMENT 209
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 209
208 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
EXTRACT OF CONSOLIDATED IFRS FINANCIAL STATEMENTS
We have adopted IFRS as issued by International Accounting Standards Board (IASB) for preparing our fi nancial statements for the purpose of fi lings with SEC. We have
furnished all our interim fi nancial reports of fi scal 2014 with SEC which were prepared under IFRS. The Annual Report in Form 20-F, when fi led with the SEC, will also be made
available at the Company’s website. A hard copy of such Annual Report in Form 20-F will be made available to the shareholders, free of charge, upon request. For details visit
www.drreddys.com.
The extract of the consolidated fi nancial statements prepared under IFRS has been provided here under.
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
ALL AMOUNTS IN INDIAN RUPEES MILLIONS, EXCEPT SHARE DATA AND PER SHARE DATA
PARTICULARS AS OF 31 MARCH 2014AS OF 31 MARCH 2013
RESTATED*
ASSETSCurrent assetsCash and cash equivalents 8,451 5,136
Other investments 25,083 16,963
Trade and other receivables 33,037 31,972
Inventories 23,992 21,600
Derivative fi nancial instruments 554 546
Current tax assets 1,298 513
Other current assets 11,332 8,984
Total current assets 103,747 85,714Non-current assetsProperty, plant and equipment 44,424 37,814
Goodwill 3,428 3,193
Other intangible assets 11,269 10,828
Investment in equity accounted investees 806 472
Other investments – non-current 0 209
Deferred tax assets 6,054 3,652
Other non-current assets 495 487
Total non-current assets 66,476 56,655Total assets 170,223 142,369LIABILITIES AND EQUITYCurrent liabilitiesTrade and other payables 10,503 11,862
Derivative fi nancial instruments 305 95
Current tax liabilities 1,192 997
Bank overdraft - 82
Short-term borrowings 20,607 18,914
Long-term borrowings, current portion 3,395 5,139
Provisions 2,819 2,288
Other current liabilities 15,242 14,714
Total current liabilities 54,063 54,091Non-current liabilitiesLong-term loans and borrowings, excluding current portion 20,740 12,625
Provisions – non-current 92 47
Deferred tax liabilities 2,744 1,838
Other non-current liabilities 1,783 963
Total non-current liabilities 25,359 15,473Total liabilities 79,422 69,564EquityShare capital 851 849
Equity shares held by controlled trust (5) (5)
Share premium 21,553 21,214
Share based payment reserve 1,008 911
Debenture redemption reserve - 1,711
Retained earnings 65,051 44,815
Other components of equity 2,343 3,290
Equity attributable to equity holders of the Company 90,801 72,785Non-controlling interests - 20Total equity 90,801 72,805Total liabilities and equity 170,223 142,369
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
209
CONSOLIDATED INCOME STATEMENT
ALL AMOUNTS IN INDIAN RUPEES MILLIONS, EXCEPT SHARE DATA AND PER SHARE DATA
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED
31 MARCH 2013
FOR THE YEAR ENDED
31 MARCH 2012
Revenues 132,170 116,266 96,737
Cost of revenues 56,369 55,687 43,432
Gross profi t 75,801 60,579 53,305
Selling, general and administrative expenses 38,783 34,272 29,907
Research and development expenses 12,402 7,674 5,911
Other (income)/expense, net (1,416) (2,479) (765)
Total operating expenses 49,769 39,467 35,053
Results from operating activities 26,032 21,112 18,252
Finance income 1,674 1,478 1,227
Finance expense (1,274) (1,018) (1,067)
Finance income/(expense), net 400 460 160
Share of profi t of equity accounted investees, net of tax 174 104 54
Profi t before tax 26,606 21,676 18,466
Tax expense (5,094) (4,900) (4,204)
Profi t for the year 21,512 16,776 14,262
Attributable to:
Equity holders of the Company 21,515 16,777 14,262
Non-controlling interests (3) (1) -
Profi t for the year 21,512 16,776 14,262
Earnings per share:
Basic earnings per share of `5/- each 126.52 98.82 84.16
Diluted earnings per share of `5/- each 126.04 98.44 83.81
Weighted average number of equity shares used in computing earnings per share:
Basic 170,044,518 169,777,458 169,469,888
Diluted 170,695,017 170,432,680 170,177,944
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEALL AMOUNTS IN INDIAN RUPEES MILLIONS, EXCEPT SHARE DATA AND PER SHARE DATA
PARTICULARSFOR THE YEAR ENDED
31 MARCH 2014
FOR THE YEAR ENDED 31 MARCH 2013
Restated*
FOR THE YEAR ENDED 31 MARCH 2012
Restated*
Profi t for the year 21,512 16,776 14,262
Other comprehensive income/(loss)
Items that will not be reclassifi ed to profi t or loss:
Actuarial gains/(losses) on post employment benefi t obligations 68 (211) 44
Tax on items that will not be reclassifi ed to profi t or loss (20) 68 (14)
Total items that will not be reclassifi ed to profi t or loss 48 (143) 30
Items that may be reclassifi ed subsequently to profi t or loss:
Changes in fair value of available for sale fi nancial instruments 40 34 2
Foreign currency translation adjustments 554 197 711
Effective portion of changes in fair value of cash fl ow hedges, net (1,650) 1,697 (2,496)
Tax on items that may be reclassifi ed subsequently to profi t or loss 64 (741) 860
Total items that may be reclassifi ed subsequently to profi t or loss (992) 1,187 (923)
Other comprehensive income/(loss) for the year, net of tax (944) 1,044 (893)
Total comprehensive income for the year 20,568 17,820 13,369
Attributable to:
Equity holders of the Company 20,567 17,822 13,369
Non-controlling interests 1 (2) -
Total comprehensive income for the year 20,568 17,820 13,369
* The Company has adopted revised IAS 19 effective 1 April 2013. The revised standard requires immediate recognition of unrecognized gains and losses through re-
measurements of the net defi ned benefi t liability/(asset) through other comprehensive income. Consequently, an amount of `30 and `(143) representing the actuarial gain/
(loss), net of `(14) and `68 representing associated tax (expense)/benefi t have been recorded in the consolidated statement of comprehensive income for the years ended
31 March 2012 and 2013, respectively. Correspondingly, other liabilities were increased by `445 as of 1 April 2013. Previously, these amounts were not recorded under the
corridor approach specifi ed in IAS 19.
IFRS CONSOLIDATED FINANCIAL STATEMENTS
210 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013-14
HEALTHY FOREVER
STA
TE
ME
NT
PU
RS
UA
NT
TO
SE
CT
ION
212
OF
TH
E C
OM
PA
NIE
S A
CT,
195
6(A
LL A
MO
UN
TS
IN
IN
DIA
N R
UP
EE
S M
ILLIO
NS
, E
XC
EP
T S
HA
RE
DA
TA
AN
D W
HE
RE
OT
HE
RW
ISE
STA
TE
D)
SL.
N
O.
NA
ME
OF
TH
E S
UB
SID
IAR
YT
HE
FIN
AN
CIA
L Y
EA
R
OF
TH
E S
UB
SID
IAR
Y
CO
MP
AN
Y E
ND
ED
ON
NU
MB
ER
OF
SH
AR
ES
IN
TH
E S
UB
SID
IAR
Y C
OM
PA
NY
H
ELD
BY
DR
. RE
DD
Y’S
LA
BO
RAT
OR
IES
LIM
ITE
D A
T
TH
E A
BO
VE
DAT
E
TH
E N
ET
AG
GR
EG
ATE
OF
PR
OF
ITS
(L
OS
SE
S) O
F T
HE
SU
BS
IDIA
RY
CO
MP
AN
Y
FO
R IT
’S F
INA
NC
IAL
YE
AR
SO
FA
R A
S T
HE
Y
CO
NC
ER
N T
HE
ME
MB
ER
S O
F D
R. R
ED
DY
’S
LAB
OR
ATO
RIE
S L
IMIT
ED
(3)
TH
E N
ET
AG
GR
EG
ATE
OF
PR
OF
ITS
(L
OS
SE
S) O
F T
HE
SU
BS
IDIA
RY
CO
MP
AN
Y
FO
R IT
’S P
RE
VIO
US
FIN
AN
CIA
L Y
EA
RS
SO
FA
R A
S T
HE
Y C
ON
CE
RN
TH
E M
EM
BE
RS
OF
D
R. R
ED
DY
’S L
AB
OR
ATO
RIE
S L
IMIT
ED
(3)
EQ
UIT
Y
SH
AR
ES
EQ
UIT
Y
HO
LDIN
G %
A) D
EA
LT W
ITH
IN
TH
E A
CC
OU
NT
O
F D
R. R
ED
DY
’S
LAB
OR
ATO
RIE
S
LIM
ITE
D F
OR
TH
E
YE
AR
EN
DE
D
31.0
3.20
14
B) N
OT
DE
ALT
WIT
H
IN T
HE
AC
CO
UN
T
OF
DR
. RE
DD
Y’S
LA
BO
RAT
OR
IES
LI
MIT
ED
FO
R T
HE
Y
EA
R E
ND
ED
31
.03.
2014
A) D
EA
LT W
ITH
IN
TH
E A
CC
OU
NT
O
F D
R. R
ED
DY
’S
LAB
OR
ATO
RIE
S
LIM
ITE
D F
OR
TH
E
YE
AR
EN
DE
D
31.0
3.20
13
B) N
OT
DE
ALT
WIT
H
IN T
HE
AC
CO
UN
T
OF
DR
. RE
DD
Y’S
LA
BO
RAT
OR
IES
LI
MIT
ED
FO
R T
HE
Y
EA
R E
ND
ED
31
.03.
2013
1A
urigene D
iscove
ry T
echnolo
gie
s (M
ala
ysia
) S
DN
BH
D3
1.0
3.2
01
4(1
) -
-
5
-
1
4
2A
urigene D
iscove
ry T
echnolo
gie
s Inc.
31
.03
.20
14
(1)
-
-
(1
9)
-
(1
0)
3A
urigene D
iscove
ry T
echnolo
gie
s L
imited
31
.03
.20
14
90
,54
4,1
04
1
00
-
79
-
1
65
4
beta
Institu
t gem
ein
nütz
ige G
mb
H3
1.0
3.2
01
4(1
) -
-
-
-
(1
)5
beta
pharm
Arz
neim
itte
l Gm
bH
31
.03
.20
14
(1)
-
-
3,3
39
-
(1
,12
4)
6C
hem
inor
Inve
stm
ents
Lim
ited
31
.03
.20
14
13
4,5
13
1
00
-
-
-
-
7C
hie
nna B
.V.
31
.03
.20
14
(1)
-
-
(1
47
) -
(1
3)
8C
hirote
ch T
echnolo
gy
Lim
ited
3
1.0
3.2
01
4(1
) -
-
(1
07
) -
(1
25
)9
Dr. R
ed
dy’
s B
io-S
cie
nces L
imited
31
.03
.20
14
34
,02
2,0
70
1
00
-
(2
) -
(1
)10
Dr. R
ed
dy’
s F
arm
aceutica D
o B
rasil
Ltd
a.
31
.03
.20
14
26
,69
9,2
30
1
00
-
(3
5)
-
72
11
Dr. R
ed
dy’
s L
ab
ora
tories (A
ustr
alia
) P
ty.
Lim
ited
31
.03
.20
14
(1)
-
-
8
-
66
12
Dr. R
ed
dy’
s L
ab
ora
tories (C
anad
a) In
c.
31
.03
.20
14
(1)
-
-
(2
4)
-
-
13
Dr. R
ed
dy’
s L
ab
ora
tories (E
U) Lim
ited
31
.03
.20
14
(1)
-
-
17
-
3
56
14
Dr. R
ed
dy’
s L
ab
ora
tories (P
rop
rieta
ry) Lim
ited
31
.03
.20
14
(1)
-
-
25
-
8
5
15
Dr. R
ed
dy’
s L
ab
ora
tories (U
K) Lim
ited
31
.03
.20
14
(1)
-
-
33
1
-
15
3
16
Dr. R
ed
dy’
s L
ab
ora
tories Inc.
31
.03
.20
14
(1)
-
-
48
4
-
32
17
Dr. R
ed
dy’
s L
ab
ora
tories Inte
rnational S
A
31
.03
.20
14
(1)
-
-
-
-
(1)
18
Dr. R
ed
dy’
s L
ab
ora
tories L
LC
, U
kra
ine
31
.03
.20
14
(1)
-
-
(6
8)
-
(8
2)
19
Dr. R
ed
dy’
s L
ab
ora
tories L
ouis
iana L
LC
31
.03
.20
14
(1)
-
-
71
7
-
1,8
24
20
Dr. R
ed
dy’
s L
ab
ora
tories N
ew
York
, In
c.
31
.03
.20
14
(1)
-
-
(8
11
) -
(4
20
)21
Dr. R
ed
dy’
s L
ab
ora
tories R
om
ania
SR
L3
1.0
3.2
01
4(1
) -
-
3
5
-
23
22
Dr. R
ed
dy’
s L
ab
ora
tories S
A,
Sw
itze
rland
31
.03
.20
14
10
5,6
40
,41
0
10
0 -
4
,90
4
-
6,6
70
23
Dr. R
ed
dy’
s L
ab
ora
tories T
ennessee,
LLC
31
.03
.20
14
(1)
-
-
(5
41
) -
(6
9)
24
Dr. R
ed
dy’
s N
ew
Zeala
nd
Lim
ited
31
.03
.20
14
(1)
-
-
(1
6)
-
9
25
Dr. R
ed
dy’
s P
harm
a S
EZ
Lim
ited
31
.03
.20
14
50
,00
0
10
0 -
-
-
-
26
Dr. R
ed
dy’
s S
ingap
ore
PTE
. LT
D.
31
.03
.20
14
(1)
-
-
(1)
-
-
27
Dr. R
ed
dy’
s S
rl3
1.0
3.2
01
4(1
) -
-
(4
) -
(1
67
)28
Dr. R
ed
dy’
s V
enezu
ela
, C
.A.
31
.03
.20
14
(1)
-
-
11
-
(1
7)
29
DR
L Im
pex L
imited
31
.03
.20
14
50
,00
0
10
0 -
5
9
-
(8
24
)30
Euro
Brid
ge C
onsultin
g B
.V.
31
.03
.20
14
(1)
-
-
(2
) -
(4
)31
Idea2E
nte
rprises (In
dia
) P
riva
te L
imited
31
.03
.20
14
2,3
77
,82
6
10
0 -
-
-
(1
4)
32
Ind
ustr
ias Q
uim
icas F
alc
on d
e M
exic
o S
.A.
de C
.V.
31
.03
.20
14
14
0,5
26
,27
0
10
0 -
(3
57
) -
(1
99
)33
I-Ven P
harm
a C
ap
ital L
imited
(und
er
liquid
ation)
31
.03
.20
14
(1)
-
-
23
8
-
25
3
34
Kunshan R
ota
m R
ed
dy
Pharm
aceutical C
om
pany
Lim
ited
31
.03
.20
14
(2)
51
.33
-
38
9
-
18
0
35
Lacock H
old
ings L
imited
31
.03
.20
14
(1)
-
-
(2
5,2
86
) -
(9
41
)36
Octo
Plu
s D
eve
lop
ment
B.V
.3
1.0
3.2
01
4(1
) -
-
6
85
-
6
8
37
Octo
Plu
s N
.V.
31
.03
.20
14
(1)
-
-
(1
38
) -
(7
5)
38
Octo
Plu
s P
oly
Active
Scie
nces B
.V.
31
.03
.20
14
(1)
-
-
-
-
-
39
Octo
Plu
s S
cie
nces B
.V.
31
.03
.20
14
(1)
-
-
(3
3)
-
(3
)40
Octo
Plu
s T
echnolo
gie
s B
.V.
31
.03
.20
14
(1)
-
-
(3
15
) -
(3
6)
41
Octo
Share
B.V
.3
1.0
3.2
01
4(1
) -
-
(2
77
) -
(2
3)
42
OO
O D
r. R
ed
dy’
s L
ab
ora
tories L
imited
31
.03
.20
14
(1)
-
-
77
6
-
(1
8)
43
OO
O D
RS
LLC
31
.03
.20
14
(1)
-
-
(2
) -
(2
2)
44
Pro
miu
s P
harm
a L
LC
31
.03
.20
14
(1)
-
-
(1
,20
0)
-
(6
39
)45
Red
dy
Antille
s N
.V.
31
.03
.20
14
1,1
31
,64
6
10
0 -
(2
32
) -
(6
1)
46
Red
dy
Chem
inor
S.A
. (u
nd
er
liquid
ation)
31
.03
.20
14
2,5
00
1
00
-
-
-
-
47
Red
dy
Hold
ing G
mb
H3
1.0
3.2
01
4(1
) -
-
(1
,67
3)
-
(1)
48
Red
dy
Sp
ecia
litie
s G
mb
H (fo
rmerly
Red
dy
beta
Gm
bH
)3
1.0
3.2
01
4(1
) -
-
-
-
-
49
Red
dy
Neth
erland
s B
.V.
31
.03
.20
14
(1)
-
-
16
4
-
(1
80
)50
Red
dy
Pharm
a Ib
eria S
A3
1.0
3.2
01
4 9
,06
6,0
00
1
00
-
14
-
9
51
Red
dy
Pharm
a Ita
lia S
.p.A
31
.03
.20
14
(1)
-
-
(3
5)
-
(1
4)
52
Red
dy
US
Thera
peutics Inc.
31
.03
.20
14
(4)
-
-
4
-
(2
2)
(1) S
tep
dow
n s
ub
sid
iary
(2
) No c
oncep
t of share
cap
ital
(3) T
he a
mo
unts
sho
wn in
this
co
lum
n r
ep
resent
the n
et
ag
gre
gate
am
ount
of p
rofi t
s /
(lo
sses) o
f th
e s
ub
sid
iary
att
rib
uta
ble
to
the d
irect
ho
ldin
g o
f th
e c
om
pany
(4
) Entity
dis
solv
ed
during t
he y
ear
IGAAP CONSOLIDATED FINANCIAL STATEMENTS
211
INF
OR
MAT
ION
ON
TH
E F
INA
NC
IALS
OF
SU
BS
IDIA
RIE
S (P
RE
PA
RE
D A
S P
ER
IGA
AP
)
(ALL A
MO
UN
TS
IN
IN
DIA
N R
UP
EE
S M
ILLIO
NS
, E
XC
EP
T S
HA
RE
DA
TA
AN
D W
HE
RE
OT
HE
RW
ISE
STA
TE
D)
NA
ME
OF
TH
E S
UB
SID
IAR
Y
AS
AT
31
MA
RC
H 2
014
FO
R T
HE
YE
AR
EN
DE
D 3
1 M
AR
CH
201
4
SL.
N
O.
CA
PIT
AL
RE
SE
RV
ES
O
TH
ER
LI
AB
ILIT
IES
TO
TAL
EQ
UIT
Y A
ND
LI
AB
ILIT
IES
PR
OP
ER
TY,
P
LAN
T A
ND
E
QU
IPM
EN
T,
NE
T
TO
TAL
AS
SE
TS
(IN
CLU
DIN
G
PP
E, N
ET
)
INV
ES
TM
EN
TS
(E
XC
L.IN
VE
ST
ME
NT
IN
SU
BS
IDIA
RIE
S)
TU
RN
OV
ER
PR
OF
IT
/ (L
OS
S)
BE
FO
RE
TA
XAT
ION
PR
OV
ISIO
N
FO
R T
AX
ATIO
N
PR
OF
IT /
(L
OS
S) A
FT
ER
TA
XAT
ION
PR
OP
OS
ED
D
IVID
EN
D
1A
urigene D
iscove
ry T
echnolo
gie
s (M
ala
ysia
) S
DN
BH
D 1
6
(2)
98
112
13
112
-
270
5
-
5
-
2A
urigene D
iscove
ry T
echnolo
gie
s Inc.
251
(257)
13
7
-
7
-
33
(19)
-
(19)
-
3A
urigene D
iscove
ry T
echnolo
gie
s L
imited
905
337
1,3
08
2,5
50
616
2,5
50
-
1,3
14
127
48
79
79
4b
eta
Institu
t gem
ein
nütz
ige G
mb
H (3
) 5
(3)
2
4
-
4
-
-
-
-
-
-
5b
eta
pharm
Arz
neim
itte
l Gm
bH
(3)
60
4,0
42
8,5
98
12,7
00
307
12,7
00
-
7,5
63
3,3
39
-
3,3
39
-
6C
hem
inor
Inve
stm
ents
Lim
ited
1
-
-
1
1
1
-
-
-
-
-
-
7C
hie
nna B
.V.
(2)
1
(657)
1,0
90
434
-
434
-
-
(147)
-
(147)
-
8C
hirote
ch T
echnolo
gy
Lim
ited
1
,060
(906)
605
759
147
759
-
1,0
42
6
113
(107)
-
9D
r. R
ed
dy’
s B
io-S
cie
nces L
imited
340
(157)
85
268
268
268
-
-
(2)
-
(2)
-
10
Dr. R
ed
dy’
s F
arm
aceutica D
o B
rasil
Ltd
a.
634
(1,0
00)
443
77
3
77
-
109
(2)
33
(35)
-
11
Dr. R
ed
dy’
s L
ab
ora
tories (A
ustr
alia
) P
ty. Lim
ited
35
(431)
1,0
18
622
-
622
-
656
5
(3)
8
-
12
Dr. R
ed
dy’
s L
ab
ora
tories (C
anad
a) In
c.
-
34
18
52
2
52
-
-
(24)
-
(24)
-
13
Dr. R
ed
dy’
s L
ab
ora
tories (E
U) Lim
ited
723
825
1,3
74
2,9
22
696
2,9
22
-
887
28
11
17
-
14
Dr. R
ed
dy’
s L
ab
ora
tories (P
rop
rieta
ry) Lim
ited
-
88
667
755
16
755
-
1,1
68
34
9
25
-
15
Dr. R
ed
dy’
s L
ab
ora
tories (U
K) Lim
ited
-
1,1
00
407
1,5
07
160
1,5
07
-
2,2
03
352
21
331
-
16
Dr. R
ed
dy’
s L
ab
ora
tories Inc.
(1)
580
5,4
85
29,1
33
35,1
98
578
35,1
98
-
54,8
54
273
(211)
484
-
17
Dr. R
ed
dy’
s L
ab
ora
tories Inte
rnational S
A
275
(3)
2
274
37
274
-
-
-
-
-
-
18
Dr. R
ed
dy’
s L
ab
ora
tories L
LC
, U
kra
ine
71
(151)
1,5
64
1,4
84
36
1,4
84
-
1,8
50
(137)
(69)
(68)
-
19
Dr. R
ed
dy’
s L
ab
ora
tories L
ouis
iana L
LC
(1
) -
4
,736
352
5,0
88
1,7
07
5,0
88
-
4,5
83
717
-
717
-
20
Dr. R
ed
dy’
s L
ab
ora
tories N
ew
York
, In
c.
1,3
37
6
180
1,5
23
1,2
98
1,5
23
-
-
(811)
-
(811)
-
21
Dr. R
ed
dy’
s L
ab
ora
tories R
om
ania
SR
L 2
4
80
42
146
1
146
-
404
44
9
35
-
22
Dr. R
ed
dy’
s L
ab
ora
tories S
A, S
witze
rland
5,0
27
33,1
08
20,5
04
58,6
39
12
58,6
39
-
14,8
46
5,1
64
260
4,9
04
-
23
Dr. R
ed
dy’
s L
ab
ora
tories T
ennessee, LLC
(1)
1,1
20
(512)
825
1,4
33
676
1,4
33
-
1,9
25
(541)
-
(541)
-
24
Dr. R
ed
dy’
s N
ew
Zeala
nd
Lim
ited
-
79
7
86
-
86
-
128
(25)
(9)
(16)
-
25
Dr. R
ed
dy’
s P
harm
a S
EZ
Lim
ited
1
(1)
-
-
-
-
-
-
-
-
-
-
26
Dr. R
ed
dy’
s S
ingap
ore
PTE
. LT
D.
25
(1)
-
24
-
24
-
-
(1)
-
(1)
-
27
Dr. R
ed
dy’
s S
rl 6
(1,0
27)
1,1
14
93
-
93
-
108
(4)
-
(4)
-
28
Dr. R
ed
dy’
s V
enezu
ela
, C
.A.
58
(36)
167
189
-
189
-
295
11
-
11
-
29
DR
L Im
pex L
imited
1
(680)
2,0
45
1,3
66
6
1,3
66
-
-
57
(2)
59
-
30
Euro
Brid
ge C
onsultin
g B
.V.
37
112
3
152
-
152
-
-
(2)
-
(2)
-
31
Idea2E
nte
rprises (In
dia
) P
riva
te L
imited
24
1,4
23
3
1,4
50
1,4
50
1,4
50
-
-
-
-
-
-
32
Ind
ustr
ias Q
uim
icas F
alc
on d
e M
exic
o S
.A. d
e C
.V.
594
(816)
4,2
25
4,0
03
1,3
45
4,0
03
-
3,4
56
(359)
(2)
(357)
-
33
I-Ven P
harm
a C
ap
ital L
imited
(und
er
liquid
ation)
1
(1)
-
-
-
-
-
361
361
123
238
-
34
Kunshan R
ota
m R
ed
dy
Pharm
aceutical C
om
pany
Lim
ited
791
381
901
2,0
73
296
2,0
73
-
2,7
81
467
78
389
-
35
Lacock H
old
ings L
imited
1
166
26,9
35
27,1
02
-
27,1
02
-
-
(25,2
38)
48
(25,2
86)
-
36
Octo
Plu
s D
eve
lop
ment
B.V
. (2
) 1
1
,148
1,0
15
2,1
64
728
2,1
64
-
1,1
94
685
-
685
-
37
Octo
Plu
s N
.V.
(2)
451
878
2,2
89
3,6
18
456
3,6
18
-
-
(138)
-
(138)
-
38
Octo
Plu
s P
oly
Active
Scie
nces B
.V.
(2)
1
-
-
1
-
1
-
-
-
-
-
-
39
Octo
Plu
s S
cie
nces B
.V.
(2)
1
110
74
185
-
185
-
-
(33)
-
(33)
-
40
Octo
Plu
s T
echnolo
gie
s B
.V.
(2)
1
(3,4
35)
3,4
80
46
-
46
-
9
(315)
-
(315)
-
41
Octo
Share
B.V
. (2
) 2
1
,097
850
1,9
49
-
1,9
49
-
1
(277)
-
(277)
-
42
OO
O D
r. R
ed
dy’
s L
ab
ora
tories L
imited
72
781
11,8
49
12,7
02
257
12,7
02
-
17,1
43
1,0
14
238
776
-
43
OO
O D
RS
LLC
30
65
136
231
213
231
-
-
(2)
-
(2)
-
44
Pro
miu
s P
harm
a L
LC
(1)
1,7
13
(4,3
41)
4,4
53
1,8
25
10
1,8
25
-
1,6
68
(1,2
00)
-
(1,2
00)
-
45
Red
dy
Antille
s N
.V.
52
(149)
330
233
-
233
-
-
(232)
-
(232)
-
46
Red
dy
Chem
inor
S.A
. (u
nd
er
liquid
ation)
2
(2)
-
-
-
-
-
-
-
-
-
-
47
Red
dy
Hold
ing G
mb
H (3
) 2
3
,902
27,8
13
31,7
17
-
31,7
17
-
-
(736)
937
(1,6
73)
-
48
Red
dy
Sp
ecia
litie
s G
mb
H (fo
rmerly
Red
dy
beta
Gm
bH
) (3
) 1
1
-
2
-
2
-
-
-
-
-
-
49
Red
dy
Neth
erland
s B
.V.
7
3,9
58
55
4,0
20
-
4,0
20
-
1,0
13
185
21
164
-
50
Red
dy
Pharm
a Ib
eria S
A 5
66
(527)
12
51
-
51
-
27
14
-
14
-
51
Red
dy
Pharm
a Ita
lia S
.p.A
63
(191)
1,3
37
1,2
09
-
1,2
09
-
-
(35)
-
(35)
-
52
Red
dy
US
Thera
peutics Inc.
-
-
-
-
-
-
-
-
4
-
4
-
(1) T
ax e
xp
ense for
these e
ntities is
com
pute
d t
ogeth
er
as p
er
the t
ax la
ws o
f U
nited
Sta
tes. The t
ota
l tax e
xp
ense is
pre
sente
d in
Sl.
No. 16 -
Dr. R
ed
dy’
s L
ab
ora
tories Inc.
(2) T
ax e
xp
ense for
these e
ntities is
com
pute
d t
ogeth
er
as p
er
the t
ax la
ws o
f N
eth
erland
s. The t
ota
l tax e
xp
ense is
pre
sente
d in
Sl.
No. 37 -
Octo
Plu
s N
.V.
(3) T
ax e
xp
ense for
these e
ntities is
com
pute
d t
ogeth
er
as p
er
the t
ax la
ws o
f G
erm
any.
The t
ota
l tax e
xp
ense is
pre
sente
d in
Sl.
No. 47 -
Red
dy
Hold
ing G
mb
H.
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013 - 14
HEALTHY FOREVER
212
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the 30th Annual General Meeting of the members of
Dr. Reddy’s Laboratories Limited (CIN: L85195TG1984PLC004507) will be held on
Thursday, 31 July 2014 at 9.30 AM at the Grand Ball Room, Hotel Taj Krishna, Road
No.1, Banjara Hills, Hyderabad 500 034, to transact the following business:
ORDINARY BUSINESS:
1. To receive, consider and adopt the Balance Sheet as at 31 March 2014 and
the Statement of Profi t and Loss of the Company for the year ended on that
date along with the Reports of the Directors’ and Auditors’ thereon.
2. To declare dividend on the equity shares for the fi nancial year 2013-14.
3. To appoint a director in place of Mr. Anupam Puri (DIN: 00209113), who
retires by rotation, and being eligible, seeks re-appointment as non-retiring
Independent Director for a period of 4 (four) years.
4. To appoint a director in place of Dr. Bruce L A Carter (DIN: 02331774), who
retires by rotation, and being eligible, seeks re-appointment as non-retiring
Independent Director for a period of 5 (fi ve) years.
5. To appoint a director in place of Mr. Sridar Iyengar (DIN: 00278512), who
retires by rotation, and being eligible, seeks re-appointment as non-retiring
Independent Director for a period of 5 (fi ve) years.
6. To appoint the Statutory Auditors and fi x their remuneration. The retiring
Auditors M/s. B S R & Co. LLP, Chartered Accountants are eligible for re-
appointment.
“RESOLVED THAT pursuant to the provisions of Section 139, 142 and other
applicable provisions, if any, of the Companies Act, 2013 and their corresponding
rules and based on the recommendations of the Audit Committee, M/s. B S R
& Co. LLP, Chartered Accountants (ICAI Firm Registration No. 101248W), who
have offered themselves for re-appointment and have confi rmed their eligibility in
terms of the provisions of Section 141 of the Companies Act, 2013 and Rule 4
of Companies (Audit and Auditors) Rules, 2014, be and are hereby re-appointed
as Statutory Auditors of the Company, to hold offi ce from the conclusion of the
30th Annual General Meeting up to the conclusion of the 32nd consecutive Annual
General Meeting (subject to ratifi cation by the members at every subsequent AGM)
at a remuneration as may be decided by the Board of Directors of the Company.”
SPECIAL BUSINESS:
7. TO APPOINT DR. ASHOK S GANGULY AS AN INDEPENDENT DIRECTOR
IN TERMS OF SECTION 149 OF THE COMPANIES ACT, 2013
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 149 and 152 read
with Schedule IV and all other applicable provisions of the Companies Act,
2013, Companies (Appointment and Qualifi cation of Directors) Rules, 2014
(including any statutory modifi cation(s) or re-enactment thereof for the time
being in force) and Clause 49 of the Listing Agreement, Dr. Ashok S Ganguly
(DIN: 00010812) an Independent Director and in respect of whom the
Company has received notice under Section 160 of the Companies Act, 2013,
from a member proposing his candidature for the offi ce of Director, be and is
hereby appointed as an Independent Director of the Company, not liable to
retire by rotation, to hold offi ce for a term of 3 (three) consecutive years up to
the conclusion of the 33rd AGM of the Company.”
8. TO APPOINT DR. J P MOREAU AS AN INDEPENDENT DIRECTOR IN
TERMS OF SECTION 149 OF THE COMPANIES ACT, 2013
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 149 and 152 read
with Schedule IV and all other applicable provisions of the Companies Act,
2013, Companies (Appointment and Qualifi cation of Directors) Rules, 2014
(including any statutory modifi cation(s) or re-enactment thereof for the time
being in force) and Clause 49 of the Listing Agreement, Dr. J P Moreau
(DIN:01519325) an Independent Director and in respect of whom the
Company has received notice under Section 160 of the Companies Act, 2013,
from a member proposing his candidature for the offi ce of Director, be and is
hereby appointed as an Independent Director of the Company, not liable to
retire by rotation, to hold offi ce for a term of 1 (one) year up to the conclusion
of the 31st AGM of the Company.”
9. TO APPOINT MS. KALPANA MORPARIA AS AN INDEPENDENT
DIRECTOR IN TERMS OF SECTION 149 OF THE COMPANIES ACT, 2013
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 149 and 152 read
with Schedule IV and all other applicable provisions of the Companies Act,
2013, Companies (Appointment and Qualifi cation of Directors) Rules, 2014
(including any statutory modifi cation(s) or re-enactment thereof for the time
being in force) and Clause 49 of the Listing Agreement, Ms. Kalpana Morparia
(DIN: 00046081) an Independent Director and in respect of whom the
Company has received notice under Section 160 of the Companies Act, 2013,
from a member proposing her candidature for the offi ce of Director, be and is
hereby appointed as an Independent Director of the Company, not liable to
retire by rotation, to hold offi ce for a term of 5 (fi ve) years up to the conclusion
of the 35th AGM of the Company.”
10. TO APPOINT DR. OMKAR GOSWAMI AS AN INDEPENDENT DIRECTOR
IN TERMS OF SECTION 149 OF THE COMPANIES ACT, 2013
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 149 and 152 read
with Schedule IV and all other applicable provisions of the Companies Act,
2013, Companies (Appointment and Qualifi cation of Directors) Rules, 2014
(including any statutory modifi cation(s) or re-enactment thereof for the time
being in force) and Clause 49 of the Listing Agreement, Dr. Omkar Goswami
(DIN: 00004258) an Independent Director and in respect of whom the
Company has received notice under Section 160 of the Companies Act, 2013,
from a member proposing his candidature for the offi ce of Director, be and is
hereby appointed as an Independent Director of the Company, not liable to
retire by rotation, to hold offi ce for a term of 5 (fi ve) consecutive years up to the
conclusion of the 35th AGM of the Company.”
NOTICE
213
NOTICE OF ANNUAL GENERAL MEETING
11. TO APPOINT MR. RAVI BHOOTHALINGAM AS AN INDEPENDENT
DIRECTOR IN TERMS OF SECTION 149 OF THE COMPANIES ACT, 2013
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 149 and 152
read with Schedule IV and all other applicable provisions of the Companies
Act, 2013, Companies (Appointment and Qualifi cation of Directors) Rules,
2014 (including any statutory modifi cation(s) or re-enactment thereof for
the time being in force) and Clause 49 of the Listing Agreement, Mr. Ravi
Bhoothalingam (DIN: 00194530) an Independent Director and in respect of
whom the Company has received notice under Section 160 of the Companies
Act, 2013, from a member proposing his candidature for the offi ce of Director,
be and is hereby appointed as an Independent Director of the Company, not
liable to retire by rotation, to hold offi ce for a term of 2 (two) consecutive years
up to the conclusion of the 32nd AGM of the Company.”
12. VARIATION IN THE TERMS OF APPOINTMENT OF MR. G V PRASAD,
CO-CHAIRMAN, MANAGING DIRECTOR AND CHIEF EXECUTIVE
OFFICER
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 152 of the
Companies Act, 2013 read with Schedule V of the Companies Act, 2013,
the approval of the Company be and is hereby accorded to vary the terms
of appointment of Mr. G V Prasad (DIN: 00057433) Co-Chairman, Managing
Director and Chief Executive Offi cer, by making his offi ce liable to retire by
rotation.”
13. VARIATION IN THE TERMS OF APPOINTMENT OF MR. SATISH REDDY,
CHAIRMAN
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 152 of the
Companies Act, 2013 read with Schedule V of the Companies Act, 2013,
the approval of the Company be and is hereby accorded to vary the terms of
appointment of Mr. Satish Reddy (DIN: 00129701), Chairman, by making his
offi ce liable to retire by rotation.”
14. TO APPROVE THE REMUNERATION PAYABLE TO COST AUDITORS,
M/S. SAGAR & ASSOCIATES FOR THE FINANCIAL YEAR 2014-15
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as an Ordinary Resolution:
“RESOLVED THAT pursuant to the provisions of Section 148 and all other
applicable provisions of the Companies Act, 2013 and the Companies
(Audit and Auditors) Rules, 2014 (including any statutory modifi cation(s) or
re-enactment thereof, for the time being in force), the Cost Auditors, M/s.
Sagar & Associates, appointed by the Board of Directors of the Company, to
conduct the audit of the cost records of the Company for the fi nancial year
ending 31 March 2015, be paid a remuneration of `6.00 lakhs (Rupees Six
Lakhs) per annum plus out of pocket expenses, at actuals.
RESOLVED FURTHER THAT the Board of Directors of the Company be and
are hereby authorized to do all such acts, matters, deeds and things as may
be necessary to give effect to the above resolution.”
15. TO APPROVE THE MATERIAL RELATED PARTY CONTRACTS/
ARRANGEMENTS/TRANSACTIONS WITH DR. REDDY’S
LABORATORIES INC., USA, A WHOLLY-OWNED SUBSIDIARY
To consider and, if thought fi t, to pass with or without modifi cation(s) the
following resolution as a Special Resolution:
“RESOLVED THAT pursuant to the provisions of revised Clause 49–VII of
the Listing Agreement (effective from 1 October 2014), the approval of the
Company be and is hereby accorded to the Board of Directors, to enter into
contracts/arrangements/transactions with Dr. Reddy’s Laboratories Inc., USA
(DRL Inc.), wholly-owned subsidiary of the Company and a ‘related party’ as
defi ned under Section 2(76) of the Companies Act, 2013 and Clause 49-VII(B)(2)
of the Listing Agreement relating to transfer or receipt of products, goods,
materials or services, for an estimated amount of up to US$ 1,100 million every
fi nancial year on such terms and conditions as may be mutually agreed upon
between the Company and DRL Inc.
RESOLVED FURTHER THAT the Board of Directors be and are hereby
authorized to decide upon the nature and value of the products, goods,
materials or services to be transacted with DRL Inc. within the aforesaid limits.
RESOLVED FURTHER THAT the Board of Directors of the Company be and
are hereby also authorized to do all such acts, matters, deeds and things as
may be necessary to give effect to the above resolution.”
NOTES:
1. The statement pursuant to Schedule IV and Section 102(1) of the Companies
Act, 2013 in respect of the ordinary business and special business respectively,
set out in the Notice is annexed hereto.
2. A member entitled to attend and vote is entitled to appoint a proxy
to attend and vote instead of himself/herself and the proxy need not
be a member of the Company. The instrument of proxy in order to be
effective, must be deposited at the Registered Offi ce of the Company,
duly completed and signed, not less than 48 hours before the meeting.
A person can act as a proxy on behalf of members not exceeding fi fty
and holding in the aggregate not more than ten percent of the total share
capital of the Company carrying voting rights. A member holding more
than ten percent of the total share capital of the Company carrying voting
rights may appoint a single person as proxy and such person shall not
act as a proxy for any other person or shareholder.
3. Corporate members intending to send their authorised representatives to
attend the Meeting are requested to send to the Company a certifi ed copy
of the Board Resolution authorizing their representative to attend and vote on
their behalf at the Meeting.
4. During the period beginning 24 hours before the time fi xed for the
commencement of the meeting and ending with the conclusion of the meeting,
a member would be entitled to inspect the proxies lodged with the Company,
at any time during the business hours of the Company, provided that not less
than three days of notice in writing is given to the Company.
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013 - 14
HEALTHY FOREVER
214
5. The Register of Directors and Key Managerial Personnel and their shareholding,
maintained under Section 170 of the Companies Act, 2013, will be available for
inspection by the members at the AGM.
6. The Register of Contracts or Arrangements in which Directors are interested,
maintained under Section 189 of the Companies Act, 2013, will be available for
inspection by the members at the AGM.
7. The Register of Members and Share Transfer Books of the Company will
remain closed from Tuesday, 15 July 2014 to Friday, 18 July 2014 (both days
inclusive).
8. The Board of Directors of the Company at their Meeting held on 13 May 2014
has recommended a dividend of `18.00 per share on equity share of `5/- each
as fi nal dividend for the fi nancial year 2013-14. Dividend, if declared, at the
Annual General Meeting, will be paid on or after 7 August 2014.
9. Pursuant to Clause 49 of the Listing Agreement with the Stock Exchanges,
additional information including brief profi le of each of the Independent
Directors has been given in the section on Corporate Governance.
10. The annual report for the fi nancial year 2013-14 has been sent through email
to those members who have opted to receive electronic communication or
who have registered their email addresses with the Company/depository
participants. The annual report is also available on our website, i.e. www.
drreddys.com. The physical copy of the annual report has been sent to those
members who have either opted for the same or have not registered their email
addresses with the Company/depository participant. The members will be
entitled to a physical copy of the annual report for the fi nancial year 2013-14,
free of cost, upon sending a request to the Company Secretary at 8-2-337,
Road No. 3, Banjara Hills, Hyderabad 500 034.
11. In case any member is desirous to receive communication from the Company in
electronic form, they may register their email address on http://www.drreddys.
com/investors/shareholder-information.html or with their depository participant
or send their consent at [email protected] along with their folio no. and
valid email address for registration.
12. Pursuant to Section 108 of the Companies Act, 2013, read with Rule 20 of
the Companies (Management and Administration) Rules, 2014 and the revised
Clause 35B of the Listing Agreement, the Company is pleased to offer e-voting
facility to the members to cast their votes electronically on all resolutions set
forth in this Notice. The detailed instructions for e-voting are given as a separate
attachment to this notice.
13. Members, desiring any information relating to the accounts, are requested to
write to the Company at an early date so as to enable the management to keep
the information ready.
14. Members are requested to kindly bring their copy of the Annual Report with
them at the Annual General Meeting, as no extra copy of Annual Report would
be made available at the Annual General Meeting. Members/proxies should
also bring the attached Attendance Slip, duly fi lled and hand it over at the
entrance to the venue.
NOTICE OF ANNUAL GENERAL MEETING
15. The certifi cate from the Auditors of the Company certifying that the Company’s
Dr. Reddy’s Employees Stock Option Scheme, 2002 and Dr. Reddy’s
Employees ADR Stock Option Scheme, 2007 are being implemented in
accordance with the SEBI (Employee Stock Option Scheme and Employee
Stock Purchase Scheme), Guidelines, 1999 and the resolution of the members
passed at the general meeting, will be available for inspection by the members
at the AGM.
16. Members are requested to intimate immediately, any change in their address or
bank mandates to their depository participants with whom they are maintaining
their demat accounts or to the Company’s Registrar & Share Transfer Agent,
M/s. Bigshare Services Private Limited, if the shares are held by them in
certifi cate form.
17. In terms of the Circular No. CIR/MRD/DP/10/2013 dated 21 March 2013
issued by the Securities and Exchange Board of India, listed companies are
required to use the Reserve Bank of India’s approved electronic mode of
payment such as Electronic Clearance Service (ECS), LECS (Local ECS)/RECS
(Regional ECS)/NECS (National ECS), NEFT, etc. for making cash payments
like dividend etc. to the members.
Accordingly, members holding securities in demat mode are requested
to update their bank details with their depository participants. Members
holding securities in physical form may send a request updating their bank
details, to the Company Secretary at 8-2-337, Road No. 3, Banjara Hills,
Hyderabad 500 034.
18. The Securities and Exchange Board of India (SEBI) has mandated the
submission of Permanent Account Number (PAN) by every participant in
securities market. Members holding shares in electronic form are, therefore,
requested to submit their PAN to their Depository Participants with whom they
are maintaining their demat accounts. Members holding shares in physical form
can submit their PAN to the Company or its Registrar & Share Transfer Agent,
M/s. Bigshare Services Private Limited.
19. Pursuant to Section 72 of the Companies Act, 2013, members are entitled to
make a nomination in respect of shares held by them. Members desirous of
making a nomination are requested to send their requests in Form No. SH.13,
pursuant to the Rule 19(1) of the Companies (Share Capital and Debentures)
Rules, 2014 (which will be made available on request) to the Registrar and
Share Transfer Agent of the Company.
By Order of the Board
Place Hyderabad Sandeep Poddar
Date 21 June 2014 Company Secretary
NOTICE
215
Statement pursuant to Schedule IV of the Companies Act, 2013
ITEM NOS. 3, 4 & 5
Mr. Anupam Puri, Dr. Bruce L A Carter and Mr. Sridar Iyengar, Independent Directors
are retiring by rotation at the ensuing AGM under the provisions of the Companies
Act, 1956. In terms of Section 149 and other applicable provisions of the Companies
Act, 2013, Mr. Anupam Puri, Dr. Bruce L A Carter and Mr. Sridar Iyengar being
eligible, offer themselves for re-appointment.
Section 149 of the Companies Act, 2013 inter alia stipulates the criteria of
independence, should a company propose to appoint an independent director on
its Board. As per the said Section 149, an independent director can hold offi ce for
a term of up to 5 (fi ve) consecutive years on the Board of a company and he shall
not be included in the total number of directors considered for retirement by rotation.
Hence, it is proposed that Mr. Anupam Puri be appointed for a term of 4 (four) years,
not liable to retire by rotation and Dr. Bruce L A Carter and Mr. Sridar Iyengar be
appointed for a term of 5 (fi ve) years respectively, not liable to retire by rotation.
The Company has received from each of Mr. Anupam Puri, Dr. Bruce L A Carter and
Mr. Sridar Iyengar (i) consent in writing to act as director in Form DIR-2 pursuant to
Rule 8 of the Companies (Appointment & Qualifi cation of Directors) Rules, 2014;
(ii) intimation in Form DIR-8 pursuant to Rule 14 of the Companies (Appointment &
Qualifi cation of Directors) Rules, 2014 to the effect that he is not disqualifi ed under
sub-section (2) of Section 164 of the Companies Act, 2013 and (iii) declaration
that he meets the criteria of independence as provided in Section 149(6) of the
Companies Act, 2013.
In the opinion of the Board, Mr. Anupam Puri, Dr. Bruce L A Carter and Mr. Sridar
Iyengar fulfi ll the conditions for their appointment as Independent Directors as
specifi ed in the Companies Act, 2013 and the Listing Agreement. Mr. Anupam Puri,
Dr. Bruce L A Carter and Mr. Sridar Iyengar are independent of the management.
A copy of the draft letter of appointment setting out the terms and conditions of
appointment of Mr. Anupam Puri, Dr. Bruce L A Carter and Mr. Sridar Iyengar is
available for inspection, without any fee, by the members at the Company’s registered
offi ce during normal hours on working days up to the date of AGM.
Mr. Anupam Puri, Dr. Bruce L A Carter and Mr. Sridar Iyengar are interested in the
resolutions set out respectively at Item Nos. 3, 4 & 5 of the Notice with regard to their
respective appointments.
The relatives of Mr. Anupam Puri, Dr. Bruce L A Carter and Mr. Sridar Iyengar may
be deemed to be interested in the resolutions set out respectively at Item Nos. 3, 4
& 5 of the Notice, to the extent of their shareholding interest, if any, in the Company.
Save and except the above, none of the other Directors/Key Managerial Personnel
of the Company/their relatives are, in any way, concerned or interested, fi nancially or
otherwise, in these resolutions.
The Board recommends the resolutions set forth in the Item Nos. 3, 4 & 5 of the
Notice for approval of the members.
ANNEXURE TO NOTICE OF AGM
Statement pursuant to Section 102(1) of the Companies Act, 2013
ITEM NOS. 7, 8, 9, 10 & 11
The Company had appointed each of Dr. Ashok S Ganguly, Dr. J P Moreau,
Ms. Kalpana Morparia, Dr. Omkar Goswami and Mr. Ravi Bhoothalingam as
Independent Directors of the Company pursuant to Clause 49 of the Listing
Agreement.
In accordance with Section 149 and 152 read with Schedule IV of the Companies
Act, 2013 that have come into effect from 1 April 2014 and subsequent notifi cation
by the Ministry of Corporate Affairs vide its General circular no.14/2014 dated 9 June
2014, the Company is required to appoint its Independent Directors, including its
existing Independent Directors in accordance with the provisions of the Companies
Act, 2013 before 31 March 2015. Further, pursuant to the above provisions, the term
of such Independent Directors is not liable to determination by rotation.
Accordingly, it is proposed to appoint Dr. Ashok S Ganguly, Dr. J P Moreau,
Ms. Kalpana Morparia, Dr. Omkar Goswami and Mr. Ravi Bhoothalingam as
Independent Directors of the Company in accordance with Section 149 of the
Companies Act, 2013, not liable to retire by rotation and to hold offi ce as under:
NAME NO. OF YEARS TERM
Dr. Ashok S Ganguly 3 Up to the conclusion of 33rd AGM
Dr. J P Moreau 1 Up to the conclusion of 31st AGM
Ms. Kalpana Morparia 5 Up to the conclusion of 35th AGM
Dr. Omkar Goswami 5 Up to the conclusion of 35th AGM
Mr. Ravi Bhoothalingam 2 Up to the conclusion of 32nd AGM
The Company has received from each of Dr. Ashok S Ganguly, Dr. J P Moreau,
Ms. Kalpana Morparia, Dr. Omkar Goswami and Mr. Ravi Bhoothalingam (i) consent
in writing to act as Director in Form DIR-2 pursuant to Rule 8 of the Companies
(Appointment & Qualifi cation of Directors) Rules, 2014; (ii) intimation in Form
DIR-8 pursuant to Rule 14 of the Companies (Appointment & Qualifi cation of
Directors) Rules, 2014 to the effect that they are not disqualifi ed in accordance
with sub-section (2) of Section 164 of the Companies Act, 2013 and (iii) declaration
that they meet the criteria of independence as provided in Section 149(6) of the
Companies Act, 2013.
The Company has also received notices from members along with the deposit of
requisite amount under Section 160 of the Act proposing the candidatures of each of
the above Directors for the offi ce of Directors of the Company.
In the opinion of the Board, Dr. Ashok S Ganguly, Dr. J P Moreau, Ms. Kalpana
Morparia, Dr. Omkar Goswami and Mr. Ravi Bhoothalingam fulfi ll the conditions for
their appointment as Independent Directors as specifi ed in the Companies Act, 2013
and the Listing Agreement and are independent of the management.
A copy of the draft letter of appointment setting out the terms and conditions
of appointment of Dr. Ashok S Ganguly, Dr. J P Moreau, Ms. Kalpana Morparia,
Dr. Omkar Goswami and Mr. Ravi Bhoothalingam is available for inspection, without
any fee, by the members at the Company’s registered offi ce during normal hours on
working days up to the date of the AGM.
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013 - 14
HEALTHY FOREVER
216
Dr. Ashok S Ganguly, Dr. J P Moreau, Ms. Kalpana Morparia, Dr. Omkar Goswami
and Mr. Ravi Bhoothalingam are interested in the resolutions set out respectively at
Item Nos. 7, 8, 9, 10 & 11 of the Notice with regard to their respective appointments.
The relatives of Dr. Ashok S Ganguly, Dr. J P Moreau, Ms. Kalpana Morparia,
Dr. Omkar Goswami and Mr. Ravi Bhoothalingam may be deemed to be interested
in the resolutions set out respectively at Item Nos. 7, 8, 9, 10 & 11 of the Notice, to
the extent of their shareholding interest, if any, in the Company.
Save and except the above, none of the other Directors/Key Managerial Personnel
of the Company/their relatives are, in any way, concerned or interested, fi nancially or
otherwise, in these resolutions.
The Board recommends the resolutions set forth in the Item Nos. 7, 8, 9, 10 & 11 of
the Notice for approval of the members.
ITEM NOS. 12 & 13
Mr. G V Prasad, was, by way of a resolution passed at the Annual General Meeting
of the Company held on July 21, 2011, re-appointed as Whole-time Director of the
Company (designated as Vice-Chairman and Chief Executive Offi cer (CEO)) with
effect from 30 January 2011 for a period of 5 (fi ve) years ending on 29 January
2016 and as per the terms of such appointment, was not liable to retire by rotation.
He was re-designated as Chairman and CEO by way of a resolution passed at
the Annual General Meeting of the Company held on 31 July 2013 and further
re-designated as Co-Chairman, Managing Director and CEO of the Company with
effect from 13 May 2014.
Mr. Satish Reddy, was, by way of a resolution passed at the Annual General Meeting
of the Company held on 20 July 2012, re-appointed as Whole-time Director of the
Company (designated as Managing Director and Chief Operating Offi cer (COO)) with
effect from 1 October 2012 for a period of 5 (fi ve) years ending on 30 September
2017 and as per the terms of such appointment, was not liable to retire by rotation.
He was re-designated as Vice-Chairman and Managing Director by way of a
resolution passed at the Annual General Meeting of the Company held on 31 July
2013 and further re-designated as Chairman with effect from 13 May 2014.
The provisions of the Companies Act, 2013 including provisions in relation to
appointment of directors have been notifi ed with effect from 1 April 2014. In
accordance with Section 152(6) of the Companies Act, 2013, the period of offi ce of
at least two-third Directors of the Company shall liable to determination by retirement
by rotation. Since the provisions of Section 152(6) are not applicable to Independent
Directors, to ensure compliance with the provisions of Section 152(6), it is proposed
that the terms of appointment of Mr. G V Prasad and Mr. Satish Reddy be amended
to provide that they shall be liable to retire by rotation at the Annual General Meeting
of the Company as per the provisions of Section 152(6) of the Companies Act,
2013. The other terms and conditions of their appointment including remuneration
approved at the general meeting held on 21 July 2011 and 20 July 2012 shall remain
unchanged.
Mr. G V Prasad and Mr. Satish Reddy are interested in the resolutions set out
respectively at Item Nos. 12 & 13 of the Notice with regard to their respective
appointments.
The relatives of Mr. G V Prasad and Mr. Satish Reddy may be deemed to be
interested in the resolutions set out respectively at Item Nos. 12 & 13 of the Notice,
to the extent of their shareholding interest, if any, in the Company.
Save and except the above, none of the other Directors/Key Managerial Personnel
of the Company/their relatives are, in any way, concerned or interested, fi nancially or
otherwise, in these resolutions.
The Board recommends the resolutions set forth in the Item Nos. 12 & 13 of the
Notice for approval of the members.
ITEM NO. 14
The Board, on the recommendations of the Audit Committee, has approved the
re-appointment of the Cost Auditors, M/s. Sagar & Associates at a remuneration of
`6.00 lakhs (Rupees Six Lakhs) per annum plus out of pocket expenses, at actuals,
to conduct the audit of the cost records of the Company for the fi nancial year ending
31 March 2015.
In accordance with the provisions of the Section 148 of the Companies Act 2013,
read with the Companies (Audit and Auditors) Rules, 2014, the remuneration
payable to the Cost Auditors has to be ratifi ed by the shareholders of the Company.
Accordingly, consent of the members is sought for passing an Ordinary Resolution
as set out at Item No. 14 of the Notice for ratifi cation of the remuneration payable to
the Cost Auditors for the fi nancial year ending 31 March 2015.
None of the Directors/Key Managerial Personnel/their relatives are, in any way,
concerned or interested, fi nancially or otherwise, in this resolution.
The Board recommends the resolution set forth in the Item No. 14 of the Notice for
approval of the members.
ITEM NO. 15
Dr. Reddy’s Laboratories Inc., USA (DRL Inc.) is a wholly-owned subsidiary of
the Company and a ‘Related Party’ within the meaning of Section 2(76) of the
Companies Act, 2013 and Clause 49-VII(B)(2) of the Listing Agreement (effective
October 1, 2014).
In terms of proviso to Clause 49-VII(C) of the Listing Agreement, the contracts/
arrangements/transactions relating to transfer or receipt of products, goods,
materials or services with DRL Inc. are material in nature as these transactions
are likely to exceed 20% of the net worth of the Company as per the last audited
fi nancial statements of the Company. Therefore, in terms of Clause 49-VII(E),
the contracts/arrangements/transactions with DRL Inc. requires the approval of
unrelated shareholders of the Company by a special resolution.
The particulars of the contracts/arrangements/transactions are as under:
1. Name of related party: Dr. Reddy’s Laboratories Inc., USA (DRL Inc.)
2. Name of director or key managerial personnel who is related: Mr. Satish Reddy
& Mr. G V Prasad, Whole-time Directors and Mr. Anupam Puri, Independent
Director of the Company are common Board members.
ANNEXURE TO NOTICE OF AGM
NOTICE
217
3. Nature of relationship: DRL Inc. is a wholly owned subsidiary of Dr. Reddy’s
Laboratories Limited.
4. Material terms of the contracts/arrangements/transactions: Transfer or receipt
of products, goods, materials or services on arm’s length basis.
5. Monetary value: Estimated amount of up to US$ 1,100 million every fi nancial
year.
6. Any other information relevant or important for the members to make a
decision on the proposed transaction: None
The contracts/arrangements/transactions with DRL Inc. have been approved by the
Audit Committee at its meeting held on 12 May 2014 and considered by the Board
of Directors at their meeting held on 13 May 2014 for recommending the same to
the unrelated shareholders of the Company for their approval.
Mr. G V Prasad, Mr. Satish Reddy and Mr. Anupam Puri are interested in the
resolution set forth in Item No. 15 of the Notice.
The relatives of Mr. G V Prasad, Mr. Satish Reddy and Mr. Anupam Puri may be
deemed to be interested in the resolution set forth in Item No. 15 of the Notice, to
the extent of their shareholding interest, if any, in the Company.
Save and except the above, none of the other Directors/Key Managerial Personnel
of the Company/their relatives are, in any way, concerned or interested, fi nancially or
otherwise, in this resolution.
The Board recommends the resolution set forth in Item No. 15 of the Notice for
approval of the unrelated shareholders of the Company.
By Order of the Board
Place Hyderabad Sandeep Poddar
Date 21 June 2014 Company Secretary
ANNEXURE TO NOTICE OF AGM
DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2013 - 14
HEALTHY FOREVER
218
INSTRUCTIONS FOR E-VOTING
Pursuant to provisions of Section 108 of the Companies Act, 2013, read with the Companies (Management and Administration) Rules, 2014, the Company is pleased to
offer e-voting facility to the members to cast their votes electronically on all resolutions set forth in the Notice convening the 30th Annual General Meeting to be held on
Thursday, 31 July 2014, at 9.30 AM IST. The Company has engaged the services of National Securities Depository Limited (NSDL) to provide the E-Voting facility.
The E-Voting facility is available at the link https://www.evoting.nsdl.com
The E-voting Event Number and period of E-voting are set out below:
EVEN (E-VOTING EVENT NUMBER) COMMENCEMENT OF E-VOTING END OF E-VOTING100386 25 July 2014 at 9.00 AM IST 27 July 2014 at 6.00 PM IST
Please read the instructions printed below before exercising your vote.
These details and instructions form an integral part of the notice for the Annual General meeting to be held on 31 July 2014.
STEPS FOR E-VOTING:
1. Open the internet browser and type the following URL:
https://www.evoting.nsdl.com
2. Click on Shareholder-Login.
3. If you are already registered with NSDL for E-voting, then you can use your
existing User ID and Password for Login.
4. If you are logging in for the fi rst time, please enter the User ID and Password.
The same shall be sent to you separately.
5. The Password Change Menu will appear on your screen. Change to a new
password of your choice, making sure that it contains a minimum of 8 digits or
characters or a combination of the two. Please take utmost care to keep your
password confi dential.
6. Once the E-Voting home page opens, click on E- Voting>Active Voting Cycles.
7. Select the EVEN (E-Voting Event Number) of Dr. Reddy’s Laboratories Limited
(the number is provided in this document). Once you enter the number, the
Cast Vote page will open. Now you are ready for e-voting.
8. Cast your vote by selecting your favored option and click Submit. Also click
Confi rm when prompted. Please note that once your vote is cast on the
selected resolution, it cannot be modifi ed.
9. Institutional shareholders (i.e members other than individuals, HUF, NRIs
etc.) are required to send a scanned copy (PDF/JPG Format) of the relevant
board resolution/authority letter, etc together with the attested specimen
signature(s) of the duly authorized signatory(ies) who are authorized to vote, to
[email protected], with a copy marked to [email protected]
GENERAL INSTRUCTIONS
a. The e-voting period commences on 25 July 2014 (9.00 A.M. IST) and ends on
27 July 2014 (6.00 P.M. IST). During this period, shareholders of the Company
holding shares either in physical form or in dematerialized form, as on the
cut-off date of 20 June 2014, may cast their votes electronically. The E-Voting
module shall be disabled by NSDL for voting thereafter. Once the vote on a
resolution is cast by the shareholder, the shareholder shall not be allowed to
change it subsequently.
b. Shareholders of the Company, holding shares either in physical form or in
dematerialized form, as on the cut-off date of 20 June 2014 and not casting
their vote electronically, may only cast their vote at the Annual General Meeting.
c. Mr. G Raghu Babu, Partner of M/s. R & A Associates, practicing Company
Secretary, Hyderabad (Membership No. F4448), has been appointed as the
Scrutinizer to scrutinize the E-Voting process in a fair and transparent manner.
d. The Scrutinizer shall, within a period of not exceeding three working days
from the conclusion of the E-Voting period, unlock the votes in the presence
of at least two witnesses, not in employment of the Company and make a
Scrutinizer’s Report of the votes cast in favor of or against, if any, forthwith to
the Chairman of the Company.
e. The voting rights of the shareholders shall be in proportion to the shares held by
them, of the paid-up equity share capital of the company as on the cut-off date of
20 June 2014.
f. The results declared along with the Scrutinizer’s Report shall be placed on the
Company’s website www.drreddys.com and on the website of NSDL within
two days of passing of the resolutions at the 30th Annual General Meeting
of the Company on 31 July 2014 and shall be communicated to BSE Ltd.,
National Stock Exchange of India Ltd. and the New York Stock Exchange, Inc.
All documents referred to in the accompanying Notice and Statement pursuant
to Schedule IV and Section 102(1) of the Companies Act 2013 will be available
for inspection at the Registered Offi ce of the Company during business hours
on all working days up to the date of declaration of the results of the 30th
Annual General Meeting of the Company.
By Order of the Board
Place Hyderabad Sandeep Poddar
Date 21 June 2014 Company Secretary
219
GLOSSARY
` Indian Rupees
AAPS American Association of Pharmaceutical Scientists
ACS American Chemical Society
ACT Advanced Characterization Technology Lab
ANDA Abbreviated New Drug Application
AS Accounting Standards
API Active Pharmaceutical Ingredient
ADR American Depository Receipt
AGM Annual General Meeting
BR Business Responsibility
BSE BSE Limited
CDSL Central Depository Services (India) Limited
CoE Centre of Excellence
CTO Chemical Technical Operations
CEO Chief Executive Offi cer
CFO Chief Financial Offi cer
COO Chief Operating Offi cer
CoBE Code of Business Conduct and Ethics
COSO Committee of Sponsoring Organizations
CIN Corporate Identity Number
CIS Commonwealth of Independent States
CAGR Compounded Annual Growth Rate
CII Confederation of Indian Industry
CSR Corporate Social Responsibility
CPS Custom Pharmaceutical Services
DP Depository Participant
DIN Director Identifi cation Number
DRF Dr. Reddy’s Foundation
DRFHE Dr. Reddy’s Foundation for Health Education
DMF Drug Master File
EBIDTA Earnings Before Interest, Taxes, Depreciation and Amortization
EPS Earnings Per Share
ESOP Employees Stock Option Plan
ERM Enterprise-wide Risk Management
FTDC Fermentation – Technology Development Center
FICCI Federation of Indian Chambers of Commerce and Industry
FY Financial Year
FTO Formulation Technical Operations
GDR Global Depository Receipt
GDP Global Domestic Product
GG Global Generics
GRI Global Reporting Index
GMP Good Manufacturing Practices
GCE Green Chemistry & Engineering
HR Human Resources
IDMA Indian Drug Manufacturers Association
IPA Indian Pharmaceutical Alliance
IACC Indo American Chamber of Commerce
ICAI Institute of Chartered Accountants of India
IMS IMS Health Inc.
IGAAP Indian Generally Accepted Accounting Principles
IT Information Technology
IPO Initial Public Offer
IPDO Integrated Product Development Organization
IP Intellectual Property
IFRS International Financial Reporting Standards
KAR-JVR Kallam Anji Reddy Vocational Junior College
KARV Kallam Anji Reddy Vidyalaya
KRAs Key Result Areas
LABS Livelihood Advancement Business School
MD&A Management Discussion & Analysis
MD Managing Director
MAbs Monoclonal Antibodies
NSDL National Securities Depository Limited
NSE National Stock Exchange of India Limited
NCEs New Chemical Entities
NYSE New York Stock Exchange, Inc.
NCDs Non-Convertible Debentures
NGO Non-Governmental Organization
NA North America
OJT On-Job Training
OTC Over-the-counter
PP Proprietary Products
PSAI Pharmaceuticals Services and Active Ingredients
PV Pharmacovigilance
PSRs Professional Sales Representatives
PAT Profi t After Tax
PACE Program to Achieve Cost and Capabilities Excellence
PBT Profi t Before Tax
POC Proof of Concept
PromOTE Promotion of Oncology Training and Education
QbD Quality by Design
R&D Research and Development
RoW Rest of the World
RoCE Return on Capital Employed
SHE Safety, Health and Environment
SOX Sarbanes Oxley Act, 2002
SEBI Securities and Exchange Board of India
SEC Securities and Exchange Commission
SEZ Special Economic Zone
SMT Self-Managed Teams
SG&A Selling, General and Administrative
SRI Skilling Rural India
SMEs Small Medium Enterprises
TDC Technology Development Center
TMB Talent Management Board
UK United Kingdom
USD/$ United States Dollar
USFDA United States Food and Drug Administration
US/USA United States of America
UN United Nations
YIM Young Investors Meet
GLOSSARY
NOTES
HEALTHY FOREVER
Dr. Reddy’s Laboratories LimitedCIN: L85195TG1984PLC004507
Regd. Offi ce: 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034
Email: [email protected] Website: www.drreddys.com
30th Annual General Meeting – Thursday, 31 July 2014
Attendance Slip
Folio No./Client Id: No. of Shares:
Name and address of
First/Sole Shareholder :
I, hereby record my presence at the 30th Annual General Meeting of the Company to be held on Thursday, 31 July 2014 at 9.30 AM at the Grand Ball
Room, Hotel Taj Krishna, Road No.1, Banjara Hills, Hyderabad 500 034.
Name of the Member/Proxy Signature of the Member/Proxy
(Block Letters)
Notes:
a) Only Member/Proxy can attend the meeting. No minors would be allowed at the meeting.
b) Member/Proxy who wish to attend the meeting must bring this attendance slip to the meeting and hand over at the entrance duly fi lled in and signed.
c) Member/Proxy should bring his/her copy of the Annual Report for reference at the meeting.
Dr. Reddy’s Laboratories LimitedCIN: L85195TG1984PLC004507
Regd. Offi ce: 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034
Email: [email protected] Website: www.drreddys.com
30th Annual General Meeting – Thursday, 31 July 2014
Proxy FormName of the Shareholder(s):
Registered Address:
E-mail ID: Folio No. /Client Id: DP ID:
I/We, being member(s) of Dr. Reddy’s Laboratories Limited, holding shares of the Company, hereby appoint:
A. Name:
Address:
E-mail Id: Signature:
Or failing him
B. Name:
Address:
E-mail Id: Signature:
Or failing him
C. Name:
Address:
E-mail Id: Signature:
as my/our proxy to attend and vote (on poll) for me/us, on my/our behalf at the 30th Annual General Meeting of the Company to be held on Thursday,
31 July 2014 at 9.30 AM at the Grand Ball Room, Hotel Taj Krishna, Road No.1, Banjara Hills, Hyderabad 500 034. and at any adjournment thereof
in respect of such resolutions as are indicated below:
Resolut ion Nos.
ResolutionsVote (see note d.)
(Please mention no. of shares)For Against Abstain
Ordinary Business1. Approval of the Balance Sheet as at 31 March 2014 and the Statement of Profi t and Loss of the
Company for the year ended on that date along with the Reports of the Directors’ and Auditors’
thereon.
2. Declaration of dividend on the equity shares for the fi nancial year 2013-14.
3. Appoint a Director in place of Mr. Anupam Puri, who retires by rotation, and being eligible, seeks re-
appointment as non-retiring Independent Director for a period of four years.
4. Appoint a Director in place of Dr. Bruce L A Carter, who retires by rotation, and being eligible, seeks
re-appointment as non-retiring Independent Director for a period of fi ve years.
5. Appoint a Director in place of Mr. Sridar Iyengar, who retires by rotation, and being eligible, seeks re-
appointment as non-retiring Independent Director for a period of fi ve years.
6. Appoint the retiring Auditors M/s. B S R & Co. LLP, Chartered Accountants as Statutory Auditors and
fi x their remuneration.
Special Business
7. Appoint Dr. Ashok S Ganguly, as an Independent Director in terms of Section 149 of the Companies
Act, 2013.
8. Appoint Dr. J P Moreau, as an Independent Director in terms of Section 149 of the Companies Act,
2013.
9. Appoint Ms. Kalpana Morparia, as an Independent Director in terms of Section 149 of the Companies
Act, 2013.
10. Appoint Dr. Omkar Goswami, as an Independent Director in terms of Section 149 of the Companies
Act, 2013.
11. Appoint Mr. Ravi Bhoothalingam, as an Independent Director in terms of Section 149 of the
Companies Act, 2013.
12. Approval of variation in the terms of appointment of Mr. G V Prasad, Co-Chairman, Managing Director
& Chief Executive Offi cer.
13. Approval of variation in the terms of appointment of Mr. Satish Reddy, Chairman.
14. Approval of remuneration payable to Cost Auditors, M/s. Sagar & Associates for the fi nancial year
2014-15.
15. Approval of Material Related Party transactions with Dr. Reddy’s Laboratories Inc., USA (a wholly-
owned subsidiary).
Signed this day of 2014
Revenue
stampSignature of the Shareholder Signature of the Proxyholder(s)
Please turn over for notes
Notes:
a) Proxy need not be a member of the Company.
b) The Proxy Form duly fi lled in and signed by the member(s) across Revenue Stamp should reach the Company’s Registered Offi ce: Dr. Reddy’s
Laboratories Limited, 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034 at least 48 hours before the commencement of the meeting.
c) Corporate members intending to send their authorized representative(s) to attend the meeting are requested to send a certifi ed copy of the Board
resolution authorizing their representative(s) to attend and vote on their behalf at the meeting.
d) It is optional to indicate your preference. If you leave the for, against or abstain column blank against any or all resolutions, your proxy will be entitled
to vote in the manner as he/she may deem appropriate.
DR. REDDY’S LABORATORIES LIMITED www.drreddys.com
HEALTHYFOREVER
DR. REDDY’S LABORATORIES LIMITEDANNUAL REPORT 2013-14
Contents
CASE STUDIES
METFORMIN: SMALL IS BIG
VIVA: COLLABORATING TO CURE
SMT: IMBIBING PATIENT-CENTRICITY
PROMIUS PROMISE: GUIDING RIGHT
10-11
16-17
20-21
24-25
CHAIRMAN’S LETTER 2
CELEBRATING GOOD HEALTH FOR DECADES 4
DOING WHAT MATTERS MOST 6
KEY PERFORMANCE INDICATORS 8
HEALTHY FOREVER
A FIRM FOUNDATION FOR SUSTAINED R&D INITIATIVES 12
BUILDING WORLD-SCALE MANUFACTURING CAPABILITIES 18
HARNESSING PEOPLE POTENTIAL 22
BOARD OF DIRECTORS 26
MANAGEMENT COUNCIL 30
BUSINESS RESPONSIBILITY REPORT 32
MANAGEMENT DISCUSSION & ANALYSIS 50
CORPORATE GOVERNANCE 62
ADDITIONAL SHAREHOLDERS’ INFORMATION 79
FIVE YEARS AT A GLANCE & RATIO ANALYSIS 90
SECRETARIAL AUDIT REPORT 92
DIRECTORS’ REPORT 94
IGAAP STANDALONE FINANCIAL STATEMENTS 103
IGAAP CONSOLIDATED FINANCIAL STATEMENTS 155
EXTRACT OF AUDITED IFRS CONSOLIDATED FINANCIAL STATEMENTS 207
STATEMENT 212 210
INFORMATION ON FINANCIALS OF SUBSIDIARIES 211
NOTICE OF THE ANNUAL GENERAL MEETING 212
HEALTHYFOREVER
DR. REDDY’S LABORATORIES LIMITEDANNUAL REPORT 2013-14
DR. REDDY’S LABORATORIES LTD.8-2-337, ROAD NO. 3, BANJARA HILLS, HYDERABAD 500034, INDIAwww.drreddys.com
DR. REDDY’S LABORATORIES LIMITED | A
NN
UA
L R
EP
OR
T 2
01
3-1
4HEALTHY FOREVER